MEDICINE USAGE PATTERNS IN POTCHEFSTROOM PRIMARY HEALTH CARE CLINICS

PART 2

G.K. JOHN

MEDICINE USAGE PATTERNS IN POTCHEFSTROOM PRIMARY HEALTH CARE CLINICS

GEORGE KUNJUNJUKUTTY JOHN B.PHARM

Dissertation submitted in partial fulfillment of the requirements for the degree Magister Pharmaciae, in Pharmacy Practice at the

North-West University, (Potchefstroom Campus).

Supervisor: Prof. Dr. M.S. Lubbe

Co-Supervisor: Prof. Dr. J.H.P. Serfontein

2004

Potchefstroom

"Rejoice in the Lord always. I will say it again: Rejoice! Let your gentleness be evident to all. The Lord is near. Do not be anxious about anything, but in everything, by prayer and petition, with thanksgiving, present your request to God. And the peace of God, which transcends all understanding, will guard your hearts and mind in Christ Jesus."

Philippians 4:4-7 (New International Version, The Holy Bible)

LIST OF APPENDICES

	PAGE
Appendix A: MEDICINE USAGE SURVEY FORM	1
Appendix B.1: THERAPEUTIC BUDGET MODEL IN PRIMARY HEALTH CARE CLINICS	6
Appendix B.2: CODES USED FOR MODEL	23
Appendix C: ABSTRACT OF PAPERS PRESENTED	29
Appendix C.1: Abstract of podium presentation [International invited speaker] in the Scientific session of the 55th Indian Pharmaceutical Congress (IPC), held in Chennai, India from the 19th-21st of December 2003.	29
Appendix C.2: Abstract of podium presentation at the South African Association of Hospital and Institutional Pharmacist (SAAHIP) conference at Drakensburg, South Africa from March 6th 2003 to March 9th 2003.	30
Appendix C.3: Abstract of poster presentation on "at the South African Association of Hospital and Institutional Pharmacist (SAAHIP) conference at Drakensburg, South Africa from March 6th 2003 to March 9th 2003.	31
Appendix C.4: Abstract of Podium presentation (Contender for the Roche Young Scientist of the year award) at the International Conference on Pharmaceutical and Pharmacological sciences (ICPPS) at Johannesburg, South Africa from September 22nd to 25th 2002.	32

Appendix 1

RESULTS OF DIAGNOSES ANALYSIS (ICD-10 Code)

Apppendix 1.1 Frequency of various diagnoses in all clinics and in each clinic 33

Apppendix 1.2 Frequency of different diagnosis according to gender in all clinics and in clinic 1,2 & 3 37

Apppendix 1.3 Frequency of various diagnosis according to gender in clinics 4,5 & 6 41

Apppendix 1.4 Frequency of different diagnosis according to age groups in all clinics 45

Apppendix 1.5 Frequency of different diagnosis according to age group in clinic 1 49

Apppendix 1.6 Frequency of different diagnosis according to age group in clinic 2 53

Apppendix 1.7 Frequency of different diagnosis according to age group in clinic 3 57

Apppendix 1.8 Frequency of different diagnosis according to age group in clinic 4 61

Apppendix 1.9 Frequency of different diagnosis according to age group in clinic 5 65

Apppendix 1.10 Frequency of different diagnosis according to age group in clinic 6 69

RESULTS OF ATC CLASSIFICATION SYSTEM ANALYSIS

Apppendix 1.11 Frequency of different medicines according to ATC classification system for all consultations in all clinics 73

Apppendix 1.12 Frequency of medicines acording to ATC classification and gender in all clnics 76

Apppendix 1.13 Frequency of medicines according to ATC classification and gender in clinics 1 & 2 78

Apppendix 1.14 Frequency of medicines according to ATC classification and gender in clinics 3 & 4 81

Appendix 1.15 Frequency of medicines according to ATC classification and gender in clinics 5 & 6 84

Apppendix 1.16 Frequency of medicines according to ATC classification in relation to age group in all clinics 87

Apppendix 1.17 Frequency of medicines according to ATC classification in relation to age group in clinic 1 90

Apppendix 1.18 Frequency of medicines according to ATC classification in relation to age group in clinic 2 93

Appendix 1.19 Frequency of medicines according to ATC classification in relation to age group in clinic 3 96

Appendix 1.20 Frequency of medicines according to ATC classification in relation to age group in clinic 4 99

Appendix 1.21 Frequency of medicines according to ATC classification in relation to age group in clinic 5 102

Appendix 1.22 Frequency of medicines according to ATC classification in relation to age group in clinic 6 105

RESULTS OF BUDGET GROUP ANALYSIS

Appendix 1.23 Therapeutic budget group parameters in all clinics 108

Appendix 1.24 Therapeutic budget group parameters in clinic 1 109

Appendix 1.25 Therapeutic budget group parameters in clinic 2 110

Appendix 1.26 Therapeutic budget group parameters in clinic 3 111

Appendix 1.27 Therapeutic budget group parameters in clinic 4 112

Appendix 1.28 Therapeutic budget group parameters in clinic 5 113

Appendix 1.29 Therapeutic budget group parameters in clinic 6 114

Appendix 1.30 Parameters of Therapeutic budget group in relation to age group in all clinics 115

Appendix 1.31 Parameters of Therapeutic budget group in relation to age group in clinic 1 117

Appendix 1.32 Parameters of Therapeutic budget group in relation to age group in clinic 2 119

Appendix 1.33 Parameters of Therapeutic budget group in relation to age group in clinic 3 121

Appendix 1.34 Parameters of Therapeutic budget group in relation to age group in clinic 4 123

Appendix 1.35 Parameters of Therapeutic budget group in relation to age group in clinic 5 125

Appendix 1.36 Parameters of Therapeutic budget group in relation to age group in clinic 6 127

Appendix 1.37 Parameters of theraputic budget group in relation to the gender in all clinics 129

Appendix 1.38 Parameters of theraputic budget group in relation to the gender in clinic1 131

Appendix 1.39 Parameters of theraputic budget group in relation to the gender in clinic 2 133

Appendix 1.40 Parameters of theraputic budget group in relation to the gender in clinic 3 135

Appendix 1.41 Parameters of theraputic budget group in relation to the gender in clinic4 137

Appendix 1.42 Parameters of theraputic budget group in relation to the gender in clinic5 139

Appendix 1.43 Parameters of theraputic budget group in relation to the gender in clinic 6 141

RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

Appendix 1.44 Parameters of pharmacological group for all consultations in all clinics 143

Appendix 1.45 Parameters of pharmacological group for all consultations in clinic 1 145

Appendix 1.46 Parameters of pharmacological group for all consultations in clinic 2 147

Appendix 1.62 Parameters of pharmacological group for all consultations according to age group in clinics 4 206

Appendix 1.63 Parameters of pharmacological group for all consultations according to age group in clinics 5 213

Appendix 1.64 Parameters of pharmacological group for all consultations according to age group in clinics 6 220

RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

Appendix 1.65 Parameters of individual medicine item description in all clinics for all consultations 227

Appendix 1.66 Parameters of individual medicine item description according to gender for all consultations in all clinics 232

Appendix 1.67 Parameters of individual medicine item description According to age group for all consultations in all clinics 240

APPENDIX A

MEDICINE USAGE SURVEY FORM

1. Primary health care clinic

2. Health district — POTCHEFSTROOM

3. Patient identification number

4. Date of consultation

D	D	M	M	Y	Y

5. Gender

Male	Female

6. Date of birth

D	D	M	M	Y	Y

7. Age in years (if D.O.B not available)

8. Patient category

Type	X
New case	
Follow up	
Previous record not available	
Re-treatment	

8.1 If re-treatment, check the appropriate category

No	Category	X
01	After previous treatment completion	
02	After previous treatment failure	
03	After previous treatment interruption	
04	New condition/diagnosis	

9 Services offered

Were any of the following services done to the patient?

9.1- Diagnostic screening tests YES ☐ NO ☐

If yes, check the appropriate category/categories

No	Nature of test	X
01	Blood glucose testing	
02	Blood pressure measuring	
03	Total serum cholesterol	
04	Pregnancy	
05	Ovulation	
06	Lung function test	
07	Body mass index	
08	HIV	
09	Tuberculosis	
10	Urine analysis (excepting ovulation)	
11	Peak flow measurement	
12	Hemoglobin estimation	
13	Pulse and heart rate	
14	Others	

If others, please specify----------

9.2 Immunizations YES ☐ NO ☐

If yes, check the appropriate one/ones

No	Type of vaccine	X
01	Bacillus Calmette Guerin (BCG)	
02	Oral Polio Vaccine (OPV)	
03	Diphtheria, Pertussis & Tetanus (DPT)	
04	Diphtheria & Tetanus (DT)	
05	Hepatitis B (Hep B)	
06	Influenza (Hi B)	
07	Tetanus toxoid (TT)	
08	Rubella	
09	Rabies	
10	Measles	
11	Others	

If others please specify----------

9.3 Laboratory tests YES ☐ NO ☐

If yes, specify the tests done and values----------

9.4 Miscellaneous services YES ☐ NO ☐

If yes, specify the details----------

---

10 Diagnosis / condition /disorder/ need of the patient.

(Check all that apply)

1	**Dental and oral**		*5*	**Gastro intestinal**		10.2	Myocardial infarction	
1.1	Aphtous ulcers		5.1	Diarrhoea		10.3	Angina	
1.2	Cold sores		5.2	Bacillary dysentery		10.4	Cardiac arrest	
1.3	Dental abscess		5.3	Constipation		10.5	Haemorrhoids	
1.4	Gingivitis		5.4	Giardiasis		10.6	Anal fissures	
1.5	Periodontitis		5.5	Amoebiasis		10.7	Congestive heart failure	
1.6	Thrush		5.6	Nausea and vomiting		10.8	Varicose veins	
1.7	Teething		5.7	Dyspepsia		10.9	Chilblains	
1.8	Toothache		5.8	Peptic ulceration		*11*	**Opthalmological**	
2	**Dermatological**		5.9	Gastritis		11.1	Blepharitis	
2.1	Acne		5.10	Heart –burn		11.2	Lid oedema	
2.2	Bacterial skin infection		5.11	Spastic colon syndrome		11.3	Dry eyes	
2.3	Boils and impetigo		5.12	Flatulence		11.4	Styes and Chalzion	
2.4	Bed sores		*6*	**Musculo-skeletal**		11.5	Glaucoma	
2.5	Nappy rash		6.1	Arthritis		11.6	Conjunctivitis	
2.6	Burn wounds		6.2	Gout		11.7	Chemical burns	
2.7	Eczema(moist,atopic)		6.3	Backache		11.8	Arc eyes	
2.8	Seborrhoeic eczema		6.4	Muscular pain		11.9	Subconjunctival bleeding	
2.9	Calluses and corns		6.5	Trauma		11.10	Foreign object in eye	
2.10	Whitlows		6.6	Fibrositis		11.11	Trachoma	
2.11	Hair loss		6.7	Bursitis		11.12	Opthalmia neonatorum	
2.12	Insect bites and stings		*7*	**Neurological**		*12*	**Parasitic**	
2.13	Pruritis		7.1	Psychosis(acute/chronic)		12.1	Malaria	
2.14	Psoriasis		7.2	Depression		12.2	Bilharzia	
2.15	Stretch mark		7.3	Headache		12.3	Tapeworm (T.W)	
2.16	Dandruff		7.4	Pain control		12.4	All worms (Exc T.W)	
2.17	Fungal skin infection		7.5	Febrile convulsions		*13*	**Respiratory**	
2.18	Viral skin infection		7.6	Fever		13.1	Allergic rhinitis	
2.19	Shingles		7.7	Delirium		13.2	Asthma	
2.20	Urticaria		7.8	Anxiety and stress		13.3	Bronchitis	
2.21	Parasitic skin infection		7.9	Epileptic		13.4	Halitosis	
2.22	Lice, scabies &ringworm		7.10	Fatigue		13.5	Cough	
3	**Genito –urinary**		7.11	Shock		13.6	Croup	
3.1	Urinary tract infection		7.12	Sleep disturbances		13.7	Pneumonia	
3.2	Cystitis		7.13	Stress conditions		13.8	Tonsillitis (bacterial)	
3.3	Pyelonephritis		*8*	**Nutritional and mineral**		13.9	Tonsilittis (viral)	
3.4	Dysmenorrhoea		8.1	Anaemia		13.10	Otitis media	
3.5	Menorriaghia		8.2	Lactation regulation		13.11	Otitis externa	
3.6	Premenstrual tension		8.3	Weight loss		13.12	Sinusitis	
3.7	Pre-clampsia		8.4	Obesity		13.13	Cold symptoms	
3.8	Vaginal bleeding		8.5	Cellulitis		13.14	Influenza	
3.9	Vaginal discharge(No std)		8.6	Malnutrition		*14*	**Specific conditions**	
3.10	Gardenella		8.7	Vitamin deficiency		14.1	Rheumatic fever	
3.11	Candidiasis		8.8	Mineral deficiency		14.2	Tuberculosis	
3.12	Kidney stone		*9*	**Endocrine**		14.3	Family Planning	
3.13	Torsion of testis		9.1	Non insulin dependant		14.4	Mumps	
3.14	Orditis		9.2	Insulin dependant		14.5	Meningitis	
3.15	Prostatitis (chronic)		9.3	Hypoglycemia		14.6	HIV	
3.16	Prostatitis (acute)		9.4	Hyperthyroidism		14.7	Typhoid	
4	**SexuallyTransmitted**		9.5	Hypothyroidism		14.8	Cholera	
4.1	Herpes		9.6	Hormone replacement		14.9	Measles	
4.2	Gonorrhea		*10*	**Vascular**		14.10	Chicken pox	
4.3	Syphilis		10.1	Hypertension		14.11	Tick bite fever	

If others please specify----------

11 Prescription / consultation outcome

Was medicine supplied to the patient ? YES ☐ NO ☐

If yes, please complete in the following details

No	Item description	Indication	Medicine dosage form	Medicine strength	Dosage regimen	Regimen duration	Pre-pack	Cost of regimen	Drug code	Disease code	Date
01											
02											
03											
04											
05											
06											
07											
08											
09											
10											

12 If no medicine was supplied then check the appropriate category

No	Category	X
01	No medicine given (advice only)	
02	No medicine given and referred	
03	No medicine stock	
04	Medicine given and referred (special case)	
05	Others	

If others please specify----------

---

13 Prescription analysis

13.1 Prescribed by

Doctor	Nurse	Others

13.2 Dispensed by

Doctor	Nurse	Others

13.3

Is the medication specified, according to the Essential Drug List (EDL) or a standard treatment guideline ?	YES	NO

13.4

Observation	x	Drugs involved	Level (1 –5) *
Adverse drug reaction			
Drug /disease interaction			
Duplication of therapy			
Inappropriate dosage form			
Inappropriate dose			
Inappropriate duration			
Others			
Drug- drug interaction*			

If others please specify----------

***

APPENDIX B 1: Therapeutic budget model for public primary health care clinics ©

Code	Budget Group	Code	Pharmacological group	Medicine item description	Individual item code							EDL Code		
1	**Anti-effectives**	01	**Anti-bacterial (Penicillin's)**	Amoxycillin 250mg capsules 15's	1	0	1	0	0	7	1	J	0	1
				Amoxycillin Suspension 125mg /5ml	1	0	1	0	3	1	1	J	0	1
				Penicillin VK Suspension 125mg /5ml	1	0	1	0	8	0	1	J	0	1
				Penicillin VK Suspension 250mg /5ml	1	0	1	0	8	1	1	J	0	1
				Penicillin VK Tablets 250mg 20's	1	0	1	0	8	2	1	J	0	1
				Benzathine Penicillin 2.4 MU injection	1	0	1	1	9	9	1	J	0	1
				Flucloxacillin suspension 125mg /5ml	1	0	1	2	5	3	1	J	0	1
				Flucloxacillin 250mg capsules 20's	1	0	1	2	5	9	1	J	0	1
				Ciprofloxacin 500mg tablets 10's	1	0	1	4	0	4	1	J	0	1
		02	**Anti-effectives (amino glycosides)**	**Not supplied in clinics**										
		03	**Anti-effectives (Cephalosporines)**	**Not supplied in clinics**										
				Not supplied in clinics										
		04	**Anti-bacterials (Chloramphenicol, erythromicins)**	Chloramphenicol sodium succ inj. 1 g	1	0	4	1	4	0	2	J	0	1
				Chloramphenicol 250mg Capsules 15's	1	0	4	1	4	1	1	J	0	1
				Chloramphenicol susp 125mg /5ml	1	0	4	1	4	2	1	J	0	1
				Ciprofloxacin tablets 500mg 10's	1	1	0	4	0	4	3	J	0	1
				Doxycycline 50mg capsules / tablets	1	0	4	4	5	1	1	J	0	1
				Doxycycline 100mg tabs, 14's	1	0	4	1	4	6	1	J	0	1
				Doxycycline 100mg tabs, 20's	1	0	4	1	4	7	1	J	0	1

APPENDIX B 1: Therapeutic budget model for public primary health care clinics ©

Code	Budget Group	Code	Pharmacological group	Medicine item description	Individual item code							EDL Code		
1	Anti-effectives	04	Anti-bacterials (Chloramphenicol, erythromicins)	Doxycycline 100mg tabs, 30's	1	0	4	1	4	9	1	J	0	1
				Erythromycin stearate (Caps/tablets) 250mg 20's	1	0	4	1	5	0	1	J	0	1
				Erythromycin stearate (Caps/tablets) 500mg 20's	1	0	4	1	4	8	1	J	0	1
				Erythromycin estolate (Caps/tablets) 250mg 20's	1	0	4	1	5	1	1	J	0	1
				Erythromycin estolate (Caps/tablets) 250mg 56's	1	0	4	1	5	3	1	J	0	1
				Erythromycin susp 125mg/5ml	1	0	4	1	6	9	1	J	0	1
				Erythromycin granules 125mg / 5ml	1	0	4	1	7	0	1	J	0	1
				Sulfadoxine 500mg/pyrimethamine 25mg tabs 4's	1	0	4	3	3	7	1	J	0	1
				Metronidazole tabs 200mg, 21's	1	0	4	2	3	0	1	J	0	1
				Metronidazole tablets 200mg 28's	1	0	4	2	3	1	1	J	0	1
				Metronidazole susp 200mg /5ml, 50ml	1	0	4	2	4	1	1	J	0	1
				Metronidazole susp 200mg /5ml, 100ml	1	0	4	2	5	1	1	J	0	1
				Spectinomycin injection 2g 1's	1	0	4	0	3	1	1	J	0	1
				Co-trimoxazole tablets 400 /80mg, 20's	1	0	4	1	0	9	1	J	0	1
				Co-trimoxazole suspension 200 /40mg /5ml 50ml	1	0	4	1	1	5	1	J	0	1
				Co-trimoxazole suspension 200 /40mg /5ml 100ml	1	0	4	1	1	6	1	J	0	1
		05	Antiviral	**Not issued in PHC**										
		06	Topical anti-effectives	**See dermatologicals**										
		07	Anti-malaria	**See anti –inflammatory pain & fever**										
		08	Anti-helmenthics	**See gastrointestinal**										
		09	Anti-tuberculosis	**See respiratory group**										

APPENDIX B 1: Therapeutic budget model for public primary health care clinics ©

Code	Budget Group	Code	Pharmacological group	Medicine item description	Individual item code							EDL Code		
1	Anti-effectives	10	Anti-fungal oral/injections	Griseofulvin tabs 125mg 28's	1	1	0	0	1	9	1	J	0	1
				Griseofulvin tabs 500mg 28's	1	1	0	1	5	1	1	J	0	1
				Nystatin susp, 20ml	1	1	0	0	6	1	1	J	0	1
		99	Special requests/ referrals											
2	Cardio-vascular agents	01	Anti-anginal	Glyceryl trinitrate sublingual tabs 0.5mg 50's	2	0	1	0	0	1	1	C	0	1
				Atenolol 50mg tablets 28's	2	0	2	0	5	5	1	C	0	2
				Captopril tabs 12.5mg	2	0	2	0	6	0	1	C	0	2
				Captopril tabs 25mg	2	0	2	0	6	1	1	C	0	2
				Captopril tabs 50mg	2	0	2	0	6	2	1	C	0	2
				Enalapril 5mg tabs 28's	2	0	2	1	8	7	1	C	0	2
				Enalapril 10 tabs 28's	2	0	2	1	9	3	1	C	0	2
				Hydrochlorthiazide 25mg tabs 14's	2	0	2	2	3	5	1	C	0	2
				Hydrochlorthiazide 25mg tabs 28's	2	0	2	2	3	6	1	C	0	2
				Methyldopa 250mg tabs, 28,s	2	0	2	3	1	9	1	C	0	2
				Methyldopa 250mg tabs, 56's	2	0	2	3	2	0	1	C	0	2
				Methyldopa 250mg tabs, 84's	2	0	2	3	2	1	1	C	0	2
				Nifedipine 5mg caps/tabs 100's	2	0	2	3	7	5	1	C	0	2
				Nifedipine 30mg XL caps, 30's	2	0	2	3	9	7	1	C	0	2
				Perindopril 4mg tabs, 28's	2	0	2	4	3	3	1	C	0	2
				Reserpine 4mg tabs	2	0	2	5	3	4	1	C	0	2
				Reserpine 0.25mg tabs	2	0	2	5	3	5	1	C	0	2

APPENDIX B 1: Therapeutic budget model for public primary health care clinics ©

Code	Budget Group	Code	Pharmacological group	Medicine item description	Individual item code							EDL Code		
2	Cardio-vascular agents	03	Congestive heart failure drugs	Digoxin 0.25mg tabs	2	0	3	1	0	0	1	C	0	3
				Hydrochlorthiazide 2.5mg tabs **(see antihypertensives)**										
				Furosemide 40mg tabs	2	0	3	1	0	8	1	C	0	3
				Furosemide 10mg / ml inj, 1's	2	0	3	1	0	9	1	C	0	3
				Potassium supplement tabs 600mg, 28's	2	0	3	1	6	3	1	C	0	3
				Potassium supplement tabs 600mg, 56's	2	0	3	1	6	4	1	C	0	3
				Potassium supplement tabs 600mg, 84's	2	0	3	1	6	5	1	C	0	3
				Reserpine 0.1mg & 0.25mg tabs **(See antihypertensives)**										
				Perindopril 4mg tabs **(see antihypertensives)**										
		04	Anti-thrombotic and anti-coagulants	Asprin tabs 300mg DT **(See antiinflammatory)**										
		05	Drugs affecting the blood	Ferrous sulphate tabs eq 65mg Fe 28's	2	0	5	0	4	3	1	B	0	3
				Ferrous salt syr,eq. 300mg of Fe gluconate, 100ml	2	0	5	0	5	5	1	B	0	3
				Ferrous lactate drops 25mg / ml	2	0	5	0	6	5	1	B	0	3
				Folic acid tabs, 5mg	2	0	5	0	6	7	1	B	0	3
				Vitamin K 0.5mg / ml inj 1's	2	0	5	3	3	3	1	B	0	3
				Vitamin K (Phytomenadione) 10mg inj	2	0	5	3	4	3	1	B	0	3
		06	Hypo-lipidaemic agents	**Not issued in PHC**										
		07	Vaso constrictors	**Not issued in PHC**										
		08	Others											
		99	Special requests											

APPENDIX B 1: Therapeutic budget model for public primary health care clinics ©

Code	Budget Group	Code	Pharmacological group	Medicine item description	Individual item code							EDL Code		
3	Dermatologicals	01	Anti-fungal (topical)	Benzoic acid 6% + salicylic acid 3% ointment (Whitefields ointment), 25g	3	0	1	0	0	1	1	D	0	1
				Clotrimazole cream 1%, 20g	3	0	1	0	1	3	1	D	0	1
				Gentian violet 0.5%, 20ml	3	0	1	0	4	3	1	D	0	1
				Miconazole cream 2%,20mg/g, 30g	3	0	1	0	6	1	1	D	0	1
				Miconazole oral gel 20mg/g, 30g	3	0	1	0	6	7	1	D	0	1
				Nystatin ointment 100 000 ug, 15g	3	0	1	0	7	3	1	D	0	1
				Selenium sulphide susp 2%, 50ml	3	0	1	1	4	5	1	D	0	1
		02	Anti-septics ,anti-virals, keratoplastic & keratolytic agents	Cetrimide conc sol. 500ml	3	0	2	0	0	8	1	D	0	8
				Chlorhexidine sol 0.05% (wounds & dental use)	3	0	2	0	2	0	2	D	0	8
				Chlorhexidine sol 0.05% in 70% alcohol, 500ml	3	0	2	0	2	1	2	D	0	8
				Chlorhexidine sol 0.05%, 200ml	3	0	2	0	2	2	2	D	0	8
				Chlorhexidine sol 0.05%, 1000ml	3	0	2	0	2	3	2	D	0	8
				Chlorhexidine 20% + isopropyl alcohol	3	0	2	0	6	1	2	D	0	8
				Chlorhexidine oint. 50g	3	0	2	0	6	2	2	D	0	8
				Chlorhexidine obst cream 1% 100ml	3	0	2	0	7	3	1	D	0	8
				Polyvidone 10% oint	3	0	2	2	1	7	1	D	0	8
				Polyvidone iodine 10% sol	3	0	2	2	1	8	1	D	0	8
				Polyvidone cream 5%, 25g	3	0	2	2	1	9	1	D	0	8
				Tincture of iodine, 50ml	3	0	2	2	2	0	1	D	0	8
				Tincture of podophyllum 20% 50ml	3	0	2	2	2	2	1	D	0	8
				Sodium hypochloride 1% sol, 100ml	3	0	2	3	1	2	1	D	0	8

APPENDIX B 1: Therapeutic budget model for public primary health care clinics ©

Code	Budget Group	Code	Pharmacological group	Medicine item description	Individual item code							EDL Code		
3	Dermatologicals	02	Anti-septics ,anti-virals, keratoplastic & keratolytic agents	Cetremide /chlorhexidine solution 1:100 ml	3	0	2	3	1	3	1	D	0	8
				Triamcinolone acetonide oint 1mg /g, 5g	3	0	2	3	2	1	1	D	0	8
				Prednisone 5mg tabs (see corticosteroids for systemic use)										
				Hydrocortisone succ 100mg inj (see corticosteroids for systemic use)										
		03	Anti-pruritic & anti-inflammatory agents	Calamine lotion 100ml	3	0	3	0	7	3	1	D	0	4
				Hydrocortisone acetate cream 1%, 25g	3	0	3	1	4	5	1	D	0	4
				Ethylchloride spray (see anaesthetic local)										
				Lidocaine gel 2% (see anaesthetic local)										
				Tetracaine cream 1% (see anaesthetic local)										
		04	Keratoplastic & keratolytic agents	Benzoyl peroxide gel 5% (cream) 5g / 100g	3	0	4	0	0	7	1	D	1	0
		05	Scabicides & Pediculocides	Benzyl benzoate lotion 25%, 100ml	3	0	5	0	0	1	1	P	0	3
				Permethrin cream 5% 56g	3	0	5	0	1	8	1	P	0	3
				Permethrin lotion 1%, 100ml	3	0	5	0	1	9	1	P	0	3
				Monosulfiram soap 5% 75g	3	0	5	0	2	5	1	P	0	3
				Gammabenzenehexachloride lotion 1g/100ml	3	0	5	0	3	0	2	P	0	3
		06	Ointments, creams, pastes, jellies, emollients, protectants, dressings & sprays	Ung emulsificans aq. 100g	3	0	6	1	1	5	1	D	0	2
				Ung emulsificans	3	0	6	1	1	6	1	D	0	2
				Zinc oxide oint 7.5g / 50g	3	0	6	1	3	0	1	D	0	2
				Zinc and castor oint, 25g	3	0	6	1	3	3	1	D	0	2
				Emolient body lotion 200ml	3	0	6	1	5	0	1	D	0	2
				Lubricating jelly sachet 2.5ml 100	3	0	6	1	4	5	1	D	0	2

APPENDIX B 1: Therapeutic budget model for public primary health care clinics ©

Code	Budget Group	Code	Pharmacological group	Medicine item description	Individual item code							EDL Code		
3	Dermatologicals	06	Ointments, creams, pastes, jellies, emollients, protectants, dressings & sprays	Ung methyl salicylate (see pain relievers)										
		07	Disinfectants, antiseptics, soaps & irrigation solutions	Sodium hypochlorite 1% sol, 500ml	3	0	7	1	4	5	1	V	0	3
				Sterile water per pour, 1000ml	3	0	7	1	5	7	1	V	0	3
				Sodium chloride for irrigation, 1000ml pour bottle	3	0	7	1	3	9	1	V	0	3
				Gluteraldehyde sol 2%, 1000ml	3	0	7	1	4	5	1	V	0	3
		08	Solvents, preservatives, fixatives, galencials, oils, powders & crystals.	Not issued in PHC										
		09	Eye preparations (Anti-infective)	Tetracycline HCl opthalmic oint, 5g	3	0	9	1	4	5	1	S	0	1
				Oxytetracycline HCL polymoxin B opthalmic oint, 5g	3	0	9	0	9	1	1	S	0	1
				Chloramphenicol opthalmic oint	3	0	9	0	1	3	1	S	0	1
		10	Eye preparations (Local anaesthetic)	Amethocainhe mimims 0.5%, 10	3	1	0	0	0	1	1	S	0	1
				Amethocaine minims 1%, 10	3	1	0	0	0	2	1	S	0	1
		11	Eye preparations (Anti-allergic & anti-inflammatory including corticosteroids & decongestants)	Antazoline & tetrazoline opthalmic drops, 5ml	3	1	1	0	0	1	1	S	0	1
				Oxymetazoline opth drops 0.025%, 5ml	3	1	1	0	0	2	1	S	0	1
		12	Eye preparations(mioyics & anti-glaucoma)	Pilocarpine HCL sol(opth) 1%	3	1	2	0	0	1	1	S	0	1
		13	Eye preparations (Mydriatics)	Atropine sulphate sol (opth), 5 ml	3	1	3	0	0	1	1	S	0	1
		14	Eye preparations (others)	Not issued in PHC										
		15	Ear and nose preparations	Acetic acid 1% in NaCL 0.9% (ear drops)	3	1	5	0	0	1	1	S	0	2
				Acetic acid 2% in Alcohol 70% (Ear drops)	3	1	5	0	0	2	1	S	0	2
				NaCl 0.9% nose drops	3	1	5	0	0	3	1	S	0	2

APPENDIX B 1: Therapeutic budget model for public primary health care clinics ©

Code	Budget Group	Code	Pharmacological group	Medicine item description	Individual item code							EDL Code		
3	Dermatologicals	15	Ear and nose preparations	Oxymetazoline drops 0.05% (nasal)	3	1	5	0	5	0	1	R	0	1
				Oxymetazoline drops 0.025% (nasal)	3	1	5	0	5	1	1	R	0	1
		99	Special requests											
4	Endocrines	01	Contraceptive hormones & other contraceptives	Not issued in PHC										
		02	Contraceptive (barrier methods)	Condoms	4	0	2	0	0	1	1	G	0	1
		03	Contraceptive (Intra-uterine)	Dalcept 250, short type 6cm, 1	4	0	3	0	0	1	1	G	0	1
				Dalcept 375, Long type >7cm, 1	4	0	3	0	0	2	1	G	0	1
		04	Contraceptive (injectables)	Medroxyprogesterone L.A 150mg inj, 1	4	0	4	0	9	7	1	G	0	3
				Norethisterone enath 200mg inj, 1	4	0	4	0	2	7	1	G	0	3
		05	Contraceptive(oral)	"Microval" tablets, 28	4	0	5	0	3	1	1	G	0	3
				"Nordette" tabs, 28	4	0	5	0	3	7	1	G	0	3
				"Ovral" tab, 28	4	0	5	0	4	9	1	G	0	3
				"Triphasil" (triphasic combination tablet), 28	4	0	5	0	4	3	1	G	0	3
		06	Hormones, androgens,oestrogens & progesterones	Oestrogen conj, 0.625 tabs, 28	4	0	6	0	1	4	1	G	0	3
		07	Anti-diabetic agents (Injections)	Insulin actraphane 10ml	4	0	7	0	0	1	1	A	1	0
				Insulin actraphane penset 3ml	4	0	7	0	0	8	1	A	1	0
				Insulin actrapid 10ml	4	0	7	0	1	9	1	A	1	0
				Insulin actrapid penset, 3ml	4	0	7	0	2	0	1	A	1	0
				Insulin monotard, 10ml	4	0	7	0	6	1	1	A	1	0
				Insulin protophane, 10ml	4	0	7	0	6	8	1	A	1	0
				Insulin protophane penset, 3ml	4	0	7	0	7	4	1	A	1	0

APPENDIX B 1: Therapeutic budget model for public primary health care clinics ©

Code	Budget Group	Code	Pharmacological group	Medicine item description	Individual item code							EDL Code		
4	Endocrines	08	Anti-diabetic agents (Oral)	Glibenclamide 5mg tabs	4	0	8	0	0	1	1	A	1	0
				Gliclazide 80mg tabs, 28	4	0	8	0	3	7	1	A	1	0
				Gliclazide 80mg tabs, 56	4	0	8	0	3	8	1	A	1	0
				Metformin 850mg tabs, 28	4	0	8	0	4	9	1	A	1	0
				Metformin 850mg tabs, 56	4	0	8	0	5	0	1	A	1	0
				Tolbutamide 200mg tabs	4	0	8	0	6	0	1	A	1	0
		09	Anti-hypoglycaemic agents	**Not issued in PHC**										
		10	Diagnostic agents	**See imunologicals**										
		11	Oxytoxins and other obstetric drugs	Oxytocin inj 10 iu	4	1	1	0	4	9	1	G	0	3
		12	Thyriod and Parathyroid preparations	Carbimazole 5mg tabs	4	1	2	0	0	1	1	H	0	3
		13	Hormones (others)	**Not issued in PHC**										
		14	Corticosteroids for systemic use (oral / injections)	Hydrocortisone sodium succ 100mg inj	4	1	4	1	3	6	1	H	0	2
		15	Hormone inhibitors and cytostatics	**Not issued in PHC**										
		99	Special requests / referrals											
5	Functional	01	Anti-epileptics	Carbamazepine tabs, 200mg, 28	5	0	1	0	0	5	1	N	0	3
				Carbamazepine tabs, 200mg, 56	5	0	1	0	0	1	1	N	0	3
				Carbamazepine tabs, 200mg, 84	5	0	1	0	0	2	1	N	0	3
				Carbamazepine CR tabs, 200mg, 30	5	0	1	0	0	7	1	N	0	3
				Carbamazepine tabs, 400mg, 28	5	0	1	0	0	8	1	N	0	3
				Carbamazepine tabs, 400mg, 30	5	0	1	0	1	9	1	N	0	3
				Carbamazepine syr 100mg / 5ml	5	0	1	0	2	0	1	N	0	3

APPENDIX B 1: Therapeutic budget model for public primary health care clinics ©

Code	Budget Group	Code	Pharmacological group	Medicine item description	Individual item code							EDL Code		
5	Functional	01	Anti-epileptics	Phenobarbitol tabs 30 mg, 28	5	0	1	1	5	1	1	N	0	3
				Phenobarbitol tabs 30 mg, 56	5	0	1	1	5	2	1	N	0	3
				Phenobarbitol tabs 30 mg, 84	5	0	1	1	5	3	1	N	0	3
				Phenobarbitol tabs 60 mg, 28	5	0	1	1	5	9	1	N	0	3
				Phenytion infants chew tabs, 50mg, 28	5	0	1	1	8	3	1	N	0	3
				Phenytoin sodium caps 100mg, 28	5	0	1	1	1	8	1	N	0	3
				Phenytoin sodium caps 100mg, 84	5	0	1	1	8	9	1	N	0	3
				Valporate sodium tabs, 200mg, 28	5	0	1	2	1	7	1	N	0	3
				Valporate sodium tabs, 500mg, 28	5	0	1	2	2	3	1	N	0	3
				Valporate sodium liq, 200mg / 5ml, 28	5	0	1	2	2	9	1	N	0	3
				Valporate acid tabs, 150mg, 28	5	0	1	3	5	1	1	N	0	3
				Valporate acid tabs, 300mg, 28	5	0	1	2	4	1	1	N	0	3
				Valporate acid tabs, 500mg, 28	5	0	1	2	4	7	1	N	0	3
		02	Anti-parkinson's	Bromocriptine 2.5mg tabs	5	0	2	0	0	1	1	N	0	4
		03	Anti-allergics & anaphylaxis	Adrenaline 1:1000ml	5	0	3	0	9	7	1	R	0	3
				Atropine sulphate inj	5	0	3	0	4	3	1	R	0	6
				Chlorphenaramine tablets 4mg	5	0	3	0	4	3	1	R	0	6
				Chlorpheneramime syr 2mg / 5ml, 50ml	5	0	3	0	5	5	1	R	0	6
				Promethazine 50mg / 2ml inj	5	0	3	1	5	1	1	R	0	6
				Promethazine 25mg / ml	5	0	3	1	4	5	1	R	0	6
				Atropine sulphate 0.5mg inj	5	0	3	0	1	9	1	R	0	6

APPENDIX B 1: Therapeutic budget model for public primary health care clinics ©

Code	Budget Group	Code	Pharmacological group	Medicine item description	Individual item code							EDL Code		
5	Functional	04	Psychotropic disorders	Not issued in PHC										
		05	Pshycotic disorders	Chlorpromazine 25mg tablets, 28's	5	0	5	0	0	1	1	N	0	3
				Haloperidol inj 5mg / ml, 1	5	0	5	1	3	9	1	N	0	5
		06	Mood disorders	Fluoxetine caps, 20mg, 10	5	0	6	1	0	0	1	N	0	6
		07	Hypnotics / sedatives	Diazepam 10mg / 2ml inj, 1	5	0	7	0	6	1	1	N	0	5
		08	Anaesthetics (Parenteral)	Not issued in PHC										
		09	Muscle relaxants (Centrally & peripherally acting)	Not issued in PHC										
		10	Anti-alcoholism drugs	Not issued in PHC										
		11	Anti-migraine agents	Not issued in PHC										
		12	Others	Not issued in PHC										
		99	Special requests / referrals											
6	Gastrolytes	01	Anti-effectives	See anti-infectives (oral / injections)										
		02	Anti-helmenthics	Mebendazole tabs 100mg	6	0	2	0	1	3	1	P	0	2
				Mebendazole susp 30ml, 100mg / 5ml	6	0	2	0	1	9	1	P	0	2
				Piperazine citrate liq, 27ml	6	0	2	0	3	1	1	P	0	2
				Niclosamide 500mg tabs, 4	6	0	2	0	2	5	1	P	0	2
		03	Anti-schisosomals	Praziquantel 600mg tabs	6	0	3	0	0	1	1	P	0	2
		04	Anti-effectives	See anti-infectives (oral / injections)										
		05	Anti-fungal	See uro-genital drugs (oral)										
		06	Antacids / anti-ulcers	Alhudrox 250mg & mag-trisil 500mg tab 30	6	0	6	0	5	8	1	A	0	2

APPENDIX B 1: Therapeutic budget model for public primary health care clinics ©

Code	Budget Group	Code	Pharmacological group	Medicine item description	Individual item code							EDL Code		
6	Gastrolytes	06	Antacids / anti-ulcers	Magnesium trisilicate co susp, 200ml	6	0	6	1	5	1	1	A	0	2
		07	Anti-emetic	Metaclorpromide 10mg / 2ml	6	0	7	0	4	9	1	A	0	4
		08	Anti-haemmorrhoidal	Bismuth subgallate co ointment	6	0	8	0	0	1	1	C	0	5
		09	Cathartic drugs / laxatives	Magnesium sulphate inj 50%	6	0	9	0	2	2	1	A	0	6
		10	Anti-diarrhoea & ulcerative coltis	ORS "Sorol" 26g	6	1	0	0	0	1	1	A	0	7
		11	Anti-spasmodics & anti- cholinergics	**Not issued in PHC**										
		12	Constipation, digestants, liver & bile preparations	Liquid parrafin, 200ml	6	1	2	0	5	5	1	A	0	6
				Sennosides A & B tabs, 7.5mg, 28	6	1	2	1	2	2	1	A	0	6
		13	Anti-obesity agents	**Not issued in PHC**										
		14	Mouthwash & throat preparations	**Not issued in PHC**										
		15	Electrolyte and acid base disturbances (Oral)	**See anti-diarrhoea**										
		16	Electrolyte and acid base disturbances (Parenteral)	Glucose 5% + Sodium Chloride 0.9%, 100ml	6	1	6	1	1	5	1	B	0	5
				Glucose inj 5%, 1000ml	6	1	6	0	1	9	1	B	0	5
				Glucose inj 10%, 1000ml	6	1	6	0	2	5	1	B	0	5
				Glucose inj 50% hypertonic, 50ml, 1	6	1	6	0	0	1	1	B	0	5
				½ strength Darrows & glucose 500ml	6	1	6	1	5	7	1	A	0	7
				NaCl 0.9% isotonic inj, 1000ml	6	1	6	0	7	9	1	A	1	2
				Water for injection, 10ml	6	1	6	4	3	3	1	A	1	2
				Sodium lactate co sol (Ringers lactate) 100ml	6	1	6	1	9	9	1	B	0	5
		17	Drugs affecting the blood	**See cardio-vascular drugs**										
		18	Vitamins & minerals	Nicotinamide tabs, 100mg, 84	6	1	8	0	9	0	1	A	1	1

APPENDIX B 1: Therapeutic budget model for public primary health care clinics ©

Code	Budget Group	Code	Pharmacological group	Medicine item description	Individual item code							EDL Code		
6	Gastrolytes	18	Vitamins & minerals	Pyridoxine HCL tabs 25mg ,28 (Vit B6)	6	1	8	1	3	1	1	A	1	1
				Retinol palmitate tabs 50,000 IU (Vit A)	6	1	8	1	5	1	1	A	1	1
				Thiamine HCL tabs 100mg (Vit B1),28	6	1	8	1	9	3	1	A	1	1
				Vitamin B complex tabs 28	6	1	8	2	1	1	1	A	1	1
				Vitamin C 100mg tabs, 28	6	1	8	2	4	1	1	A	1	1
				Calcium gluconate tabs 300mg, 84	6	1	8	0	5	0	1	A	1	1
				Multi-vitamin syrup 100ml	6	1	8	1	0	9	1	A	1	1
				Multi-vitamin tabs, 28	6	1	8	1	1	5	1	A	1	1
		19	Feeding and nutritional suplements (oral)	PVM maize meal mix 1kg	6	1	9	1	0	2	1	A	1	3
				Feeding milk powder, 500g, 1's	6	1	9	1	0	1	1	A	1	3
		20	Feeding and nutritional suplements (Parenteral)	**Not issued in PHC**										
		21	Enzymes & other agents	**Not issued in PHC**										
		22	Special requests/ referrals											
7	Pain relievers	01	Anaesthetics (local)	Lidocaine HCL inj 1%	7	0	1	0	7	9	1	N	0	1
				Lidocaine HCL inj 2%	7	0	1	0	8	5	1	N	0	1
		02	Anaesthetics (general)	**Not issued in PHC**										
		03	Analgesics, non opoids including NSAIDS, gold & anti-gout preparations.	Asprin soluble tabs 300mg, 14	7	0	3	0	2	0	1	N	0	2
				Colchicine 1mg tabs, 20	7	0	3	0	4	9	1	M	0	4
				Ibuprofen 200mg tabs, 14	7	0	3	1	2	1	1	N	0	2
				Ibuprofen 200mg tabs, 14	7	0	3	1	2	1	1	N	0	2
				Paracetamol 500mg tab, 10	7	0	3	2	0	5	1	N	0	2

APPENDIX B 1: Therapeutic budget model for public primary health care clinics ©

Code	Budget Group	Code	Pharmacological group	Medicine item description	Individual item code							EDL Code		
7	Pain relievers	03	Analgesics, non opoids including NSAIDS, gold & anti-gout preparations.	Paracetamol syrup 120mg / 5ml, 50ml	7	0	3	2	1	1	1	N	0	2
				Methylsalycilate ointment, 25g	7	0	3	2	5	9	1	N	0	2
		04	Anti-inflamatory (Corticosteroids)	See dermatologicals										
		05	Analgesics (opoids) / narcotic analgesics	Codeine phosphate tabs 30mg	7	0	5	0	0	1	1	N	0	2
				Codeine phosphate syrup 25mg /5ml	7	0	5	0	0	2	1	N	0	2
				Morphine sulphate inj,10mg	7	0	5	0	0	3	1	N	0	2
				Morphine oral solution 20mg /ml	7	0	5	0	0	4	1	N	0	2
				Morphine sulphate CR 10mg tab	7	0	5	0	0	5	1	N	0	2
				Pethidine HCL inj 25mg /ml	7	0	5	0	0	6	1	N	0	2
		06	Sedatives, hypnotics and mood disorders	See functional, psychotic drugs & mood disorders										
		07	Anti-malaria	Quinine sulphate 300mg tabs, 24	7	0	7	0	7	3	1	P	0	1
		08	Anti-migraine agents	Not issued in PHC										
		99	Special requests/ referrals											
8	Immunologicals	01	Sera & immunologicals	Anti-D- Immunoglobin inj 100mcg / 2ml	8	0	1	0	4	3	1	J	0	6
				Rabies immunoglobin 150 IU /ml (RIG)	8	0	1	0	5	0	1	J	0	6
				Anti-tetanus immunoglobin inj 250 IU / 2ml (TIG)	8	0	1	0	6	0	1	J	0	6
				Polyval anti-venom serum inj	8	0	1	0	7	0	1	J	0	6
		02	Vaccines	BCG (dried) vaccine inj, 20 doses	8	0	2	0	0	1	1	J	0	7
				Diptheria-pertusis-tetanus (DPT) vaccine inj, 20 dose	8	0	2	0	1	3	1	J	0	7
				Diptheria-tetanus vaccine inj 20 dose	8	0	2	0	1	9	1	J	0	7
				Hepatitis-B vaccine inj 1.5ug /0.5ml, 5ml	8	0	2	0	3	7	1	J	0	7

APPENDIX B 1: Therapeutic budget model for public primary health care clinics ©

Code	Budget Group	Code	Pharmacological group	Medicine item description	Individual item code							EDL Code		
8	Immunologicals	02	Vaccines	Measles vaccine inj 10 dose	8	0	2	0	7	0	1	J	0	7
				Poliomyelitis vaccine oral sol (OPV) 10 dose	8	0	2	1	3	3	1	J	0	7
				Tetanus vaccine inj, 20 dose (TT)	8	0	2	1	6	9	1	J	0	7
				Rabies vaccine inj	8	0	2	0	3	5	1	J	0	7
				Haemophilius influenzae conj- vaccine 10 dose	8	0	2	0	3	1	1	J	0	7
		03	Immuno-suppresants	**Not issued in PHC**										
		04	Diagnostic agents	"pregnancy test, 25	8	0	4	0	8	5	1	V	0	3
				Glucose-blood test	8	0	4	1	0	9	1	V	0	3
				"Rapid test"	8	0	4	1	8	3	1	V	0	3
		05	Diagnostic agents (Radiology)	**Not issued in PHC**										
		06	Antidotes (General)	Activated charcoal powder 100g	8	0	6	0	0	1	1	V	0	3
		07	Antidotes (Specific)	**Not issued in PHC**										
		99	Special requests / referrals											
9	Respiratory agents	01	Anti-asthmatic & mucolytic	Aminophylline 250mg /10ml inj	9	0	1	0	0	1	1	R	0	3
				Beclomethasone 100ug inhaler, 300dose	9	0	1	0	5	5	1	R	0	3
				Ipratropium bromide UDV 0.25ug / actuation inhaler	9	0	1	2	5	9	1	R	0	3
				Salbutamol sulphate inhaler 100ug /actuation, 300 dose	9	0	1	3	0	1	1	R	0	3
				Salbutamol respirator solution 100ug /20ml	9	0	1	3	0	2	1	R	0	3
				Theophylline sustained release tab 200mg, 28	9	0	1	4	4	5	1	R	0	3
				Theophylline sustained release tab 200mg, 56	9	0	1	4	4	6	1	R	0	3
				Theophylline sustained release tab 300mg, 28	9	0	1	4	5	9	1	R	0	3

APPENDIX B 1: Therapeutic budget model for public primary health care clinics ©

Code	Budget Group	Code	Pharmacological group	Medicine item description	Individual item code							EDL Code		
9	Respiratory agents	01	Anti-asthmatic & mucolytic	Theophylline sustained release tab 300mg, 56	9	0	1	4	5	7	1	R	0	3
				Adrenaline 1mg /ml inj, 1	9	0	1	2	5	1	1	R	0	3
		02	Cough mixtures	Mist Expectorant stim (Simple linctus), 200ml	9	0	2	0	1	9	1	R	0	5
				Mist Tussi infants, 100ml	9	0	2	0	3	1	1	R	0	5
		03	Anti-tuberculosis	Ethambutol tabs, 400mg, 100	9	0	3	0	0	7	1	J	0	4
				Isoniazid tablet 100mg	9	0	3	0	5	1	1	J	0	4
				Rifampicin 120mg / INH60mg / PZA 300mg / Ethambutol 200mg tabs - "Rifafour", 100	9	0	3	1	2	5	1	J	0	4
				Rifampicin 150/ INH 100mg tabs, 20	9	0	3	1	1	5	1	J	0	4
				Rifampicin 300/ INH 150mg tabs, 20	9	0	3	1	2	1	1	J	0	4
				Streptomycin sulphate 1g /3ml inj, 1	9	0	3	1	3	0	1	J	0	4
				Rifampicin 60mg / INH 30 mg, 4	9	0	3	1	2	2	1	J	0	4
				Rifampicin 60mg / INH 30mg /PZA 150mg tabs, 80	9	0	3	1	2	7	1	J	0	4
				Rifampicin/ INH/ PZA + Ethambutol "Myrin plus" ,100	9	0	3	1	2	3	1	J	0	4
				Rifampicin 60mg / INH 60mg,100	9	0	3	1	3	5	1	J	0	4
				Rifampicin syrup 100mg /5ml , 180ml	9	0	3	0	9	1	1	J	0	4
				Rifampicin cap / tab 600mg, 100	9	0	3	0	8	5	1	J	0	4
		04	Decongestants (Cold/ flu)	Oxymetazoline nose drops 0.025%	9	0	4	0	1	0	1	R	0	1
		05	Other respiratories	Not issued in PHC										
		99	Special requests / referrals											
10	Uro-genital drugs	01	Anti-effective, anti bacterials & others	See anti-effectives oral /inj										
		02	Anti-fungal	Clotrimazole vaginal tab 500mg	10	0	2	0	0	7	1	G	0	1

APPENDIX B 1: Therapeutic budget model for public primary health care clinics ©

Code	Budget Group	Code	Pharmacological group	Medicine item description	Individual item code							EDL Code		
10	Uro-genital drugs	02	Anti-fungal	Micanazole vaginal cream, 40g	10	0	2	0	6	8	1	G	0	1
		03	Diuretics	See antihypertensives										
		04	Urinary alkalizers & ion-exchange preparations	Not issued in PHC										
		05	Urinary antiseptics	Not issued in PHC										
		06	Other urinary agents	Not issued in PHC										
		99	Special requests / referrals											

APPENDIX B 2: CODES USED FOR MODEL

Code for diagnosis (ICD-10)

CODE	DIAGNOSIS	CODE	DIAGNOSIS	CODE	DIAGNOSIS	CODE	DIAGNOSIS
A03.9	Bacillary dysentery	DT1	Diagnostic test	J30.4	Allergic rhinitis	N92.0	Vaginal bleeding
A06.0	Amoebiasis	E10	Insulin dependant diabetes	J45	Asthma	N94.6	Dysmenorhoea
A09	Diarrhoea	E11	Non Insulin dependant diabetes	K04.7	Dental abscess	O99.0	Antenatal care
A16.9	Tuberculosis	E56.9	Vitamin deficiency	K30.0	Heartburn / Dyspepsia	O99.1	Pregnancy test
A50.0	STD suspicion	E57.9	Mineral deficiency	K59.0	Constipation	R05	Cough
A54.9	Vaginal discharge	E87.4	Acid-base balance	K60.2	Anal fissures	R11	Nausea
A63.0	Genital warts	G40.9	Epileptic	K90.0	Teething	R50.9	Fever
A90.0	Syphilis	GC1	General check-up	K92.0	Toothache	R51	Headache
B00.2	Herpes / Cold sores	H10.1	Conjunctivitis	L02.9	Boils/Impetigo	R52.9	Pain control
B01.9	Chicken pox	H60.9	Otitis externa	L 20.9	Eczema (moist)	R57.9	Shock
G03.9	Meningitis	H66.9	Otitis media	L21.9	Sebhorric eczema	R62.8	Malnutrition
B29.9	Mumps	I 10	Hypertension	L22	Nappy rash	T14.1	Insects bites
B35	Fungal skin infection	I 21.9	Myocardial infarction	L29.9	Pruritis	T30.0	Burn wounds
B35.9	Ringworm	I 84.9	Haemorrhoids	L40.9	Psoriasis	UD1	Unknown diagnosis
B37.0	Candidiasis	J01.9	Sinusitis	L50.9	Urticaria	Z26.9	Immunisation
B82.0	All worms / except Tape worm	J03	Tonsillitis (viral)	L70.0	Acne	Z30.0	Family planning
B35.9	Lice	J03.9	Tonsillitis (bacterial)	M11	Backache		
B35.9	Scabies	J11.1	Cold / influenza	M19.9	Arthritis		
D50.9	Anaemia	J20.9	Bronchitis	N39.0	Urinary tract infection		

APPENDIX B 2: CODES USED FOR MODEL

Codes for budget group

Code	Budget group
1	Anti-effectives
2	Cardiovascular agents
3	Dermatologicals
4	Endocrine
5	Functional
6	Gastro-intestinals
7	Pain relievers
8	Immunologicals
9	Respiratory agents
10	Uro-genital

APPENDIX B 2: CODES USED FOR MODEL

Code for pharmacological group

CODE	Pharmacological group	CODE	Pharmacological group	CODE	Pharmacological group
101	Antibacterial (Penicillin's)	406	Hormones, androgens and progesterones	703	Analgesics (non opoids) and NSAIDS
102	Anti-effectives (amino glycosides)	407	Anti diabetic agents	802	Vaccines
104	Antibacterials (Chloramphenicol & erythromicins)	408	Oral anti diabetic agents	804	Diagnostic agents
110	Antifungal oral / injections	414	Corticosteroids for systemic use	901	Anti-asthmatic and mucolytics
201	Antianginal	501	Anti-epileptics	902	Cough mixtures
202	Antihypertensives	503	Anti allergic (for anaphylaxis)	903	Antimycobacterials
203	Congestive heart failure drugs	505	Psychotic disorders	1002	Antifungals
205	Drugs affecting blood	602	Anti-helmenthics		
301	Antifungal (topical)	606	Antacids / antiulcer		
302	Antiseptics / dermatological disinfectants	607	Anti emetics		
303	Antipruritics	608	Anti-hemorrhoidals		
305	Scabicides and Pedicullocides	609	Cathartic drugs / laxatives		
306	Other ointments, creams and emollients	612	Constipation drugs and digestants		
309	Anti-effective eye preparations	615	Oral electrolytes and anti acid base disturbance agents		
311	Anti allergic eye preparations	614	Mouth wash and throat preparations		
315	Other ear and nose preparations	616	Parenteral electrolytes and anti acid base disturbance agents		
404	Contraceptives (injectables)	618	Vitamins and minerals		
405	Oral contraceptives	619	Feeding and nutritional supplements		

APPENDIX B 2: CODES USED FOR MODEL

Codes for individual medicine item description

CODE	Individual medicine description	CODE	Individual medicine description	CODE	Individual medicine description	CODE	Individual medicine description
1010071	Amoxycillin 250mg capsules 15's	**1100681**	**See 10020681**	**2050551**	Ferrous gluconate syrup 100ml	**4050431**	Triphasil tablets 28's
1010311	Amoxycillin Suspension 125mg / 5ml	**1101511**	Griseofulvin 500mg tablets 28's	**2050671**	Folic acid 5mg tablets 28's	**4050491**	Ovral tablets 28's
1010801	Penicillin VK Suspension 125mg / 5ml	**2010011**	Glyceryltrinaitrate 0.5mg sublingual tablets, 50's	**3010011**	Benzoic acid ointment 25g	**4141361**	Prednisone 5mg tablets 28's
1010811	Penicillin VK Suspension 250mg / 5ml	**2020551**	Atenelol 50mg tablets 28's	**3010131**	Clotrimazole 1% cream 20g	**5010011**	Carbamazepine 200mg tablets 56's
1010821	Penicillin VK Tablets 250mg 20's	**2021871**	Enalapril 5mg tablets 28's	**3010431**	Gentian violet 0.5% 20ml	**5010021**	Carbamazepine 200mg tablets 84's
1011991	Benzathine Penicillin 2.4 MU injection	**2021931**	Enalapril 10mg tablets 28's	**3010671**	Micanazole oral gel 30g	**5010051**	Carbamazepine 200mg tablets 28's
1012531	Flucloxacillin suspension 125mg / 5ml	**2022351**	Hydrochlorthiazide 25mg tablets 14's	**3010731**	Nystatin ointment 15g	**5011531**	Phenobarbitone 30mg tablets 84's
1012591	Flucloxacillin 250mg capsules 20's	**2022361**	Hydrochlorthiazide 25mg tablets 28's	**3022171**	Povidone iodine ointment 25g	**5011871**	Phenytoin 100mg tablets 28,s
1014041	Ciprofloxacin 500mg tablets 10's	**2023191**	Methyldopa 250mg tablets 28's	**3030731**	Calamine lotion 100ml	**5012171**	Sodium valporate 200mg tablets 28's
1041091	Cotrimoxazole 400 / 80mg tablets 20's	**2023201**	Methyldopa 250mg tablets 56's	**3031451**	Hydrocortisone 1% cream 25g	**5012231**	Sodium valporate 500mg tablets 28's
1041151	Cotrimoxazole 200 / 40mg / 5ml suspension	**2023211**	Methyldopa 250mg tablets 84's	**3050251**	Monosulfiram soap 5% 75g	**5031451**	Promethazine25mg / 2ml injection
1041461	Doxycycline 100mg capsules 14's	**2023751**	Nifedipine 5mg tablets 100's	**3061011**	Methylsalicylate ointment 25g	**6080011**	Bismuth subgallate ointment
1041471	Doxycycline 100mg capsules 20's	**2023971**	Nifedipine 30mg XL capsule 30's	**3061101**	Aqueous cream	**6090231**	Sennoside 7.5mg A& B tablets, 28's
1041481	Doxycycline 100mg capsules 30's	**2024001**	Indapamide tablets 28's	**3061331**	Zinc & castor oil ointment 25g	**6181091**	Multivitamin syrup 100ml
1041511	Erythromycin 250mg capsules 20's	**2024331**	Perindropil 4mg tablets 28's	**3090131**	Chloramphenicol ophthalmic ointment	**6181151**	Multivitamin tablets 28's
1041531	Erythromycin 250 mg capsules 56's	**2025351**	Reserpine 0.25mg tablets 14's	**3110011**	Antazoline & tetrazoline eye drops 5ml	**6181311**	Pyridoxine 25mg tablets 28's
1041691	Erythromycin suspension 125mg / 5ml	**2031001**	Digoxin 0.25mg tablets 28's	**3151031**	Sodium chloride 0.9% nasal drops	**6181931**	Thiamine HCL 100mg tablets 28's
1042311	Metronidazole 200mg tablets 28's	**2031081**	Furosemide 40mg tablets 28's	**3151091**	Oxymethazoline 0.025% nasal drops	**6182111**	Vitamin B complex tablets 28's
1042411	Metronidazole 200mg / 5ml suspension	**2031091**	Potassium chloride 600mg tablets 28's	**4040271**	Norethisterone enath 200mg injection	**6182411**	Vitamin C 100mg tablets 28's
1100601	Nystatin ointment 15g	**2031641**	Potassium chloride 600mg tablets 84's	**4040971**	Medroxyprogesterone 150mg injection	**6191011**	Feeding milk 500g
1100611	Nystatin suspension 20ml	**2050431**	Ferrous sulphate tablets 28's	**4050311**	Microval tablets 28's	**6191021**	PVM maize meal mix 1kg

APPENDIX B 2: CODES USED FOR MODEL

Codes for individual medicine item description

CODE	Individual medicine description	CODE	Individual medicine description	CODE	Individual medicine description	CODE	Individual medicine description
7030201	Asprin Soluble tablets 300mg	**9020311**	Mist tussi infant 100ml				
7031211	Ibuprofen 200mg tablets	**9020351**	Mist expectorant stim 200ml				
7032051	Paracetamol 500mg tablets	**9030071**	Ethambutol HCL 400mg tablets, 100's				
7032111	Paracetamol 120mg / 5ml syrup 50ml	**9031211**	Rifampicin 300/ 150 INH tablets 20's				
8020011	BCG vaccine injection 20 dose	**9031221**	Rifampicin 60mg INH 30 mg tablets 4's				
8020131	DPT vaccine injection 20dose	**9031251**	HRZ-E-200 tablets 100,s				
8020191	DT vaccine injection 20 dose	**9031261**	HREZ-Myrin plus tablets,100's				
8020371	Hepatitis B vaccine injection 10 dose	**9031271**	Rifampicin 60mg / INH 30mg PZA150mg tablets 80's				
8020701	Measles vaccine 10 dose	**9031301**	Streptomycin1g / 3ml injection				
8021331	Poliomyelitis vaccine oral solution 10 dose	**10020071**	Cotrimazole vaginal tablets 500mg 1's				
8021691	Tetanus vaccine injection 20 dose	**10020681**	Micanazole vaginal cream 40g				
8023311	Heamophillius influenzae conjunct vaccine 10 dose						
8040851	Pregnancy test kit						
9010551	Beclamethasone inhaler 100ug 300 dose						
9011011	Aminophylline 250mg / 10ml injection						
9013011	Salbutamol sulphate inhaler 100ug / dose 300dose						
9013311	Salbutamol nebule 5mg / 2.5ml						
9014451	Theophylline sustained release tablet 200mg 28's						
9014461	Theophylline sustained release tablet 200mg 56's						
9014591	Theophylline sustained release tablet 300mg 28's						
1100611	Nystatin suspension 20ml						

APPENDIX B 2: CODES USED FOR MODEL

Anatomical Therapeutic Chemical class (ATC) codes

CODE	Class description	CODE	Class description
A01	Stomatological preparations	G01	Gyenacological anti-infectives and antiseptics
A02	Antacids, drugs for treatment of peptic ulcer and flatulence	G03	Sex hormones and modulators of the genital system
A03	Antispasmodic and anticholinergic agents	H02	Corticosteroids fpr systemic use
A04	Antiemetics and antinauseants	J01	Antibacterials for systemic use
A06	Laxatives	J04	Antimycobacterials
A07	Antidiarrhoeals	J06	Immune sera and immunoglobins
A09	Digestives, including enzymes	J07	Vaccines
A10	Oral hypoglycemics	M01	Anti-inflammatory and anti-rheumatic agents
A11	Vitamins	M02	Topical products for joint and muscular pain
A12	Mineral supplements	N02	Analgesics
A13	Food supplements	N03	Anti-epileptics
B03	Antianaemic preparations	N05	Psycholeptics
B05	Plasma substitutes and perfusion solutions	N06	Psychoanaleptics
C01	Cardiac therapy	P01	Anti-protozoals
C02	Antihypertensives	P02	Anthelmentics
C03	Diuretics	P03	Ectoparasiticides, including scabicides
C05	Vasoprotectives	R01	Nasal preparations
C07	Beta blocking agents	R03	Antiastmatic agents
D01	Antifungals for dermatological use	R05	Cough and cold preparations
D02	Emollients and protectants	R06	Antihistamines for systemic use
D04	Antipruritics and topical anaesthetics	S01	Opthalmologicals
D07	Corticosteroids for dermatological use	S02	Otologicals
D08	Antiseptics and disinfectants	V03	All other therapeutic products
D10	Anti-acne preparations		

APPENDIX C: ABSTRACT OF PAPERS PRESENTED

Appendix C 1

Abstract of podium presentation [International invited speaker] in the plenary session (scientific) of the 55th Indian Pharmaceutical Congress (IPC), held in Chennai, India from the 19th-21st of December 2003.

THERAPEUTIC BUDGET MODELING: AN ACCURATE ROAD TO BUDGETARY ALLOCATIONS IN THE PUBLIC HEALTH CARE SETTING.

George K John*, Martie S Lubbe* and Jan HP Serfontein*

*Pharmacy Practice, School of Pharmacy, Faculty of Health Sciences, Potchefstroom University, Potchefstroom, South Africa.

(E-mail:fptgkj@puknet.puk.ac.za, Tel: +27-18-299 4290, Fax: +27-18-299 4244).

In South Africa in the health sector, 80% of the countries population are dependent on the public health care sector for their health care needs. The primary health care structure was established as a solution to the above, with the view of providing a level of basic care for all. The objective of the study was to analyse the cost related perspectives for the formulation of a therapeutic budget model, for use as a planning and control instrument in the usage of medicines at a primary care level in the public sector. Data utilised in this study were obtained from patient records of six local authorities primary health care clinics [N=1313] in Potchefstroom over a 24-day period.

The average cost of medicines per consultation was R7.02 ± 9.52 [N=R19669.50] for all medicines (including diagnosis for which medicines was not supplied) and R 8.25 ± 10.97 [N=R13672.86] excluding antimycobacterials. Due to the nature of treatment of tuberculosis by the DOT system the prevalence and average cost of antimycobacterials were separately analysed.

The average cost per medicine item was R 4.19 ± 3.85 [N=4691] for all medicines [N=R19669.50] and R4.59 ± 5.33 [N=2978] excluding antimycobacterials [N=R13672.86]. The budget and pharmacological groups which were having an average cost of treatment and prevalence of ≥10% constituted 70.79% and 43.62% of the total medicines used (excluding antimycobacterials) [N=2978] and 71.33% and 31.88% of the cost [N=R13672.86], respectively, of medicines issued to patients in the clinics.

From the study it was projected that for all the six clinics in Potchefstroom an amount of R2, 607,357.28 was needed for optimal functioning and management of the clinics. This amount was 231.23% more than the actual annual budget allocation of R1, 127,607.00, in variance.

It is thus foreseen that the compiling of a therapeutic budget modeling system can significantly help the public sector to prepare and plan budgetary policies for better formulary and resource management, as the preliminary reports are promising.

APPENDIX C: ABSTRACT OF PAPERS PRESENTED

Appendix C 2

Abstract of podium presentation in the scientific session at the 17th South African Association of Hospital and Institutional Pharmacist (SAAHIP) annual conference held at Drakensburg, South Africa from 6th - 9th of March 2003.

A PHARMACOECONOMIC INTROSPECTION OF MEDICINE COSTS IN PUBLIC PRIMARY HEALTH CARE CLINICS

john gk*,lubbe ms* and serfontein jhp*

*Pharmacy Practice, School of Pharmacy, Faculty of Health Sciences, PU for CHE, Potchefstroom, South Africa, 2520.

(e-mail:fptgkj@puknet.puk.ac.za , Tel: 018-299 4290, Fax: 018-299 4244).

SAAHIP membership number: 20738 (PSSA)

The objective of the study was to analyse the cost related perspectives for the formulation of a therapeutic budget model, for use as a planning and control instrument in the usage of medicines at a primary care level in the public sector. Data utilised in this study were obtained from patient records of six local authorities primary health care clinics [N=1313] in Potchefstroom over a 24-day period.

The average cost of medicines per consultation was R7.02 ± 9.52 [N=R19669.50] for all medicines (including diagnosis for which medicines was not supplied) and R 8.25 ± 10.97 [N=R13672.86] excluding antimycobacterials. Due to the nature of treatment of tuberculosis by the DOT system the prevalence and average cost of antimycobacterials were separately analysed.

The average cost per medicine item was R 4.19 ± 3.85 [N=4691] for all medicines [N=R19669.50] and R4.59 ± 5.33 [N=2978] excluding antimycobacterials [N=R13672.86]. The budget and pharmacological groups which were having an average cost of treatment and prevalence of ≥10% constituted 70.79% and 43.62% of the total medicines used (excluding antimycobacterials) [N=2978] and 71.33% and 31.88% of the cost [N=R13672.86], respectively, of medicines issued to patients in the clinics.

From the study it was projected that for all the six clinics in Potchefstroom an amount of R2, 607,357.28 was needed for optimal functioning and management of the clinics. This amount was 231.23% more than the actual annual budget allocation of R1, 127,607.00, in variance.

It is thus foreseen that the compiling of a therapeutic budget modeling system can significantly help the public sector to prepare and plan budgetary policies for better formulary and resource management, as the preliminary reports are promising.

APPENDIX C: ABSTRACT OF PAPERS PRESENTED

Appendix C 3

Abstract of poster presentation in the scientific session at the 17th South African Association of Hospital and Institutional Pharmacist (SAAHIP) annual conference held at Drakensburg, South Africa from 6th - 9th of March 2003.

MEDICINE USAGE PATTERNS IN PUBLIC PRIMARY HEALTH CARE CLINICS

john gk*,lubbe ms*and serfontein jhp*

*Pharmacy Practice, School of Pharmacy, Faculty of Health Sciences, PU for CHE, Potchefstroom, South Africa, 2520.

(e-mail:fptgkj@puknet.puk.ac.za , Tel: 018-299 4290, Fax:018 299 4244).

SAAHIP membership number: 20738 (PSSA)

The objective of this study was to present the usage patterns of medicines at a primary health care level in the public sector. The results were then used as a planning and control instrument for the usage of medicines in regards to demand-procurement and inventory controls strategies.

The WHO model for investigating medicine use in health facilities was adopted as the model for this study. A retrospective sample of 1313 patients visiting six local authority primary health care clinics in Potchefstroom was selected. The medicines used by these patients were coded using the proposed medicine budget group, pharmacological groups, individual item descriptions and the ATC classification system.

The interpretation of the results showed that the overall gender frequency was 26.47% males and 73.53% females, the five most prevalent diagnosis / conditions excluding tuberculosis were family planning (15.72%), hypertension (11.94%), vitamin deficiency (9.77%), pain control (9.62%) and malnutrition / lactation regulation (8.32%) and the five most prevalent medicine items used for all consultations excluding antimycobacterials were Pyridoxine [Vit.B_6] 5mg tablet (7.02%), Vitamin B complex tablet (6.25%), Hydrochlorthiazide 25mg tablet (5.95%), Paracetamol 500mg tablet (5.44%) and PVM Maize meal mix [1kg] (5.11%).

It was concluded there could be an overuse and tendency to prescribe vitamins and feeding supplements to the patients regardless of the clinical merit, the prevalence and use of antihypertensives in the clinics where high and that the possibility of over prescribing of non-opoid analgesics in the clinics cannot be ruled out.

The implementation of similar studies is encouraged for better report and data management, improved procurement-demand-inventory control strategies and ways to evaluate clinical and operational policies in the public primary health care sector.

APPENDIX C: ABSTRACT OF PAPERS PRESENTED

Appendix C 4

Abstract of podium presentation (contender for the Roche Young Scientist of the year award) in the scientific session at the 3rd International Conference on Pharmaceutical and Pharmacological Sciences (ICPPS) held at Johannesburg, South Africa from 22nd - 25th of September 2002.

THE MEDICINE USAGE PATTERNS IN PUBLIC PRIMARY HEALTH CARE CLINICS: PRELIMINARY REPORT

GK John*, MS Lubbe*and JHP Serfontein*
* Pharmacy Practice, School of Pharmacy, Faculty of Health Sciences, PU for CHE, Potchefstroom, South Africa, 2520. (e-mail: fptgkj@puknet.puk.ac.za).

The objective of the study was to analyse the different prevalence and cost related perspectives for the formulation of a therapeutic budget model, to be used as a planning and control instrument for the usage of medicines at a primary care level in the public sector. Data utilised in this study were obtained from patient records of six local authorities primary health care clinics [N=1313] in Potchefstroom over a 24-day period. The medicines were coded using the proposed medicine budget group, pharmacological groups, individual item descriptions and the ATC classification system.
The average cost of medicines per consultation was R7.02 ±9.52 [N=R19669.50] for all medicines (including diagnosis for which medicines was not supplied) and R 8.25 ±10.97 [N=R13672.86] excluding antimycobacterials. Due to the nature of treatment of tuberculosis by the DOT system the prevalence and average cost of antimycobacterials were separately analysed.
The average cost per medicine item was R 4.19 ±3.85 [N=4691] for all medicines [N=R19645.38] and R4.59 ±5.33 [N=2978] excluding antimycobacterials [N=R13672.86]. The most prevalent (≥10%) budget and pharmacological group and the average cost of treatment are listed in the table below. These groups constituted 70.79% and 43.62% of the total medicines used (excluding antimycobacterials) [N=2978] and 71.33% and 31.88% of the cost [N=R13672.86], respectively, of medicines issued to patients in the clinics.

Budget Group (B.G)	Average cost of medicines according to B.G. Rands (R)	Frequency percentage of number of medicines items. (%)	Percentage of total costs of medicines according to B.G.(%)
Vitamins, minerals and nutritional products	4.54 ± 6.07	25.67	25.23
Cardiovascular	6.41 ± 7.81	21.14	29.32
Anti-inflammatory drugs	0.60 ± 0.13	12.02	1.55
Endocrine products	6.02 ± 3.90	11.96	15.23
Pharmacological Group (P.G)	**According to P.G**	**According to P.G**	**According to P.G**
Antihypertensives	16.22 ±14.14	15.83	27.05
Vitamins and minerals	1.31 ± 2.90	15.83	3.28
Non-opoid analgesics including NSAIDS	0.61 ± 0.14	11.96	1.55

It is foreseen that the compiling of a therapeutic budget modeling system can significantly help the public sector to prepare and plan budgetary policies for better formulary and resource management, as the preliminary reports are promising.

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

Appendix 1.1: The frequency of various diagnoses in all clinics and in each clinic

DIAGNOSES IN EACH CLINIC	All clinics		Clinic 1		Clinic 2		Clinic 3		Clinic 4		Clinic 5		Clinic 6	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Bacillary dysentery	4	0.12					1	0.12	3	0.78				
Amoebiasis	2	0.06							1	0.26			1	0.14
Diarrhoea	14	0.42					4	0.50	2	0.52	2	0.42	6	0.83
Tuberculosis	1423	42.39			688	82.89	164	20.45	33	8.55	169	35.50	369	51.11
STD suspicion	15	0.45	1	0.71	2	0.24	5	0.62	4	1.04	3	0.63		
Vaginal discharge	25	0.74	1	0.71			15	1.87	7	1.81	2	0.42		
Genital warts	3	0.09	1	0.71			2	0.25						
Syphillis	8	0.24	1	0.71			4	0.50					3	0.42
Herpes / Cold sores	3	0.09					1	0.12			2	0.42		
Chicken pox	4	0.12											4	0.55
Meningitis	3	0.09			3	0.36								
Mumps	1	0.03											1	0.14
Fungal skin infection	9	0.27	3	2.13			1	0.12	1	0.26	3	0.63	1	0.14
Ringworm	2	0.06					1	0.12			1	0.21		
Candidiasis	15	0.45	2	1.42	1	0.12	8	1.00	1	0.26	0	0.00	3	0.42
All worms / except TW	4	0.12					2	0.25	1	0.26	1	0.21		
Lice	2	0.06					1	0.12			1	0.21		
Scabies	2	0.06					1	0.12			1	0.21		

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.1 CONT'D DIAGNOSES IN EACH CLINIC	All clinics		Clinic 1		Clinic 2		Clinic 3		Clinic 4		Clinic 5		Clinic 6	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Anemia	9	0.27	1	0.71			7	0.87			1	0.21		
Diagnostic test	18	0.54												
Insulin dependant diabetes	7	0.21					2	0.25			4	0.84	1	0.14
Non Insulin dependant diabetes	20	0.60	1	0.71	5	0.60	3	0.37			10	2.10	1	0.14
Vitamin deficiency	189	5.63	2	1.42			149	18.58	29	7.51	9	1.89		
Mineral deficiency	17	0.51	3	2.13			4	0.50	4	1.04	6	1.26		
Acid-base balance	2	0.06					2	0.25						
Epileptic	22	0.66	1	0.71	1	0.12	3	0.37	8	2.07	5	1.05	4	0.55
General check-up	40	1.19	10	7.09	1	0.12	10	1.25	4	1.04	9	1.89	6	0.83
Conjunctivitis	8	0.24	1	0.71			2	0.25	3	0.78	1	0.21	1	0.14
Otitis externa	1	0.03											1	0.14
Otitis media	12	0.36					5	0.62	2	0.52	3	0.63	2	0.28
Hypertension	231	6.88	29	20.57	27	3.25	56	6.98	25	6.48	53	11.13	41	5.68
Myocardial infarction	1	0.03							1	0.26				
Haemorrhoids	3	0.09	1	0.71					1	0.26			1	0.14
Sinusitis	4	0.12					2	0.25	1	0.26			1	0.14
Tonsillitis (viral)	1	0.03							1	0.26				
Tonsillitis (bacterial)	15	0.45					3	0.37	2	0.52	3	0.63	7	0.97
Cold / influenza	8	0.24	1	0.71			1	0.12	2	0.52	1	0.21	3	0.42

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.1 CONT'D DIAGNOSES IN EACH CLINIC	All clinics		Clinic 1		Clinic 2		Clinic 3		Clinic 4		Clinic 5		Clinic 6	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Bronchitis	14	0.42	3	2.13	2	0.24	1	0.12	4	1.04	1	0.21	3	0.42
Allergic rhinitis	7	0.21	3	2.13			2	0.25	2	0.52				
Asthma	13	0.39	1	0.71	2	0.24	3	0.37	1	0.26	4	0.84	2	0.28
Dental abscess	1	0.03									1	0.21		
Heartburn / Dyspepsia	44	1.31	12	8.51	2	0.24	8	1.00	9	2.33	10	2.10	3	0.42
Constipation	3	0.09	1	0.71							1	0.21	1	0.14
Anal fissures	1	0.03									1	0.21		
Teething	1	0.03					1	0.12						
Toothache	1	0.03											1	0.14
Boils / Impetigo	4	0.12	1	0.71			1	0.12	1	0.26	1	0.21		
Eczema (moist)	4	0.12	1	0.71			1	0.12					2	0.28
Sebhorric eczema	3	0.09	1	0.71							2	0.42		
Nappy rash	10	0.30	1	0.71			2	0.25	2	0.52	2	0.42	3	0.42
Pruritis	8	0.24					1	0.12	3	0.78	2	0.42	2	0.28
Psoriasis	1	0.03											1	0.14
Urticaria	2	0.06							1	0.26			1	0.14
Acne	1	0.03							1	0.26				
Backache	40	1.19					7	0.87	10	2.59	14	2.94	9	1.25
Arthritis	4	0.12							1	0.26	2	0.42	1	0.14

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.1 CONT'D DIAGNOSES IN EACH CLINIC	All clinics		Clinic 1		Clinic 2		Clinic 3		Clinic 4		Clinic 5		Clinic 6	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Urinary tract infection	5	0.15					4	0.50			1	0.21		
Vaginal bleeding	1	0.03									1	0.21		
Dysmenorrhoea	3	0.09					3	0.37						
Antenatal care	54	1.61	2	1.42			10	1.25	18	4.66	7	1.47	17	2.35
Pregnancy test	9	0.27	4	2.84	1	0.12	1	0.12			2	0.42	1	0.14
Cough	132	3.93	13	9.22	5	0.60	24	2.99	28	7.05	21	4.41	41	5.68
Nausea	2	0.06	1	0.71					1	0.26				
Fever	2	0.06											2	0.28
Headache	6	0.18	1	0.71			3	0.37	1	0.26			1	0.14
Pain control	186	5.54	14	9.93	6	0.72	69	8.60	38	9.84	36	7.56	23	3.19
Shock	1	0.03	1	0.71										
Malnutrition	161	4.80			1	0.12	33	4.11	64	16.58	12	2.52	51	7.06
Insects bites	6	0.18	1	0.71			1	0.12			3	0.63	1	0.14
Burn wounds	13	0.39					2	0.25	4	1.04	4	0.84	3	0.42
Unknown diagnosis	42	1.25	20	14.18	5	0.60	2	0.25					15	2.08
Immunisation	108	3.22			1	0.12	48	5.99	13	3.37	17	3.57	29	4.02
Family planning	304	9.06			74	8.92	101	12.59	43	11.14	37	7.77	49	6.79
Total	**3344**	**99.99**												

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

Appendix 1.2: Frequency of different diagnosis according to gender in all clinics and clinic 1, 2 & 3

DIAGNOSES IN CLINICS 1, 2 & 3	All clinics				Clinic 1				Clinic 2				Clinic 3			
	Male		Female		Male		Female		Male		Female		Male		Female	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Bacillary dysentery	1	0.07	3	0.15											1	0.19
Amoebiasis			2	0.10												
Diarrhoea	9	0.65	5	0.25											4	0.74
Tuberculosis	850	61.11	573	29.15					433	95.37	255	67.82	91	34.60	73	13.54
STD suspicion	5	0.36	10	0.51			1	1.03	2	0.44			1	0.38	4	0.74
Vaginal discharge	1	0.07	24	1.22			1	1.03					1	0.38	14	2.60
Genital warts					1	2.27							2	0.76		
Syphillis	4	0.29	4	0.20	1	2.27							3	1.14	1	0.19
Herpes/ Cold sores			3	0.15											1	0.19
Chicken pox			4	0.20												
Meningitis			3	0.15							3	0.80				
Mumps			1	0.05												
Fungal skin infection	4	0.29	5	0.25	2	4.55	1	1.03							1	0.19
Ringworm			2	0.10											1	0.19
Candidiasis	5	0.36	10	0.51	1	2.27	1	1.03			1	0.27	1	0.38	7	1.30
All worms / except TW			4	0.20											2	0.37
Lice			2	0.10											1	0.19

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.2 CONT'D DIAGNOSES IN CLINICS 1, 2 & 3	All clinics				Clinic 1				Clinic 2				Clinic 3			
	Male		Female		Male		Female		Male		Female		Male		Female	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Scabies			2	0.10											1	0.19
Anemia	1	0.07	8	0.41	1	2.27									7	1.30
Diagnostic tests	6	0.43	12	0.61					2	0.44	1	0.27	1	0.38	8	1.48
Insulin dependant diabetes	1	0.07	6	0.31											2	0.37
Non Insulin dependant diabetes	3	0.22	17	0.86			1	1.03	1	0.22	4	1.06			3	0.56
Vitamin deficiency	87	6.25	102	5.19	1	2.27	1	1.03					66	25.10	83	15.40
Mineral deficiency	5	0.36	12	0.61	2	4.55	1	1.03					1	0.38	3	0.56
Acid-base balance			2	0.10											2	0.37
Epileptic	14	1.01	8	0.41	1	2.27			1	0.22			2	0.76	1	0.19
General check-up	16	1.15	24	1.22	4	9.09	6	6.19	1	0.22			5	1.90	5	0.93
Conjunctivitis	2	0.14	6	0.31			1	1.03							2	0.37
Otitis externa			1	0.05												
Otitis media	6	0.43	6	0.31									4	1.52	1	0.19
Hypertension	43	3.09	188	9.56	4	9.09	25	25.77	5	1.10	22	5.85	7	2.66	49	9.09
Myocardial infarction			1	0.05												
Haemorrhoids	1	0.07	2	0.10			1	1.03								
Sinusitis	1	0.07	3	0.15											2	0.37
Tonsillitis (viral)	1	0.07														
Tonsillitis (bacterial)	9	0.65	6	0.31									2	0.76	1	0.19

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.2 CONT'D DIAGNOSES IN CLINICS 1, 2 & 3	All clinics				Clinic 1				Clinic 2				Clinic 3			
	Male		Female		Male		Female		Male		Female		Male		Female	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Cold / influenza	2	0.14	6	0.31			1	1.03							1	0.19
Bronchitis	6	0.43	8	0.41	1	2.27	2	2.06	2	0.44			1	0.38		
Allergic rhinitis	1	0.07	6	0.31	1	2.27	2	2.06							2	0.37
Asthma	8	0.58	5	0.25	1	2.27					2	0.53	2	0.76	1	0.19
Dental abscess	1	0.07														
Heartburn / Dyspepsia	11	0.79	33	1.68	3	6.82	9	9.28	1	0.22	1	0.27	2	0.76	6	1.11
Constipation			3	0.15			1	1.03								
Anal fissures			1	0.05												
Teething	1	0.07											1	0.38		
Toothache			1	0.05												
Boils / Impetigo	2	0.14	2	0.10			1	1.03					1	0.38		
Eczema (moist)	2	0.14	2	0.10	1	2.27									1	0.19
Sebhorric eczema			3	0.15			1	1.03								
Nappy rash	4	0.29	6	0.31			1	1.03					1	0.38	1	0.19
Pruritis	2	0.14	6	0.31											1	0.19
Psoriasis			1	0.05												
Urticaria			2	0.10												
Acne			1	0.05												
Backache	14	1.01	26	1.32									1	0.38	6	1.11

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.2 CONT'D DIAGNOSES IN CLINICS 1, 2 & 3	All clinics				Clinic 1				Clinic 2				Clinic 3			
	Male		Female		Male		Female		Male		Female		Male		Female	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Arthritis	2	0.14	2	0.10												
Urinary tract infection	2	0.14	3	0.15									1	0.38	3	0.56
Vaginal bleeding			1	0.05												
Dysmenorhoea			3	0.15											3	0.56
Antenatal care			54	2.75			2	2.06							10	1.86
Pregnancy test	1	0.07	8	0.41			4	4.12			1	0.27			1	0.19
Cough	45	3.24	87	4.43	7	15.91	6	6.19			5	1.33	4	1.52	20	3.71
Nausea			2	0.10			1	1.03								
Fever	2	0.14														
Headache	1	0.07	5	0.25			1	1.03							3	0.56
Pain control	57	4.10	129	6.56	3	6.82	11	11.34	3	0.66	3	0.80	22	8.37	47	8.72
Shock			1	0.05			1	1.03								
Malnutrition	76	5.46	85	4.32					1	022			15	5.70	18	3.34
Insects bites	2	0.14	4	0.20			1	1.03							1	0.19
Burn wounds	6	0.43	7	0.36									2	0.76		
Unknown diagnosis	15	1.08	27	1.37	9	20.45	11	11.34	2	0.44	3	0.80			2	0.37
Immunisation	43	3.09	65	3.31							1	0.27	19	7.22	29	5.38
Family planning			304	15.46							74	19.68			101	18.74

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

Appendix 1.3: Frequency of different diagnosis according to gender in clinics 4, 5 & 6

DIAGNOSES IN CLINICS 4, 5 & 6	Clinic 4				Clinic 5				Clinic 6			
	Male		Female		Male		Female		Male		Female	
	n	%	n	%	n	%	n	%	n	%	n	%
Bacillary dysentery	1	0.73	2	0.80	1	0.73	2	0.80				
Amoebiasis			1	0.40			1	0.40			1	0.25
Diarrhoea	2	1.46			2	1.46			5	1.53	1	0.25
Tuberculosis	24	17.52	9	3.61	24	17.52	9	3.61	231	70.64	138	34.94
STD suspicion	2	1.46	2	0.80	2	1.46	2	0.80				
Vaginal discharge			7	2.81			7	2.81				
Genital warts												
Syphillis											3	0.76
Herpes / Cold sores												
Chicken pox											4	1.01
Meningitis												
Mumps											1	0.25
Fungal skin infection	1	0.73			1	0.73					1	0.25
Ringworm												
Candidiasis	1	0.73			1	0.73			2	0.61	1	0.25
All worms/except TW			1	0.40			1	0.40				
Lice												

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.3 CONT'D DIAGNOSES IN CLINICS 4, 5 & 6	Clinic 4				Clinic 5				Clinic 6			
	Male		Female		Male		Female		Male		Female	
	n	%	n	%	n	%	n	%	n	%	n	%
Scabies												
Anemia												
Diagnostic tests			1	0.40			1	0.40				
Insulin dependant diabetes									1	0.31		
Non Insulin dependant diabetes											1	0.25
Vitamin deficiency	15	10.95	14	5.62	15	10.95	14	5.62				
Mineral deficiency	1	0.73	3	1.20	1	0.73	3	1.20				
Acid-base balance												
Epileptic	3	2.19	5	2.01	3	2.19	5	2.01	3	0.92	1	0.25
General check-up			4	1.61			4	1.61	2	0.61	4	1.01
Conjunctivitis	1	0.73	2	0.80	1	0.73	2	0.80			1	0.25
Otitis externa											1	0.25
Otitis media	1	0.73	1	0.40	1	0.73	1	0.40			2	0.51
Hypertension	2	1.46	23	9.24	2	1.46	23	9.24	6	1.83	35	8.86
Myocardial infarction			1	0.40			1	0.40				
Haemorrhoids			1	0.40			1	0.40	1	0.31		
Sinusitis	1	0.73			1	0.73					1	0.25
Tonsillitis (viral)	1	0.73			1	0.73						
Tonsillitis (bacterial)	2	1.46			2	1.46			4	1.22	3	0.76

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.3 CONT'D DIAGNOSES IN CLINICS 4, 5 & 6	Clinic 4				Clinic 5				Clinic 6			
	Male		Female		Male		Female		Male		Female	
	n	%	n	%	n	%	n	%	n	%	n	%
Cold / influenza	1	0.73	1	0.40	1	0.73	1	0.40			3	0.76
Bronchitis	1	0.73	3	1.20	1	0.73	3	1.20	1	0.31	2	0.51
Allergic rhinitis			2	0.80			2	0.80				
Asthma			1	0.40			1	0.40	1	0.31	1	0.25
Dental abscess												
Heartburn / Dyspepsia	3	2.19	6	2.41	3	2.19	6	2.41			3	0.76
Constipation											1	0.25
Anal fissures												
Teething												
Toothache											1	0.25
Boils / Impetigo			1	0.40			1	0.40				
Eczema (moist)									1	0.31	1	0.25
Sebhorric eczema												
Nappy rash	1	0.73	1	0.40	1	0.73	1	0.40	2	0.61	1	0.25
Pruritis	1	0.73	2	0.80	1	0.73	2	0.80			2	0.51
Psoriasis											1	0.25
Urticaria			1	0.40			1	0.40			1	0.25
Acne			1	0.40			1	0.40				
Backache	5	3.65	5	2.01	5	3.65	5	2.01	2	0.61	7	1.77

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.3 CONT'D	Clinic 4				Clinic 5				Clinic 6			
	Male		Female		Male		Female		Male		Female	
DIAGNOSES IN CLINICS 4, 5 & 6	n	%	n	%	n	%	n	%	n	%	n	%
Arthritis			1	0.40			1	0.40	1	0.31		
Urinary tract infection												
Vaginal bleeding												
Dysmenorhoea												
Antenatal care			18	7.23			18	7.23			17	4.30
Pregnancy test											1	0.25
Cough	8	5.84	20	8.03	8	5.84	20	8.03	18	5.50	23	5.82
Nausea			1	0.40			1	0.40				
Fever									2	0.61		
Headache			1	0.40			1	0.40	1	0.31		
Pain control	11	8.03	27	10.84	11	8.03	27	10.84	8	2.45	15	3.80
Shock												
Malnutrition	35	25.55	29	11.65	35	25.55	29	11.65	22	6.73	29	7.34
Insects bites									1	0.31		
Burn wounds	1	0.73	3	1.20	1	0.73	3	1.20	1	0.31	2	0.51
Unknown diagnosis									4	1.22	11	2.78
Immunisation	10	7.30	3	1.20	10	7.30	3	1.20	6	1.83	23	5.82
Family planning			43	17.27			43	17.27			49	12.41

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

Appendix 1.4: Frequency of different diagnosis according to age groups in all clinics

DIAGNOSIS IN ALL CLINICS	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Bacillary dysentery												
Amoebiasis												
Diarrhoea							2	0.66				
Tuberculosis	4	6.35					92	30.26	70	53.03		
STD suspicion							5	1.64	1	0.76		
Vaginal discharge					1	2.70	3	0.99				
Genital warts							1	0.33				
Syphilis							1	0.33				
Herpes / Cold sores												
Chicken pox	1	1.59			2	5.41	1	0.33				
Meningitis												
Mumps	1	1.59										
Fungal skin infection					1	2.70	2	0.66				
Ringworm												
Candidiasis					1	2.70	3	0.99	1	0.76		
All worms / except TW												
Lice												

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.4 CONT'D DIAGNOSIS IN ALL CLINICS	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Scabies												
Anemia									1	0.76		
Diagnostic test					1	2.70	4	1.32				
Insulin dependant diabetes												
Non Insulin dependant diabetes											1	3.57
Vitamin deficiency									3	2.27		
Mineral deficiency							2	0.66	1	0.76		
Acid-base balance												
Epileptic	1	1.59							2	1.52		
General check-up	1	1.59	1	7.14	2	5.41	7	2.30	3	2.27	2	7.14
Conjunctivitis					1	2.70			1	0.76		
Otitis externa							1	0.33				
Otitis media	1	1.59										
Hypertension							6	1.97	12	9.09	13	46.43
Myocardial infarction							1	0.33				
Haemorrhoids							3	0.99				
Sinusitis							1	0.33				
Tonsillitis (viral)												

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.4 CONT'D DIAGNOSIS IN ALL CLINICS	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Tonsillitis (bacterial)	1	1.59	2	14.29	3	8.11	1	0.33				
Cold / influenza					1	2.70	2	0.66				
Bronchitis	1	1.59					5	1.64	1	0.76		
Allergic rhinitis							2	0.66	1	0.76		
Asthma							1	0.33				
Dental abscess												
Heartburn / Dyspepsia							10	3.29	4	3.03	3	10.71
Constipation											1	3.57
Anal fissures												
Teething												
Toothache							1	0.33				
Boils / Impetigo									1	0.76		
Eczema (moist)	1	1.59			1	2.70						
Sebhorric eczema							1	0.33				
Nappy rash	2	3.17										
Pruritis							2	0.66				
Psoriasis							1	0.33				
Urticaria			1	7.14								

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.4 CONT'D	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
DIAGNOSIS IN ALL CLINICS	n	%	n	%	n	%	n	%	n	%	n	%
Backache							3	0.99	6	4.55		
Arthritis					1	2.70						
Vaginal bleeding												
Dysmenorhoea												
Antenatal care							3	0.99	1	0.76		
Pregnancy test							6	1.97				
Cough	12	19.05	3	21.43	1	2.70	7	2.30	4	3.03	1	3.57
Nausea							1	0.33				
Fever									1	0.76		
Headache							1	0.33	1	0.76		
Pain control	1	1.59	1	7.14			15	4.93	4	3.03	4	14.29
Shock							1	0.33				
Malnutrition	30	47.62	3	21.43			17	5.59				
Insects bites							1	0.33	1	0.76		
Burn wounds			1	7.14			1	0.33				
Unknown diagnosis	4	6.35	2	14.29	3	8.11	14	4.61	10	7.58	3	10.71
Immunisation	1	1.59										
Family planning					16	43.24	72	23.68	2	1.52		

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

Appendix 1.5: Frequency of different diagnosis according to age group in clinic 1

DIAGNOSES IN CLINIC 1	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Bacillary dysentery												
Amoebiasis												
Diahorrhea												
Tuberculosis												
STD suspicion									1	2.63		
Vaginal discharge							1	1.79				
Genital warts							1	1.79				
Syphilis							1	1.79				
Herpes / Cold sores												
Chicken pox												
Meningitis												
Mumps												
Fungal skin infection					1	25.00	2	3.57				
Ringworm												
Candidiasis							1	1.79	1	2.63		
All worms / except TW												
Lice												

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.5 CONT'D DIAGNOSIS IN CLINIC 1	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Scabies												
Anemia									1	2.63		
Diagnostic test												
Insulin dependant diabetes												
Non Insulin dependant diabetes											1	3.85
Vitamin deficiency									2	5.26		
Mineral deficiency							2	3.57	1	2.63		
Acid-base balance												
Epileptic	1	9.09										
General check-up			1	25.00	1	25.00	3	5.36	3	7.89	2	7.69
Conjunctivitis									1	2.63		
Otitis externa												
Otitis media												
Hypertension							5	8.93	10	26.32	13	50.00
Myocardial infarction												
Haemorrhoids							1	1.79				
Sinusitis												
Tonsillitis (viral)												

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.5 CONT'D	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
DIAGNOSIS IN CLINIC 1	n	%	n	%	n	%	n	%	n	%	n	%
Tonsillitis (bacterial)												
Bronchitis	1	9.09					1	1.79	1	2.63		
Allergic rhinitis							2	3.57	1	2.63		
Asthma							1	1.79				
Dental abscess												
Heartburn / Dyspepsia							6	10.71	3	7.89	3	11.54
Constipation											1	3.85
Anal fissures												
Teething												
Toothache												
Boils / Impetigo									1	2.63		
Eczema (moist)	1	9.09										
Sebhorric eczema							1	1.79				
Nappy rash	1	9.09										
Pruritis												
Psoriasis												
Urticaria												
Acne												

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.5 CONT'D	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
DIAGNOSIS IN CLINIC 1	n	%	n	%	n	%	n	%	n	%	n	%
Backache												
Urinary tract infection												
Vaginal bleeding												
Dysmenorhoea												
Antenatal care							2	3.57				
Pregnancy test							4	7.14				
Cough	4	36.36	2	50.00			2	3.57	3	7.89	1	3.85
Nausea							1	1.79				
Fever												
Headache									1	2.63		
Pain control	1	9.09	1	25.00	1	25.00	7	12.50	1	2.63	3	11.54
Shock							1	1.79				
Malnutrition												
Insects bites									1	2.63		
Burn wounds												
Unknown diagnosis	1	9.09			1	25.00	10	17.86	6	15.79	2	7.69
Immunisation												
Family planning												

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

Appendix 1.6: Frequency of different diagnosis according to age group in clinic 2

DIAGNOSES IN CLINIC 2	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Bacillary dysentery												
Amoebiasis												
Diarrhoea												
Tuberculosis							73	83.91	24	88.89		
STD suspicion							2	2.30				
Vaginal discharge												
Genital warts												
Syphilis												
Herpes / Cold sores												
Chicken pox												
Meningitis												
Mumps												
Fungal skin infection												
Ringworm												
Candidiasis					1	50.00						
All worms / except TW												

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.6 CONT'D DIAGNOSES IN CLINIC 2	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Lice												
Scabies												
Anemia												
Diagnostic test					1	50.00	1	1.15				
Insulin dependant diabetes												
Non Insulin dependant diabetes												
Vitamin deficiency												
Mineral deficiency												
Acid-base balance												
Epileptic									1	3.70		
General check-up							1	1.15				
Conjunctivitis												
Otitis externa												
Otitis media												
Hypertension									2	7.41		
Myocardial infarction												
Haemorrhoids												
Sinusitis												

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.6 CONT'D DIAGNOSES IN CLINIC 2	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Tonsillitis (viral)												
Tonsillitis (bacterial)												
Cold / influenza												
Bronchitis							1	1.15				
Allergic rhinitis												
Asthma												
Dental abscess												
Heartburn / Dyspepsia							2	2.30				
Constipation												
Anal fissures												
Teething												
Toothache												
Boils / Impetigo												
Eczema (moist)												
Sebhorric eczema												
Nappy rash												
Pruritis												
Psoriasis												

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.6 CONT'D DIAGNOSES IN CLINIC 2	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Acne												
Backache												
Arthritis												
Vaginal bleeding												
Dysmenorhoea												
Antenatal care												
Pregnancy test							1	1.15				
Cough	2	50.00					3	3.45				
Nausea												
Fever												
Headache												
Pain control							1	1.15			1	100.00
Shock												
Malnutrition							1	1.15				
Burn wounds												
Unknown diagnosis	1	25.00					1	1.15				
Immunisation	1	25.00										
Family planning												

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

Appendix 1.7: Frequency of different diagnosis according to age group in clinic 3

DIAGNOSES IN CLINIC 3	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Bacillary dysentery												
Amoebiasis												
Diarrhoea												
Tuberculosis												
STD suspicion												
Vaginal discharge												
Genital warts												
Syphilis												
Herpes / Cold sores												
Chicken pox												
Meningitis												
Mumps												
Fungal skin infection												
Ringworm												
Candidiasis												
All worms / except TW												
Lice												

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.7 CONT'D DIAGNOSES IN CLINIC 3	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Scabies												
Anemia												
Diagnostic test												
Insulin dependant diabetes												
Non Insulin dependant diabetes												
Vitamin deficiency												
Mineral deficiency												
Acid-base balance												
Epileptic												
General check-up												
Conjunctivitis												
Otitis externa												
Otitis media												
Hypertension												
Myocardial infarction												
Haemorrhoids												
Sinusitis												
Tonsillitis (viral)												

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.7 CONT'D DIAGNOSES IN CLINIC 3	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Tonsillitis (bacterial)												
Cold / influenza												
Bronchitis												
Allergic rhinitis												
Asthma												
Dental abscess												
Heartburn / Dyspepsia												
Constipation												
Anal fissures												
Teething												
Toothache												
Boils / Impetigo												
Eczema (moist)												
Sebhorric eczema												
Nappy rash												
Pruritis												
Psoriasis												
Urticaria												

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.7 CONT'D DIAGNOSES IN CLINIC 3	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Acne												
Backache												
Arthritis												
Urinary tract infection												
Vaginal bleeding												
Antenatal care												
Pregnancy test												
Cough												
Nausea												
Fever												
Headache												
Pain control												
Malnutrition												
Insects bites												
Burn wounds												
Unknown diagnosis												
Immunisation												
Family planning												

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

Appendix 1.8: Frequency of different diagnosis according to age group in clinic 4

DIAGNOSES IN CLINIC 4	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Bacillary dysentery												
Amoebiasis												
Diarrhoea												
Tuberculosis												
STD suspicion							2	3.64				
Vaginal discharge					1	12.50	2	3.64				
Genital warts												
Syphilis												
Herpes / Cold sores												
Chicken pox												
Meningitis												
Mumps												
Fungal skin infection												
Ringworm												
Candidiasis												
All worms / except TW												
Lice												

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.8 CONT'D DIAGNOSES IN CLINIC 4	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Scabies												
Anemia												
Diagnostic test												
Insulin dependant diabetes												
Non Insulin dependant diabetes												
Vitamin deficiency									1	20.00		
Mineral deficiency												
Acid-base balance												
Epileptic									1	20.00		
General check-up												
Conjunctivitis												
Otitis externa												
Otitis media												
Hypertension							1	1.82				
Myocardial infarction							1	1.82				
Haemorrhoids							1	1.82				
Sinusitis												
Tonsillitis (viral)												

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.8 CONT'D DIAGNOSES IN CLINIC 4	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Tonsillitis (bacterial)												
Cold / influenza												
Bronchitis												
Allergic rhinitis												
Asthma												
Dental abcess												
Heartburn/Dyspepsia												
Constipation												
Anal fissures												
Teething												
Toothache												
Boils / Impetigo												
Eczema (moist)												
Sebhorric eczema												
Nappy rash												
Pruritis												
Psoriasis												
Urticaria												

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.8 CONT'D DIAGNOSES IN CLINIC 4	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Acne												
Backache									1	20.00		
Arthritis												
Urinary tract infection												
Dysmenorhoea												
Antenatal care												
Pregnancy test												
Nausea												
Fever												
Headache												
Pain control							1	1.82				
Shock												
Malnutrition	30	100.00	3	100.00			14	25.45				
Insects bites												
Burn wounds												
Unknown diagnosis												
Immunisation												
Family planning					7	87.50	33	60.00	2	40.00		

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

Appendix 1.9: Frequency of different diagnosis according to age group in clinic 5

DIAGNOSES IN CLINIC 5	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Bacillary dysentery												
Amoebiasis												
Diarrhoea												
Tuberculosis							19	70.37				
STD suspicion							1	3.70				
Vaginal discharge												
Genital warts												
Syphilis												
Herpes / Cold sores												
Chicken pox												
Meningitis												
Mumps												
Fungal skin infection												
Ringworm												
Candidiasis												
All worms / except TW												
Lice												

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.9 CONT'D DIAGNOSES IN CLINIC 5	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Scabies												
Anemia												
Diagnostic test							3	11.11				
Insulin dependant diabetes												
Non Insulin dependant diabetes												
Vitamin deficiency												
Mineral deficiency												
Acid-base balance												
Epileptic												
General check-up												
Conjunctivitis												
Otitis externa												
Otitis media												
Hypertension												
Myocardial infarction												
Haemorrhoids												
Sinusitis												
Tonsillitis (viral)												
Tonsillitis (bacterial)			1	100.00								

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.9 CONT'D DIAGNOSES IN CLINIC 5	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Cold / influenza												
Bronchitis												
Allergic rhinitis												
Asthma												
Dental abscess												
Heartburn / Dyspepsia												
Constipation												
Anal fissures												
Teething												
Toothache												
Boils/Impetigo												
Eczema (moist)												
Sebhorric eczema												
Nappy rash												
Pruritis												
Psoriasis												
Urticaria												
Acne												
Backache							1	3.70				

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.9 CONT'D	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
DIAGNOSES IN CLINIC 5	n	%	n	%	n	%	n	%	n	%	n	%
Arthritis												
Urinary tract infection												
Vaginal bleeding												
Dysmenorhoea												
Antenatal care												
Pregnancy test												
Cough							1	3.70				
Nausea												
Fever												
Headache												
Pain control												
Shock												
Malnutrition							2	7.41				
Insects bites												
Burn wounds												
Unknown diagnosis												
Immunisation												
Family planning												

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

Appendix 1.10: Frequency of different diagnosis according to age group in clinic 6

DIAGNOSES IN CLINIC 6	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Bacillary dysentery												
Amoebiasis												
Diarrhoea							2	2.53				
Tuberculosis	4	22.22							46	74.19		
STD suspicion												
Vaginal discharge												
Genital warts												
Syphilis												
Herpes / Cold sores												
Chicken pox	1	5.56			2	8.70	1	1.27				
Meningitis												
Mumps	1	5.56										
Fungal skin infection												
Ringworm												
Candidiasis							2	2.53				
All worms / except TW												
Lice												

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.10 CONT'D	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
DIAGNOSES IN CLINIC 6	n	%	n	%	n	%	n	%	n	%	n	%
Scabies												
Anemia												
Diagnostic test												
Insulin dependant diabetes												
Non Insulin dependant diabetes												
Vitamin deficiency												
Mineral deficiency												
Acid-base balance												
Epileptic												
General check-up	1	5.56			1	4.35	3	3.80				
Conjunctivitis					1	4.35						
Otitis externa							1	1.27				
Otitis media	1	5.56										
Hypertension												
Myocardial infarction												
Haemorrhoids							1	1.27				
Sinusitis							1	1.27				
Tonsillitis (viral)												

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.10 CONT'D DIAGNOSES IN CLINIC 6	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Tonsillitis (bacterial)	1	5.56	1	16.67	3	13.04	1	1.27				
Cold / influenza					1	4.35	1	1.27				
Bronchitis							3	3.80				
Allergic rhinitis												
Asthma												
Dental abscess												
Heartburn / Dyspepsia							2	2.53	1	1.61		
Constipation												
Anal fissures												
Teething												
Toothache							1	1.27				
Boils / Impetigo												
Eczema (moist)					1	4.35						
Sebhorric eczema												
Nappy rash	1	5.56										
Pruritis							2	2.53				
Psoriasis							1	1.27				
Urticaria			1	16.67								
Acne												

APPENDIX 1: RESULTS OF DIAGNOSES (ICD-10 CODE) ANALYSIS

APPENDIX 1.10 CONT'D DIAGNOSES IN CLINIC 6	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Backache							2	2.53	5	8.06		
Arthritis					1	4.35						
Urinary tract infection												
Vaginal bleeding												
Dysmenorhoea												
Antenatal care							1	1.27	1	1.61		
Pregnancy test							1	1.27				
Cough	6	33.33	1	16.67	1	4.35	1	1.27	1	1.61		
Nausea												
Fever									1	1.61		
Headache							1	1.27				
Pain control					1	4.35	6	7.59	3	4.84		
Shock												
Malnutrition												
Insects bites							1	1.27				
Burn wounds			1	16.67			1	1.27				
Unknown diagnosis	2	11.11	2	33.33	2	8.70	3	3.80	4	6.45	1	100.00
Immunisation												
Family planning					9	39.13	39	49.37				

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

Appendix 1.11: Frequency of different medicines according to ATC classification system for all consultations in all clinics

ATC CLASSIFICATION IN ALL CLINICS	Clinic 1		Clinic 2		Clinic 3		Clinic 4		Clinic 5		Clinic 6	
	n	%	n	%	n	%	n	%	n	%	n	%
Stomatological preparations					1	0.08	2	0.38	2	0.32	2	0.20
Antacids, drugs for treatment of peptic ulcer and flatulence	12	5.24	2	0.18	8	0.66	9	1.71	10	1.60	5	0.50
Antispasmodic and anticholinergic agents												
Anti-emetics and anti-nauseants	1	0.44										
Laxatives									1	0.16	3	0.30
Anti-diarrhoeals	3	1.31	1	0.09	4	0.33	5	0.95	2	0.32	3	0.30
Digestives, including enzymes												
Oral hypoglycemics	1	0.44	8	0.73	8	0.66			20	3.19	3	0.30
Vitamins	12	5.24	70	6.35	279	23.12	54	10.29	25	3.99	34	3.40
Mineral supplements	1	0.44										
Food supplements			1	0.09	38	3.15	64	12.19	10	1.60	99	9.89
Anti-anaemic preparations	5	2.18			32	2.65	25	4.76	6	0.96	14	1.40
Plasma substitutes and perfusion solutions												
Cardiac therapy					1	0.08						
Antihypertensives	23	10.04	35	3.17	64	5.30	32	6.10	67	10.70	46	4.60
Diuretics	37	16.16	28	2.54	55	4.56	33	6.29	55	8.79	43	4.30
Vasoprotectives	1	0.44					1	0.19	1	0.16	1	0.10
Beta blocking agents	6	2.62	5	0.45	3	0.25	3	0.57	6	0.96	1	0.10

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

APPENDIX 1.11 CONT'D ATC CLASSIFICATION IN ALL CLINICS	Clinic 1		Clinic 2		Clinic 3		Clinic 4		Clinic 5		Clinic 6	
	n	%	n	%	n	%	n	%	n	%	n	%
Antifungals for dermatological use	7	3.06	1	0.09	6	0.50	4	0.76	5	0.80	7	0.70
Emollients and protectants	3	1.31	1	0.09	1	0.08	1	0.19	5	0.80	3	0.30
Antipruritics and topical anaesthetics	1	0.44			3	0.25	2	0.38	2	0.32	5	0.50
Corticosteroids for dermatological use	2	0.87			1	0.08					5	0.50
Antiseptics and disinfectants					2	0.17	5	0.95	3	0.48	4	0.40
Anti-acne preparations												
Gyaenacological anti-infectives and antiseptics	1	0.44			5	0.41	1	0.19	1	0.16		
Sex hormones and modulators of the genital system			77	6.98	101	8.37	42	8.00	37	5.91	49	4.90
Corticosteroids for systemic use	1	0.44										
Antibacterials for systemic use	24	10.48	6	0.54	68	5.63	36	6.86	20	3.19	35	3.50
Antimycobacterials			841	76.25	248	20.55	47	8.95	183	29.23	387	38.66
Immune sera and immunoglobins												
Vaccines			1	0.09	106	9.61	29	5.52	34	5.43	75	7.49
Anti-inflammatory and anti-rheumatic agents												
Topical products for joint and muscular pain	4	1.75	2	0.18	5	0.41	8	1.52	20	3.19	4	0.40
Analgesics	46	20.09	13	1.18	89	7.37	56	10.67	58	9.27	93	9.29
Anti-epileptics	1	0.44			3	0.25	10	1.90	5	0.80	5	0.50
Psycholeptics												

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

APPENDIX 1.11 CONT'D ATC CLASSIFICATION IN ALL CLINICS	Clinic 1		Clinic 2		Clinic 3		Clinic 4		Clinic 5		Clinic 6	
	n	%	n	%	n	%	n	%	n	%	n	%
Psychoanaleptics												
Anti-protozoals	1	0.44			12	0.99	7	1.33	2	0.32	3	0.30
Anthelmentics					2	0.17	1	0.19	1	0.16	1	0.10
Ectoparasiticides, including scabicides					2	0.17	3	0.57	3	0.48	4	0.40
Nasal preparations					3	0.25	2	0.38			1	0.10
Anti-astmatic agents	18	7.86	9	0.82	30	2.49	30	5.71	33	5.27	50	5.00
Cough and cold preparations												
Antihistamines for systemic use	11	4.80			13	1.08	7	1.33	4	0.64	14	1.40
Opthalmologicals	3	1.31			3	0.25	5	0.95	1	0.16	1	0.10
Otologicals												
All other therapeutic products	3	1.31	2	0.18	1	0.08	1	0.19	4	0.64	1	0.10
Total	**229**	**99.99**	**1103**	**100.01**	**1207**	**99.98**	**525**	**99.99**	**626**	**100.01**	**1001**	**100.00**

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

Appendix 1.12: Frequency of medicines according to ATC classification and gender in all clinics

ATC CLASS IN ALL CLINICS	Female		Male		ATC class in all clinics	Female		Male	
	n	%	n	%		n	%	n	%
Stomatological preparations	3	0.11	4	0.20	Vaccines	138	5.49	107	5.36
Antacids, drugs for treatment of peptic ulcer and flatulence	33	1.22	13	0.65	Anti-inflammatory and anti-rheumatic agents				
Antispasmodic and anticholinergic agents					Topical products for joint and muscular pain	28	1.04	15	0.75
Antiemetics and antinauseants	1	0.04			Analgesics	233	8.65	122	6.11
Laxatives	6	0.22	1	0.05	Anti-epileptics	9	0.33	15	0.75
Antidiarrhoeals	6	0.22	9	0.45	Psycholeptics				
Digestives, including enzymes					Psychoanaleptics				
Oral hypoglycemics	33	1.22	7	0.35	Anti-protozoals	24	0.89	1	0.05
Vitamins	212	7.87	262	13.12	Anthelmentics	4	0.15	1	0.05
Mineral supplements			1	0.05	Ectoparasiticides, including scabicides	6	0.22	6	0.30
Food supplements	120	4.45	92	4.61	Nasal preparations	4	0.15	2	0.10
Antianaemic preparations	76	2.82	6	0.30	Antiastmatic agents	101	3.75	69	3.46
Plasma substitutes and perfusion solutions					Cough and cold preparations				
Cardiac therapy	1	0.04			Antihistamines for systemic use	39	1.45	10	0.50
Antihypertensives	215	7.98	52	2.60	Opthalmologicals	9	0.33	4	0.20
Diuretics	203	7.54	48	2.40	Otologicals				

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

APPENDIX 1.12 CONT'D ATC CLASS IN ALL CLINICS	Female		Male	
	n	%	n	%
Vasoprotectives	3	0.11	1	0.05
Beta blocking agents	21	0.78	3	0.15
Antifungals for dermatological use	16	0.59	14	0.70
Emollients and protectants	10	0.37	4	0.20
Antipruritics and topical anaesthetics	11	0.41	2	0.10
Corticosteroids for dermatological use	7	0.26	1	0.05
Antiseptics and disinfectants	7	0.26	7	0.35
Anti-acne preparations				
Gyaenecological anti-infectives and antiseptics	8	0.30		
Sex hormones and modulators of the genital system	306	11.36		
Corticosteroids fpr systemic use	1	0.04		
Antibacterials for systemic use	119	4.42	70	3.51
Antimycobacterials	669	24.46	1046	52.43
Immune sera and immunoglobins				

ATC class in all clinics	Female		Male	
	n	%	n	%
All other therapeutic products	11	0.41	1	0.05

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

Appendix 1.13: Frequency of medicines according to ATC classification and gender in clinics 1 & 2

ATC GROUP IN CLINIC 1 & 2	CLINIC 1				CLINIC 2			
	Male		Female		Male		Female	
	n	%	n	%	n	%	n	%
Stomatological preparations								
Antacids, drugs for treatment of peptic ulcer and flatulence	3	4.35	9	5.63	1	0.15	1	0.23
Antispasmodic and anticholinergic agents								
Anti-emetics and anti-nauseants			1	0.63				
Laxatives			3	1.88				
Anti-diarrhoeals					1	0.15		
Digestives, including enzymes								
Oral hypoglycemics			1	0.63	3	0.45	5	1.14
Vitamins	5	7.25	7	4.38	66	9.94	4	0.91
Mineral supplements	1	1.45						
Food supplements					1	0.15		
Anti-anaemic preparations	3	4.35	2	1.25				
Plasma substitutes and perfusion solutions								
Cardiac therapy								
Antihypertensives	3	4.35	20	12.50	6	0.90	29	6.61
Diuretics	6	8.70	31	19.38	5	0.75	23	5.24
Vasoprotectives			1	0.63				

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

APPENDIX 1.13 CONT'D	CLINIC 1				CLINIC 2			
	Male		Female		Male		Female	
ATC group in clinic 1 & 2	n	%	n	%	n	%	n	%
Beta blocking agents	1	1.45	5	3.13	1	0.15	4	0.91
Anti-fungals for dermatological use	4	5.80	3	1.88			1	0.23
Emollients and protectants	1	1.45	2	1.25	1	0.15		
Anti-pruritics and topical anaesthetics			1	0.63				
Corticosteroids for dermatological use			2	1.25				
Antiseptics and disinfectants								
Anti-acne preparations								
Gyaenecological anti-infectives and antiseptics			1	0.63				
Sex hormones and modulators of the genital system							77	17.54
Corticosteroids for systemic use			1	0.63				
Antibacterials for systemic use	10	14.49	14	8.75	5	0.75	1	0.23
Antimycobacterials					567	85.39	274	62.41
Immune sera and immunoglobins								
Vaccines							1	0.23
Anti-inflammatory and anti-rheumatic agents								
Topical products for joint and muscular pain	2	2.90	2	1.25			2	0.46
Analgesics	15	21.74	31	19.38	6	0.90	7	1.59
Anti-epileptics	1	1.45						
Psycholeptics								

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

APPENDIX 1.13 CONT'D	CLINIC 1				CLINIC 2			
	Male		Female		Male		Female	
ATC group in clinic 1 & 2	n	%	n	%	n	%	n	%
Psychoanaleptics								
Anti-protozoals			1	0.63				
Anthelmentics								
Ectoparasiticides, including scabicides								
Nasal preparations								
Anti-astmatic agents	10	14.49	8	5.00	1	0.15	8	1.82
Cough and cold preparations								
Antihistamines for systemic use	3	4.35	8	5.00				
Opthalmologicals	1	1.45	2	1.25				
Otologicals								
All other therapeutic products			3	1.88			2	0.46

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

Appendix 1.14: Frequency of medicines according to ATC classification and gender in clinics 3 & 4

ATC group in clinic 3 & 4	CLINIC 3				CLINIC 4			
	Male		Female		Male		Female	
	n	%	n	%	n	%	n	%
Stomatological preparations	1	0.24			2	0.97		
Antacids, drugs for treatment of peptic ulcer and flatulence	2	0.47	6	0.76	3	1.45	6	1.89
Antispasmodic and anticholinergic agents								
Anti-emetics and anti-nauseants								
Laxatives								
Antidiarrhoeals			4	0.51	3	1.45	2	0.63
Digestives, including enzymes								
Oral hypoglycemics			8	1.02				
Vitamins	124	29.38	164	19.75	36	17.39	18	5.66
Mineral supplements								
Food supplements	20	4.74	18	2.29	35	16.91	29	9.12
Anti-anaemic preparations	1	0.24	31	3.95	1	0.48	24	7.55
Plasma substitutes and perfusion solutions								
Cardiac therapy			1	0.13				
Antihypertensives	8	1.90	56	7.13	3	1.45	29	9.12
Diuretics	7	1.66	48	6.11	4	1.93	29	9.12
Vasoprotectives							1	0.31
Beta blocking agents			3	0.38			3	0.94

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

APPENDIX 1.14 CONT'D	CLINIC 3				CLINIC 4			
	Male		Female		Male		Female	
ATC group in clinic 3 & 4	n	%	n	%	n	%	n	%
Antifungals for dermatological use	2	0.47	4	0.51	3	1.45	1	0.31
Emollients and protectants			1	0.13	1	0.48		
Anti-pruritics and topical anaesthetics			3	0.38			2	0.63
Corticosteroids for dermatological use			1	0.13				
Antiseptics and disinfectants	1	0.24	1	0.13	2	0.97	3	0.94
Anti-acne preparations								
Gyaenecological anti-infectives and antiseptics			5	0.64			1	0.31
Sex hormones and modulators of the genital system			101	12.87			42	13.21
Corticosteroids for systemic use								
Antibacterials for systemic use	22	5.21	46	5.86	11	5.31	25	7.86
Antimycobacterials	139	32.94	109	13.89	38	18.36	9	2.83
Immune sera and immunoglobins								
Vaccines	50	11.85	56	8.41	22	10.63	7	2.20
Anti-inflammatory and anti-rheumatic agents								
Topical products for joint and muscular pain	1	0.24	4	0.51	5	2.42	3	0.94
Analgesics	28	6.64	61	7.77	19	9.18	37	11.64
Anti-epileptics	2	0.47	1	0.13	5	2.42	5	1.57
Psycholeptics								
Psychoanaleptics								

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

APPENDIX 1.14 CONT'D	CLINIC 3				CLINIC 4			
	Male		Female		Male		Female	
ATC group in clinic 3 & 4	n	%	n	%	n	%	n	%
Anti-protozoals			12	1.53			7	2.20
Anthelmentics			2	0.25			1	0.31
Ectoparasiticides, including scabicides	1	0.24	1	0.13	1	0.48	2	0.63
Nasal preparations			3	0.38	2	0.97		
Anti-astmatic agents	9	2.13	21	2.68	9	4.35	21	6.60
Cough and cold preparations								
Antihistamines for systemic use	3	0.71	10	1.27	1	0.48	6	1.89
Opthalmologicals	1	0.24	2	0.25	1	0.48	4	1.26
Otologicals								
All other therapeutic products			1	0.13			1	0.31

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

Appendix 1.15: Frequency of medicines according to ATC classification and gender in clinics 5 & 6

ATC group in clinic 5 & 6	CLINIC 5				CLINIC 6			
	Male		Female		Male		Female	
	n	%	n	%	n	%	n	%
Stomatological preparations			2	0.49	1	0.24	1	0.17
Antacids, drugs for treatment of peptic ulcer and flatulence	2	0.92	8	1.96	2	0.48	3	0.51
Antispasmodic and anticholinergic agents								
Antiemetics and antinauseants								
Laxatives			1	0.25	1	0.24	2	0.34
Anti-diarrhoeals	2	0.92			3	0.72		
Digestives, including enzymes								
Oral hypoglycemics	3	1.38	17	4.17	1	0.24	2	0.34
Vitamins	9	4.13	16	3.92	22	5.28	12	2.05
Mineral supplements								
Food supplements	1	0.46	9	2.21	35	8.39	64	10.96
Anti-anaemic preparations			6	1.47	1	0.24	13	2.23
Plasma substitutes and perfusion solutions								
Cardiac therapy								
Antihypertensives	25	11.47	42	10.29	7	1.68	39	6.68
Diuretics	20	9.17	35	8.58	6	1.44	37	6.34
Vasoprotectives			1	0.25	1	0.24		
Beta blocking agents	1	0.46	5	1.23			1	0.17

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

APPENDIX 1.15 CONT'D	CLINIC 5				CLINIC 6			
	Male		Female		Male		Female	
ATC group in clinic 5 & 6	n	%	n	%	n	%	n	%
Antifungals for dermatological use	1	0.46	4	0.98	4	0.96	3	0.51
Emollients and protectants	1	0.46	4	0.98			3	0.51
Anti-pruritics and topical anaesthetics	2	0.92					5	0.86
Corticosteroids for dermatological use					1	0.24	4	0.68
Antiseptics and disinfectants	2	0.92	1	0.25	2	0.48	2	0.34
Anti-acne preparations								
Gyaenecological anti-infectives and antiseptics			1	0.25				
Sex hormones and modulators of the genital system			37	9.07			49	8.39
Corticosteroids fpr systemic use								
Antibacterials for systemic use	6	2.75	14	3.43	16	3.84	19	3.25
Antimycobacterials	72	33.03	111	27.21	231	55.40	156	26.71
Immune sera and immunoglobins								
Vaccines	17	7.80	17	4.17	18	4.32	57	9.76
Anti-inflammatory and anti-rheumatic agents								
Topical products for joint and muscular pain	6	2.75	14	3.43	1	0.24	3	0.51
Analgesics	20	9.17	38	9.31	34	8.15	59	10.10
Anti-epileptics	4	1.83	1	0.25	3	0.72	2	0.34
Psycholeptics								
Psychoanaleptics								

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

APPENDIX 1.15 CONT'D	CLINIC 5				CLINIC 6			
	Male		Female		Male		Female	
ATC group in clinic 5 & 6	n	%	n	%	n	%	n	%
Anti-protozoals			2	0.49	1	0.24	2	0.34
Anthelmentics			1	0.25	1	0.24		
Ectoparasiticides, including scabicides	1	0.46	2	0.49	3	0.72	1	0.17
Nasal preparations							1	0.17
Anti-astmatic agents	20	9.17	13	3.19	20	4.80	30	5.14
Cough and cold preparations								
Antihistamines for systemic use	1	0.46	3	0.74	2	0.48	12	2.05
Opthalmologicals	1	0.46					1	0.17
Otologicals								
All other therapeutic products	1	0.46	3	0.74			1	0.17

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

Appendix 1.16: Frequency of medicines according to ATC classification in relation to age group in all clinics

ATC group in all clinics	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Stomatological preparations	3	0.39	2	3.28			1	0.05	1	0.08		
Antacids, drugs for treatment of peptic ulcer and flatulence	2	0.26					27	1.38	9	0.70	8	2.31
Antispasmodic and anticholinergic agents												
Anti-emetics and anti-nauseants							1	0.05				
Laxatives							3	0.15	1	0.08	3	0.86
Anti-diarrhoeals	8	1.04					6	0.31	1	0.08		
Digestives, including enzymes												
Oral hypoglycemics							2	0.10	13	1.01	25	7.20
Vitamins	44	5.74	3	4.92	10	8.85	270	13.81	127	9.82	18	5.19
Mineral supplements							1	0.05				
Food supplements	137	17.89	3	4.92			44	2.25	27	2.09		
Anti-anaemic preparations	2	0.26			7	6.19	68	3.48	3	0.23	1	0.29
Plasma substitutes and perfusion solutions												
Cardiac therapy											1	0.29
Antihypertensives	2	0.26					39	1.99	131	10.13	93	26.80

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

APPENDIX 1.16 CONT'D ATC group in all clinics	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Diuretics	1	0.13					41	2.10	117	9.05	88	25.36
Vasoprotectives							3	0.15	1	0.08		
Beta blocking agents	1	0.13					4	0.20	16	1.24	3	0.86
Antifungals for dermatological use	4	0.52	3	4.92	4	3.54	10	0.51	9	0.70		
Emollients and protectants	5	0.65	1	1.64	1	0.88	6	0.31	1	0.08		
Antipruritics and topical anaesthetics	3	0.39	1	1.64	2	1.77	4	0.20	3	0.23		
Corticosteroids for dermatological use	2	0.26					4	0.20	2	0.15		
Antiseptics and disinfectants	3	0.39	5	8.20	1	0.88	3	0.15	1	0.08	1	0.29
Anti-acne preparations												
Gyaenecological anti-infectives and antiseptics					1	0.88	6	0.31	1	0.08		
Sex hormones and modulators of the genital system					21	18.58	155	7.93	16	1.24	1	0.29
Corticosteroids for systemic use											1	0.29
Antibacterials for systemic use	37	4.83	7	11.48	9	7.96	109	5.58	24	1.86	3	0.86
Antimycobacterials	110	14.36			24	21.24	915	46.80	627	48.49	10	2.88
Immune sera and immunoglobins												
Vaccines	224	29.24	6	9.84	3	2.65	16	0.82				

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

APPENDIX 1.16 CONT'D ATC group in all clinics	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Anti-inflammatory and anti-rheumatic agents												
Topical products for joint and muscular pain	1	0.13	1	1.64			7	0.36	14	1.08	19	5.48
Analgesics	75	9.79	15	24.59	15	13.27	104	5.32	94	7.27	49	14.12
Anti-epileptics	1	0.13			2	1.77	10	0.51	9	0.70	2	0.58
Psycholeptics												
Psychoanaleptics												
Anti-protozoals					1	0.88	19	0.97	5	0.39		
Anthelmentics	2	0.26	1	1.64			1	0.05	1	0.08		
Ectoparasiticides, including scabicides	5	0.65	1	1.64			3	0.15	3	0.23		
Nasal preparations					1	0.88	4	0.20	1	0.08		
Anti-astmatic agents	69	9.01	9	14.75	3	2.65	40	2.05	26	2.01	20	5.76
Cough and cold preparations												
Antihistamines for systemic use	19	2.48	3	4.92	5	4.42	16	0.82	5	0.39	1	0.29
Opthalmologicals	6	0.78			1	0.88	3	0.15	3	0.23		
Otologicals												
All other therapeutic products					2	1.77	10	0.51				

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

Appendix 1.17: Frequency of medicines according to ATC classification system and age group in clinic 1

CLINIC 1 ATC group	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Stomatological preparations							6	7.59				
Antacids, drugs for treatment of peptic ulcer and flatulence									3	4.76	3	6.12
Antispasmodic and anticholinergic agents							1	1.27				
Anti-emetics and anti-nauseants							2	2.53				
Laxatives											1	2.04
Anti-diarrhoeals												
Digestives, including enzymes												
Oral hypoglycemics											1	2.04
Vitamins	1	4.76					4	5.06	5	7.94	2	4.08
Mineral supplements							1	1.27				
Food supplements												
Antianaemic preparations							3	3.80	2	3.17		
Plasma substitutes and perfusion solutions												
Cardiac therapy												
Antihypertensives							4	5.06	9	14.29	10	20.41

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

APPENDIX 1.17 CONT'D ATC group in clinic 1	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Diuretics							5	6.33	9	14.29	20	40.82
Vasoprotectives							1	1.27				
Beta blocking agents							2	2.53	3	4.76	1	2.04
Antifungals for dermatological use					2	28.57	3	3.80	2	3.17		
Emollients and protectants	2	9.52					1	1.27				
Antipruritics and topical anaesthetics									1	1.59		
Corticosteroids for dermatological use							2	2.53				
Antiseptics and disinfectants												
Anti-acne preparations												
Gyaenecological anti-infectives and antiseptics							1	1.27				
Sex hormones and modulators of the genital system												
Corticosteroids for systemic use											1	2.04
Antibacterials for systemic use	3	14.29			1	14.29	14	17.72	6	9.52		
Antimycobacterials												
Immune sera and immunoglobins												
Vaccines												

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

APPENDIX 1.17 CONT'D ATC group in clinic 1	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Anti-inflammatory and anti-rheumatic agents												
Topical products for joint and muscular pain							1	1.27	1	1.59	1	2.04
Analgesics			3	60.00	3	42.86	16	20.25	13	20.63	8	16.33
Anti-epileptics	1	4.76										
Psycholeptics												
Psychoanaleptics												
Anti-protozoals							1	1.27				
Anthelmentics												
Ectoparasiticides, including scabicides												
Nasal preparations												
Anti-astmatic agents	5	23.81	2	40.00			4	5.06	5	7.94	1	2.04
Cough and cold preparations												
Antihistamines for systemic use	5	23.81			1	14.29	4	5.06	1	1.59		
Opthalmologicals	1	4.76							2	3.17		
Otologicals												
All other therapeutic products							3	3.80				

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

Appendix 1.18: Frequency of medicines according to ATC classification system and age group in clinic 2

CLINIC 2 ATC group	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Stomatological preparations												
Antacids, drugs for treatment of peptic ulcer and flatulence							2	0.44				
Antispasmodic and anticholinergic agents												
Anti-emetics and anti-nauseants												
Laxatives												
Antidiarrhoeals							1	0.22				
Digestives, including enzymes												
Oral hypoglycemics									5	1.09	3	7.14
Vitamins							48	10.55	20	4.37	1	2.38
Mineral supplements												
Food supplements							1	0.22				
Anti-anaemic preparations												
Plasma substitutes and perfusion solutions												
Cardiac therapy												
Antihypertensives									16	3.49	19	45.24

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

APPENDIX 1.18 CONT'D CLINIC 2 ATC group	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Diuretics							1	0.22	16	3.49	11	26.19
Vasoprotectives												
Beta blocking agents							1	0.22	3	0.66	1	2.38
Antifungals for dermatological use					1	50.00						
Emollients and protectants							1	0.22				
Anti-pruritics and topical anaesthetics												
Corticosteroids for dermatological use												
Antiseptics and disinfectants												
Anti-acne preparations												
Gyaenecological anti-infectives and antiseptics												
Sex hormones and modulators of the genital system												
Corticosteroids fpr systemic use												
Antibacterials for systemic use							5	1.10			1	2.38
Antimycobacterials	43	89.58					384	84.40	394	86.03		
Immune sera and immunoglobins												
Vaccines	1	2.08										

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

APPENDIX 1.18 CONT'D CLINIC 2 ATC group	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Anti-inflammatory and anti-rheumatic agents												
Topical products for joint and muscular pain									1	0.22	1	2.38
Analgesics	2	4.17					6	1.32	3	0.66	2	4.76
Anti-epileptics												
Psycholeptics												
Psychoanaleptics												
Anti-protozoals												
Anthelmentics												
Ectoparasiticides, including scabicides												
Nasal preparations												
Anti-astmatic agents	2	4.17					4	0.88			3	7.14
Cough and cold preparations												
Antihistamines for systemic use												
Opthalmologicals												
Otologicals												
All other therapeutic products					1	50.00	1	0.22				

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

Appendix 1.19: Frequency of medicines according to ATC classification system and age group in clinic 3

CLINIC 3 ATC group	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Stomatological preparations	1	0.52										
Antacids, drugs for treatment of peptic ulcer and flatulence	1	0.52					6	1.01			1	1.75
Antispasmodic and anticholinergic agents												
Anti-emetics and anti-nauseants												
Laxatives												
Anti-diarrhoeals	3	1.57					1	0.17				
Digestives, including enzymes												
Oral hypoglycemics									3	0.92	5	8.77
Vitamins	11	5.76	1	7.69	5	23.08	174	29.29	84	25.85	4	7.02
Mineral supplements												
Food supplements	24	12.57					7	1.18	7	2.15		
Anti-anaemic preparations	1	0.52			4	19.05	27	4.55				
Plasma substitutes and perfusion solutions												
Cardiac therapy											1	1.75
Antihypertensives	2	1.05					7	1.18	40	12.31	13	22.81

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

APPENDIX 1.19 CONT'D CLINIC 3 ATC group	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Diuretics	1	0.52					16	2.69	29	8.92	8	14.04
Vasoprotectives												
Beta blocking agents	1	0.52							1	0.31	1	1.75
Antifungals for dermatological use							5	0.84	1	0.31		
Emollients and protectants	1	0.52										
Antipruritics and topical anaesthetics							2	0.34	1	0.31		
Corticosteroids for dermatological use									1	0.31		
Antiseptics and disinfectants							2	0.34				
Anti-acne preparations												
Gyaenecological anti-infectives and antiseptics					1	4.76	4	0.67				
Sex hormones and modulators of the genital system					5	23.81	82	13.80	14	4.31		
Corticosteroids for systemic use												
Antibacterials for systemic use	11	5.76	1	7.639			46	7.74	9	2.77	1	1.75
Antimycobacterials	4	2.09					145	24.41	89	27.38	10	17.54
Immune sera and immunoglobins												
Vaccines	90	47.12	5	38.46	3	14.29	16	2.69				

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

APPENDIX 1.19 CONT'D CLINIC 3 ATC group	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Anti-inflammatory and anti-rheumatic agents												
Topical products for joint and muscular pain			1	7.69			1	0.17	2	0.62	1	1.75
Analgesics	22	11.52	3	23.08	1	4.76	29	4.88	26	8.00	7	12.28
Anti-epileptics							1	0.17	2	0.62		
Psycholeptics												
Psychoanaleptics												
Anti-protozoals							9	1.52	3	0.92		
Anthelmentics			1	7.69			1	0.17				
Ectoparasiticides, including scabicides							2	0.34				
Nasal preparations					1	4.76	1	0.17	1	0.31		
Antiastmatic agents	9	4.71	1	7.69			6	1.01	9	2.77	5	8.77
Cough and cold preparations												
Antihistamines for systemic use	7	3.66			1	4.76	2	0.34	3	0.92		
Opthalmologicals	2	1.05					1	0.17				
Otologicals												
All other therapeutic products							1	0.17				

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

Appendix 1.20: Frequency of medicines according to ATC classification system and age group in clinic 4

CLINIC 4 ATC group	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Stomatological preparations			2	11.76								
Antacids, drugs for treatment of peptic ulcer and flatulence							6	2.33	3	3.19		
Antispasmodic and anticholinergic agents												
Anti-emetics and anti-nauseants												
Laxatives												
Anti-diarrhoeals	1	0.85					3	1.17	1	1.06		
Digestives, including enzymes												
Oral hypoglycemics												
Vitamins	9	7.69	1	5.88	3	13.64	31	12.06	8	8.51	2	11.11
Mineral supplements												
Food supplements	32	27.35	3	17.65			24	9.34	5	5.32		
Anti-anaemic preparations	1	0.85			1	4.55	23	8.95				
Plasma substitutes and perfusion solutions												
Cardiac therapy												
Antihypertensives							13	5.06	16	17.02	3	16.67

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

APPENDIX 1.20 CONT'D CLINIC 4 ATC group	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Diuretics							13	5.06	16	17.02	4	22.22
Vasoprotectives							1	0.39				
Beta blocking agents							1	0.39	2	2.13		
Antifungals for dermatological use	1	0.85	2	11.76			1	0.39				
Emollients and protectants	1	0.85										
Anti-pruritics and topical anaesthetics	2	1.71										
Corticosteroids for dermatological use												
Antiseptics and disinfectants	1	0.85	3	17.65	1	4.55						
Anti-acne preparations												
Gyaenecological anti-infectives and antiseptics							1	0.39				
Sex hormones and modulators of the genital system					7	31.82	33	12.84	2	2.13		
Corticosteroids fpr systemic use												
Antibacterials for systemic use	3	2.56	1	5.88	4	18.18	23	8.95	5	5.32		
Antimycobacterials							42	16.34	5	5.32		
Immune sera and immunoglobins												
Vaccines	29	24.79										

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

APPENDIX 1.20 CONT'D CLINIC 4 ATC group	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Anti-inflammatory and anti-rheumatic agents												
Topical products for joint and muscular pain							1	0.39	3	3.19	4	22.22
Analgesics	13	11.11	4	23.53	2	9.09	18	7.00	14	14.89	5	27.78
Anti-epileptics					2	9.09	3	1.17	5	5.32		
Psycholeptics												
Psychoanaleptics												
Anti-protozoals					1	4.55	5	1.95	1	1.06		
Anthelmentics	1	0.85										
Ectoparasiticides, including scabicides	2	1.71							1	1.06		
Nasal preparations							2	0.78				
Anti-astmatic agents	17	14.53			1	4.55	6	2.33	6	6.38		
Cough and cold preparations												
Antihistamines for systemic use	1	0.85	1	5.88			4	1.56	1	1.06		
Opthalmologicals	3	2.56					2	0.78				
Otologicals												
All other therapeutic products							1	0.39				

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

Appendix 1.21: Frequency of medicines according to ATC classification system and age group in clinic 5

CLINIC 5 ATC group	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Stomatological preparations	1	1.45							1	0.91		
Antacids, drugs for treatment of peptic ulcer and flatulence							4	1.72	2	1.82	4	3.13
Antispasmodic and anticholinergic agents												
Antiemetics and antinauseants												
Laxatives											1	0.78
Antidiarrhoeals	1	1.45					1	0.43				
Digestives, including enzymes												
Oral hypoglycemics							2	0.86	4	3.64	14	10.94
Vitamins	6	8.70	1	5.26	1	3.57	4	1.72	4	3.64	8	6.25
Mineral supplements												
Food supplements	1	1.45					9	3.86				
Anti-anaemic preparations							4	1.72	1	0.91	1	0.78
Plasma substitutes and perfusion solutions												
Cardiac therapy												
Antihypertensives							3	1.29	29	26.36	35	27.34

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

APPENDIX 1.21 CONT'D CLINIC 5 ATC group	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Diuretics							1	0.43	25	22.73	29	22.66
Vasoprotectives									1	0.91		
Beta blocking agents									6	5.45		
Antifungals for dermatological use	2	2.90							3	2.73		
Emollients and protectants	1	1.45					3	1.29	1	0.91		
Antipruritics and topical anaesthetics			1	5.26			1	0.43				
Corticosteroids for dermatological use												
Antiseptics and disinfectants	1	1.45	1	5.26			1	0.43				
Anti-acne preparations												
Gyaenecological anti-infectives and antiseptics									1	0.91		
Sex hormones and modulators of the genital system											1	0.78
Corticosteroids for systemic use												
Antibacterials for systemic use	5	7.25	4	21.05			8	3.43	3	2.73		
Antimycobacterials	2	2.90			24	85.71	157	67.38				
Immune sera and immunoglobins												
Vaccines	33	47.83	1	5.26								

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

APPENDIX 1.21 CONT'D CLINIC 5 ATC group	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Anti-inflammatory and anti-rheumatic agents												
Topical products for joint and muscular pain	1	1.45					4	1.72	6	5.45	9	7.03
Analgesics	12	17.39	4	21.05	1	3.57	9	3.86	13	11.82	18	14.06
Anti-epileptics							3	1.29	2	1.82		
Psycholeptics												
Psychoanaleptics												
Anti-protozoals							1	0.43	1	0.91		
Anthelmentics									1	0.91		
Ectoparasiticides, including scabicides			1	5.26					2	1.82		
Nasal preparations												
Anti-astmatic agents	3	4.35	5	26.32	1	3.57	13	5.58	3	2.73	7	5.47
Cough and cold preparations												
Antihistamines for systemic use			1	5.26			2	0.86			1	0.78
Opthalmologicals									1	0.91		
Otologicals												
All other therapeutic products					1	3.57	3	1.29				

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

Appendix 1.22: Frequency of medicines according to ATC classification system and age group in clinic 6

CLINIC 6 ATC group	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Stomatological preparations	1	0.31					1	0.30				
Antacids, drugs for treatment of peptic ulcer and flatulence	1	0.31					3	0.89	1	0.41		
Antispasmodic and anticholinergic agents												
Anti-emetics and anti-nauseants												
Laxatives							1	0.30	1	0.41	1	1.89
Antidiarrhoeals	3	0.94										
Digestives, including enzymes												
Oral hypoglycemics									1	0.41	2	3.77
Vitamins	17	5.31			1	3.03	9	2.67	6	2.47	1	1.89
Mineral supplements												
Food supplements	80	25.00					3	0.89	15	6.17		
Anti-anaemic preparations					2	6.06	11	3.26				
Plasma substitutes and perfusion solutions												
Cardiac therapy												
Antihypertensives							12	3.56	21	8.64	13	24.53

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

APPENDIX 1.22 CONT'D CLINIC 6 ATC group	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Diuretics							5	1.48	22	9.05	16	30.19
Vasoprotectives							1	0.30				
Beta blocking agents									1	0.41		
Antifungals for dermatological use	1	0.31	1	14.29	1	3.03	1	0.30	3	1.23		
Emollients and protectants			1	14.29	1	3.03	1	0.30				
Antipruritics and topical anaesthetics	1	0.31			2	6.06	1	0.30	1	0.41		
Corticosteroids for dermatological use	2	0.63					2	0.59	1	0.41		
Antiseptics and disinfectants	1	0.31	1	14.29					1	0.41	1	1.89
Anti-acne preparations												
Gyaenecological anti-infectives and antiseptics												
Sex hormones and modulators of the genital system					9	27.27	40	11.87				
Corticosteroids for systemic use												
Antibacterials for systemic use	15	4.69	1	14.29	4	12.12	13	3.86	1	0.41	1	1.89
Antimycobacterials	61	19.06					187	55.49	139	57.20		
Immune sera and immunoglobins												
Vaccines	71	22.19										

APPENDIX 1: RESULTS OF ATC CLASS ANALYSIS

APPENDIX 1.22 CONT'D CLINIC 6 ATC group	Age Group 0 ≥ 6 years		Age Group 6 ≥ 12 years		Age Group 12 ≥ 19 years		Age Group 19 ≥ 40 years		Age Group 40 ≥ 60 years		Age Group >60 years	
	n	%	n	%	n	%	n	%	n	%	n	%
Anti-inflammatory and anti-rheumatic agents												
Topical products for joint and muscular pain									1	0.41	3	5.66
Analgesics	23	7.19	1	14.29	8	24.24	26	7.72	25	10.29	9	16.98
Anti-epileptics							3	0.89			2	3.77
Psycholeptics												
Psychoanaleptics												
Anti-protozoals							3	0.89				
Anthelmentics	1	0.31										
Ectoparasiticides, including scabicides	3	0.94					1	0.30				
Nasal preparations							1	0.30				
Antiastmatic agents	33	10.31	1	14.29	1	3.03	7	2.08	3	1.23	4	7.55
Cough and cold preparations												
Antihistamines for systemic use	6	1.88	1	14.29	3	9.09	4	1.19				
Opthalmologicals					1	3.03						
Otologicals												
All other therapeutic products							1	0.30				

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Appendix 1.23 : Therapeutic budget group parameters in all clinics

Therapeutic budget group	Frequency parameters		Cost related parameters			
	Frequency n	Frequency Percentage) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Anti-effectives	226	4.82	4.85 ±8.02	1096.57	5.57	1.16
Cardiovascular agents	627	13.37	6.42 ±7.82	4026.85	20.47	1.53*
Dermatologicals	147	3.13	2.45 ±4.86	359.44	1.83	0.58
Endocrine	347	7.40	6.04 ±3.91	2095.72	10.65	1.44
Functional	26	0.55	18.95 ±18.95	492.73	2.51	4.56*
Gastro-intestinals	766	16.33	4.52 ±6.05	3460.98	17.59	1.08
Pain relievers	356	7.59	0.59 ±0.13	212.34	1.08	0.14
Immunologicals	259	5.52	4.95 ±8.16	1281.54	6.52	1.18
Respiratory agents	1931	41.16	3.37 ±4.25	6503.59	33.06	0.80
Uro-genital	06	0.13	23.29 ±6.39	139.74	0.71	5.46*
Total	**4691**	**100.00**		**19669.50**	**99.99**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Appendix 1.24 : Therapeutic budget group parameters in clinic 1

Therapeutic budget group	Frequency parameters		Cost related parameters			
	Frequency n	Frequency Percentage) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Anti-effectives	28	12.23	4.99 ±5.43	139.74	19.00	1.55*
Cardiovascular agents	71	31.00	4.29 ±4.39	304.60	41.41	1.34
Dermatologicals	17	7.42	1.98 ±2.07	33.74	4.59	0.62
Endocrine	02	0.87	4.84 ±4.45	9.67	1.31	1.51*
Functional	02	0.87	16.21 ±21.41	32.42	4.41	5.07*
Gastro-intestinals	31	13.54	4.44 ±4.20	137.62	18.71	1.38
Pain relievers	47	20.52	0.53 ±0.02	25.07	3.41	0.17
Immunologicals	03	1.31	1.86 ±0.00	5.58	0.76	0.58
Respiratory agents	28	12.23	1.68 ±1.23	47.13	6.41	0.52
Uro-genital	0.0	0.0		0.00	0.00	
Total	**229**	**99.99**		**735.57**	**100.01**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Appendix 1.25 : Therapeutic budget group parameters in clinic 2

Therapeutic budget group	Frequency parameters		Cost related parameters			
	Frequency n	Frequency Percentage %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Anti-effectives	06	0.54	3.61 ±1.77	21.65	0.68	1.26
Cardiovascular agents	68	6.17	6.58 ±6.11	447.60	14.16	2.29*
Dermatologicals	04	0.36	2.07 ±2.79	8.27	0.26	0.72
Endocrine	85	7.71	6.24 ±3.94	530.71	16.79	2.18*
Functional	00	0.00		0.00	0.00	
Gastro-intestinals	74	6.71	0.29 ±1.47	22.10	0.69	0.10
Pain relievers	13	1.18	0.56 ±0.09	7.27	0.23	0.17
Immunologicals	03	0.27	1.41 ±0.78	4.23	0.13	0.48
Respiratory agents	850	77.06	2.49 ±1.27	2119.47	67.04	0.87
Uro-genital	00	0.00		0.00	0.00	
Total	**1103**	**100**		**3161.3**	**99.98**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Appendix 1.26 : Therapeutic budget group parameters in clinic 3

Therapeutic budget group	Frequency parameters		Cost related parameters			
	Frequency n	Frequency Percentage %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Anti-effectives	81	6.71	6.71 ±12.21	543.44	9.15	1.36
Cardiovascular agents	155	12.84	7.51 ±10.52	1163.67	19.60	1.53*
Dermatologicals	25	2.07	3.35 ±6.59	83.78	1.41	0.68
Endocrine	109	9.03	6.51 ±4.39	709.43	11.95	1.32
Functional	03	0.25	41.61 ±45.41	124.83	2.10	8.40*
Gastro-intestinals	331	27.42	1.96 ±3.75	648.98	10.93	0.39
Pain relievers	89	7.37	0.62 ±0.14	55.19	0.93	0.13
Immunologicals	109	9.03	5.39 ±8.52	586.98	9.89	1.09
Respiratory agents	300	24.86	6.37 ±8.12	1909.92	32.17	1.29
Uro-genital	05	0.40	22.12 ±6.39	110.61	1.87	4.68*
Total	**1207**	**99.98**		**5936.83**	**100.00**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Appendix 1.27 : Therapeutic budget group parameters in clinic 4

Therapeutic budget group	Frequency parameters		Cost related parameters			
	Frequency n	Frequency Percentage n %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Anti-effectives	45	8.57	2.92 ±1.73	131.29	4.66	0.54
Cardiovascular agents	93	17.71	4.66 ±6.06	433.38	15.38	0.87
Dermatologicals	28	5.33	2.45 ±2.39	68.62	2.43	0.46
Endocrine	42	8.00	5.09 ±1.11	214.05	7.59	0.95
Functional	11	2.10	11.41 ±9.59	125.47	4.45	2.12*
Gastro-intestinals	136	25.90	7.99 ±8.43	1086.21	38.54	1.49
Pain relievers	56	10.67	0.61 ±0.13	33.91	1.20	0.11
Immunologicals	30	5.71	5.44 ±8.55	163.10	5.79	1.01
Respiratory agents	83	15.81	6.42 ±8.07	532.95	18.91	1.19
Uro-genital	01	0.19	29.13 ±0.00	29.13	1.03	5.42*
Total	**525**	**99.99**		**2818.11**	**99.98**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Appendix 1.28 : Therapeutic budget group parameters in clinic 5

Therapeutic budget group	Frequency parameters		Cost related parameters			
	Frequency n	Frequency Percentage %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Anti-effectives	23	3.67	4.99 ±5.89	114.91	3.96	1.08
Cardiovascular agents	134	21.41	7.95 ±8.31	1064.63	36.73	1.72*
Dermatologicals	41	6.55	2.66 ±7.22	109.17	3.77	0.58
Endocrine	57	9.11	6.44 ±4.29	366.91	12.66	1.39
Functional	05	0.80	23.42 ±15.75	117.10	4.04	5.05*
Gastro-intestinals	51	8.15	5.88 ±5.52	299.92	10.35	1.27
Pain relievers	58	9.27	0.60 ±0.15	35.07	1.21	0.13
Immunologicals	38	6.07	3.23 ±6.63	122.91	4.24	0.69
Respiratory agents	219	34.98	3.05 ±3.91	668.16	23.05	0.66
Uro-genital	00	0.00		0.00	0.00	
Total	**626**	**100.01**		**2898.78**	**100.01**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Appendix 1.29 : Therapeutic budget group parameters in clinic 6

Therapeutic budget group	Frequency parameters		Cost related parameters			
	Frequency n	Frequency Percentage %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Anti-effectives	43	4.30	3.38 ±2.68	145.53	3.53	0.82
Cardiovascular agents	106	10.59	5.78 ±5.92	612.97	14.88	1.41
Dermatologicals	32	3.20	1.75 ±0.91	55.86	1.36	0.43
Endocrine	52	5.19	5.09 ±3.65	264.95	6.43	1.24
Functional	05	0.50	18.58 ±7.14	92.91	2.26	4.52*
Gastro-intestinals	143	14.29	8.85 ±5.07	1266.15	30.74	2.15*
Pain relievers	93	9.29	0.60 ±0.14	55.83	1.36	0.15
Immunologicals	76	7.59	5.25 ±8.48	398.74	9.68	1.28
Respiratory agents	451	45.05	2.72 ±1.22	1225.97	29.76	0.66
Uro-genital	00	0.00		0.00	0.00	
Total	**1001**	**100.00**		**4118.91**	**100.00**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Appendix 1.30 : Parameters of Therapeutic budget group in relation to age group in all clinics

Therapeutic budget group in all clinics	Age Group (years)	Frequency parameters		Cost related parameters			
		Frequency n	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Anti-effectives	0 ≥ 6	37	16.37	3.24 ±2.21	119.96	10.94	0.67
	6 ≥ 12	10	4.42	5.38 ±2.19	53.84	4.91	1.10
	12 ≥ 19	11	4.87	3.17 ±1.67	34.91	3.18	0.65
	19 ≥ 40	133	58.84	5.28 ±9.81	702.53	64.07	1.09
	40 ≥ 60	32	14.16	5.02 ±6.08	160.54	14.64	1.03
	>60	03	1.33	8.26 ±10.24	24.78	2.26	1.70*
Total		**226**	**99.99**		**1096.56**	**100.00**	
Cardiovascular agents	0 ≥ 6	06	0.97	8.37 ±5.46	50.23	1.26	1.29
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	07	1.13	1.42 ±0.56	9.91	0.25	0.22
	19 ≥ 40	154	24.84	4.05 ±6.35	622.94	15.61	0.63
	40 ≥ 60	267	43.06	7.13 ±8.66	1902.74	47.69	1.11
	>60	186	30.00	7.55 ±7.47	1404.32	35.19	1.17
Total		**620**	**100.00**		**3990.14**	**100.00**	
Dermatologicals	0 ≥ 6	31	21.09	4.46 ±8.11	138.41	38.51	1.83*
	6 ≥ 12	09	6.12	1.97 ±0.88	17.74	4.94	0.81
	12 ≥ 19	09	6.12	2.37 ±1.84	21.30	5.93	0.97
	19 ≥ 40	41	27.89	1.79 ±1.70	73.19	20.36	0.73
	40 ≥ 60	37	25.17	2.56 ±5.55	94.66	26.33	1.05
	>60	20	13.61	0.71 ±0.58	14.14	3.93	0.29
Total		**147**	**100.00**		**359.44**	**100.00**	
Endocrine	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	21	8.97	5.23 ±0.62	109.73	7.30	0.81
	19 ≥ 40	157	67.09	5.29 ±1.48	830.25	55.24	0.82
	40 ≥ 60	29	12.39	9.49 ±9.03	275.10	18.30	1.48
	>60	27	11.54	10.66 ±7.41	287.88	19.15	1.66*
Total		**234**	**99.99**		**1502.96**	**99.99**	
Functional	0 ≥ 6	01	3.85	31.35	31.35	6.36	1.65*
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	02	7.69	7.70	15.40	3.13	0.41
	19 ≥ 40	12	46.15	15.76 ±12.79	189.07	38.37	0.83
	40 ≥ 60	09	34.62	25.12 ±28.03	226.13	45.89	1.33
	>60	02	7.69	15.39	30.78	6.25	0.81
Total		**26**	**100.00**		**492.73**	**100.00**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Therapeutic budget group in all clinics	Age Group (Years)	Frequency n	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Gastro-intestinals	0 ≥ 6	192	25.16	9.03 ±5.47	1733.46	50.12	1.99*
	6 ≥ 12	09	1.18	4.69 ±5.46	42.18	1.22	1.03
	12 ≥ 19	11	1.44	1.85 ±3.53	20.36	0.59	0.41
	19 ≥ 40	354	46.39	2.89 ±5.79	1022.05	29.55	0.64
	40 ≥ 60	168	22.02	3.00 ±4.87	504.63	14.59	0.66
	>60	29	3.80	4.68 ±5.26	135.70	3.92	1.03
	Total	**763**	**99.99**		**3458.38**	**99.99**	
Pain relievers	0 ≥ 6	75	21.31	0.80 ±0.09	60.28	28.76	1.35
	6 ≥ 12	15	4.26	0.68 ±0.16	10.21	4.87	1.14
	12 ≥ 19	15	4.26	0.55 ±0.08	8.31	3.97	0.93
	19 ≥ 40	104	29.55	0.53 ±0.02	55.54	26.50	0.89
	40 ≥ 60	94	26.70	0.53 ±0.02	49.82	23.77	0.89
	>60	49	13.92	0.52 ±0.03	25.42	12.13	0.87
	Total	**352**	**100.00**		**209.58**	**100.00**	
Immunologicals	0 ≥ 6	226	89.33	5.33 ±8.46	1204.10	97.69	1.09
	6 ≥ 12	06	2.37	0.49 ±0.07	2.97	0.24	0.10
	12 ≥ 19	03	1.19	1.36 ±0.87	4.07	0.33	0.28
	19 ≥ 40	18	7.11	1.19 ±0.77	21.40	1.74	0.24
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**253**	**100.00**		**1232.54**	**100.00**	
Respiratory agents	0 ≥ 6	198	10.38	2.21 ±2.61	438.44	6.76	0.65
	6 ≥ 12	12	0.63	0.99 ±0.29	11.87	0.18	0.29
	12 ≥ 19	33	1.73	3.06 ±4.69	100.98	1.56	0.90
	19 ≥ 40	977	51.21	3.56 ±3.88	3476.52	53.61	1.05
	40 ≥ 60	657	34.43	3.33 ±4.71	2190.13	33.77	0.98
	>60	31	1.62	8.61 ±8.59	266.89	4.12	2.54*
	Total	**1908**	**100.00**		**6484.83**	**100.00**	
Uro-genital	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	16.67	29.13	29.13	20.85	1.25
	19 ≥ 40	05	83.33	22.12 ±6.39	110.61	79.15	0.95
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**06**	**100.00**		**139.74**	**100.00**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Appendix 1.31 : Parameters of Therapeutic budget group in relation to age group in clinic 1

Therapeutic budget group in clinic 1	Age Group (years)	Frequency parameters		Cost related parameters			
		Frequency n	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Anti-effectives	0 ≥ 6	03	10.71	5.04 ±3.81	15.13	10.83	1.01
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	02	7.14	4.36 ±2.67	8.72	6.24	0.87
	19 ≥ 40	17	60.71	5.53 ±6.64	94.04	67.29	1.11
	40 ≥ 60	06	21.43	3.64 ±2.83	21.85	15.64	0.73
	>60	00	0.00	0.00	0.00	0.00	00
Total		**28**	**99.99**		**139.74**	**100.00**	
Cardiovascular agents	0 ≥ 6	00	0.00	0.00	0.00	0.00	00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	00
	19 ≥ 40	14	20.59	2.97 ±1.06	41.59	13.90	0.68
	40 ≥ 60	23	33.82	4.00 ±3.36	92.09	30.78	0.91
	>60	31	45.59	5.34 ±5.79	165.49	55.32	1.21
Total		**68**	**100.00**		**299.17**	**100.00**	
Dermatologicals	0 ≥ 6	03	17.65	1.75 ±1.50	5.24	15.53	0.88
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	5.88	0.64	0.64	1.89	0.32
	19 ≥ 40	06	35.29	1.39 ±0.78	8.39	24.87	0.70
	40 ≥ 60	06	35.29	3.16 ±3.05	18.95	56.16	1.59*
	>60	01	5.88	0.52	0.52	1.54	0.26
Total		**17**	**99.99**		**33.74**	**99.99**	
Endocrine	0 ≥ 6	00	0.00	0.00	0.00	0.00	00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	00
	>60	02	100.00	4.84 ±4.45	9.67	100.00	1.00
Total		**02**	**100.00**		**9.67**	**100.00**	
Functional	0 ≥ 6	01	50.00	31.35	31.35	96.69	1.93*
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	00
	19 ≥ 40	01	50.00	1.07	1.07	3.31	0.06
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
Total		**02**	**100.00**		**32.42**	**100.00**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Therapeutic budget group in clinic 1	Age Group (Years)	Frequency n	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Gastro-intestinals	0 ≥ 6	01	3.23	0.65	0.65	0.47	0.15
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	00
	19 ≥ 40	15	48.39	5.78 ±4.52	86.68	62.98	1.30
	40 ≥ 60	09	29.03	3.55 ±4.52	31.98	23.24	0.80
	>60	06	19.35	3.05 ±2.04	18.31	13.30	0.69
	Total	**31**	**100.00**		**137.62**	**99.99**	
Pain relievers	0 ≥ 6	03	6.52	0.55	1.65	6.73	1.03
	6 ≥ 12	03	6.52	0.55	1.65	6.73	1.03
	12 ≥ 19	03	6.52	0.54 ±0.02	1.61	6.57	1.01
	19 ≥ 40	16	34.78	0.53 ±0.02	8.49	34.62	0.99
	40 ≥ 60	13	28.26	0.53 ±0.02	6.88	28.06	0.99
	>60	08	17.39	0.52 ±0.03	4.24	17.29	0.99
	Total	**46**	**99.99**		**24.52**	**100.00**	
Immunologicals	0 ≥ 6	00	0.00	0.00	0.00	0.00	00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	00
	19 ≥ 40	03	100.00	1.86	5.58	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	00
	>60	00	0.00	0.00	0.00	0.00	00
	Total	**03**	**100.00**		**5.58**	**100.00**	
Respiratory agents	0 ≥ 6	10	37.03	1.35 ±0.42	13.45	29.07	0.79
	6 ≥ 12	02	7.41	0.86	1.72	3.72	0.50
	12 ≥ 19	01	3.70	1.69	1.69	3.65	0.99
	19 ≥ 40	07	25.93	2.23 ±1.88	15.63	33.78	1.30
	40 ≥ 60	06	22.22	2.04 ±1.53	12.22	26.41	1.19
	>60	01	3.70	1.56	1.56	3.37	0.91
	Total	**27**	**99.99**		**46.27**	**100.00**	
Uro-genital	0 ≥ 6	0	0	0.00	0.00	0.00	00
	6 ≥ 12	0	0	0.00	0.00	0.00	00
	12 ≥ 19	0	0	0.00	0.00	0.00	00
	19 ≥ 40	0	0	0.00	0.00	0.00	00
	40 ≥ 60	0	0	0.00	0.00	0.00	00
	>60	0	0	0.00	0.00	0.00	00
	Total	**0**	**0**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Appendix 1.32 : Parameters of Therapeutic budget group in relation to age group in clinic 2

Therapeutic budget group in clinic 2	Age Group (years)	Frequency parameters		Cost related parameters			
		Frequency n	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Anti-effectives	0 ≥ 6	00	00	0.00	0.00	0.00	00
	6 ≥ 12	00	00	0.00	0.00	0.00	00
	12 ≥ 19	00	00	0.00	0.00	0.00	00
	19 ≥ 40	05	83.33	3.88 ±1.83	19.42	83.33	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	00
	>60	01	16.67	2.23	2.23	16.67	1.00
Total		**06**	**100.00**		**21.65**	**100.00**	
Cardiovascular agents	0 ≥ 6	00	0.00	0.00	0.00	0.00	00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	00
	19 ≥ 40	02	2.94	2.97 ±1.06	5.31	1.19	0.40
	40 ≥ 60	35	51.47	4.00 ±3.36	184.91	41.31	0.80
	>60	31	45.59	5.34 ±5.79	257.38	57.50	1.26
Total		**68**	**100.00**		**447.60**	**100.00**	
Dermatologicals	0 ≥ 6	00	0.00	0.00	0.00	0.00	00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	25.00	6.25	6.25	75.57	3.02*
	19 ≥ 40	01	25.00	0.98	0.98	11.85	0.47
	40 ≥ 60	01	25.00	0.52	0.52	6.29	0.25
	>60	01	25.00	0.52	0.52	6.29	0.25
Total		**04**	**100.00**		**8.27**	**100.00**	
Endocrine	0 ≥ 6	00	0.00	0.00	0.00	0.00	00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	00
	40 ≥ 60	05	62.50	12.14 ±11.77	62.05	53.51	0.86
	>60	03	37.50	17.97	53.91	46.49	1.24
Total		**08**	**100.00**		**115.96**	**100.00**	
Functional	0 ≥ 6	00	00	0.00	0.00	0.00	00
	6 ≥ 12	00	00	0.00	0.00	0.00	00
	12 ≥ 19	00	00	0.00	0.00	0.00	00
	19 ≥ 40	00	00	0.00	0.00	0.00	00
	40 ≥ 60	00	00	0.00	0.00	0.00	00
	>60	00	00	0.00	0.00	0.00	00
Total		**00**	**00**		**00**	**00**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Therapeutic budget group in clinic 2	Age Group (Years)	Frequency n	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Gastro-intestinals	0 ≥ 6	00	00	0.00	0.00	0.00	00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	00
	19 ≥ 40	52	71.23	0.37 ±1.74	19.10	92.05	1.29
	40 ≥ 60	20	27.40	0.05	1.00	4.82	0.18
	>60	01	1.37	0.65	0.65	3.13	2.28*
	Total	**73**	**100.00**		**20.75**	**100.00**	
Pain relievers	0 ≥ 6	02	15.38	0.70 ±0.21	1.39	19.12	1.24
	6 ≥ 12	00	00	0.00	0.00	0.00	00
	12 ≥ 19	00	00	0.00	0.00	0.00	00
	19 ≥ 40	06	46.15	0.53 ±0.02	3.22	44.29	0.96
	40 ≥ 60	03	23.08	0.55	1.65	22.70	0.98
	>60	02	15.38	0.51 ±0.06	1.01	13.89	0.90
	Total	**13**	**99.99**		**7.27**	**100.00**	
Immunologicals	0≤ 6	01	33.33	0.51	0.51	12.06	0.36
	6≤12	00	0.00	0.00	0.00	0.00	00
	12≤19	01	33.33	1.86	1.86	43.97	1.32
	19≤40	01	33.33	1.86	1.86	43.97	1.32
	40≤60	00	0.00	0.00	0.00	0.00	00
	>60	00	0.00	0.00	0.00	0.00	00
	Total	**03**	**99.99**		**4.23**	**100.00**	
Respiratory agents	0 ≥ 6	45	5.42	3.20 ±1.20	143.78	6.80	1.25
	6 ≥ 12	00	00	0.00	0.00	0.00	00
	12 ≥ 19	00	00	0.00	0.00	0.00	00
	19 ≥ 40	388	46.75	2.23 ±1.88	967.90	46.02	0.98
	40 ≥ 60	394	47.47	2.04 ±1.53	956.77	45.49	0.96
	>60	03	0.36	1.56	34.84	1.66	4.61*
	Total	**830**	**100.00**		**2103.29**	**99.97**	
Uro-genital	0 ≥ 6	00	0.00	0.00	0.00	0.00	00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	00
	>60	00	0.00	0.00	0.00	0.00	00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Appendix 1.33 : Parameters of Therapeutic budget group in relation to age group in clinic 3

Therapeutic budget group in clinic 3	Age Group (years)	Frequency parameters		Cost related parameters			
		Frequency n	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Anti-effectives	0 ≥ 6	09	11.11	3.08 ±1.51	27.73	5.10	0.46
	6 ≥ 12	01	1.23	3.28	3.28	0.60	0.49
	12 ≥ 19	00	0.00	0.00	0.00	0.00	00
	19 ≥ 40	57	70.37	7.53 ±14.14	429.10	78.96	1.12
	40 ≥ 60	13	16.05	4.87 ±5.15	63.25	11.64	0.73
	>60	01	1.23	20.08	20.08	3.69	3.00*
Total		**81**	**99.99**		**543.44**	**99.99**	
Cardiovascular agents	0 ≥ 6	05	3.29	8.31 ±6.11	41.57	3.67	1.12
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	04	2.63	1.66 ±0.66	6.64	0.59	0.22
	19 ≥ 40	50	32.89	3.92 ±7.64	196.02	17.29	0.53
	40 ≥ 60	70	46.05	9.04 ±12.32	632.58	55.81	1.21
	>60	23	15.13	11.16 ±9.91	256.67	22.64	1.50*
Total		**152**	**99.99**		**1133.48**	**100.00**	
Dermatologicals	0 ≥ 6	04	16.00	10.18 ±15.86	40.73	48.62	3.04*
	6 ≥ 12	01	4.00	0.52	0.52	0.62	0.16
	12 ≥ 19	01	4.00	4.16	4.16	4.97	1.24
	19 ≥ 40	12	48.00	2.30 ±2.06	27.54	32.87	0.68
	40 ≥ 60	06	24.00	1.72 ±1.38	10.31	12.31	0.51
	>60	01	4.00	0.52	0.52	0.62	0.16
Total		**25**	**100.00**		**83.78**	**100.01**	
Endocrine	0 ≥ 6	00	0.00	0.00	0.00	0.00	00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	05	4.59	5.72 ±1.08	28.61	4.03	0.88
	19 ≥ 40	82	75.23	5.68 ±1.49	465.88	65.67	0.87
	40 ≥ 60	17	15.60	7.03 ±6.18	119.44	16.84	1.08
	>60	05	4.59	19.10 ±10.42	95.50	13.40	2.92*
Total		**109**	**100.01**		**709.43**	**99.94**	
Functional	0 ≥ 6	00	0.00	0.00	0.00	0.00	00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	00	0.00	7.70	0.00	0.00	00
	19 ≥ 40	01	33.33	15.39	15.39	12.33	0.37
	40 ≥ 60	02	66.67	54.72 ±55.62	109.44	87.67	1.31
	>60	00	0.00	0.00	0.00	0.00	00
Total		**03**	**100.00**		**124.83**	**100.00**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Therapeutic budget group in clinic 3	Age Group (Years)	Frequency n	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Gastro-intestinals	0 ≥ 6	39	11.78	7.52 ±5.38	293.35	45.20	3.84*
	6 ≥ 12	02	0.60	1.14 ±0.30	2.27	0.35	0.58
	12 ≥ 19	05	1.51	0.93 ±0.38	4.65	0.72	0.48
	19 ≥ 40	189	57.10	1.03 ±2.19	193.87	29.87	0.52
	40 ≥ 60	91	27.49	1.64 ±3.73	149.16	22.98	0.84
	>60	05	1.51	1.14 ±0.46	5.68	0.88	0.58
	Total	**331**	**99.99**		**648.98**	**100.00**	
Pain relievers	0 ≥ 6	22	25.00	0.84	18.48	33.80	1.35
	6 ≥ 12	03	3.41	0.74±0.17	2.23	4.08	1.20
	12 ≥ 19	01	1.14	0.55	0.55	1.01	0.89
	19 ≥ 40	29	32.95	0.54 ±0.02	15.71	28.73	0.87
	40 ≥ 60	26	29.55	0.54 ±0.02	13.94	25.49	0.86
	>60	07	7.95	0.54 ±0.02	3.77	6.89	0.87
	Total	**88**	**100.00**		**54.68**	**100.00**	
Immunologicals	0 ≥ 6	92	85.98	6.29 ±8.99	578.46	98.71	1.15
	6 ≥ 12	05	4.67	0.51 ±0.07	2.54	0.43	0.09
	12 ≥ 19	01	0.93	0.35	0.35	0.06	0.06
	19 ≥ 40	09	8.41	0.52 ±0.50	4.66	0.80	0.10
	40 ≥ 60	00	0.00	0.00	0.00	0.00	00
	>60	00	0.00	0.00	0.00	0.00	00
	Total	**107**	**99.99**		**586.01**	**100.00**	
Respiratory agents	0 ≥ 6	20	6.67	4.12 ±6.62	82.31	4.31	0.65
	6 ≥ 12	01	0.33	1.56	1.56	0.08	0.24
	12 ≥ 19	03	1.00	14.65 ±11.26	43.94	2.30	2.30*
	19 ≥ 40	161	53.67	6.31 ±6.29	1015.13	53.15	0.99
	40 ≥ 60	100	33.33	6.51 ±10.85	650.69	34.07	1.02
	>60	15	5.00	7.75 ±4.34	116.29	6.09	1.22
	Total	**300**	**100.00**		**1909.92**	**100.00**	
Uro-genital	0 ≥ 6	00	0.00	0.00	0.00	0.00	00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	01	20.00	29.13	29.13	26.34	1.32
	19 ≥ 40	04	80.00	20.37 ±5.84	81.48	73.66	0.92
	40 ≥ 60	00	0.00	0.00	0.00	0.00	00
	>60	00	0.00	0.00	0.00	0.00	00
	Total	**05**	**100.00**		**110.61**	**100.00**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Appendix 1.34 : Parameters of Therapeutic budget group in relation to age group in clinic 4

Therapeutic budget group in clinic 4	Age Group (years)	Frequency parameters		Cost related parameters			
		Frequency n	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Anti-effectives	0 ≥ 6	03	6.67	1.90 ±0.50	5.69	4.33	0.65
	6 ≥ 12	03	6.67	5.84 ±0.66	17.53	13.35	2.00*
	12 ≥ 19	05	11.11	2.74 ±1.76	13.72	10.45	0.02
	19 ≥ 40	28	62.22	2.79 ±1.73	78.21	59.57	0.96
	40 ≥ 60	06	13.33	2.69 ±1.22	16.14	12.29	0.92
	>60	00	0.00	0.00	0.00	0.00	00
Total		**45**	**100.00**		**131.29**	**99.99**	
Cardiovascular agents	0 ≥ 6	01	1.08	8.66	8.66	2.00	1.85*
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	01	1.08	1.09	1.09	0.25	0.23
	19 ≥ 40	50	53.76	3.72 ±6.23	186.12	42.95	0.80
	40 ≥ 60	34	36.56	5.71 ±5.83	194.27	44.83	1.23
	>60	07	7.53	6.18 ±6.17	43.24	9.98	1.33
Total		**93**	**100.01**		**433.38**	**100.01**	
Dermatologicals	0 ≥ 6	10	35.71	3.53 ±2.91	35.25	51.37	1.44
	6 ≥ 12	03	10.71	2.39	7.17	10.45	0.98
	12 ≥ 19	01	3.57	2.39	2.39	3.48	0.97
	19 ≥ 40	06	21.43	2.83 ±2.81	16.97	24.73	1.15
	40 ≥ 60	04	14.29	1.19 ±1.34	4.76	6.94	0.49
	>60	04	14.29	0.52	2.08	3.03	0.21
Total		**28**	**100.00**		**68.62**	**100.00**	
Endocrine	0 ≥ 6	00	0.00	0.00	0.00	0.00	00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	07	16.67	5.24	36.68	17.14	1.03
	19 ≥ 40	33	78.57	5.08 ±1.25	167.57	78.29	0.99
	40 ≥ 60	02	4.76	4.90 ±0.48	9.80	4.58	0.96
	>60	00	0.00	0.00	0.00	0.00	00
Total		**42**	**100.00**		**214.05**	**100.01**	
Functional	0 ≥ 6	00	0.00	0.00	0.00	0.00	00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	02	18.18	7.70	15.40	12.27	0.67
	19 ≥ 40	04	36.36	11.81 ±13.03	47.25	37.66	1.04
	40 ≥ 60	05	45.46	12.56 ±9.70	62.82	50.07	1.10
	>60	00	0.00	0.00	0.00	0.00	00
Total		**11**	**100.00**		**125.47**	**100.00**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Therapeutic budget group in clinic 4	Age Group (Years)	Frequency n	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Gastro-intestinals	0 ≥ 6	43	31.62	10.17 ±6.61	437.19	40.25	1.27
	6 ≥ 12	06	4.41	6.50 ±5.99	38.99	3.59	0.81
	12 ≥ 19	03	2.21	0.65	1.95	0.18	0.08
	19 ≥ 40	65	47.79	7.99 ±10.00	519.90	47.86	1.00
	40 ≥ 60	17	12.50	5.11 ±5.86	86.88	7.99	0.64
	>60	02	1.47	0.65	1.30	0.12	0.08
	Total	**136**	**100.00**		**1086.21**	**99.99**	
Pain relievers	0 ≥ 6	13	23.21	0.79 ±0.13	10.23	30.17	1.30
	6 ≥ 12	04	7.14	0.70 ±0.17	2.78	8.20	1.15
	12 ≥ 19	02	3.57	0.53 ±0.03	1.06	3.12	0.87
	19 ≥ 40	18	32.14	0.54 ±0.02	9.68	28.55	0.89
	40 ≥ 60	14	25.00	0.54 ±0.03	7.52	22.18	0.89
	>60	05	8.93	0.53 ±0.03	2.64	7.78	0.87
	Total	**56**	**99.99**		**33.91**	**100.00**	
Immunologicals	0 ≥ 6	29	96.67	5.56 ±8.68	161.24	98.86	1.02
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	00
	19 ≥ 40	01	3.33	1.86	1.86	1.14	0.34
	40 ≥ 60	00	0.00	0.00	0.00	0.00	00
	>60	00	0.00	0.00	0.00	0.00	00
	Total	**30**	**100.00**		**163.10**	**100.00**	
Respiratory agents	0 ≥ 6	18	21.69	1.18 ±1.01	21.26	3.99	0.18
	6 ≥ 12	01	1.20	0.87	0.87	0.16	0.13
	12 ≥ 19	01	1.20	1.56	1.56	0.29	0.24
	19 ≥ 40	51	61.45	8.29 ±8.99	423.03	79.38	1.29
	40 ≥ 60	12	14.46	7.19 ±7.08	86.23	16.18	1.12
	>60	00	0.00	0.00	0.00	0.00	00
	Total	**83**	**100.00**		**532.95**	**100.00**	
Uro-genital	0 ≥ 6	00	0.00	0.00	0.00	0.00	00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	00
	19 ≥ 40	01	100.00	29.13	29.13	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	00
	>60	00	0.00	0.00	0.00	0.00	00
	Total	**01**	**100.00**		**0.00**	**100.00**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Appendix 1.35 : Parameters of Therapeutic budget group in relation to age group in clinic 5

Therapeutic budget group in clinic 5	Age Group (years)	Frequency parameters		Cost related parameters			
		Frequency n	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Anti-effectives	0 ≥ 6	05	21.74	4.41 ±3.52	22.06	19.20	0.88
	6 ≥ 12	04	17.39	6.07 ±3.22	24.29	21.14	1.22
	12 ≥ 19	00	0.00	0.00	0.00	0.00	00
	19 ≥ 40	09	39.13	3.08 ±2.04	27.69	24.10	0.62
	40 ≥ 60	05	21.74	8.17 ±11.84	40.87	35.57	1.64*
	>60	00	0.00	0.00	0.00	0.00	00
Total		**23**	**100.00**		**114.91**	**100.01**	
Cardiovascular agents	0 ≥ 6	00	0.00	0.00	0.00	0.00	00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	00
	19 ≥ 40	08	5.97	8.89 ±9.92	71.15	6.68	1.12
	40 ≥ 60	61	45.52	8.56 ±8.98	522.14	49.04	1.08
	>60	65	48.51	7.25 ±7.49	471.34	44.27	0.91
Total		**134**	**100.00**		**1064.63**	**99.99**	
Dermatologicals	0 ≥ 6	06	14.63	6.52 ±13.45	39.10	35.84	2.45*
	6 ≥ 12	03	7.32	2.23 ±1.06	6.68	6.32	0.86
	12 ≥ 19	00	0.00	0.00	0.00	0.00	00
	19 ≥ 40	09	21.95	0.93 ±0.60	8.40	7.69	0.35
	40 ≥ 60	14	34.15	3.59 ±8.79	50.31	45.86	1.34
	>60	09	21.95	0.52	4.68	4.29	0.20
Total		**41**	**100.00**		**109.17**	**100.00**	
Endocrine	0 ≥ 6	00	0.00	0.00	0.00	0.00	00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	00
	19 ≥ 40	02	9.52	8.15 ±5.88	16.29	8.62	0.91
	40 ≥ 60	04	19.05	13.37 ±12.05	53.47	28.31	1.49
	>60	15	71.43	7.94 ±3.85	119.14	63.07	0.88
Total		**21**	**100.00**		**188.9**	**100.00**	
Functional	0 ≥ 6	00	0.00	0.00	0.00	0.00	00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	00
	19 ≥ 40	03	60.00	21.08 ±18.49	63.23	54.00	0.90
	40 ≥ 60	02	40.00	26.94 ±16.33	53.87	46.00	1.15
	>60	00	0.00	0.00	0.00	0.00	00
Total		**05**	**100.00**		**117.10**	**100.00**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Therapeutic budget group in clinic 5	Age Group (Years)	Frequency n	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Gastro-intestinals	0 ≥ 6	08	16.00	2.87 ±4.12	22.92	7.67	0.48
	6 ≥ 12	01	2.00	0.92	0.92	0.31	0.16
	12 ≥ 19	02	4.00	6.56 ±8.34	13.11	4.38	1.10
	19 ≥ 40	18	36.00	7.32 ±5.49	131.76	44.07	1.22
	40 ≥ 60	08	16.00	2.98 ±3.33	23.82	7.97	0.50
	>60	13	26.00	8.19 ±6.10	106.47	35.61	1.37
	Total	**50**	**100.00**		**299.00**	**100.01**	
Pain relievers	0 ≥ 6	12	21.05	0.82 ±0.08	9.79	28.60	1.36
	6 ≥ 12	04	7.02	0.75 ±0.18	3.00	8.76	1.25
	12 ≥ 19	01	1.75	0.84	0.84	2.45	1.40
	19 ≥ 40	09	15.79	0.52 ±0.03	4.65	13.58	0.86
	40 ≥ 60	13	22.81	0.52 ±0.03	6.70	19.57	0.86
	>60	18	31.58	0.51 ±0.02	9.25	27.02	0.86
	Total	**57**	**100.00**		**34.23**	**99.98**	
Immunologicals	0 ≥ 6	33	86.84	3.49 ±7.09	115.04	93.60	1.08
	6 ≥ 12	01	2.63	0.43	0.43	0.35	0.13
	12 ≥ 19	01	2.63	1.86	1.86	1.51	0.57
	19 ≥ 40	03	7.89	1.86	5.58	4.54	0.58
	40 ≥ 60	00	0.00	0.00	0.00	0.00	00
	>60	00	0.00	0.00	0.00	0.00	00
	Total	**38**	**99.99**		**122.91**	**100.00**	
Respiratory agents	0 ≥ 6	05	2.29	5.08 ±5.99	25.38	3.80	1.66*
	6 ≥ 12	06	2.75	0.99 ±0.34	5.99	0.90	0.33
	12 ≥ 19	24	11.01	2.07 ±0.26	49.62	7.44	0.68
	19 ≥ 40	172	78.90	2.79 ±2.21	480.53	72.01	0.91
	40 ≥ 60	03	1.38	1.56	4.68	0.70	0.51
	>60	08	3.67	12.64 ±14.74	101.10	15.15	4.13*
	Total	**218**	**100.00**		**667.30**	**100.00**	
Uro-genital	0 ≥ 6	00	0.00	0.00	0.00	0.00	00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	00
	>60	00	0.00	0.00	0.00	0.00	00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Appendix 1.36 : Parameters of Therapeutic budget group in relation to age group in clinic 6

Therapeutic budget group in clinic 6	Age Group (years)	Frequency parameters		Cost related parameters			
		Frequency n	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Anti-effectives	0 ≥ 6	17	39.53	2.90 ±1.84	49.35	33.91	0.86
	6 ≥ 12	02	4.65	4.37 ±1.54	8.74	6.01	1.29
	12 ≥ 19	04	9.30	3.12 ±1.24	12.47	8.67	0.93
	19 ≥ 40	17	39.53	3.18 ±2.16	54.07	37.15	0.94
	40 ≥ 60	02	4.65	9.21 ±9.54	18.43	12.66	2.72*
	>60	01	2.33	2.47	2.47	1.69	0.73
Total		**43**	**99.99**		**145.53**	**100.09**	
Cardiovascular agents	0 ≥ 6	00	0.00	0.00	0.00	0.00	00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	02	1.90	1.09	2.18	0.36	0.19
	19 ≥ 40	30	28.57	4.09 ±4.14	122.75	20.06	0.70
	40 ≥ 60	44	41.90	6.29 ±6.16	276.75	45.23	1.08
	>60	29	27.62	7.25 ±6.89	210.20	34.35	1.24
Total		**105**	**99.99**		**611.88**	**100.00**	
Dermatologicals	0 ≥ 6	08	25.00	2.26 ±0.99	18.09	32.38	1.29
	6 ≥ 12	02	6.25	1.69 ±0.99	3.37	6.03	0.96
	12 ≥ 19	05	15.63	1.57 ±0.81	7.86	14.07	0.90
	19 ≥ 40	07	21.86	1.56 ±1.00	10.91	19.53	0.89
	40 ≥ 60	06	18.75	1.64 ±0.71	9.81	17.56	0.94
	>60	04	12.50	1.46 ±1.08	5.82	10.42	0.83
Total		**32**	**99.99**		**55.86**	**99.99**	
Endocrine	0 ≥ 6	00	0.00	0.00	0.00	0.00	00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	09	17.31	4.94 ±0.36	44.44	16.77	0.97
	19 ≥ 40	40	76.92	4.51 ±0.81	180.51	68.13	0.89
	40 ≥ 60	01	1.92	30.34	30.34	11.45	5.96*
	>60	02	3.85	4.83 ±1.19	9.66	3.65	0.95
Total		**52**	**100.00**		**264.95**	**100.00**	
Functional	0 ≥ 6	00	0.00	0.00	0.00	0.00	00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	00
	19 ≥ 40	03	60.00	20.71 ±9.21	62.13	66.87	1.11
	40 ≥ 60	00	0.00	0.00	0.00	0.00	00
	>60	02	40.00	15.39	30.78	33.13	0.83
Total		**05**	**100.00**		**92.91**	**100.00**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Therapeutic budget group in clinic 6	Age Group (Years)	Frequency n	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Gastro-intestinals	0 ≥ 6	101	71.13	9.69 ±4.59	979.35	77.37	1.09
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	01	0.70	0.65	0.65	0.05	0.07
	19 ≥ 40	15	10.56	4.71 ±5.08	70.74	5.59	0.53
	40 ≥ 60	23	16.19	9.21 ±5.28	211.79	16.73	1.03
	>60	02	1.41	1.65 ±1.41	3.29	0.26	0.18
	Total	**142**	**99.99**		**1265.82**	**100.00**	
Pain relievers	0 ≥ 6	23	25.00	0.81 ±0.08	18.74	34.09	1.36
	6 ≥ 12	01	1.09	0.55	0.55	1.00	0.92
	12 ≥ 19	08	8.69	0.53 ±0.03	4.25	7.73	0.89
	19 ≥ 40	26	28.26	0.53 ±0.02	13.79	25.09	0.89
	40 ≥ 60	25	27.17	0.53 ±0.02	13.13	23.89	0.88
	>60	09	9.78	0.50 ±0.02	4.51	8.20	0.84
	Total	**92**	**99.99**		**54.97**	**100.00**	
Immunologicals	0 ≥ 6	71	98.61	4.91 ±8.26	348.85	99.47	1.01
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	00
	19 ≥ 40	01	1.39	1.86	1.86	0.53	0.38
	40 ≥ 60	00	0.00	0.00	0.00	0.00	00
	>60	00	0.00	0.00	0.00	0.00	00
	Total	**72**	**100.00**		**350.71**	**100.00**	
Respiratory agents	0 ≥ 6	100	22.22	1.52 ±0.69	152.26	12.43	0.55
	6 ≥ 12	02	0.44	0.87 ±0.01	1.73	0.14	0.32
	12 ≥ 19	04	0.88	1.04 ±0.35	4.17	0.34	0.39
	19 ≥ 40	198	44.00	2.90 ±1.08	574.30	46.88	1.07
	40 ≥ 60	142	31.55	3.38 ±0.90	479.54	39.14	1.24
	>60	04	0.88	3.28 ±3.43	13.10	1.07	1.22
	Total	**450**	**99.97**		**1225.10**	**100.00**	
Uro-genital	0 ≥ 6	00	0.00	0.00	0.00	0.00	00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	00
	>60	00	0.00	0.00	0.00	0.00	00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Appendix 1.37 : Parameters of theraputic budget group in relation to the gender in all clinics

Therapeutic budget group in all clinics	Gender	Frequency parameters		Cost related parameters			
		Frequency n	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Anti-effectives	Male	77	34.07	5.56 ±9.40	428.19	39.05	1.15
	Female	149	65.93	4.49 ±7.22	668.37	60.95	0.92
	Total	**226**	**100.00**		**1096.56**	**100.00**	
Cardiovascular agents	Male	111	17.70	8.70 ±11.69	965.92	23.98	1.35
	Female	516	82.29	5.93 ±6.61	3060.93	76.01	0.92
	Total	**627**	**99.99**		**4026.85**	**99.99**	
Dermatologicals	Male	51	34.69	2.37 ±4.75	121.31	33.75	0.97
	Female	96	65.31	2.48 ±4.93	238.13	66.25	1.01
	Total	**147**	**100.00**		**359.44**	**100.00**	
Endocrine	Male	07	2.01	11.69 ±12.80	81.84	3.91	1.95*
	Female	340	97.98	5.92 ±3.47	2013.88	96.09	0.99
	Total	**347**	**99.99**		**2095.72**	**100.00**	
Functional	Male	15	57.69	24.35 ±22.01	365.22	74.12	1.28
	Female	11	42.31	11.59 ±10.81	127.51	25.88	0.61
	Total	**26**	**100.00**		**492.73**	**100.00**	
Gastro-intestinals	Male	380	49.61	3.79 ±5.62	1439.33	41.58	0.84
	Female	386	50.39	5.24 ±6.37	2021.65	58.41	1.16
	Total	**766**	**100.00**		**3460.98**	**99.99**	
Pain relievers	Male	123	34.55	0.61 ±0.14	75.60	35.60	1.03
	Female	233	65.45	0.59 ±0.12	136.74	64.39	0.98
	Total	**356**	**100.00**		**212.34**	**99.99**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Therapeutic budget group in all clinics	Gender	Frequency (F)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Immunologicals	Male	108	41.69	4.59 ±7.94	496.44	38.74	0.92
	Female	151	58.30	5.19 ±8.34	785.10	61.26	1.05
	Total	**259**	**99.99**		**1281.54**	**100.00**	
Respiratory agents	Male	1125	58.26	3.33 ±4.21	3758.75	57.71	1.36
	Female	806	41.74	3.42 ±4.30	2754.84	42.29	1.01
	Total	**1931**	**100.00**		**6513.59**	**100.00**	
Uro-genital	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	06	100.00	23.29 ±6.39	139.74	100.00	1.00
	Total	**06**	**100.00**		**139.74**	**100.00**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Appendix 1.38 : Parameters of theraputic budget group in relation to the gender in clinic 1

Therapeutic budget group in clinic 1	Gender	Frequency parameters		Cost related parameters			
		Frequency n	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Anti-effectives	Male	10	35.71	3.96 ±2.48	39.58	28.32	0.79
	Female	18	64.29	5.56 ±6.53	100.16	71.68	1.11
	Total	**28**	**100.00**		**139.74**	**100.00**	
Cardiovascular agents	Male	13	18.31	3.92 ±4.52	50.95	16.73	0.91
	Female	58	81.69	4.37 ±4.39	253.65	83.27	1.02
	Total	**71**	**100.00**		**304.6**	**100.00**	
Dermatologicals	Male	07	41.18	1.78 ±2.14	12.48	36.98	0.89
	Female	10	58.82	2.12 ±2.12	21.26	63.01	1.07
	Total	**17**	**100.00**		**33.74**	**100.00**	
Endocrine	Male	00	0.00	0.00	0.00	0.00	00
	Female	02	100.00	4.84 ±4.45	9.67	100.00	1.00
	Total	**02**	**100.00**		**9.67**	**100.00**	
Functional	Male	01	50.00	31.35	31.35	96.69	1.94*
	Female	01	50.00	1.07	1.07	3.30	0.07
	Total	**02**	**100.00**		**32.42**	**99.99**	
Gastro-intestinals	Male	09	29.03	4.74 ±4.94	42.62	30.97	1.07
	Female	22	70.97	4.32 ±3.98	95.00	69.03	0.97
	Total	**31**	**100.00**		**137.62**	**100.00**	
Pain relievers	Male	16	34.04	0.53 ±0.02	8.52	33.98	0.99
	Female	31	65.96	0.53 ±0.02	16.55	66.02	1.00
	Total	**47**	**100.00**		**25.07**	**100.00**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Therapeutic budget group in clinic 1	Gender	Frequency n	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Immunologicals	Male	00	0.00	0.00	0.00	0.00	00
	Female	03	100.00	1.86	5.58	100.00	1.00
	Total	**03**	**100.00**		**5.58**	**100.00**	
Respiratory agents	Male	13	46.42	2.11 ±1.69	27.38	58.09	1.25
	Female	15	53.57	1.32 ±0.39	19.75	41.91	0.78
	Total	**28**	**99.99**		**47.13**	**100.00**	
Uro-genital	Male	00	0.00	0.00	0.00	0.00	00
	Female	00	0.00	0.00	0.00	0.00	00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Appendix 1.39 : Parameters of theraputic budget group in relation to the gender in clinic 2

Therapeutic budget group in clinic 2	Gender	Frequency parameters		Cost related parameters			
		Frequency n	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Anti-effectives	Male	05	83.33	3.88 ±1.83	19.42	89.69	1.08
	Female	01	16.67	2.23	2.23	10.30	0.62
	Total	**06**	**100.00**		**21.65**	**99.99**	
Cardiovascular agents	Male	12	17.65	6.76 ±7.02	81.16	18.13	1.03
	Female	56	82.35	6.54 ±5.97	366.44	81.87	0.99
	Total	**68**	**100.00**		**447.60**	**100.00**	
Dermatologicals	Male	01	25.00	0.98	0.98	11.85	0.47
	Female	03	75.00	2.43 ±3.31	7.29	88.15	1.18
	Total	**04**	**100.00**		**8.27**	**100.00**	
Endocrine	Male	03	3.53	12.06 ±15.87	36.17	6.82	1.93*
	Female	82	96.47	6.03 ±2.92	494.54	93.18	0.97
	Total	**85**	**100.00**		**530.71**	**100.00**	
Functional	Male	00	0.00	0.00	0.00	0.00	00
	Female	00	0.00	0.00	0.00	0.00	00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Gastro-intestinals	Male	69	93.24	0.29 ±1.51	20.22	91.49	0.98
	Female	05	6.76	0.38 ±0.73	1.88	8.51	1.26
	Total	**74**	**100.00**		**22.10**	**100.00**	
Pain relievers	Male	06	46.15	0.54 ±0.02	3.22	44.29	0.96
	Female	07	53.85	0.58 ±0.12	4.05	55.71	1.03
	Total	**13**	**100.00**		**7.27**	**100.00**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Therapeutic budget group in clinic 2	Gender	Frequency n	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Immunologicals	Male	00	0.00	0.00	0.00	0.00	00
	Female	03	100.00	1.41 ±0.78	4.23	100.00	1.00
	Total	**03**	**100.00**		**4.23**	**100.00**	
Respiratory agents	Male	568	66.82	2.49 ±1.28	1416.95	66.85	1.00
	Female	282	33.18	2.49 ±1.25	702.52	33.15	0.99
	Total	**850**	**100.00**		**2119.47**	**100.00**	
Uro-genital	Male	00	0.00	0.00	0.00	0.00	00
	Female	00	0.00	0.00	0.00	0.00	00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Appendix 1.40 : Parameters of theraputic budget group in relation to the gender in clinic 3

Therapeutic budget group in clinic 3	Gender	Frequency parameters		Cost related parameters			
		Frequency n	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Anti-effectives	Male	22	27.16	10.17 ±16.59	223.72	41.17	1.52*
	Female	59	72.84	5.42 ±9.99	319.72	58.83	0.81
	Total	**81**	**100.00**		**543.44**	**100.00**	
Cardiovascular agents	Male	16	10.32	15.12 ±23.72	241.93	20.79	2.01*
	Female	139	89.68	6.63 ±7.39	921.74	79.21	0.88
	Total	**155**	**100.00**		**1163.67**	**100.00**	
Dermatologicals	Male	07	28.00	6.32 ±12.23	44.27	52.84	1.89*
	Female	18	72.00	2.19 ±1.89	39.51	47.16	0.66
	Total	**25**	**100.00**		**83.78**	**100.00**	
Endocrine	Male	00	0.00	0.00	0.00	0.00	00
	Female	109	100.00	6.51 ±4.39	709.43	100.00	1.00
	Total	**109**	**100.00**		**709.43**	**100.00**	
Functional	Male	02	66.67	54.72 ±55.62	109.44	87.67	1.31
	Female	01	33.33	15.39	15.39	12.33	0.37
	Total	**03**	**100.00**		**124.83**	**100.00**	
Gastro-intestinals	Male	146	44.11	2.19 ±3.89	320.20	49.34	1.12
	Female	185	55.89	1.78 ±3.63	328.78	50.66	0.91
	Total	**331**	**100.00**		**648.98**	**100.00**	
Pain relievers	Male	28	31.46	0.65 ±0.15	18.10	32.79	1.04
	Female	61	68.54	0.61 ±0.13	37.09	67.20	0.98
	Total	**89**	**100.00**		**55.19**	99.99	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Therapeutic budget group in clinic 3	Gender	Frequency n	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Immunologicals	Male	50	45.87	4.91 ±8.21	245.42	41.77	0.91
	Female	59	54.13	5.79 ±8.82	341.56	58.19	1.08
	Total	**109**	**100.00**		**586.98**	**99.96**	
Respiratory agents	Male	151	50.33	6.24 ±8.19	942.04	48.38	0.96
	Female	149	49.67	6.49 ±8.07	967.88	50.68	1.02
	Total	**300**	**100.00**		**1909.92**	**99.06**	
Uro-genital	Male	00	0.00	0.00	0.00	0.00	00
	Female	05	100.00	22.12 ±6.39	110.61	100.00	1.00
	Total	**05**	**100.00**		**110.61**	**100.00**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Appendix 1.41 : Parameters of theraputic budget group in relation to the gender in clinic 4

Therapeutic budget group in clinic 4	Gender	Frequency parameters		Cost related parameters			
		Frequency n	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Anti-effectives	Male	13	28.89	3.48 ±1.96	45.30	34.50	1.19
	Female	32	71.11	2.69 ±1.60	85.99	65.49	0.92
	Total	**45**	**100.00**		**131.29**	**99.99**	
Cardiovascular agents	Male	08	8.60	6.49 ±5.78	51.90	11.98	1.39
	Female	85	91.39	4.49 ±6.09	381.48	88.02	0.96
	Total	**93**	**99.99**		**433.38**	**100.00**	
Dermatologicals	Male	13	46.43	1.89 ±2.09	44.09	64.25	1.38
	Female	15	53.57	2.94 ±2.59	24.53	35.75	0.67
	Total	**28**	**100.00**		**68.62**	**100.00**	
Endocrine	Male	00	0.00	0.00	0.00	0.00	00
	Female	42	100.00	5.09 ±1.11	214.05	100.00	1.00
	Total	**42**	**100.00**		**214.05**	**100.00**	
Functional	Male	05	45.45	12.56 ±9.69	62.82	50.07	1.10
	Female	06	54.55	10.44 ±10.31	62.65	49.93	0.92
	Total	**11**	**100.00**		**125.47**	**100.00**	
Gastro-intestinals	Male	79	58.09	6.59 ±7.56	520.22	47.89	0.82
	Female	57	41.91	9.93 ±9.23	565.99	52.11	1.24
	Total	**136**	**100.00**		**1086.21**	**100.00**	
Pain relievers	Male	19	33.93	0.61 ±0.14	11.68	34.44	1.02
	Female	37	66.07	0.60 ±0.13	22.23	65.56	0.99
	Total	**56**	**100.00**		**33.91**	**100.00**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Therapeutic budget group in clinic 4	Gender	Frequency n	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Immunologicals	Male	22	73.33	4.95 ±8.36	108.80	66.71	0.91
	Female	08	26.67	6.79 ±9.53	54.30	33.29	1.25
	Total	**30**	**100.00**		**163.10**	**100.00**	
Respiratory agents	Male	48	57.83	6.79 ±8.12	326.32	61.23	1.06
	Female	35	42.17	5.90 ±8.09	206.63	38.77	0.92
	Total	**83**	**100.00**		**532.95**	**100.00**	
Uro-genital	Male	00	0.00	0.00	0.00	0.00	00
	Female	01	100.00	29.13	29.13	100.00	1.00
	Total	**01**	**100.00**		**29.13**	**100.00**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Appendix 1.42 : Parameters of theraputic budget group in relation to the gender in clinic 5

Therapeutic budget group in clinic 5	Gender	Frequency parameters		Cost related parameters			
		Frequency n	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Anti-effectives	Male	06	26.09	6.02 ±3.81	36.09	31.41	1.20
	Female	17	73.91	4.64 ±6.53	78.82	68.59	0.93
	Total	**23**	**100.00**		**114.91**	**100.00**	
Cardiovascular agents	Male	46	34.33	9.24 ±9.09	425.18	39.94	1.16
	Female	88	65.67	7.27 ±7.84	639.45	60.06	0.91
	Total	**134**	**100.00**		**1064.63**	**100.00**	
Dermatologicals	Male	14	34.15	1.27 ±0.99	17.71	16.22	0.47
	Female	27	65.85	3.39 ±8.84	91.46	83.78	1.27
	Total	**41**	**100.00**		**109.17**	**100.00**	
Endocrine	Male	03	5.26	5.11 ±0.97	15.33	4.18	0.79
	Female	54	94.74	6.51 ±4.39	351.58	95.82	1.01
	Total	**57**	**100.00**		**366.91**	**100.00**	
Functional	Male	04	80.00	28.86 ±11.54	115.44	98.58	1.19
	Female	01	20.00	1.66	1.66	1.42	0.07
	Total	**05**	**100.00**		**117.10**	**100.00**	
Gastro-intestinals	Male	15	29.41	4.27 ±4.98	63.98	21.33	0.30
	Female	36	70.59	6.55 ±5.66	235.94	78.67	1.14
	Total	**51**	**100.00**		**299.92**	**100.00**	
Pain relievers	Male	20	34.48	0.622 ±0.17	12.44	35.47	1.03
	Female	38	65.52	0.59 ±0.14	22.63	64.53	0.98
	Total	**58**	**100.00**		**35.07**	**100.00**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Therapeutic budget group in clinic 5	Gender	Frequency n	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Immunologicals	Male	18	47.37	1.97 ±5.08	35.40	28.80	0.61
	Female	20	52.63	4.38 ±7.72	87.51	71.19	1.35
	Total	**38**	**100.00**		**122.91**	**99.99**	
Respiratory agents	Male	92	42.01	3.96 ±5.84	364.09	54.49	1.29
	Female	127	57.99	2.39 ±0.88	304.07	45.51	0.78
	Total	**219**	**100.00**		**668.16**	**100.00**	
Uro-genital	Male	00	0.00	0.00	0.00	0.00	00
	Female	00	0.00	0.00	0.00	0.00	00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Appendix 1.43 : Parameters of theraputic budget group in relation to the gender in clinic 6

Therapeutic budget group in clinic 6	Gender	Frequency parameters		Cost related parameters			
		Frequency n	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Anti-effectives	Male	21	48.84	3.05 ±1.73	64.08	44.03	0.90
	Female	22	51.16	3.70 ±3.37	81.45	55.97	1.09
	Total	**43**	**100.00**		**145.53**	**100.00**	
Cardiovascular agents	Male	16	15.09	7.18 ±7.18	114.80	18.73	1.24
	Female	90	84.91	5.54 ±5.68	498.17	81.27	0.96
	Total	**106**	**100.00**		**612.97**	**100.00**	
Dermatologicals	Male	09	28.13	2.37 ±0.85	21.34	38.20	1.36
	Female	23	71.88	1.50 ±0.82	34.52	61.79	0.86
	Total	**32**	**100.01**		**55.86**	**99.99**	
Endocrine	Male	01	1.92	30.34	30.34	11.45	5.96*
	Female	51	98.08	4.60 ±0.77	234.61	88.55	0.90
	Total	**52**	**100.00**		**264.95**	**100.00**	
Functional	Male	03	60.00	15.39	46.17	49.69	3.23
	Female	02	40.00	23.37 ±11.29	46.74	50.31	1.26
	Total	**05**	**100.00**		**92.91**	**100.00**	
Gastro-intestinals	Male	62	43.36	7.61 ±5.53	472.09	37.29	0.86
	Female	81	56.64	9.80 ±4.51	794.06	62.71	1.19
	Total	**143**	**100.00**		**1266.15**	**100.00**	
Pain relievers	Male	34	36.56	0.64 ±0.15	21.64	38.76	1.01
	Female	59	63.44	0.58 ±0.12	34.19	61.24	0.97
	Total	**93**	**100.00**		**55.83**	**100.00**	

APPENDIX 1: RESULTS OF BUDGET GROUP ANALYSIS

Therapeutic budget group in clinic 6	Gender	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Immunologicals	Male	18	23.68	5.93 ±8.98	106.82	26.79	1.13
	Female	58	76.32	5.03 ±8.39	291.92	73.21	0.96
	Total	**76**	**100.00**		**398.74**	**100.00**	
Respiratory agents	Male	253	56.09	2.66 ±1.08	671.97	54.48	0.97
	Female	198	43.90	2.79 ±1.37	553.99	45.19	1.03
	Total	**451**	**99.99**		**1225.96**	**99.67**	
Uro-genitals	Male	00	0.00	0.00	0.00	0.00	00
	Female	00	0.00	0.00	0.00	0.00	00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

Appendix 1.44 : Parameters of pharmacological group for all consultations in all clinics

PHARMACOLOGICAL GROUP IN ALL CLINICS	Frequency parameters		Cost related parameters			
	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Antibacterial (Penicillin's)	120	2.58	4.59 ±3.68	551.83	2.85	1.10
Anti-effectives (amino glycosides)	01	0.02	29.13	29.13	0.15	7.50*
Antibacterials (Chloramphenicol, erythromicns)	93	1.99	4.46 ±11.20	414.92	2.14	1.08
Anti-fungal oral / injections	12	0.26	8.39 ±7.26	100.69	0.52	2.00*
Anti-anginal	01	0.02	17.24	17.24	0.09	4.5
Antihypertensives	471	10.11	7.85 ±8.50	3699.22	19.09	1.89**
Congestive heart failure drugs	73	1.57	2.27 ±0.84	165.97	0.86	0.55
Drugs affecting blood	82	1.76	1.76 ±1.23	144.42	0.75	0.43
Anti-fungal (topical)	25	0.54	5.36 ±10.88	133.89	0.69	1.28
Antiseptics / dermatological disinfectants	12	0.26	2.39	28.68	0.15	0.58
Anti-pruritics	25	0.54	1.62 ±0.69	40.51	0.21	0.39
Scabicides and Pedicullocides	11	0.24	3.20	35.20	0.18	0.75
Other ointments, creams and emollients	55	1.18	0.66 ±0.30	36.51	0.19	0.16
Anti-effective eye preparations	11	0.24	5.44 ±2.42	59.79	0.31	1.29
Anti -allergic eye preparations	02	0.04	3.48	6.96	0.04	1.00
Other ear and nose preparations	06	0.13	2.98 ±1.82	17.90	0.09	0.69
Contraceptives (injectables)	246	5.28	4.83 ±0.36	1187.65	6.13	1.16
Oral contraceptives	59	1.27	7.02 ±1.87	414.05	2.14	1.69*
Hormones, androgens and progesterones	01	0.02	13.00	13.00	0.07	3.50*
Anti-diabetic agents	08	0.17	24.01 ±8.73	192.11	0.99	5.82*
Oral anti diabetic agents	32	0.69	8.98 ±6.16	287.22	1.48	2.15*

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN ALL CLINICS	Frequency n	Frequency Percentage	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Corticosteroids for systemic use	01	0.02	1.69	1.69	0.09	4.5*
Anti-epileptics	24	0.52	20.44 ±18.98	490.59	2.53	4.86*
Anti allergic (for anaphylaxis)	01	0.02	1.07	1.07	0.01	0.50
Psychotic disorders	01	0.02	1.07	1.07	0.01	0.50
Anti-helmenthics	04	0.08	2.19 ±1.68	8.75	0.04	0.50
Antacids / antiulcer	46	0.99	3.17 ±1.57	145.70	0.75	0.76
Anti emetics	01	0.02	1.11	1.11	0.06	3.00*
Anti haemmorrhoidal	04	0.08	9.92	39.68	0.20	2.5*
Cathartic drugs / laxatives	03	0.06	2.96	8.80	0.05	0.83
Constipation drugs and digestants	04	0.08	2.64	10.56	0.05	0.63
Oral Electrolytes and anti acid base disturbance agents	02	0.04	1.08	2.16	0.01	0.25
Mouth wash and throat preparations	17	0.36	0.99 ±1.89	16.83	0.09	0.25
Parenteral electrolytes and anti acid base disturbance agent	01	0.02	10.94	10.94	0.06	3.00*
Vitamins and minerals	471	10.11	0.95 ±2.48	448.87	2.32	0.23
Feeding and nutritional supplements	213	4.57	12.99 ±3.84	2767.50	14.28	3.12*
Analgesics (non opoids) and NSAIDS	356	7.64	0.59 ±0.13	212.34	1.09	0.14
Vaccines	247	5.31	5.09 ±8.33	1259.22	6.49	1.22
Diagnostic agents	12	0.26	1.86	22.32	0.12	0.46
Anti-asthmatic and mucolytics	25	0.54	11.93 ±8.38	298.25	1.54	1.00
Cough mixtures	191	4.09	1.22 ±0.45	232.85	1.20	0.29
Anti-mycobacterials	1715	36.81	3.48 ±4.21	5972.49	30.81	0.84
Anti-fungals	06	0.13	23.29 ±6.39	139.74	0.72	5.54*
Total	**4691**	**99.99**		**19669.50**	**100.01**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

Appendix 1.45 : Parameters of pharmacological group for all consultations in clinic 1

PHARMACOLOGICAL GROUP IN CLINIC 1	Frequency parameters		Cost related parameters			
	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Antibacterial (Penicillin's)	20	8.77	4.25 ±2.83	85.13	11.70	1.33
Anti-effectives (amino glycosides)	01	0.44	29.13	29.13	4.00	9.09*
Antibacterials (Chloramphenicol, erythromicns)	05	2.19	2.59 ±2.25	12.98	1.78	0.81
Anti-fungal oral / injections	02	0.88	6.25	12.50	1.72	1.95*
Anti-anginal	00	0.00	0.00	0.00	0.00	0.00
Antihypertensives	53	23.25	5.09 ±4.82	269.82	37.08	1.59*
Congestive heart failure drugs	13	5.70	1.91 ±0.90	24.77	3.40	0.59
Drugs affecting blood	05	2.19	2.02 ±0.51	10.01	1.38	0.63
Anti-fungal (topical)	05	2.19	1.99 ±2.43	9.96	1.37	0.63
Antiseptics / dermatological disinfectants	00	0.00	0.00	0.00	0.00	0.00
Anti-pruritics	03	1.32	1.85 ±0.66	5.55	0.76	0.58
Scabicides and Pedicullocides	00	0.00	0.00	0.00	0.00	0.00
Other ointments, creams and emollients	06	2.63	0.72 ±0.22	4.30	0.59	0.22
Anti-effective eye preparations	02	0.88	5.23 ±3.27	10.45	1.44	1.64*
Anti allergic eye preparations	01	0.44	3.48	3.48	0.48	1.09
Other ear and nose preparations	00	0.00	0.00	0.00	0.00	0.00
Contraceptives (injectables)	00	0.00	0.00	0.00	0.00	0.00
Oral contraceptives	00	0.00	0.00	0.00	0.00	0.00
Hormones, androgens and progesterones	00	0.00	0.00	0.00	0.00	0.00
Anti-diabetic agents	00	0.00	0.00	0.00	0.00	0.00
Oral anti diabetic agents	01	0.44	7.98	7.98	1.09	2.48*

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC1	Frequency n	Frequency Percentage	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Corticosteroids for systemic use	01	0.44	1.69	1.69	0.23	0.52
Anti-epileptics	01	0.44	31.35	31.35	4.31	9.79*
Anti allergic (for anaphylaxis)	01	0.44	1.07	1.07	0.15	0.34
Psychotic disorders	00	0.00	0.00	0.00	0.00	0.00
Anti-helmenthics	00	0.00	0.00	0.00	0.00	0.00
Antacids / antiulcer	12	5.27	4.79	57.48	7.90	1.49
Anti emetics	01	0.44	1.11	1.11	0.15	0.34
Anti haemmorrhoidal	01	0.44	9.92	9.92	1.36	3.09*
Cathartic drugs / laxatives	01	0.44	2.96	2.96	0.41	0.93
Constipation drugs and digestants	02	0.88	2.64	5.28	0.73	0.83
Oral Electrolytes and anti acid base disturbance agents	00	0.00	0.00	0.00	0.00	0.00
Mouth wash and throat preparations	00	0.00	0.00	0.00	0.00	0.00
Parenteral electrolytes and anti acid base disturbance agent	01	0.44	10.94	10.94	1.50	3.41*
Vitamins and minerals	13	5.72	3.84 ±5.99	49.93	6.86	1.19
Feeding and nutritional supplements	00	0.00	0.00	0.00	0.00	0.00
Analgesics (non opoids) and NSAIDS	47	20.68	0.53 ±0.02	25.07	3.45	0.17
Vaccines	00	0.00	0.00	0.00	0.00	0.00
Diagnostic agents	03	1.32	1.86	5.58	0.77	0.58
Anti-asthmatic and mucolytics	02	0.88	5.11	10.22	1.40	1.59*
Cough mixtures	26	11.44	1.42 ±0.78	36.91	5.07	0.44
Anti-mycobacterials	00	0.00	0.00	0.00	0.00	0.00
Anti-fungals	00	0.00	0.00	0.00	0.00	0.00
Total	**229**	**100.01**		**735.57**	**99.99**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

Appendix 1.46 : Parameters of pharmacological group for all consultations in clinic 2

PHARMACOLOGICAL GROUP IN CLINIC 2	Frequency parameters		Cost related parameters			
	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Antibacterial (Penicillin's)	04	0.36	3.20 ±1.16	12.81	0.42	1.17
Anti-effectives (amino glycosides)	00	0.00	0.00	0.00	0.00	0.00
Antibacterials (Chloramphenicol, erythromicns)	02	0.18	4.42 ±3.09	8.84	0.29	1.61*
Anti-fungal oral/injections	00	0.00	0.00	0.00	0.00	0.00
Anti-anginal	00	0.00	0.00	0.00	0.00	0.00
Antihypertensives	61	5.49	7.08 ±6.27	431.62	14.03	2.56*
Congestive heart failure drugs	07	0.63	2.28 ±0.77	15.98	0.52	0.83
Drugs affecting blood	00	0.00	0.00	0.00	0.00	0.00
Anti-fungal (topical)	00	0.00	0.00	0.00	0.00	0.00
Antiseptics / dermatological disinfectants	01	0.09	6.25	6.25	0.20	2.22*
Anti-pruritics	00	0.00	0.00	0.00	0.00	0.00
Scabicides and Pedicullocides	00	0.00	0.00	0.00	0.00	0.00
Other ointments, creams and emollients	00	0.00	0.00	0.00	0.00	0.00
Anti-effective eye preparations	03	0.27	0.67 ±0.27	2.02	0.07	0.26
Anti allergic eye preparations	00	0.00	0.00	0.00	0.00	0.00
Other ear and nose preparations	00	0.00	0.00	0.00	0.00	0.00
Contraceptives (injectables)	65	5.85	4.96 ±0.34	322.14	10.47	1.79
Oral contraceptives	12	1.08	7.72 ±0.55	92.61	3.01	2.79*
Hormones, androgens and progesterones	00	0.00	0.00	0.00	0.00	0.00
Anti-diabetic agents	01	0.09	30.34	30.34	0.98	10.89*
Oral anti diabetic agents	07	0.63	12.23 ±7.36	85.62	2.78	4.41*

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 2	Frequency n	Frequency Percentage	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Corticosteroids for systemic use	00	0.00	0.00	0.00	0.00	0.00
Anti-epileptics	00	0.00	0.00	0.00	0.00	0.00
Anti allergic (for anaphylaxis)	00	0.00	0.00	0.00	0.00	0.00
Psychotic disorders	00	0.00	0.00	0.00	0.00	0.00
Anti-helmenthics	00	0.00	0.00	0.00	0.00	0.00
Antacids / antiulcer	02	0.18	1.68	3.36	0.11	0.61
Anti emetics	00	0.00	0.00	0.00	0.00	0.00
Anti haemmorrhoidal	00	0.00	0.00	0.00	0.00	0.00
Cathartic drugs/laxatives	00	0.00	0.00	0.00	0.00	0.00
Constipation drugs and digestants	00	0.00	0.00	0.00	0.00	0.00
Oral Electrolytes and anti acid base disturbance agents	00	0.00	0.00	0.00	0.00	0.00
Mouth wash and throat preparations	01	0.09	0.33	0.33	0.01	0.11
Parenteral electrolytes and anti acid base disturbance agent	00	0.00	0.00	0.00	0.00	0.00
Vitamins and minerals	70	6.30	0.09 ±0.18	5.96	0.19	0.03
Feeding and nutritional supplements	01	0.09	12.45	12.45	0.40	4.44*
Analgesics (non opoids) and NSAIDS	13	1.17	0.56 ±0.09	7.27	0.24	0.21
Vaccines	01	0.09	0.51	0.51	0.02	0.22
Diagnostic agents	02	0.18	1.86	3.72	0.12	0.67
Anti-asthmatic and mucolytics	03	0.27	11.61 ±5.53	34.84	1.13	4.19*
Cough mixtures	06	0.54	1.44 ±0.29	8.66	0.28	0.52
Antimycobacterials	841	76.73	2.47 ±1.12	2075.97	67.49	0.88
Anti-fungals	00	0.00	0.00	0.00	0.00	0.00
Total	**1103**	**99.98**		**3161.30**	**99.98**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

Appendix 1.47 : Parameters of pharmacological group for all consultations in clinic 3

PHARMACOLOGICAL GROUP IN CLINIC 3	Frequency parameters		Cost related parameters			
	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Antibacterial (Penicillin's)	44	3.66	5.69 ±5.17	250.52	4.28	1.17
Anti-effectives (amino glycosides)	00	0.00	0.00	0.00	0.00	0.00
Antibacterials (Chloramphenicol, erythromicns)	35	2.91	8.01 ±17.72	280.42	4.79	1.65*
Anti-fungal oral/injections	02	0.17	6.25	12.50	0.21	1.24
Anti-anginal	01	0.08	17.24	17.24	0.29	3.63*
Antihypertensives	120	9.99	9.02 ±11.42	1082.16	18.47	1.85*
Congestive heart failure drugs	02	0.17	2.36	4.72	0.08	0.47
Drugs affecting blood	32	2.56	1.86 ±1.37	59.55	1.02	0.39
Anti-fungal (topical)	05	0.40	7.54 ±14.76	37.68	0.64	1.6*
Antiseptics / dermatological disinfectants	02	0.17	2.39	4.78	0.08	0.47
Anti-pruritics	05	0.40	1.20 ±0.62	6.02	0.10	0.25
Scabicides and Pedicullocides	0	0.00	0.00	0.00	0.00	0.00
Other ointments, creams and emollients	02	0.17	3.20	6.40	0.11	0.59
Anti-effective eye preparations	05	0.40	0.61 ±0.21	3.06	0.05	0.13
Anti allergic eye preparations	03	0.24	4.45 ±2.67	13.36	0.23	0.96
Other ear and nose preparations	03	0.24	4.16	12.48	0.21	0.88
Contraceptives (injectables)	72	5.99	4.76 ±0.31	342.60	5.85	0.98
Oral contraceptives	29	2.32	7.84 ±0.55	227.34	3.89	1.68*
Hormones, androgens and progesterones	00	0.00	0.00	0.00	0.00	0.00
Anti-diabetic agents	02	0.17	30.34	60.68	1.04	6.12*
Oral anti diabetic agents	06	0.48	13.14 ±8.93	78.81	1.34	2.79*

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 3	Frequency n	Frequency Percentage	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Corticosteroids for systemic use	00	0.00	0.00	0.00	0.00	0.00
Anti-epileptics	03	0.24	41.61 ±45.41	124.83	2.13	8.88*
Anti allergic (for anaphylaxis)	00	0.00	0.00	0.00	0.00	0.00
Psychotic disorders	00	0.00	0.00	0.00	0.00	0.00
Anti-helmenthics	02	0.16	1.35	2.70	0.05	0.31
Antacids / antiulcer	08	0.64	1.68	13.44	0.23	0.36
Anti emetics	00	0.00	0.00	0.00	0.00	0.00
Anti haemmorrhoidal	00	0.00	0.00	0.00	0.00	0.00
Cathartic drugs / laxatives	00	0.00	0.00	0.00	0.00	0.00
Constipation drugs and digestants	00	0.00	0.00	0.00	0.00	0.00
Oral Electrolytes and anti acid base disturbance agents	00	0.00	0.00	0.00	0.00	0.00
Mouth wash and throat preparations	04	0.32	0.33	1.32	0.02	0.06
Parenteral electrolytes and anti acid base disturbance agent	00	0.00	0.00	0.00	0.00	0.00
Vitamins and minerals	277	23.06	0.65 ±1.28	181.17	3.09	0.13
Feeding and nutritional supplements	40	3.2	11.26 ±2.54	450.35	7.69	2.40*
Analgesics (non opoids) and NSAIDS	89	7.12	0.62 ±0.14	55.19	0.94	0.13
Vaccines	108	8.99	5.42 ±8.55	585.12	9.99	1.11
Diagnostic agents	01	0.08	1.86	1.86	0.03	0.38
Anti-asthmatic and mucolytics	05	0.40	9.36 ±5.29	46.79	0.79	1.98*
Cough mixtures	38	3.04	1.35 ±0.36	51.22	0.87	0.29
Antimycobacterials	257	21.39	7.05 ±8.49	1811.91	30.93	1.44
Anti-fungals	05	0.40	22.12 ±6.39	110.61	1.89	4.73*
Total	**1207**	**99.98**		**5936.83**	**99.99**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

Appendix 1.48 : Parameters of pharmacological group for all consultations in clinic 4

PHARMACOLOGICAL GROUP IN CLINIC 4	Frequency parameters		Cost related parameters			
	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Antibacterial (Penicillin's)	22	4.19	3.75 ±1.58	82.39	2.92	0.69
Anti-effectives (amino glycosides)	00	0.00	0.00	0.00	0.00	0.00
Antibacterials (Chloramphenicol, erythromicns)	21	4.00	1.81 ±1.13	37.98	1.35	0.34
Anti-fungal oral / Injections	02	0.38	5.46	10.92	0.39	1.03
Anti-anginal	00	0.00	0.00	0.00	0.00	0.00
Antihypertensives	55	10.48	6.45 ±7.31	355.02	12.60	1.20
Congestive heart failure drugs	15	2.86	2.29 ±0.28	34.32	1.22	0.42
Drugs affecting blood	23	4.38	1.91 ±1.58	44.04	1.56	0.36
Anti-fungal (topical)	02	0.38	0.67 ±0.03	1.32	0.05	0.13
Antiseptics / dermatological disinfectants	04	0.76	2.39	9.56	0.34	0.45
Anti-pruritics	04	0.76	1.94 ±1.04	7.77	0.28	0.37
Scabicides and Pedicullocides	02	0.38	3.20	6.40	0.23	0.61
Other ointments, creams and emollients	09	1.71	0.57 ±0.15	5.14	0.18	0.11
Anti-effective eye preparations	04	0.76	7.54	30.16	1.07	1.41
Anti allergic eye preparations	01	0.19	3.48	3.48	0.12	0.63
Other ear and nose preparations	02	0.38	2.39 ±2.49	4.79	0.17	0.45
Contraceptives (injectables)	35	6.67	4.87 ±0.34	170.48	6.05	0.91
Oral contraceptives	07	1.33	6.22 ±2.44	43.57	1.55	1.17
Hormones, androgens and progesterones	00	0.00	0.00	0.00	0.00	0.00
Anti-diabetic agents	00	0.00	0.00	0.00	0.00	0.00
Oral anti diabetic agents	00	0.00	0.00	0.00	0.00	0.00

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 4	Frequency n	Frequency Percentage	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Corticosteroids for systemic use	00	0.00	0.00	0.00	0.00	0.00
Anti-epileptics	10	1.90	12.44 ±9.44	124.40	4.42	2.33*
Anti allergic (for anaphylaxis)	00	0.00	0.00	0.00	0.00	0.00
Psychotic disorders	01	0.19	1.07	1.07	0.04	0.21
Anti-helmenthics	01	0.19	4.70	4.07	0.14	0.74
Antacids / antiulcer	09	1.71	1.68	15.12	0.54	0.32
Anti emetics	00	0.00	0.00	0.00	0.00	0.00
Anti haemmorrhoidal	01	0.19	9.92	9.92	0.35	1.84*
Cathartic drugs / laxatives	00	0.00	0.00	0.00	0.00	0.00
Constipation drugs and digestants	00	0.00	0.00	0.00	0.00	0.00
Oral Electrolytes and anti acid base disturbance agents	02	0.38	1.08	2.16	0.08	0.21
Mouth wash and throat preparations	05	0.95	0.33	1.65	0.06	0.06
Parenteral electrolytes and anti acid base disturbance agent	00	0.00	0.00	0.00	0.00	0.00
Vitamins and minerals	54	10.26	1.07 ±2.65	57.60	2.04	0.19
Feeding and nutritional supplements	64	12.16	15.55 ±5.93	995.06	35.32	2.90*
Analgesics (non opoids) and NSAIDS	56	10.64	0.61 ±0.13	33.91	1.20	0.11
Vaccines	29	5.51	5.56 ±8.68	161.24	5.72	1.04
Diagnostic agents	01	0.19	1.86	1.86	0.07	0.37
Anti-asthmatic and mucolytics	01	0.19	5.11	5.11	0.18	0.95
Cough mixtures	35	6.66	1.15 ±0.35	40.08	1.42	0.21
Antimycobacterials	47	8.93	10.38 ±8.88	487.76	17.31	1.94*
Anti-fungals	01	0.19	29.13	29.13	1.03	5.42*
Total	**525**	**99.95**		**2818.18**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

Appendix 1.49 : Parameters of pharmacological group for all consultations in clinic 5

PHARMACOLOGICAL GROUP IN CLINIC 5	Frequency parameters		Cost related parameters			
	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Antibacterial (Penicillin's)	11	1.76	5.51 ±2.77	60.61	2.09	1.19
Anti-effectives (amino glycosides)	00	0.00	0.00	0.00	0.00	0.00
Antibacterials (Chloramphenicol, erythromicns)	11	1.76	2.29 ±1.47	25.17	0.87	0.49
Anti-fungal oral / injections	01	0.16	29.13	29.13	1.00	6.25*
Anti-anginal	00	0.00	0.00	0.00	0.00	0.00
Antihypertensives	107	17.12	9.36 ±8.74	1001.13	34.54	2.02**
Congestive heart failure drugs	21	3.36	2.49 ±1.19	52.40	1.81	0.54
Drugs affecting blood	06	0.96	1.85 ±0.59	11.10	0.38	0.39
Anti-fungal (topical)	07	1.12	10.32 ±16.14	72.21	2.49	2.22*
Antiseptics / dermatological disinfectants	03	0.48	2.39	7.17	0.25	0.52
Anti-pruritics	02	0.32	1.09	2.18	0.08	0.25
Scabicides and Pedicullocides	03	0.48	3.20	9.60	0.33	0.69
Other ointments, creams and emollients	25	4.00	0.60 ±0.17	15.10	0.52	0.13
Anti-effective eye preparations	01	0.16	2.91	2.91	0.01	0.06
Anti allergic eye preparations	00	0.00	0.00	0.00	0.00	0.00
Other ear and nose preparations	00	0.00	0.00	0.00	0.00	0.00
Contraceptives (injectables)	29	4.64	4.75 ±0.31	137.68	4.75	1.02
Oral contraceptives	07	1.12	5.76 ±2.42	40.33	1.39	1.24
Hormones, androgens and progesterones	01	0.16	13.00	13.00	0.45	2.81*
Anti-diabetic agents	04	0.64	17.69 ±8.44	70.75	2.44	3.81*
Oral anti diabetic agents	16	2.56	6.57 ±3.12	105.15	3.63	1.42

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 5	Frequency n	Frequency Percentage	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Corticosteroids for systemic use	00	0.00	0.00	0.00	0.00	0.00
Anti-epileptics	05	0.80	23.42 ±15.75	117.10	4.04	5.05*
Anti allergic (for anaphylaxis)	00	0.00	0.00	0.00	0.00	0.00
Psychotic disorders	00	0.00	0.00	0.00	0.00	0.00
Anti-helmenthics	01	0.16	1.35	1.35	0.05	0.31
Antacids / antiulcer	10	1.60	3.55 ±1.61	35.46	1.22	0,76
Anti emetics	01	0.16	9.92	9.92	0.34	2.13*
Anti haemmorrhoidal	01	0.16	2.96	2.96	0.10	0.63
Cathartic drugs / laxatives	00	0.00	0.00	0.00	0.00	0.00
Constipation drugs and digestants	00	0.00	0.00	0.00	0.00	0.00
Oral Electrolytes and anti acid base disturbance agents	02	0.32	5.94 ±1.40	11.88	0.40	1.25
Mouth wash and throat preparations	00	0.00	0.00	0.00	0.00	0.00
Parenteral electrolytes and anti acid base disturbance agent	00	0.00	0.00	0.00	0.00	0.00
Vitamins and minerals	25	4.00	4.06 ±5.91	101.40	3.49	0.87
Feeding and nutritional supplements	11	1.76	12.45	136.95	4.72	2.68*
Analgesics (non opoids) and NSAIDS	58	9.28	0.60 ±0.15	35.07	1.21	0.13
Vaccines	34	5.44	3.39 ±6.99	115.47	3.98	0.73
Diagnostic agents	04	0.64	1.86	7.44	0.26	0.41
Anti-asthmatic and mucolytics	12	1.92	15.31 ±10.37	183.74	6.34	3.30*
Cough mixtures	25	4.00	1.20 ±0.36	30.06	1.04	0.26
Antimycobacterials	182	29.12	2.49 ±1.05	454.36	15.67	0.54
Anti-fungals	00	0.00	0.00	0.00	0.00	0.00
Total	**626**	**100.10**		**2898.78**	**99.98**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

Appendix 1.50 : Parameters of pharmacological group for all consultations in clinic 6

PHARMACOLOGICAL GROUP IN CLINIC 6	Frequency parameters		Cost related parameters			
	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Antibacterial (Penicillin's)	19	1.89	3.18 ±1.63	60.36	1.47	0.78
Anti-effectives (amino glycosides)	00	0.00	0.00	0.00	0.00	0.00
Antibacterials (Chloramphenicol, erythromicns)	19	1.89	2.61 ±1.92	49.53	1.20	0.63
Anti-fungal oral / injections	05	0.49	7.13 ±5.14	35.64	0.87	1.78*
Anti-anginal	00	0.00	6.04 ±3.91	0.00	0.00	0.00
Antihypertensives	75	7.49	7.46 ±6.31	559.47	13.58	1.81**
Congestive heart failure drugs	15	1.49	2.25 ±0.58	33.78	0.82	0.55
Drugs affecting blood	16	1.59	1.23 ±0.39	19.72	0.48	0.30
Anti-fungal (topical)	05	0.49	1.29 ±0.68	6.47	0.16	0.33
Antiseptics / dermatological disinfectants	03	0.29	2.39	7.17	0.17	0.59
Anti-pruritics	11	1.09	1.73 ±0.61	18.99	0.46	0.42
Scabicides and Pedicullocides	04	0.39	3.20	12.80	0.31	0.79
Other ointments, creams and emollients	07	0.69	0.98 ±0.66	6.89	0.17	0.25
Anti-effective eye preparations	01	0.09	2.91	2.91	0.07	0.78
Anti allergic eye preparations	00	0.00	0.00	0.00	0.00	0.00
Other ear and nose preparations	01	0.09	0.63	0.63	0.02	0.22
Contraceptives (injectables)	45	4.49	4.77 ±0.47	214.75	5.21	1.16
Oral contraceptives	04	0.39	2.55	10.20	0.25	0.64
Hormones, androgens and progesterones	00	0.00	0.00	0.00	0.00	0.00
Anti-diabetic agents	01	0.09	30.34	30.34	0.74	8.22*
Oral anti diabetic agents	02	0.19	4.83 ±1.19	9.66	0.23	1.21

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 6	Frequency n	Frequency Percentage	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Corticosteroids for systemic use	00	0.00	0.00	0.00	0.00	0.00
Anti-epileptics	05	0.49	18.58 ±7.14	92.91	2.26	4.61*
Anti allergic (for anaphylaxis)	00	0.00	0.00	0.00	0.00	0.00
Psychotic disorders	00	0.00	0.00	0.00	0.00	0.00
Anti-helmenthics	00	0.00	0.00	0.00	0.00	0.00
Antacids / antiulcer	05	0.49	4.17 ±1.39	20.84	0.51	1.04
Anti emetics	00	0.00	0.00	0.00	0.00	0.00
Anti haemmorrhoidal	01	0.09	9.92	9.92	0.24	2.67*
Cathartic drugs / laxatives	01	0.09	2.96	2.96	0.07	0.78
Constipation drugs and digestants	02	0.19	2.64	5.28	0.13	0.68
Oral Electrolytes and anti acid base disturbance agents	00	0.00	0.00	0.00	0.00	0.00
Mouth wash and throat preparations	05	0.49	0.33	1.65	0.04	0.08
Parenteral electrolytes and anti acid base disturbance agent	00	0.00	0.00	0.00	0.00	0.00
Vitamins and minerals	32	3.19	1.65 ±3.34	52.81	1.28	0.40
Feeding and nutritional supplements	97	9.69	12.09 ±0.65	1172.69	28.47	2.94**
Analgesics (non opoids) and NSAIDS	93	9.29	0.60 ±0.14	55.83	1.36	0.15
Vaccines	75	7.49	5.29 ±8.53	396.88	9.64	1.29
Diagnostic agents	01	0.09	1.86	1.86	0.05	0.56
Anti-asthmatic and mucolytics	02	0.19	8.78 ±0.50	17.55	0.43	2.26*
Cough mixtures	61	6.09	1.08 ±0.34	65.92	1.60	0.26
Antimycobacterials	388	38.76	2.94 ±1.02	1142.49	27.74	0.72
Anti-fungals	00	0.00	0.00	0.00	0.00	0.00
Total	**1001**	**99.96**		**4118.90**	**100.03**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

Appendix 1.51 : Parameters of pharmacological group for all consultations according to gender in all clinics

PHARMACOLOGICAL GROUP IN ALL CLINICS	Gender	Frequency parameters		Cost related parameters			
		Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Antibacterial (Penicillin's)	Male	42	35.29	5.02 ±4.15	210.81	38.06	1.08
	Female	77	64.71	4.43 ±3.48	341.01	61.94	0.96
	Total	**119**	**100.00**		**551.82**	**100.00**	
Anti-effectives (amino glycosides)	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	29.13	29.13	100.00	1.00
	Total	**01**	**100.00**		**29.13**	**100.00**	
Antibacterials (Chloramphenicol,	Male	29	40.85	6.44 ±14.61	186.78	45.02	1.10
	Female	42	59.15	5.43 ±11.29	228.14	54.98	0.93
erythromicns)	**Total**	**71**	**100.00**		**414.92**	**100.00**	
Anti-fungal oral / Injections	Male	06	50.00	11.68 ±9.39	30.60	30.39	0.61
	Female	06	50.00	5.01 ±1.31	70.09	69.61	1.39
	Total	**12**	**100.00**		**100.69**	**100.00**	
Anti-anginal	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	17.24	17.24	100.00	1.00
	Total	**01**	**100.00**		**17.24**	**100.00**	
Antihypertensives	Male	42	18.42	21.26 ±19.16	892.71	24.13	1.31
	Female	186	81.58	15.09 ±12.53	2806.51	75.87	0.93
	Total	**228**	**100.00**		**3699.22**	**100.00**	
Congestive heart failure drugs	Male	13	22.41	3.45 ±1.79	44.79	26.99	1.20
	Female	45	77.58	2.69 ±0.97	121.18	73.01	0.94
	Total	**58**	**99.99**		**165.97**	**100.00**	
Drugs affecting blood	Male	07	12.07	4.06 ±3.21	28.42	19.68	1.63
	Female	51	87.93	2.27 ±1.03	116.00	80.32	0.91
	Total	**58**	**100.00**		**144.42**	**100.00**	
Anti-fungal (topical)	Male	11	44.00	4.28 ±9.98	47.04	35.13	0.79
	Female	14	56.00	6.20 ±11.84	86.85	64.87	1.16
	Total	**25**	**100.00**		**133.89**	**100.00**	
Antiseptics / dermatological disinfectants	Male	05	41.67	2.39	11.95	41.67	1.00
	Female	07	58.33	2.39	16.73	58.33	1.00
	Total	**12**	**100.00**		**28.68**	**100.00**	
Anti-pruritics	Male	06	24.00	2.07 ±0.83	12.39	30.59	1.27
	Female	19	76.00	1.48 ±0.60	28.12	69.41	0.89
	Total	**25**	**100.00**		**40.51**	**100.00**	
Scabicides and Pedicullocides	Male	05	45.45	3.20	16.00	45.45	1.00
	Female	06	54.55	3.20	19.20	54.55	1.00
	Total	**11**	**100.00**		**35.20**	**100.00**	
Other ointments, creams and emollients	Male	18	33.33	0.72 ±0.45	12.87	35.25	1.06
	Female	36	66.67	0.66 ±0.28	23.64	64.75	0.97
	Total	**54**	**100.00**		**36.51**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN ALL CLINICS	Gender	Frequency n	FP	(AC) (Rands)	(TC) (Rands)	(PC) %	(CPI)
Anti-effective eye preparations	Male	04	36.36	4.07 ±2.32	16.27	27.21	0.75
	Female	07	63.64	6.22 ±2.26	43.52	72.79	1.14
	Total	**11**	**100.00**		**59.79**	**100.00**	
Anti allergic eye preparations	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	02	100.00	3.48	6.96	100.00	1.00
	Total	**02**	**100.00**		**6.96**	**100.00**	
Other ear and nose preparations	Male	02	33.33	2.39 ±2.49	4.79	26.76	0.80
	Female	04	66.67	3.28 ±1.77	13.11	73.24	1.10
	Total	**06**	**100.00**		**17.9**	**100.00**	
Contraceptives (injectables)	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	246	100.00	4.83 ±0.36	1187.65	100.00	1.00
	Total	**246**	**100.00**		**1187.65**	**100.00**	
Oral contraceptives	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	59	100.00	7.02 ±1.87	414.05	100.00	1.00
	Total	**59**	**100.00**		**414.05**	**100.00**	
Hormones, androgens and progesterones	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	13.00	13.00	100.00	1.00
	Total	**01**	**100.00**		**13**	**100.00**	
Anti-diabetic agents	Male	02	25.00	30.34	60.68	31.59	1.26
	Female	06	75.00	21.91 ±9.24	131.43	68.41	0.91
	Total	**08**	**100.00**		**192.11**	**100.00**	
Oral anti diabetic agents	Male	03	15.00	7.05 ±2.26	21.16	7.37	0.49
	Female	17	85.00	15.65 ±8.94	266.06	92.63	1.09
	Total	**20**	**100.00**		**287.22**	**100.00**	
Corticosteroids for systemic use	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	1.69	1.69	100.00	1.00
	Total	**01**	**100.00**		**1.69**	**100.00**	
Anti-epileptics	Male	13	61.90	28.09 ±22.03	365.22	74.45	1.20
	Female	08	38.10	15.67 ±15.33	125.37	25.55	0.67
	Total	**21**	**100.00**		**490.59**	**100.00**	
Anti allergic (for anaphylaxis)	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	1.07	1.07	100.00	1.00
	Total	**01**	**100.00**		**1.07**	**100.00**	
Psychotic disorders	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	1.07	1.07	100.00	1.00
	Total	**01**	**100.00**		**1.07**	**100.00**	
Anti-helmenthics	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	04	100.00	2.19 ±1.68	8.75	100.00	1.00
	Total	**04**	**100.00**		**8.75**	**100.00**	
Antacids / antiulcer	Male	13	28.26	2.88 ±1.57	37.39	25.66	0.91
	Female	33	71.74	3.28 ±1.58	108.31	74.34	1.04
	Total	**46**	**100.00**		**145.7**	**100.00**	
Anti emetics	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	1.11	1.11	100.00	1.00
	Total	**01**	**100.00**		**1.11**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN ALL CLINICS	Gender	Frequency n	FP	(AC) (Rands)	(TC) (Rands)	(PC) %	(CPI)
Anti haemmorrhoidal	Male	01	25.00	9.92	9.92	25.00	1.00
	Female	03	75.00	9.92	29.76	75.00	1.00
	Total	**04**	**100.00**		**39.68**	**100.00**	
Cathartic drugs / laxatives	Male	01	33.33	2.96	2.96	33.33	1.00
	Female	02	66.67	2.96	5.92	66.67	1.00
	Total	**03**	**100.00**		**8.88**	**100.00**	
Constipation drugs and digestants	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	04	100.00	2.64	10.56	100.00	1.00
	Total	**04**	**100.00**		**10.56**	**100.00**	
Oral Electrolytes and anti acid base disturbance agents	Male	09	52.94	1.58 ±2.52	14.19	84.31	1.59*
	Female	08	47.06	0.33	2.64	15.69	2.99*
	Total	**17**	**100.00**		**16.83**	**100.00**	
Mouth wash and throat preparations	Male	02	100.00	1.08	2.16	100.00	1.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**2**	**100.00**		**2.16**	**100.00**	
Parenteral electrolytes and anti acid base disturbance agent	Male	01	100.00	10.94	10.94	100.00	1.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**10.94**	**100.00**	
Vitamins and minerals	Male	199	58.36	0.85 ±1.84	169.61	37.79	0.65
	Female	142	41.64	1.97 ±3.84	279.26	62.21	1.49
	Total	**341**	**100.00**		**448.87**	**100.00**	
Feeding and nutritional supplements	Male	88	42.93	13.55 ±4.41	1192.16	43.08	1.00
	Female	117	57.07	13.46 ±4.29	1575.34	56.92	0.99
	Total	**205**	**100.00**		**2767.5**	**100.00**	
Analgesics (non opoids) and NSAIDS	Male	116	33.53	0.65 ±0.17	75.60	35.60	1.06
	Female	230	66.47	0.59 ±0.13	136.74	64.40	0.97
	Total	**346**	**100.00**		**212.34**	**100.00**	
Vaccines	Male	44	40.37	11.24 ±12.36	494.58	39.28	0.97
	Female	65	59.63	11.76 ±12.33	764.64	60.72	1.02
	Total	**109**	**100.00**		**1259.22**	**100.00**	
Diagnostic agents	Male	01	8.33	1.86	1.86	8.33	1.00
	Female	11	91.67	1.86	20.46	91.67	1.00
	Total	**12**	**100.00**		**22.32**	**100.00**	
Anti-asthmatic and mucolytics	Male	09	64.29	26.56 ±28.66	239.02	80.22	1.25
	Female	05	35.71	11.85 ±8.36	59.23	19.86	0.56
	Total	**14**	**100.00**		**298.25**	**100.08**	
Cough mixtures	Male	56	32.56	1.33 ±0.68	74.67	32.07	0.98
	Female	116	67.44	136 ±0.58	158.18	67.93	1.01
	Total	**172**	**100.00**		**232.85**	**100.00**	
Antimycobacterials	Male	850	59.69	4.04 ±4.58	3435.06	57.51	0.96
	Female	574	40.31	4.42 ±5.21	2537.43	42.49	1.05
	Total	**1424**	**100.00**		**5972.49**	**100.00**	
Anti-fungals	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	06	100.00	23.29 ±6.39	139.74	100.00	1.00
	Total	**06**	**100.00**		**139.74**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

Appendix 1.52 : Parameters of pharmacological group for all consultations according to gender in clinic 1

PHARMACOLOGICAL GROUP IN CLINIC 1	Gender	Frequency parameters		Cost related parameters			
		Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Antibacterial (Penicillin's)	Male	08	42.10	3.91 ±2.49	31.27	74.28	1.76*
	Female	11	57.90	4.89 ±3.64	53.86	93.02	1.61*
	Total	**19**	**100.00**		**85.13**	**100.00**	
Anti-effectives (amino glycosides)	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	29.13	29.13	100.00	1.00
	Total	**01**	**100.00**		**29.13**	**100.00**	
Antibacterials (Chloramphenicol, erythromicns)	Male	02	50.00	4.16 ±3.47	8.31	64.02	1.28
	Female	02	50.00	2.34 ±0.91	4.67	35.98	0.72
	Total	**04**	**100.00**		**12.98**	**100.00**	
Anti-fungal oral / injections	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	02	100.00	6.25	12.50	100.00	1.00
	Total	**02**	**100.00**		**12.50**	**100.00**	
Anti-anginal	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Antihypertensives	Male	04	13.79	10.15 ±12.33	40.61	15.05	1.09
	Female	25	86.21	9.17 ±9.69	229.21	84.95	0.99
	Total	**29**	**100.00**		**269.82**	**100.00**	
Congestive heart failure drugs	Male	01	11.11	3.65	3.65	14.74	1.33
	Female	08	88.89	2.64 ±0.46	21.12	85.26	0.96
	Total	**09**	**100.00**		**24.77**	**100.00**	
Drugs affecting blood	Male	03	75.00	2.23	6.69	66.83	0.89
	Female	01	25.00	3.32	3.32	33.17	1.33
	Total	**04**	**100.00**		**10.01**	**100.00**	
Anti-fungal (topical)	Male	04	80.00	2.04 ±2.80	8.17	82.03	1.03
	Female	01	20.00	1.79	1.79	17.97	0.90
	Total	**05**	**100.00**		**9.96**	**100.00**	
Antiseptics / dermatological disinfectants	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-pruritics	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	03	100.00	1.85 ±0.66	5.55	100.00	1.00
	Total	**03**	**100.00**		**5.55**	**100.00**	
Scabicides and Pedicullocides	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	00	0.00		0.00	0.00	
Other ointments, creams and emollients	Male	02	33.33	0.70 ±0.25	1.40	32.56	0.98
	Female	04	66.67	0.73 ±0.24	2.90	67.44	1.01
	Total	**06**	**100.00**		**4.30**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 1	Gender	Frequency n	FP	(AC) (Rands)	(TC) (Rands)	(PC) %	(CPI)
Anti-effective eye preparations	Male	01	50.00	2.91	2.91	27.85	0.56
	Female	01	50.00	7.54	7.54	72.15	1.44
	Total	**02**	**100.00**		**10.45**	**100.00**	
Anti allergic eye preparations	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	3.48	3.48	100.00	1.00
	Total	**01**	**100.00**		**3.48**	**100.00**	
Other ear and nose preparations	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Contraceptives (injectables)	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Oral contraceptives	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Hormones, androgens and progesterones	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-diabetic agents	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Oral anti diabetic agents	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	7.98	7.98	100.00	1.00
	Total	**01**	**100.00**		**7.98**	**100.00**	
Corticosteroids for systemic use	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	1.69	1.69	100.00	1.00
	Total	**01**	**100.00**		**1.69**	**100.00**	
Anti-epileptics	Male	01	100.00	31.35	31.35	100.00	1.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**31.35**	**100.00**	
Anti allergic (for anaphylaxis)	Male	00	0.00	0.00	0.00	0.00	0.00.
	Female	01	100.00	1.07	1.07	100.00	1.00
	Total	**01**	**100.00**		**1.07**	**100.00**	
Psychotic disorders	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-helmenthics	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Antacids / antiulcer	Male	03	25.00	4.79	14.37	25.00	1.00
	Female	09	75.00	4.79	43.11	75.00	1.00
	Total	**12**	**100.00**		**57.48**	**100.00**	
Anti emetics	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	1.11	1.11	100.00	1.00
	Total	**01**	**100.00**		**1.11**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 1	Gender	Frequency n	FP	(AC) (Rands)	(TC) (Rands)	(PC) %	(CPI)
Anti haemmorrhoidal	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	9.92	9.92	100.00	1.00
	Total	**01**	**100.00**		**9.92**	**100.00**	
Cathartic drugs / laxatives	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	2.96	2.96	100.00	1.00
	Total	**01**	**100.00**		**2.96**	**100.00**	
Constipation drugs and digestants	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	02	100.00	2.64	5.28	100.00	1.00
	Total	**02**	**100.00**		**5.28**	**100.00**	
Oral Electrolytes and anti acid base disturbance agents	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Mouth wash and throat preparations	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Parenteral electrolytes and anti acid base disturbance agent	Male	01	100.00	10.94	10.94	100.00	1.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**10.94**	**100.00**	
Vitamins and minerals	Male	05	38.46	3.46 ±6.09	17.31	34.67	0.90
	Female	08	61.54	4.08 ±6.35	32.62	65.33	1.06
	Total	**13**	**100.00**		**49.93**	**100.00**	
Feeding and nutritional supplements	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Analgesics (non opoids) and NSAIDS	Male	16	35.56	0.53 ±0.02	8.52	33.98	0.96
	Female	29	64.44	0.57 ±0.14	16.55	66.02	1.02
	Total	**45**	**100.00**		**25.07**	**100.00**	
Vaccines	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Diagnostic agents	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	03	100.00	1.86	5.58	100.00	1.00
	Total	**03**	**100.00**		**5.58**	**100.00**	
Anti-asthmatic and mucolytics	Male	02	100.00	5.11	10.22	100.00	1.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**10.22**	**100.00**	
Cough mixtures	Male	10	43.48	1.71 ±1.21	17.16	46.49	1.07
	Female	13	56.52	1.52 ±0.57	19.75	53.51	0.95
	Total	**23**	**100.00**		**36.91**	**100.00**	
Antimycobacterials	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-fungals	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

Appendix 1.53 : Parameters of pharmacological group for all consultations according to gender in clinic 2

PHARMACOLOGICAL GROUP IN CLINIC 2	Gender	Frequency parameters		Cost related parameters			
		Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Antibacterial (Penicillin's)	Male	04	100.00	3.20 ±1.16	12.81	100.00	1.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**04**	**100.00**		**12.81**	**100.00**	
Anti-effectives (amino glycosides)	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Antibacterials (Chloramphenicol, erythromicns)	Male	01	50.00	6.61	6.61	74.77	1.49
	Female	01	50.00	2.23	2.23	25.23	0.50
	Total	**02**	**100.00**		**8.84**	**100.00**	
Anti-fungal oral / injections	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-anginal	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Antihypertensives	Male	05	19.23	14.87 ±9.96	74.35	17.23	0.89
	Female	21	80.77	17.02 ±10.09	357.27	82.77	1.02
	Total	**26**	**100.00**		**431.62**	**100.00**	
Congestive heart failure drugs	Male	02	50.00	3.41 ±1.48	6.81	42.62	0.85
	Female	02	50.00	4.59 ±3.15	9.17	57.38	1.15
	Total	**04**	**100.00**		**15.98**	**100.00**	
Drugs affecting blood	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-fungal (topical)	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	6.25	6.25	100.00	1.00
	Total	**01**	**100.00**		**6.25**	**100.00**	
Antiseptics / dermatological disinfectants	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-pruritics	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Scabicides and Pedicullocides	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Other ointments, creams and emollients	Male	01	33.33	0.98	0.98	48.51	1.46
	Female	02	66.67	0.52	1.04	51.49	0.77
	Total	**03**	**100.00**		**2.02**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 2	Gender	Frequency n	FP	(AC) (Rands)	(TC) (Rands)	(PC) %	(CPI)
Anti-effective eye preparations	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti allergic eye preparations	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Other ear and nose preparations	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Contraceptives (injectables)	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	65	100.00	4.96 ±0.34	322.14	100.00	1.00
	Total	**65**	**100.00**		**322.14**	**100.00**	
Oral contraceptives	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	12	100.00	7.72 ±0.55	92.61	100.00	1.00
	Total	**12**	**100.00**		**92.61**	**100.00**	
Hormones, androgens and progesterones	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-diabetic agents	Male	01	100.00	30.34	30.34	100.00	1.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**30.34**	**100.00**	
Oral anti diabetic agents	Male	01	20.00	5.83	5.83	6.81	0.34
	Female	04	80.00	19.95 ±3.96	79.79	93.19	1.16
	Total	**05**	**100.00**		**85.62**	**100.00**	
Corticosteroids for systemic use	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-epileptics	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti allergic (for anaphylaxis)	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Psychotic disorders	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-helmenthics	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Antacids / antiulcer	Male	01	50.00	1.68	1.68	50.00	1.00
	Female	01	50.00	1.68	1.68	50.00	1.00
	Total	**02**	**100.00**		**3.36**	**100.00**	
Anti emetics	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 2	Gender	Frequency n	FP	(AC) (Rands)	(TC) (Rands)	(PC) %	(CPI)
Anti haemmorrhoidal	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Cathartic drugs / laxatives	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Constipation drugs and digestants	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Oral Electrolytes and anti acid base disturbance agents	Male	01	100.00	0.33	0.33	100.00	1.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**0.33**	**100.00**	
Mouth wash and throat preparations	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Parenteral electrolytes and anti acid base disturbance agent	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Vitamins and minerals	Male	66	94.29	0.09 ±0.19	5.76	96.64	1.02
	Female	04	5.71	0.05	0.20	3.36	0.59
	Total	**70**	**100.00**		**5.96**	**100.00**	
Feeding and nutritional supplements	Male	01	100.00	12.45	12.45	100.00	1.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**12.45**	**100.00**	
Analgesics (non opoids) and NSAIDS	Male	06	46.15	0.54 ±0.02	3.22	44.29	0.96
	Female	07	53.85	0.58 ±0.12	4.05	55.71	1.03
	Total	**13**	**100.00**		**7.27**	**100.00**	
Vaccines	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	0.51	0.51	100.00	1.00
	Total	**01**	**100.00**		**0.51**	**100.00**	
Diagnostic agents	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	02	100.00	1.86	3.72	100.00	1.00
	Total	**02**	**100.00**		**3.72**	**100.00**	
Anti-asthmatic and mucolytics	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	02	100.00	17.42 ±12.73	34.84	100.00	1.00
	Total	**02**	**100.00**		**34.84**	**100.00**	
Cough mixtures	Male	01	16.67	1.56	1.56	18.01	1.08
	Female	05	83.33	1.42 ±0.31	7.10	81.99	0.98
	Total	**06**	**100.00**		**8.66**	**100.00**	
Antimycobacterials	Male	433	62.94	3.27 ±1.64	1415.39	68.18	1.08
	Female	255	37.06	2.59 ±1.39	660.58	31.82	0.86
	Total	**688**	**100.00**		**2075.97**	**100.00**	
Anti-fungals	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

Appendix 1.54 : Parameters of pharmacological group for all consultations according to gender in clinic 3

PHARMACOLOGICAL GROUP IN CLINIC 3	Gender	Frequency parameters		Cost related parameters			
		Frequency (F)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Antibacterial (Penicillin's)	Male	15	34.09	6.66 ±5.89	99.90	39.88	1.17
	Female	29	65.91	5.19 ±4.79	150.62	60.12	0.91
	Total	**44**	**100.00**		**250.52**	**100.00**	
Anti-effectives (amino glycosides)	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Antibacterials (Chloramphenicol,	Male	07	30.43	17.69 ±28.020	123.82	44.16	1.45
	Female	16	69.57	9.79 ±17.66	156.60	55.84	0.80
erythromicns)	**Total**	**23**	**100.00**		**280.42**	**100.00**	
Anti-fungal oral / injections	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	02	100.00	6.25	12.50	100.00	1.00
	Total	**02**	**100.00**		**12.5**	**100.00**	
Anti-anginal	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	17.24	17.24	100.00	1.00
	Total	**01**	**100.00**		**17.24**	**100.00**	
Antihypertensives	Male	07	12.50	33.32 ±37.87	233.27	21.56	1.72
	Female	49	87.50	17.32 ±15.63	848.89	78.44	0.89
	Total	**56**	**100.00**		**1082.16**	**100.00**	
Congestive heart failure drugs	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	02	100.00	2.36	4.72	100.00	1.00
	Total	**02**	**100.00**		**4.72**	**100.00**	
Drugs affecting blood	Male	01	5.00	8.66	8.66	14.54	2.88*
	Female	19	95.00	2.68 ±0.93	50.89	85.46	0.89
	Total	**20**	**100.00**		**59.55**	**100.00**	
Anti-fungal (topical)	Male	03	60.00	11.75 ±19.21	35.25	93.55	1.56
	Female	02	40.00	1.21 ±0.81	2.43	6.45	0.16
	Total	**05**	**100.00**		**37.68**	**100.00**	
Antiseptics / dermatological disinfectants	Male	01	50.00	2.39	2.39	50.00	1.00
	Female	01	50.00	2.39	2.39	50.00	1.00
	Total	**02**	**100.00**		**4.78**	**100.00**	
Anti-pruritics	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	05	100.00	1.20 ±0.62	6.02	100.00	1.00
	Total	**05**	**100.00**		**6.02**	**100.00**	
Scabicides and Pedicullocides	Male	01	50.00	3.20	3.20	50.00	1.00
	Female	01	50.00	3.20	3.20	50.00	1.00
	Total	**02**	**100.00**		**6.4**	**100.00**	
Other ointments, creams and emollients	Male	01	20.00	0.52	0.52	16.99	0.85
	Female	04	80.00	0.64 ±0.23	2.54	83.01	1.04
	Total	**05**	**100.00**		**3.06**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 3	Gender	Frequency n	FP	(AC) (Rands)	(TC) (Rands)	(PC) %	(CPI)
Anti-effective eye preparations	Male	01	33.33	2.91	2.91	21.78	0.65
	Female	02	66.67	5.23 ±3.27	10.45	78.22	1.17
	Total	**03**	**100.00**		**13.36**	**100.00**	
Anti allergic eye preparations	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Other ear and nose preparations	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	03	100.00	4.16	12.48	100.00	1.00
	Total	**03**	**100.00**		**12.48**	**100.00**	
Contraceptives (injectables)	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	72	100.00	4.76 ±0.31	342.60	100.00	1.00
	Total	**72**	**100.00**		**342.60**	**100.00**	
Oral contraceptives	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	29	100.00	7.84 ±0.55	227.34	100.00	1.00
	Total	**29**	**100.00**		**227.34**	**100.00**	
Hormones, androgens and progesterones	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-diabetic agents	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	02	100.00	30.34	60.68	100.00	1.00
	Total	**02**	**100.00**		**60.68**	**100.00**	
Oral anti diabetic agents	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	03	100.00	26.27 ±10.93	78.81	100.00	1.00
	Total	**03**	**100.00**		**78.81**	**100.00**	
Corticosteroids for systemic use	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-epileptics	Male	02	66.67	54.72 ±55.62	109.44	87.67	1.31
	Female	01	33.33	15.39	15.39	12.33	0.37
	Total	**03**	**100.00**		**124.83**	**100.00**	
Anti allergic (for anaphylaxis)	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Psychotic disorders	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-helmenthics	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	02	100.00	1.35	2.70	100.00	1.00
	Total	**02**	**100.00**		**2.70**	**100.00**	
Antacids / antiulcer	Male	02	25.00	1.68	3.36	25.00	1.00
	Female	06	75.00	1.68	10.08	75.00	1.00
	Total	**08**	**100.00**		**13.44**	**100.00**	
Anti emetics	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 3	Gender	Frequency n	FP	(AC) (Rands)	(TC) (Rands)	(PC) %	(CPI)
Anti haemmorrhoidal	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Cathartic drugs / laxatives	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Constipation drugs and digestants	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Oral Electrolytes and anti acid base disturbance agents	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	04	100.00	0.33	1.32	100.00	1.00
	Total	**04**	**100.00**		**1.32**	**100.00**	
Mouth wash and throat preparations	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Parenteral electrolytes and anti acid base disturbance agent	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Vitamins and minerals	Male	67	43.79	1.18 ±0.85	79.35	43.17	0.99
	Female	86	56.21	1.18 ±0.85	101.82	56.83	1.01
	Total	**153**	**100.00**		**183.81**	**100.00**	
Feeding and nutritional supplements	Male	16	47.06	14.84 ±6.59	237.49	52.73	1.12
	Female	18	52.94	11.83 ±3.92	212.86	47.27	0.89
	Total	**34**	**100.00**		**450.35**	**100.00**	
Analgesics (non opoids) and NSAIDS	Male	27	30.68	0.67 ±0.17	18.10	32.80	1.07
	Female	61	69.82	0.61 ±0.13	37.09	67.20	0.96
	Total	**88**	**100.00**		**55.19**	**100.00**	
Vaccines	Male	19	39.58	12.92 ±12.67	245.42	41.94	1.06
	Female	29	60.42	11.71 ±12.59	339.70	58.06	0.96
	Total	**48**	**100.00**		**585.12**	**100.00**	
Diagnostic agents	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	1.86	1.86	100.00	1.00
	Total	**01**	**100.00**		**1.86**	**100.00**	
Anti-asthmatic and mucolytics	Male	02	66.67	18.32 ±18.68	36.64	78.31	1.17
	Female	01	33.33	10.15	10.15	21.69	0.58
	Total	**03**	**100.00**		**46.79**	**100.00**	
Cough mixtures	Male	06	20.00	1.91 ±0.49	11.47	22.39	1.12
	Female	24	80.00	1.66 ±0.58	39.75	77.61	0.97
	Total	**30**	**100.00**		**51.22**	**100.00**	
Antimycobacterials	Male	91	55.49	9.32 ±9.96	893.93	49.34	0.89
	Female	73	44.51	12.58 ±9.44	917.98	50.66	1.14
	Total	**164**	**100.00**		**1811.91**	**100.00**	
Anti-fungals	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	05	100.00	22.12 ±6.39	110.61	100.00	1.00
	Total	**05**	**100.00**		**110.61**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

Appendix 1.55 : Parameters of pharmacological group for all consultations according to gender in clinic 4

PHARMACOLOGICAL GROUP IN CLINIC 4	Gender	Frequency parameters		Cost related parameters			
		Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Antibacterial (Penicillin's)	Male	05	22.73	3.79 ±1.80	18.93	22.98	1.01
	Female	17	77.27	3.73 ±1.57	63.46	77.02	0.99
	Total	**22**	**100.00**		**82.39**	**100.00**	
Anti-effectives (amino glycosides)	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Antibacterials (Chloramphenicol, erythromicns)	Male	06	37.50	2.58 ±1.99	15.45	40.68	1.08
	Female	10	62.50	2.25 ±0.78	22.53	59.32	0.95
	Total	**16**	**100.00**		**37.98**	**100.00**	
Anti-fungal oral / injections	Male	02	100.00	5.46	10.92	100.00	1.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**10.92**	**100.00**	
Anti-anginal	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Antihypertensives	Male	02	7.69	19.26 ±2.72	36.52	10.35	1.35
	Female	24	92.31	13.19 ±12.03	316.50	89.65	0.97
	Total	**26**	**100.00**		**353.02**	**100.00**	
Congestive heart failure drugs	Male	02	14.29	2.36	4.72	13.75	0.96
	Female	12	85.71	2.47 ±0.37	29.60	86.25	1.01
	Total	**14**	**100.00**		**34.32**	**100.00**	
Drugs affecting blood	Male	01	6.67	8.66	8.66	19.66	2.95*
	Female	14	93.33	2.53 ±1.02	35.38	80.34	0.86
	Total	**15**	**100.00**		**44.04**	**100.00**	
Anti-fungal (topical)	Male	01	50.00	0.64	0.64	48.48	0.97
	Female	01	50.00	0.68	0.68	51.51	1.03
	Total	**02**	**100.00**		**1.32**	**99.99**	
Antiseptics / dermatological disinfectants	Male	01	25.00	2.39	2.39	25.00	1.00
	Female	03	75.00	2.39	7.17	75.00	1.00
	Total	**04**	**100.00**		**9.56**	**100.00**	
Anti-pruritics	Male	02	50.00	2.79 ±0.57	5.59	71.94	1.44
	Female	02	50.00	1.09	2.18	28.06	0.56
	Total	**04**	**100.00**		**7.77**	**100.00**	
Scabicides and Pedicullocides	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	02	100.00	3.20	6.40	100.00	1.00
	Total	**02**	**100.00**		**6.4**	**100.00**	
Other ointments, creams and emollients	Male	06	66.67	0.59 ±0.19	3.58	69.65	1.04
	Female	03	33.33	0.52	1.56	30.35	0.91
	Total	**09**	**100.00**		**5.14**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 4	Gender	Frequency n	FP	(AC) (Rands)	(TC) (Rands)	(PC) %	(CPI)
Anti-effective eye preparations	Male	01	25.00	7.54	7.54	25.00	1.00
	Female	03	75.00	7.54	22.62	75.00	1.00
	Total	**04**	**100.00**		**30.16**	**100.00**	
Anti allergic eye preparations	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	3.48	3.48	100.00	1.00
	Total	**01**	**100.00**		**3.48**	**100.00**	
Other ear and nose preparations	Male	02	100.00	2.39 ±2.49	4.79	100.00	1.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**4.79**	**100.00**	
Contraceptives (injectables)	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	35	100.00	4.87 ±0.34	170.48	100.00	1.00
	Total	**35**	**100.00**		**170.48**	**100.00**	
Oral contraceptives	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	07	100.00	6.22 ±2.44	43.57	100.00	1.00
	Total	**07**	**100.00**		**43.57**	**100.00**	
Hormones, androgens and progesterones	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-diabetic agents	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Oral anti diabetic agents	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Corticosteroids for systemic use	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-epileptics	Male	03	37.50	20.94 ±11.47	62.82	50.50	1.35
	Female	05	62.50	12.32 ±10.32	61.58	49.50	0.79
	Total	**08**	**100.00**		**124.40**	**100.00**	
Anti allergic (for anaphylaxis)	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Psychotic disorders	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	1.07	1.07	100.00	1.00
	Total	**01**	**100.00**		**1.70**	**100.00**	
Anti-helmenthics	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	4.70	4.70	100.00	0.00
	Total	**01**	**100.00**		**4.70**	**100.00**	
Antacids / antiulcer	Male	03	33.33	1.68	5.04	33.33	1.00
	Female	06	66.67	1.68	10.08	66.67	1.00
	Total	**09**	**100.00**		**15.12**	**100.00**	
Anti emetics	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 4	Gender	Frequency n	FP	(AC) (Rands)	(TC) (Rands)	(PC) %	(CPI)
Anti haemmorrhoidal	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	9.92	9.92	100.00	1.00
	Total	**01**	**100.00**		**9.92**	**100.00**	
Cathartic drugs / laxatives	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Constipation drugs and digestants	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Oral Electrolytes and anti acid base disturbance agents	Male	03	60.00	0.33	0.99	60.00	1.00
	Female	02	40.00	0.33	0.66	40.00	1.00
	Total	**05**	**100.00**		**1.65**	**100.00**	
Mouth wash and throat preparations	Male	02	100.00	1.08	2.16	100.00	1.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**2.16**	**100.00**	
Parenteral electrolytes and anti acid base disturbance agent	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Vitamins and minerals	Male	35	68.63	0.48 ±0.38	16.78	29.13	0.42
	Female	16	31.37	2.55 ±4.62	40.82	70.87	2.26*
	Total	**51**	**100.00**		**57.60**	**100.00**	
Feeding and nutritional supplements	Male	35	54.69	14.15 ±5.01	495.25	49.77	0.91
	Female	29	45.31	17.24 ±6.58	499.81	50.23	1.11
	Total	**64**	**100.00**		**995.06**	**100.00**	
Analgesics (non opoids) and NSAIDS	Male	18	33.33	0.65 ±0.17	11.68	34.44	1.03
	Female	36	66.67	0.62 ±0.15	22.23	65.56	0.98
	Total	**54**	**100.00**		**33.91**	**100.00**	
Vaccines	Male	10	76.92	10.88 ±12.94	108.80	67.48	0.88
	Female	03	23.08	17.48 ±14.60	52.44	32.52	1.41
	Total	**13**	**100.00**		**161.24**	**100.00**	
Diagnostic agents	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	1.86	1.86	100.00	1.00
	Total	**01**	**100.00**		**1.86**	**100.00**	
Anti-asthmatic and mucolytics	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	5.11	5.11	100.00	1.00
	Total	**01**	**100.00**		**5.11**	**100.00**	
Cough mixtures	Male	10	30.30	1.21 ±0.37	12.11	30.21	0.99
	Female	23	69.70	1.22 ±0.51	27.97	69.78	1.00
	Total	**33**	**100.00**		**40.08**	**99.99**	
Antimycobacterials	Male	24	72.73	13.09 ±8.21	314.21	64.42	0.89
	Female	09	27.27	19.28 ±2.21	173.55	35.58	1.30
	Total	**33**	**100.00**		**487.76**	**100.00**	
Anti-fungals	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	29.13	29.13	100.00	1.00
	Total	**01**	**100.00**		**29.13**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

Appendix 1.56 : Parameters of pharmacological group for all consultations according to gender in clinic 5

PHARMACOLOGICAL GROUP IN CLINIC 5	Gender	Frequency parameters		Cost related parameters			
		Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Antibacterial (Penicillin's)	Male	04	36.36	7.03 ±4.07	28.10	46.36	1.28
	Female	07	63.64	4.64 ±1.44	32.51	53.64	0.84
	Total	**11**	**100.00**		**60.61**	**100.00**	
Anti-effectives (amino glycosides)	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Antibacterials (Chloramphenicol, erythromicns)	Male	02	25.00	3.99 ±3.26	7.99	31.96	1.28
	Female	06	75.00	2.86 ±0.97	17.18	68.04	0.72
	Total	**08**	**100.00**		**25.17**	**100.00**	
Anti-fungal oral / injections	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	29.13	29.13	100.00	1.00
	Total	**01**	**100.00**		**29.13**	**100.00**	
Anti-anginal	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Antihypertensives	Male	18	36.00	22.35 ±14.20	402.38	40.19	1.12
	Female	32	64.00	18.71 ±13.26	598.75	59.81	0.93
	Total	**50**	**100.00**		**1001.13**	**100.00**	
Congestive heart failure drugs	Male	07	36.84	3.26 ±1.94	22.80	43.51	1.18
	Female	12	63.16	2.47 ±0.37	29.60	56.49	0.89
	Total	**19**	**100.00**		**52.4**	**100.00**	
Drugs affecting blood	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	05	100.00	2.22 ±0.79	11.10	100.00	1.00
	Total	**05**	**100.00**		**11.10**	**100.00**	
Anti-fungal (topical)	Male	01	14.29	0.64	0.64	0.89	0.06
	Female	06	85.71	11.93 ±17.05	71.57	99.11	1.16
	Total	**07**	**100.00**		**72.21**	**100.00**	
Antiseptics / dermatological disinfectants	Male	02	66.67	2.39	4.78	66.67	1.00
	Female	01	33.33	2.39	2.39	33.33	1.00
	Total	**03**	**100.00**		**7.17**	**100.00**	
Anti-pruritics	Male	02	100.00	1.09	2.18	100.00	1.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**2.18**	**100.00**	
Scabicides and Pedicullocides	Male	01	33.33	3.20	3.20	33.33	1.00
	Female	02	66.67	3.20	6.40	66.67	1.00
	Total	**03**	**100.00**		**9.60**	**100.00**	
Other ointments, creams and emollients	Male	07	29.17	0.57 ±0.14	4.00	26.49	0.91
	Female	17	70.83	0.65 ±0.34	11.10	73.51	1.04
	Total	**24**	**100.00**		**15.10**	100.00	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 5	Gender	Frequency n	FP	(AC) (Rands)	(TC) (Rands)	(PC) %	(CPI)
Anti-effective eye preparations	Male	01	100.00	2.91	2.91	100.00	1.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	01	100.00		2.91	100.00	
Anti allergic eye preparations	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Other ear and nose preparations	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Contraceptives (injectables)	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	29	100.00	4.75 ±0.31	137.68	100.00	1.00
	Total	**29**	**100.00**		**137.68**	**100.00**	
Oral contraceptives	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	07	100.00	5.76 ±2.42	40.33	100.00	1.00
	Total	**07**	**100.00**		**40.33**	**100.00**	
Hormones, androgens and progesterones	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	13.00	13.00	100.00	1.00
	Total	**01**	**100.00**		**13.00**	**100.00**	
Anti-diabetic agents	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	04	100.00	17.69 ±8.44	70.75	100.00	1.00
	Total	**04**	**100.00**		**70.75**	**100.00**	
Oral anti diabetic agents	Male	02	20.00	7.67 ±2.82	15.33	14.58	0.72
	Female	08	80.00	11.23 ±6.87	89.82	85.42	1.07
	Total	**10**	**100.00**		**105.15**	**100.00**	
Corticosteroids for systemic use	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-epileptics	Male	04	80.00	28.86 ±11.54	115.44	98.58	1.23
	Female	01	20.00	1.66	1.66	1.42	0.07
	Total	**05**	**100.00**		**117.1**	**100.00**	
Anti allergic (for anaphylaxis)	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Psychotic disorders	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-helmenthics	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	1.35	1.35	100.00	1.00
	Total	**01**	**100.00**		**1.35**	**100.00**	
Antacids / antiulcer	Male	02	20.00	3.24 ±2.19	6.47	18.25	0.91
	Female	08	80.00	3.62 ±1.61	28.99	81.75	1.02
	Total	**10**	**100.00**		**35.46**	**100.00**	
Anti emetics	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 5	Gender	Frequency n	FP	(AC) (Rands)	(TC) (Rands)	(PC) %	(CPI)
Anti haemmorrhoidal	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	9.92	9.92	100.00	1.00
	Total	**01**	**100.00**		**9.92**	**100.00**	
Cathartic drugs / laxatives	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.0	2.96	2.96	100.00	1.00
	Total	**01**	**100.00**		**2.96**	**100.00**	
Constipation drugs and digestants	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Oral Electrolytes and anti acid base disturbance agents	Male	02	100.00	5.94 ±1.40	11.88	100.00	1.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**11.88**	**100.00**	
Mouth wash and throat preparations	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Parenteral electrolytes and anti acid base disturbance agent	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Vitamins and minerals	Male	08	33.33	2.59 ±4.76	20.73	20.45	0.61
	Female	16	66.67	5.04 ±6.49	80.67	79.55	1.19
	Total	**24**	**100.00**		**101.4**	**100.00**	
Feeding and nutritional supplements	Male	02	18.18	12.45	24.90	18.18	1.00
	Female	09	81.82	12.45	112.05	81.82	1.00
	Total	**11**	**100.00**		**136.95**	**100.00**	
Analgesics (non opoids) and NSAIDS	Male	16	29.63	0.78 ±0.19	12.44	35.47	1.20
	Female	38	70.37	0.59 ±0.14	22.63	64.53	0.92
	Total	**54**	**100.00**		**35.07**	**100.00**	
Vaccines	Male	08	47.06	4.19 ±8.84	33.54	29.05	0.62
	Female	09	52.94	9.10 ±12.58	81.93	70.95	1.34
	Total	**17**	**100.00**		**115.47**	**100.00**	
Diagnostic agents	Male	01	25.00	1.86	1.86	25.00	1.00
	Female	03	75.00	1.86	5.58	75.00	1.00
	Total	**04**	**100.00**		**7.44**	**100.00**	
Anti-asthmatic and mucolytics	Male	04	100.00	45.94 ±33.34	183.74	100.00	1.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**04**	**100.00**		**183.74**	**100.00**	
Cough mixtures	Male	09	36.00	1.26 ±0.38	11.37	37.82	1.05
	Female	16	64.00	1.17 ±0.36	18.69	62.18	0.97
	Total	**25**	**100.00**		**30.06**	**100.00**	
Antimycobacterials	Male	71	42.01	2.38 ±1.37	168.98	37.19	0.89
	Female	98	57.99	2.91 ±1.34	285.38	62.81	1.08
	Total	**169**	**100.00**		**454.36**	**100.00**	
Anti-fungals	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

Appendix 1.57 : Parameters of pharmacological group for all consultations according to gender in clinic 6

PHARMACOLOGICAL GROUP IN CLINIC 6	Gender	Frequency parameters		Cost related parameters			
		Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Antibacterial (Penicillin's)	Male	06	31.58	3.30 ±0.91	19.80	32.80	1.04
	Female	13	68.42	3.12 ±1.91	40.56	67.20	0.98
	Total	**19**	**100.00**		**60.36**	**100.00**	
Anti-effectives (amino glycosides)	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Antibacterials (Chloramphenicol, erythromicns)	Male	11	61.11	2.24 ±1.61	24.60	49.67	0.81
	Female	07	38.89	3.56 ±2.67	24.93	50.33	1.29
	Total	**18**	**100.00**		**49.53**	**100.00**	
Anti-fungal oral / injections	Male	04	80.00	4.92 ±1.65	19.68	55.22	0.69
	Female	01	20.00	15.96	15.96	44.78	2.24*
	Total	**05**	**100.00**		**35.64**	**100.00**	
Anti-anginal	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Antihypertensives	Male	06	14.63	17.26 ±7.98	103.58	18.51	1.27
	Female	35	85.37	13.03 ±8.39	455.89	81.49	0.95
	Total	**41**	**100.00**		**559.47**	**100.00**	
Congestive heart failure drugs	Male	01	10.00	6.81	6.81	20.16	2.01*
	Female	09	90.00	2.99 ±1.49	26.97	79.84	0.89
	Total	**10**	**100.00**		**33.78**	**100.00**	
Drugs affecting blood	Male	02	14.29	2.21 ±1.58	4.41	22.36	1.56*
	Female	12	85.71	1.28 ±0.64	15.31	77.64	0.91
	Total	**14**	**100.00**		**19.72**	**100.00**	
Anti-fungal (topical)	Male	02	40.00	1.17 ±0.88	2.34	36.17	0.90
	Female	03	60.00	1.38 ±0.72	4.13	63.83	1.06
	Total	**05**	**100.00**		**6.47**	**100.00**	
Antiseptics / dermatological disinfectants	Male	01	33.33	2.39	2.39	33.33	1.00
	Female	02	66.67	2.39	4.78	66.67	1.00
	Total	**03**	**100.00**		**7.17**	**100.00**	
Anti-pruritics	Male	02	18.18	2.31 ±0.11	4.62	24.33	1.34
	Female	09	81.82	1.59 ±0.60	14.37	75.67	0.93
	Total	**11**	**100.00**		**18.99**	**100.00**	
Scabicides and Pedicullocides	Male	03	75.00	3.20	9.60	75.00	1.00
	Female	01	25.00	3.20	3.20	25.00	1.00
	Total	**04**	**100.00**		**12.80**	**100.00**	
Other ointments, creams and emollients	Male	01	14.29	2.39	2.39	34.69	2.43*
	Female	06	85.71	0.75 ±0.25	4.50	65.31	0.76
	Total	**07**	**100.00**		**6.89**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 6	Gender	Frequency n	FP	(AC) (Rands)	(TC) (Rands)	(PC) %	(CPI)
Anti-effective eye preparations	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	2.91	2.91	100.00	1.00
	Total	01	100.00		2.91	100.00	
Anti allergic eye preparations	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Other ear and nose preparations	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	0.63	0.63	100.00	1.00
	Total	**01**	**100.00**		**0.63**	**100.00**	
Contraceptives (injectables)	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	45	100.00	4.77 ±0.47	214.75	100.00	1.00
	Total	**45**	**100.00**		**214.75**	**100.00**	
Oral contraceptives	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	04	100.00	2.55	10.20	100.00	1.00
	Total	**04**	**100.00**		**10.2**	**100.00**	
Hormones, androgens and progesterones	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-diabetic agents	Male	01	100.00	30.34	30.34	100.00	1.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**30.34**	**100.00**	
Oral anti diabetic agents	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	9.66	9.66	100.00	1.00
	Total	**01**	**100.00**		**9.66**	**100.00**	
Corticosteroids for systemic use	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-epileptics	Male	03	75.00	15.39	46.17	49.69	0.66
	Female	01	25.00	46.74	46.74	50.31	2.01*
	Total	**04**	**100.00**		**92.91**	**100.00**	
Anti allergic (for anaphylaxis)	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Psychotic disorders	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-helmenthics	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Antacids / antiulcer	Male	02	40.00	3.24 ±2.19	6.47	31.05	0.78
	Female	03	60.00	4.79	14.37	68.95	1.15
	Total	05	100.00		20.84	100.00	
Anti emetics	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	

(PC) %	(CPI)
100.00	1.00
0.00	0.00
100.00	
100.00	1.00
0.00	0.00
100.00	
0.00	0.00
100.00	1.00
100.00	
60.00	1.00
40.00	1.00
100.00	
0.00	0.00
0.00	0.00
0.00	
0.00	0.00
0.00	0.00
0.00	
56.20	0.94
43.80	1.09
100.00	
35.99	1.01
64.01	0.99
100.00	
38.76	1.08
61.24	0.95
100.00	
26.91	1.15
73.09	0.95
100.00	
0.00	0.00
00.00	1.00
00.00	
47.98	0.96
52.02	1.04
00.00	
57.76	1.59
42.24	0.67
00.00	
56.24	0.90
43.76	1.16
00.00	
0.00	0.00
0.00	0.00
0.00	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

Appendix 1.58 : Parameters of pharmacological group for all consultations according to age group in all clinics

PHARMACOLOGICAL GROUP IN ALL CLINICS	Age Group	Frequency parameters		Cost related parameters			
	(years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Antibacterial (Penicillin's)	0 ≥ 6	16	13.33	3.99 ±2.38	63.82	11.59	0.87
	6 ≥ 12	05	4.17	4.91 ±3.16	24.55	4.47	1.07
	12 ≥ 19	07	5.83	3.31 ±1.43	23.17	4.20	0.72
	19 ≥ 40	68	56.67	4.66 ±3.57	316.87	57.46	1.01
	40 ≥ 60	22	18.33	4.58 ±4.10	100.86	18.19	0.99
	>60	02	1.67	11.28 ±12.45	22.55	4.09	2.45*
	Total	**120**	**100.00**		**551.82**	**100.00**	
Anti-effectives (amino glycosides)	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	100.00	29.13	29.13	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**1132.77**	**100.00**	
Antibacterials (Chloramphenicol, erythromicns)	0 ≥ 6	20	21.51	2.49 ±1.80	49.89	12.02	0.56
	6 ≥ 12	02	2.15	6.46 ±0.22	12.91	3.11	1.45
	12 ≥ 19	02	2.15	1.49 ±0.29	2.98	0.72	0.33
	19 ≥ 40	60	64.52	5.54 ±13.80	332.32	80.09	1.24
	40 ≥ 60	08	8.60	1.82 ±0.88	14.59	3.52	0.41
	>60	01	1.08	2.23	2.23	0.54	0.50
	Total	**93**	**100.01**		**414.92**	**100.00**	
Anti-fungal oral / injections	0 ≥ 6	01	8.33	6.25	6.25	6.21	0.75
	6 ≥ 12	03	25.00	5.46	16.38	16.27	0.65
	12 ≥ 19	02	16.67	4.38 ±2.64	8.76	8.70	0.52
	19 ≥ 40	04	33.33	6.05 ±0.39	24.21	24.04	0.72
	40 ≥ 60	02	16.67	22.55 ±9.31	45.09	44.78	2.69*
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**12**	**100.00**		**100.69**	**100.00**	
Anti-anginal	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	01	100.00	17.24	17.24	100.00	1.00
	Total	**01**	**100.00**		**17.24**	**100.00**	
Antihypertensives	0 ≥ 6	04	0.86	8.23 ±7.05	32.91	0.90	1.05
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	78	16.70	6.37 ±8.29	496.88	13.55	0.81
	40 ≥ 60	232	49.79	7.84 ±9.07	1819.95	49.64	0.99
	>60	153	32.76	8.61 ±7.74	1316.80	35.91	1.10
	Total	**467**	**100.11**		**3666.54**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN ALL CLINICS	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Congestive heart failure drugs	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	08	11.27	2.36	18.88	11.57	1.03
	40 ≥ 60	32	45.07	2.38	76.20	46.71	1.04
	>60	31	43.66	2.19 ±0.72	68.05	41.72	0.96
	Total	**71**	**100.00**		**163.13**	**100.00**	
Drugs affecting blood	0 ≥ 6	02	2.50	8.66	17.32	12.09	4.84*
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	07	8.75	1.42 ±0.56	9.91	7.93	0.91
	19 ≥ 40	68	85.00	1.58 ±0.57	107.18	74.99	0.88
	40 ≥ 60	03	3.75	2.23	6.69	4.99	1.33
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**80**	**100.00**		**143.33**	**100.00**	
Anti-fungal (topical)	0 ≥ 6	06	24.00	11.72 ±17.19	70.37	52.56	2.19*
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	03	12.00	2.89 ±2.96	8.68	6.48	0.54
	19 ≥ 40	07	28.00	0.79 ±0.44	5.58	4.17	0.15
	40 ≥ 60	09	36.00	5.47 ±10.81	49.26	36.79	1.02
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**25**	**100.00**		**133.89**	**100.00**	
Antiseptics / dermatological disinfectants	0 ≥ 6	03	25.00	2.39	7.17	25.00	1.00
	6 ≥ 12	04	33.33	2.39	9.56	33.33	1.00
	12 ≥ 19	01	8.33	2.39	2.39	8.33	1.00
	19 ≥ 40	03	25.00	2.39	7.17	25.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	01	8.33	2.39	2.39	8.33	1.00
	Total	**12**	**99.99**		**28.68**		
Anti-pruritics	0 ≥ 6	05	20.00	1.55 ±0.62	7.73	19.08	0.95
	6 ≥ 12	02	8.00	1.74 ±0.92	3.48	8.59	1.07
	12 ≥ 19	02	8.00	1.09	2.18	5.38	0.67
	19 ≥ 40	09	36.00	1.53 ±0.69	13.80	34.07	0.95
	40 ≥ 60	07	28.00	1.90 ±0.83	13.32	32.88	1.17
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**25**	**100.00**		**40.51**	**100.00**	
Scabicides and Pedicullocides	0≤ 6	05	45.45	3.20	16.00	45.45	1.00
	6≤12	01	9.09	3.20	3.20	9.09	1.00
	12≤19	00	0.00	0.00	0.00	0.00	0.00
	19≤40	03	27.27	3.20	9.60	27.27	1.00
	40≤60	02	18.18	3.20	6.40	18.18	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**11**	**99.99**		**35.2**	**99.99**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN ALL CLINICS	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Other ointments, creams and emollients	0 ≥ 6	06	10.91	0.87 ±0.18	5.22	14.30	1.31
	6 ≥ 12	02	3.64	0.75 ±0.33	1.50	4.11	1.13
	12 ≥ 19	01	1.82	0.98	0.98	2.68	1.47
	19 ≥ 40	12	21.82	0.74 ±0.23	8.90	24.38	1.12
	40 ≥ 60	15	27.27	0.54 ±0.09	8.16	22.35	0.82
	>60	19	34.55	0.62 ±0.43	11.75	32.18	0.93
	Total	**55**	**100.01**		**36.51**	**100.00**	
Anti-effective eye preparations	0 ≥ 6	05	45.45	5.69 ±2.54	28.44	47.57	1.05
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	9.09	2.91	2.91	4.87	0.58
	19 ≥ 40	02	18.18	7.54	15.08	25.22	1.39
	40 ≥ 60	03	27.27	4.45 ±2.67	13.36	22.34	0.82
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**11**	**99.99**		**59.79**	**100.00**	
Anti allergic eye preparations	0 ≥ 6	01	50.00	3.48	3.48	50.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	50.00	3.48	3.48	50.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**6.96**	**100.00**	
Other ear and nose preparations	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	16.67	4.16	4.16	23.24	1.39
	19 ≥ 40	04	66.67	2.39 ±2.04	9.58	53.52	0.80
	40 ≥ 60	01	16.67	4.16	4.16	23.24	1.39
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**06**	**100.01**		**17.90**	**100.00**	
Contraceptives (injectables)	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	20	13.16	5.10 ±0.28	102.08	14.03	1.07
	19 ≥ 40	119	78.29	4.74 ±0.37	564.43	77.55	0.99
	40 ≥ 60	13	8.55	0.52 ±0.03	61.32	8.43	0.99
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**152**	**100.00**		**727.83**	**100.01**	
Oral contraceptives	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	2.50	7.65	7.65	2.72	1.09
	19 ≥ 40	36	90.00	6.93 ±2.03	249.53	88.77	0.99
	40 ≥ 60	03	7.50	7.97 ±0.59	23.93	8.51	1.13
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**40**	**100.00**		**281.11**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

Pharmacological group in all clinics	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Hormones, androgens and progesterones	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	01	100.00	13.00	13.00	100.00	1.00
	Total	**01**	**100.00**		**13.00**	**100.00**	
Anti-diabetic agents	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	05	62.50	26.97 ±7.54	134.83	70.18	1.12
	>60	03	37.50	19.09 ±9.74	57.28	29.82	0.80
	Total	**08**	**100.00**		**192.11**	**100.00**	
Oral- hypoglycemics	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	02	6.25	8.15 ±5.88	16.29	5.67	0.91
	40 ≥ 60	08	25.00	6.88 ±4.91	55.02	19.16	0.77
	>60	22	68.75	9.81 ±6.62	215.91	75.17	1.09
	Total	**32**	**100.00**		**287.22**	**100.00**	
Corticosteroids for systemic use	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	01	100.00	1.69	1.69	100.00	1.00
	Total	**01**	**100.00**		**1.69**	**100.00**	
Anti-epileptics	0 ≥ 6	01	4.17	31.35	31.35	6.39	1.53*
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	02	8.33	7.70	15.40	3.14	0.38
	19 ≥ 40	10	41.67	18.69 ±11.93	186.93	38.10	0.91
	40 ≥ 60	09	37.50	25.13 ±28.03	226.13	46.09	1.23
	>60	02	8.33	15.39	30.78	6.27	0.75
	Total	**24**	**100.00**		**490.59**	**99.99**	
Anti allergic (for anaphylaxis)	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	100.00	1.07	1.07	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**1.07**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

Pharmacological group in all clinics	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Psychotic disorders	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	100.00	1.07	1.07	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**1.07**	**100,00**	
Anti-helmenthics	0 ≥ 6	01	25.00	4.70	4.70	53.71	2.15*
	6 ≥ 12	01	25.00	1.35	1.35	15.43	0.62
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	25.00	1.35	1.35	15.43	0.62
	40 ≥ 60	01	25.00	1.35	1.35	15.43	0.62
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**04**	**100.00**		**8.75**	**100.00**	
Antacids / antiulcer	0 ≥ 6	02	4.35	1.68	3.36	2.31	0.53
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	27	58.70	2.83 ±1.53	76.46	52.48	0.89
	40 ≥ 60	09	19.57	3.75 ±1.55	33.78	23.18	1.18
	>60	08	17.39	4.01 ±1.44	32.10	22.03	1.27
	Total	**46**	**100.01**		**145.70**	**100.00**	
Anti emetics	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	100.00	1.11	1.11	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**1.11**	**100.00**	
Anti haemmorrhoidal	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	03	75.00	1.86	29.76	75.00	1.00
	40 ≥ 60	01	25.00	0.00	9.92	25.00	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**04**	**100.00**		**39.68**	**100.00**	
Cathartic drugs / laxatives	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	02	66.67	2.23 ±1.88	5.92	66.67	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	01	33.33	1.56	2.96	33.33	1.00
	Total	**03**	**100.00**		**8.88**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

Pharmacological group in all clinics	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Constipation drugs and digestants	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	25.00	0.00	2.64	25.00	1.00
	40 ≥ 60	01	25.00		2.64	25.00	1.00
	>60	02	50.00		5.28	50.00	1.00
	Total	**04**	**100.00**		**10.56**	**100.00**	
Oral Electrolytes and anti acid base disturbance agents	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	02	100.00		2.16	100.00	1.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**2.16**	**100.00**	
Mouth wash and throat preparations	0 ≥ 6	08	50.00		7.26	44.00	0.88
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	07	43.75	2.97 ±1.06	8.91	54.00	1.23
	40 ≥ 60	01	6.25	4.00 ±3.36	0.33	2.00	0.32
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**16**	**100.00**		**16.50**	**100.00**	
Parenteral electrolytes and anti acid base disturbance agent	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	100.00	1.39 ±0.78	10.94	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**10.94**	**100.00**	
Vitamins and minerals	0 ≥ 6	43	9.17		39.29	8.80	0.96
	6 ≥ 12	03	0.64		2.84	0.64	1.00
	12 ≥ 19	10	2.13		7.91	1.77	0.83
	19 ≥ 40	267	56.93		179.22	40.13	0.70
	40 ≥ 60	128	27.29		121.98	27.31	1.00
	>60	18	3.84	4.84 ±4.45	95.36	21.35	5.56*
	Total	**469**	**100.00**		**446.60**	**100.00**	
Feeding and nutritional supplements	0 ≥ 6	133	47.92	31.35	1678.75	60.66	1.27
	6 ≥ 12	03	1.04		35.83	1.29	1.24
	12 ≥ 19	01	0.35	7.70	12.45	0.45	1.29
	19 ≥ 40	44	15.28	15.76 ±12.79	705.74	25.50	1.67*
	40 ≥ 60	27	9.38	25.12 ±28.03	334.63	12.09	1.29
	>60	75	26.04	0.00	0.00	0.00	0.00
	Total	**288**	**100.01**		**2767.40**	**99.99**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

Pharmacological group in all clinics	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Analgesics (non	0 ≥ 6	75	21.93	0.80 ±0.09	60.28	28.76	**1.31**
	6 ≥ 12	15	4.39	0.68 ±0.16	10.21	4.87	1.11
opoids) and NSAIDS	12 ≥ 19	14	4.09	0.59 ±0.16	8.31	3.97	0.97
	19 ≥ 40	102	29.82	0.54 ±0.08	55.54	26.50	0.89
	40 ≥ 60	91	26.61	0.55 ±0.09	49.82	23.77	0.89
	>60	45	13.16	0.56 ±0.14	25.42	12.13	0.92
	Total	**342**	**100.00**		**209.58**	**100.00**	
Vaccines	0 ≥ 6	94	88.68	12.81 ±12.38	1204.10	99.49	1.12
	6 ≥ 12	03	2.83	0.99 ±0.59	2.97	0.25	0.09
	12 ≥ 19	01	0.94	0.35	0.35	0.03	0.09
	19 ≥ 40	08	7.55	0.35	2.80	0.23	0.66
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	**106**	**100.00**		**1210.22**	**100.00**	
Diagnostic agents	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	02	16.67	1.86	3.72	16.67	1.00
	12 ≥ 19	10	83.33	1.86	18.60	83.33	1.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	**12**	**100.00**		**22.32**	**100.00**	
Anti-asthmatic and mucolytics	0 ≥ 6	01	7.14	5.11	5.11	1.71	0.33
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	04	28.57	23.33±12.85	93.30	31.28	1.09
	40 ≥ 60	02	14.28	7.12±2.84	14.24	4.77	0.33
	>60	07	50.00	26.51 ±32.07	185.60	62.23	1.24
	Total	**14**	**99.99**		**298.25**	**99.99**	
Cough mixtures	0 ≥ 6	72	42.60	1.29 ±0.70	92.53	40.10	0.94
	6 ≥ 12	12	7.10	0.99 ±0.29	11.87	5.14	0.72
	12 ≥ 19	08	4.73	1.24 ±0.40	9.92	4.31	0.91
	19 ≥ 40	42	24.85	1.49 ±0.68	62.37	27.09	1.09
	40 ≥ 60	27	15.98	1.55 ±0.35	41.79	18.15	1.14
	>60	08	4.73	1.47 ±0.24	11.79	5.12	1.08
	Total	**169**	**99.99**		**230.27**	**99.91**	
Antimycobacterials	0 ≥ 6	111	7.91	3.07 ±3.19	340.80	5.72	0.72
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	25	1.78	3.64 ±5.27	91.06	1.53	0.86
	19 ≥ 40	775	55.19	4.28 ±4.35	3320.85	55.75	1.01
	40 ≥ 60	488	34.76	4.37 ±5.75	2134.10	35.83	1.03
	>60	05	0.36	13.90	69.50	1.17	3.25*
	Total	**1404**	**100.00**		**5956.31**	**100.00**	
Anti-fungals	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	01	16.67	29.13	29.13	20.85	1.25
	12 ≥ 19	05	83.33	22.12 ±11.87	110.61	79.15	0.95
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	**06**	**100.00**		**139.74**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

Appendix 1.59 : Parameters of pharmacological group for all consultations according to age group in clinic 1

PHARMACOLOGICAL GROUP IN CLINIC 1	Age Group (years)	Frequency parameters		Cost related parameters			
		Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Antibacterial	0 ≥ 6	03	15.79	5.04 ±3.81	15.13	17.78	1.13
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
(Penicillin's)	12 ≥ 19	01	5.26	2.47	2.47	2.90	0.55
	19 ≥ 40	10	52.63	4.57 ±2.87	45.68	53.67	1.02
	40 ≥ 60	05	26.32	4.37 ±4.23	21.83	25.65	0.97
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**19**	**100.00**		**85.11**	**100.00**	
Anti-effectives	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
(amino glycosides)	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	100.00	29.13	29.13	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**29.13**	**100.00**	
Antibacterials	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
(Chloramphenicol,	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	04	100.00	3.25 ±2.32	12.98	100.00	1.00
erythromicns)	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**04**	**100.00**		**12.98**	**100.00**	
Anti-fungal oral /	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
injections	12 ≥ 19	01	50.00	6.25	6.25	50.00	1.00
	19 ≥ 40	01	50.00	6.25	6.25	50.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**12.5**	**100.00**	
Anti-anginal	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Antihypertensives	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	05	17.86	6.74 ±3.20	33.68	12.60	0.71
	40 ≥ 60	10	35.71	8.53 ±7.83	85.27	31.91	0.89
	>60	13	46.43	11.41 ±12.85	148.28	55.49	1.20
	Total	**28**	**100.00**		**267.23**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 1	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Congestive heart failure drugs	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	12.50	2.36	2.36	10.76	0.86
	40 ≥ 60	01	12.50	2.36	2.36	10.76	0.86
	>60	06	75.00	2.87±0.63	17.21	78.48	1.05
	Total	**08**	**100.00**		**21.93**	**100.00**	
Drugs affecting blood	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	02	50.00	2.77 ±0.77	5.55	55.44	1.11
	40 ≥ 60	02	50.00	2.23	4.46	44.56	0.89
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**04**	**100.00**		**10.01**	**100.00**	
Anti-fungal (topical)	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	20.00	0.64	0.64	6.43	0.55
	19 ≥ 40	02	40.00	1.22 ±0.81	2.43	24.40	0.61
	40 ≥ 60	02	40.00	3.45 ±3.97	6.89	69.18	1.73*
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**05**	**100.00**		**9.96**	**100.01**	
Antiseptics / dermatological disinfectants	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-pruritics	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	02	66.67	2.23	4.46	80.36	1.21
	40 ≥ 60	01	33.33	1.09	1.09	19.64	0.59
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**03**	**100.00**		**5.55**	**100.00**	
Scabicides and Pedicullocides	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 1	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Other ointments, creams and emollients	0 ≥ 6	02	33.33	0.88	1.76	40.93	1.23
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	02	33.33	0.75 ±0.33	1.50	34.88	1.05
	40 ≥ 60	01	16.67	0.52	0.52	12.09	0.73
	>60	01	16.67	0.52	0.52	12.09	0.73
	Total	**06**	**100.00**		**4.30**	**99.99**	
Anti-effective eye preparations	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	02	100.00	5.23±3.27	10.45	100.00	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**10.45**	**100.00**	
Anti allergic eye preparations	0 ≥ 6	01	100.00	3.48	3.48	100.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**3.48**	**100.00**	
Other ear and nose preparations	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Contraceptives (injectables)	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Oral contraceptives	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 1	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Hormones, androgens and progesterones	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-diabetic agents	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Corticosteroids for systemic use	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	01	100.00	1.69	1.69	100.00	1.00
	Total	**01**	**100.00**		**1.69**	**100.00**	
Anti-epileptics	0 ≥ 6	01	100.00	31.35	31.35	100.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**31.35**	**100.00**	
Anti allergic (for anaphylaxis)	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Psychotic disorders	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 1	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Anti-helmenthics	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Antacids / antiulcer	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	06	50.00	4.79	28.74	76.68	1.53*
	40 ≥ 60	03	25.00	4.79	4.37	11.66	0.47
	>60	03	25.00	4.79	4.37	11.66	0.47
	Total	**12**	**100.00**		**37.48**	**100.00**	
Anti emetics	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	100.00	1.11	1.11	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**1.11**	**100.00**	
Anti haemmorrhoidal	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	100.00	9.92	9.92	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**9.92**	**100.00**	
Cathartic drugs /	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
laxatives	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	100.00	2.96	2.96	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**2.96**	**100.00**	
Constipation drugs	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
and digestants	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	50.00	2.64	2.64	50.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	01	50.00	2.64	2.64	50.00	1.00
	Total	**02**	**100.00**		**5.28**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 1	Age Group (years)	Frequency parameters		Cost related parameters			
		Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Oral Electrolytes and anti acid base disturbance agents	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Mouth wash and throat preparations	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Parenteral electrolytes and anti acid base disturbance agent	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	100.00	10.94	10.94	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**10.94**	**100.00**	
Vitamins and minerals	0 ≥ 6	01	7.69	0.65	0.65	1.30	0.17
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	04	30.77	7.59 ±7.82	30.37	60.83	1.98*
	40 ≥ 60	06	46.15	2.94 ±5.59	17.61	35.27	0.76
	>60	02	15.38	0.65	1.30	2.60	0.17
	Total	**13**	**99.99**		**49.93**	**100.00**	
Feeding and nutritional supplements	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Analgesics (non opoids) and NSAIDS	0 ≥ 6	03	6.82	0.55	1.65	6.73	0.99
	6 ≥ 12	03	6.82	0.55	1.65	6.73	6.99*
	12 ≥ 19	02	4.55	0.81 ±0.36	1.61	6.57	1.44
	19 ≥ 40	15	34.09	0.57 ±0.14	8.49	34.63	1.02
	40 ≥ 60	13	29.55	0.53 ±0.02	6.88	28.06	0.95
	>60	08	18.18	0.53 ±0.02	4.24	17.29	0.95
	Total	**44**	**100.01**		**24.52**	**100.01**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 1	Age group (years)	Frequency parameters		Cost related parameters			
		Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Vaccines	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Diagnostic agents	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	03	100.00	1.86	5.58	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**03**	**100.00**		**5.58**	**100.00**	
Anti-asthmatic and mucolytics	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	50.00	5.11	5.11	50.00	1.00
	40 ≥ 60	01	50.00	5.11	5.11	50.00	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**10.22**	**100.00**	
Cough mixtures	0 ≥ 6	07	31.82	1.92 ±0.65	13.45	37.31	1.17
	6 ≥ 12	02	9.09	0.86	1.72	4.77	0.52
	12 ≥ 19	01	4.55	1.69	1.69	4.69	1.03
	19 ≥ 40	06	27.27	1.75 ±1.53	10.52	29.18	1.07
	40 ≥ 60	05	22.73	1.42 ±0.31	7.11	19.72	0.87
	>60	01	4.55	1.56	1.56	4.33	0.95
	Total	**22**	**100.01**		**36.05**	**100.00**	
Antimycobacterials	0≤ 6	00	0.00	0.00	0.00	0.00	0.00
	6≤12	00	0.00	0.00	0.00	0.00	0.00
	12≤19	00	0.00	0.00	0.00	0.00	0.00
	19≤40	00	0.00	0.00	0.00	0.00	0.00
	40≤60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-fungals	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

Appendix 1.60 : Parameters of pharmacological group for all consultations according to age group in clinic 2

PHARMACOLOGICAL GROUP IN CLINIC 2	Age Group (years)	Frequency parameters		Cost related parameters			
		Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Antibacterial (Penicillin's)	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	04	100.00	3.20 ±1.16	12.81	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**04**	**100.00**		**12.81**	**100.00**	
Anti-effectives (amino glycosides)	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Antibacterials (Chloramphenicol, erythromicns)	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	50.00	6.61	6.61	74.77	1.50*
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	01	50.00	2.23	2.23	25.23	0.50
	Total	**02**	**100.00**		**8.84**	**100.00**	
Anti-fungal oral/injections	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-anginal	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**		
Antihypertensives	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	3.85	5.31	5.31	1.23	0.32
	40 ≥ 60	13	50.00	13.18 ±7.85	171.29	39.69	0.79
	>60	12	46.15	21.25 ±10.33	255.02	59.08	1.28
	Total	**26**	**100.00**		**431.62**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 2	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Congestive heart failure drugs	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	03	75.00	4.54 ±2.23	13.62	85.23	1.14
	>60	01	25.00	2.36	2.36	14.77	0.59
	Total	**04**	**100.00**		**15.98**	**100.00**	
Drugs affecting blood	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-fungal (topical)	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	100.00	6.25	6.25	100.00	1.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**100.00**		**6.25**	**100.00**	
Antiseptics / dermatological disinfectants	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-pruritics	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Scabicides and Pedicullocides	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 2	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Other ointments, creams and emollients	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	33.33	0.98	0.98	48.51	1.46
	40 ≥ 60	01	33.33	0.52	0.52	25.74	0.77
	>60	01	33.33	0.52	0.52	25.74	0.77
	Total	**03**	**99.99**		**2.02**	**99.99**	
Anti-effective eye preparations	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti allergic eye preparations	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Other ear and nose preparations	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Contraceptives (injectables)	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Oral contraceptives	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 2	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Hormones, androgens and progesterones	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-diabetic agents	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	01	100.00	30.34	30.34	100.00	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**30.34**	**100.00**	
Corticosteroids for systemic use	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-epileptics	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti allergic (for anaphylaxis)	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Psychotic disorders	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 2	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Anti-helmenthics	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Antacids / antiulcer	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	02	100.00	1.68	3.36	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**3.36**	**100.00**	
Anti emetics	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti haemmorrhoidal	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Cathartic drugs /	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
laxatives	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Constipation drugs	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
and digestants	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 2	Age Group (years)	Frequency parameters		Cost related parameters			
		Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Oral Electrolytes and anti acid base disturbance agents	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	100.00	0.33	0.33	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**0.33**	**100.00**	
Mouth wash and throat preparations	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Parenteral electrolytes and anti acid base disturbance agent	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Vitamins and minerals	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	48	69.57	0.06 ±0.09	2.96	64.21	0.92
	40 ≥ 60	20	28.99	0.05	1.00	21.69	0.75
	>60	01	1.45	0.65	0.65	14.10	9.72*
	Total	**69**	**100.01**		**4.61**	**100.00**	
Feeding and nutritional supplements	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	100.00	12.45	12.45	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**12.45**	**100.00**	
Analgesics (non opoids) and NSAIDS	0 ≥ 6	02	15.38	0.69 ±0.21	1.39	19.12	1.24
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	06	46.15	0.54 ±0.02	3.22	44.29	0.96
	40 ≥ 60	03	23.08	0.55	1.65	22.70	0.98
	>60	02	15.38	0.51 ±0.06	1.01	13.89	0.90
	Total	**13**	**99.99**		**7.27**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 2	Age group (years)	Frequency parameters		Cost related parameters			
		Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Vaccines	0 ≥ 6	01	100.00	0.51	0.51	100.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**0.51**	**100.00**	
Diagnostic agents	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	50.00	1.86	1.86	50.00	1.00
	19 ≥ 40	01	50.00	1.86	1.86	50.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**3.72**	**100.00**	
Anti-asthmatic and mucolytics	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	02	100.00	17.42 ±12.73	34.84	100.00	1.00
	Total	**02**	**100.00**		**34.84**	**100.00**	
Cough mixtures	0 ≥ 6	02	33.33	1.21 ±0.49	2.42	27.94	0.84
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	04	66.67	1.56	6.24	72.06	1.08
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**06**	**100.00**		**8.66**	**100.00**	
Antimycobacterials	0 ≥ 6	43	6.44	3.29 ±1.15	141.36	6.86	1.07
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	336	50.30	2.86 ±1.31	961.66	46.69	0.93
	40 ≥ 60	289	43.26	3.31 ±1.82	956.77	46.45	1.07
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**668**	**100.00**		**2059.79**	**100.00**	
Anti-fungals	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

Appendix 1.61 : Parameters of pharmacological group for all consultations according to age group in clinic 3

PHARMACOLOGICAL GROUP IN CLINIC 3	Age Group (years)	Frequency parameters		Cost related parameters			
		Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Antibacterial	0 ≥ 6	05	11.36	3.37 ±0.19	16.84	6.72	0.59
	6 ≥ 12	01	2.27	3.28	3.28	1.31	0.58
(Penicillin's)	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	29	65.91	5.41 ±4.83	156.87	62.62	0.95
	40 ≥ 60	08	18.18	6.68 ±5.91	53.45	21.34	1.17
	>60	01	2.27	20.08	20.08	8.02	3.53*
	Total	**44**	**99.99**		**250.52**	**100.01**	
Anti-effectives	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
(amino glycosides)	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Antibacterials	0 ≥ 6	04	17.39	2.72 ±2.39	10.89	3.88	0.22
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
(Chloramphenicol,	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	16	69.57	16.23 ±24.23	259.73	92.62	1.33
erythromicns)	40 ≥ 60	03	13.04	3.27 ±2.14	9.80	3.49	0.27
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**23**	**100.00**		**280.42**	**99.99**	
Anti-fungal oral /	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
-injections	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	02	100.00	6.25	12.50	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**12.5**	**100.00**	
Anti-anginal	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	01	100.00	17.24	17.24	100.00	1.00
	Total	**01**	**100.00**		**17.24**	**100.00**	
Antihypertensives	0 ≥ 6	01	1.81	32.91	32.91	3.13	1.73*
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	17	30.91	8.93 ±15.76	151.77	14.43	0.47
	40 ≥ 60	27	49.09	23.25 ±22.96	627.86	59.68	1.22
	>60	10	18.18	23.94 ±12.66	239.43	22.76	1.25
	Total	**55**	**99.99**		**1051.97**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 3	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Congestive heart failure drugs	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	02	100.00	2.36	4.72	100.00	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**4.72**	**100.00**	
Drugs affecting blood	0 ≥ 6	01	5.00	8.66	8.66	14.54	2.91*
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	02	10.00	3.32	6.64	11.15	1.12
	19 ≥ 40	17	85.00	2.60 ±0.96	44.25	74.31	0.87
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**20**	**100.00**		**59.55**	**100.00**	
Anti-fungal (topical)	0 ≥ 6	01	20.00	33.93	33.93	90.05	4.50*
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	03	60.00	0.65 ±0.02	1.96	5.20	0.09
	40 ≥ 60	01	20.00	1.79	1.79	4.75	0.24
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**05**	**100.00**		**37.68**	**100.00**	
Antiseptics / dermatological disinfectants	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	02	100.00	2.39	4.78	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**4.78**	**100.00**	
Anti-pruritics	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	03	60.00	0.90 ±0.33	2.70	44.85	0.75
	40 ≥ 60	02	40.00	1.66 ±0.81	3.32	55.15	1.38
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**05**	**100.00**		**6.02**	**100.00**	
Scabicides and Pedicullocides	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	02	100.00	3.20	6.40	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**6.4**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 3	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Other ointments, creams and emollients	0 ≥ 6	01	20.00	0.98	0.98	32.03	1.60
	6 ≥ 12	01	20.00	0.52	0.52	16.99	0.85
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	02	40.00	0.52	1.04	33.99	0.85
	>60	01	20.00	0.52	0.52	16.99	0.85
	Total	**05**	**100.00**		**3.06**	**100.00**	
Anti-effective eye preparations	0 ≥ 6	02	66.67	2.91	5.82	43.56	0.65
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	33.33	7.54	7.54	56.44	1.69
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**03**	**100.00**		**13.36**	**100.00**	
Anti allergic eye preparations	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Other ear and nose preparations	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	33.33	4.16	4.16	33.33	1.00
	19 ≥ 40	01	33.33	4.16	4.16	33.33	1.00
	40 ≥ 60	01	33.33	4.16	4.16	33.33	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**03**	**100.00**		**12.48**	**99.99**	
Contraceptives (injectables)	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	04	5.56	5.24	20.96	6.12	1.10
	19 ≥ 40	57	79.17	4.74 ±0.30	270.12	78.84	0.99
	40 ≥ 60	11	15.28	4.68 ±0.28	51.52	15.04	0.98
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**72**	**100.00**		**342.60**	**100.00**	
Oral contraceptives	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	3.45	7.65	7.65	3.37	0.98
	19 ≥ 40	25	86.21	7.83 ±0.57	195.76	86.11	0.99
	40 ≥ 60	03	10.34	7.98 ±0.59	23.93	10.53	1.02
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**29**	**100.00**		**227.34**	**100.01**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 3	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Hormones, androgens and progesterones	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-diabetic agents	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	01	50.00	30.34	30.34	50.00	1.00
	>60	01	50.00	30.34	30.34	50.00	1.00
	Total	**02**	**100.00**		**60.68**	**100.00**	
Corticosteroids for systemic use	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-epileptics	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	33.33	15.39	15.39	12.33	0.37
	40 ≥ 60	02	66.67	54.72 ±55.62	109.44	87.67	1.31
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**03**	**100.00**		**124.83**	**100.00**	
Anti allergic (for anaphylaxis)	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Psychotic disorders	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 3	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Anti-helmenthics	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	01	50.00	1.35	1.35	50.00	1.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	50.00	1.35	1.35	50.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**2.70**	**100.00**	
Antacids / antiulcer	0 ≥ 6	01	12.50	1.68	1.68	12.50	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	06	75.00	1.68	10.08	75.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	01	12.50	1.68	1.68	12.50	1.00
	Total	**08**	**100.00**		**13.44**	**100.00**	
Anti emetics	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti haemmorrhoidal	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Cathartic drugs / laxatives	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Constipation drugs and digestants	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 3	Age Group (years)	Frequency parameters		Cost related parameters			
		Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Oral Electrolytes and anti acid base disturbance agents	0 ≥ 6	03	75.00	0.33	0.99	75.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	25.00	0.33	0.33	25.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**04**	**100.00**		**1.32**	**100.00**	
Mouth wash and throat preparations	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Parenteral electrolytes and anti acid base disturbance agent	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Vitamins and minerals	0 ≥ 6	10	6.54	0.92	0.92	0.53	0.08
	6 ≥ 12	01	0.65	0.92	0.92	0.53	0.88
	12 ≥ 19	03	1.96	1.55 ±0.78	4.65	2.69	1.37
	19 ≥ 40	90	58.82	1.09 ±0.91	98.87	57.19	0.97
	40 ≥ 60	47	30.72	1.35 ±2.89	63.53	36.75	1.20
	>60	02	1.31	2.00	4.00	2.31	1.76*
	Total	**153**	**100.00**		**172.89**	**100.00**	
Feeding and nutritional supplements	0 ≥ 6	22	64.71	0.84	281.48	62.50	0.97
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	05	14.71	16.65 ±10.12	83.24	18.48	1.26
	40 ≥ 60	07	20.59	12.23 ±0.57	85.63	19.01	0.92
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**34**	**100.01**		**450.35**	**99.99**	
Analgesics (non opoids) and NSAIDS	0 ≥ 6	22	25.29	0.84	18.48	33.80	1.34
	6 ≥ 12	03	3.45	0.74 ±0.17	2.23	4.08	1.18
	12 ≥ 19	01	1.15	0.55	0.55	1.01	0.88
	19 ≥ 40	29	33.33	0.54 ±0.02	15.71	28.73	0.86
	40 ≥ 60	25	28.74	0.56 ±0.12	13.94	25.49	0.89
	>60	07	8.05	0.54 ±0.02	3.77	6.89	0.86
	Total	**87**	**100.01**		**54.68**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 3	Age group (years)	Frequency parameters		Cost related parameters			
		Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Vaccines	0 ≥ 6	36	76.60	16.07 ±12.16	578.46	99.03	1.29
	6 ≥ 12	02	4.26	1.27 ±0.49	2.54	0.43	0.10
	12 ≥ 19	01	2.13	0.35	0.35	0.06	0.03
	19 ≥ 40	08	17.02	0.35	2.80	0.48	0.02
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**47**	**100.01**		**584.15**	**100.00**	
Diagnostic agents	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	100.00	1.86	1.86	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**1.86**	**100.00**	
Anti-asthmatic and mucolytics	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	03	100.00	15.59 ±14.03	46.79	100.00	1.00
	Total	**03**	**100.00**		**46.79**		
Cough mixtures	0 ≥ 6	10	33.33	2.03 ±0.72	20.27	39.57	1.19
	6 ≥ 12	01	3.33	1.56	1.56	3.05	0.92
	12 ≥ 19	01	3.33	1.64	1.64	3.20	0.96
	19 ≥ 40	07	23.33	1.59 ±0.45	11.10	21.67	0.93
	40 ≥ 60	11	36.67	1.51 ±0.41	16.65	32.51	0.89
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**30**	**99.99**		**51.22**	**100.00**	
Antimycobacterials	0 ≥ 6	04	2.44	1.35 ±0.42	62.04	3.42	1.40
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	02	1.22	21.15	42.30	2.33	1.91*
	19 ≥ 40	98	59.76	10.25 ±6.32	1004.03	55.41	0.93
	40 ≥ 60	55	33.54	11.53 ±14.39	634.04	34.99	1.04
	>60	05	3.05	13.90	69.50	3.84	1.26
	Total	**164**	**100.01**		**1811.91**	**99.99**	
Anti-fungals	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	20.00	29.13	29.13	26.34	1.32
	19 ≥ 40	04	80.00	20.37 ±5.84	81.48	73.66	0.92
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**05**	**100.00**		**110.61**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

Appendix 1.62 : Parameters of pharmacological group for all consultations according to age group in clinic 4

PHARMACOLOGICAL GROUP IN CLINIC 4	Age Group (years)	Frequency parameters		Cost related parameters			
		Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Antibacterial (Penicillin's)	0 ≥ 6	01	4.55	2.47	2.47	3.00	0.66
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	03	13.64	3.58 ±1.89	10.74	13.04	0.96
	19 ≥ 40	13	59.09	4.18 ±1.66	54.32	65.93	1.12
	40 ≥ 60	05	22.73	2.97 ±1.12	14.86	18.04	0.79
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**22**	**100.01**		**82.39**	**100.01**	
Anti-effectives (amino glycosides)	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Antibacterials (Chloramphenicol, erythromicns)	0 ≥ 6	02	12.50	1.61 ±0.11	3.22	8.48	0.68
	6 ≥ 12	01	6.25	6.61	6.61	17.40	2.78*
	12 ≥ 19	01	6.25	2.98	2.98	7.85	1.26
	19 ≥ 40	11	68.75	2.17±0.68	23.89	62.90	0.91
	40 ≥ 60	01	6.25	1.28	1.28	3.37	0.54
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**16**	**100.00**		**37.98**	**100.00**	
Anti-fungal oral / injections	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	02	100.00	5.46	10.92	100.00	1.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**10.92**	**100.00**	
Anti-anginal	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Antihypertensives	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	11	42.31	12.52 ±14.09	137.67	38.78	0.92
	40 ≥ 60	13	50.00	13.76 ±10.54	178.83	50.37	1.01
	>60	02	7.69	19.26 ±2.72	38.52	10.85	1.41
	Total	**26**	**100.00**		**355.02**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 4	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Other ointments, creams and emollients	0 ≥ 6	01	11.11	0.98	0.98	19.07	1.72*
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	11.11	0.52	0.52	10.12	0.91
	40 ≥ 60	03	33.33	0.52	1.56	30.35	0.91
	>60	04	44.44	0.52	2.08	40.47	0.91
	Total	**09**	**99.99**		**5.14**	**100.01**	
Anti-effective eye preparations	0 ≥ 6	03	75.00	7.54	22.62	75.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	25.00	7.54	7.54	25.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**04**	**100.00**		**30.16**	**100.00**	
Anti allergic eye preparations	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	100.00	3.48	3.48	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**3.48**	**100.00**	
Other ear and nose preparations	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	02	100.00	2.39 ±2.49	4.79	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**4.79**	**100.00**	
Contraceptives (injectables)	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	07	20.00	5.24	36.68	21.52	1.08
	19 ≥ 40	26	74.29	4.77 ±0.32	124.00	72.74	0.98
	40 ≥ 60	02	5.71	4.90 ±0.48	9.80	5.75	1.01
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**35**	**100.00**		**170.48**	**100.01**	
Oral contraceptives	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	07	100.00	6.22 ±2.44	43.57	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**07**	**100.00**		**43.57**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 4	Age Group (years)	Frequency parameters		Cost related parameters			
		Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Oral Electrolytes and anti acid base disturbance agents	0 ≥ 6	01	20.00	0.33	0.33	20.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	03	60.00	0.33	0.99	60.00	1.00
	40 ≥ 60	01	20.0	0.33	0.33	20.00	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**05**	**100.00**		**1.65**	**100.00**	
Mouth wash and throat preparations	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	02	100.00	1.08	2.16	100.00	1.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**2.16**	**100.00**	
Parenteral electrolytes and anti acid base disturbance agent	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Vitamins and minerals	0 ≥ 6	09	17.65	0.92	8.28	14.38	0.81
	6 ≥ 12	01	1.96	100	1.00	1.74	0.89
	12 ≥ 19	03	5.88	0.65	1.95	3.39	0.58
	19 ≥ 40	29	56.86	0.89 ±2.62	25.81	44.81	0.79
	40 ≥ 60	07	13.73	2.75 ±5.13	19.26	33.43	2.44*
	>60	02	3.92	0.65	1.30	2.26	0.58
	Total	**51**	**100.00**		**57.60**	**100.01**	
Feeding and nutritional supplements	0 ≥ 6	32	50.00	13.25 ±4.53	423.88	42.60	0.85
	6 ≥ 12	03	4.69	11.94 ±0.88	35.83	3.60	0.77
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	24	37.50	19.71 ±6.27	473.10	47.54	1.27
	40 ≥ 60	05	7.81	12.45	62.25	6.26	0.80
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**64**	**100.00**		**995.06**	**100.00**	
Analgesics (non opoids) and NSAIDS	0 ≥ 6	13	24.07	0.79 ±0.13	10.23	30.17	1.25
	6 ≥ 12	04	7.41	0.69 ±0.17	2.78	8.20	1.11
	12 ≥ 19	02	3.70	0.53 ±0.03	1.06	3.13	0.85
	19 ≥ 40	18	33.33	0.54 ±0.02	9.68	28.55	0.86
	40 ≥ 60	13	24.07	0.58 ±0.14	7.52	22.18	0.92
	>60	04	7.41	0.66 ±0.27	2.64	7.78	1.05
	Total	**54**	**99.99**		**33.91**	**100.01**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 4	Age group (years)	Frequency parameters		Cost related parameters			
		Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Vaccines	0 ≥ 6	13	100.00	12.40 ±13.02	161.24	100.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**13**	**100.00**		**161.24**	**100.00**	
Diagnostic agents	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	100.00	1.86	1.86	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**1.86**	**100.00**	
Anti-asthmatic and mucolytics	0 ≥ 6	01	100.00	5.11	5.11	100.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**5.11**	**100.01**	
Cough mixtures	0 ≥ 6	17	51.52	0.95 ±0.26	16.15	40.29	0.78
	6 ≥ 12	01	3.03	0.87	0.87	2.17	0.72
	12 ≥ 19	01	3.03	1.56	1.56	3.89	1.28
	19 ≥ 40	08	24.24	1.41 ±0.54	11.27	28.12	1.16
	40 ≥ 60	06	18.18	1.71 ±0.36	10.23	25.52	1.40
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**33**	**100.00**		**40.08**	**99.99**	
Antimycobacterials	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	28	84.85	14.71 ±8.25	411.76	84.42	0.99
	40 ≥ 60	05	15.15	15.20	76.00	15.58	1.03
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**33**	**100.00**		**487.76**	**100.00**	
Anti-fungals	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	100.00	29.13	29.13	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**29.13**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

Appendix 1.63 : Parameters of pharmacological group for all consultations according to age group in clinic 5

PHARMACOLOGICAL GROUP IN CLINIC 5	Age Group (years)	Frequency parameters		Cost related parameters			
		Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Antibacterial	0 ≥ 6	03	27.27	5.70 ±4.19	17.11	28.23	1.04
	6 ≥ 12	03	27.27	5.99 ±3.94	17.99	29.68	1.09
(Penicillin's)	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	03	27.27	5.76	17.28	28.51	1.05
	40 ≥ 60	02	18.18	4.12 ±2.33	8.23	13.59	0.75
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**11**	**99.99**		**60.61**	**100.01**	
Anti-effectives	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
(amino glycosides)	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Antibacterials	0 ≥ 6	02	25.00	2.48 ±1.34	4.95	19.67	0.79
	6 ≥ 12	01	12.50	6.30	6.30	25.03	2.00*
(Chloramphenicol,	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	04	50.00	2.60 ±1.05	10.41	41.36	0.83
erythromicns)	40 ≥ 60	01	12.50	3.51	3.51	13.95	1.12
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**08**	**100.00**		**25.17**	**100.01**	
Anti-fungal	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
oral/injections	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	01	100.00	29.13	29.13	100.00	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**29.13**	**100.00**	
Anti-anginal	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Antihypertensives	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	03	6.00	21.50 ±3.09	64.51	6.44	1.07
	40 ≥ 60	22	44.00	22.44 ±17.32	493.74	49.32	1.12
	>60	25	50.00	17.71 ±10.09	442.88	44.24	0.88
	Total	**50**	**100.00**		**1001.13**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 5	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Congestive heart failure drugs	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	09	47.37	2.91 ±1.68	26.17	49.94	1.05
	>60	10	52.63	2.62 ±0.67	26.23	50.06	0.95
	Total	**19**	**100.00**		**52.40**	**100.00**	
Drugs affecting blood	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	03	60.00	2.21 ±1.12	6.64	59.82	0.99
	40 ≥ 60	01	20.00	2.23	2.23	20.09	1.00
	>60	01	20.00	2.23	2.23	20.09	1.00
	Total	**05**	**100.00**		**11.10**	**100.00**	
Anti-fungal (topical)	0 ≥ 6	03	42.86	11.74 ±19.22	35.21	48.76	1.14
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	04	57.14	9.25 ±16.46	37.00	51.24	0.90
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**07**	**100.00**		**72.21**	**100.00**	
Antiseptics / dermatological disinfectants	0 ≥ 6	01	33.33	2.39	2.39	33.33	1.00
	6 ≥ 12	01	33.33	2.39	2.39	33.33	1.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	33.33	2.39	2.39	33.33	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**03**	**99.99**		**7.17**	**99.99**	
Anti-pruritics	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	01	50.00	1.09	1.09	50.00	1.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	50.00	1.09	1.09	50.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**2.18**	**100.00**	
Scabicides and Pedicullocides	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	01	33.33	3.20	3.20	33.33	1.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	02	66.67	3.20	6.40	66.67	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**03**	**100.00**		**9.60**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 5	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Other ointments, creams and emollients	0 ≥ 6	02	8.33	0.75 ±0.33	1.50	9.93	1.19
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	06	25.00	0.82 ±0.54	4.92	32.58	1.30
	40 ≥ 60	07	29.17	0.57 ±0.14	4.00	26.49	0.91
	>60	09	37.50	0.52	4.68	30.99	0.83
	Total	**24**	**100.00**		**15.10**	**99.99**	
Anti-effective eye preparations	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	01	100.00	2.91	2.91	100.00	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**2.91**	**100.00**	
Anti allergic eye preparations	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Other ear and nose preparations	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Contraceptives (injectables)	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Oral contraceptives	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 5	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Hormones, androgens and progesterones	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	01	100.00	13.00	13.00	100.00	1.00
	Total	**01**	**100.00**		**13.00**	**100.00**	
Anti-diabetic agents	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	02	50.00	21.91 ±11.93	43.81	61.92	1.24
	>60	02	50.00	13.47	26.94	38.08	0.76
	Total	**04**	**100.00**		**70.75**	**100.00**	
Corticosteroids for systemic use	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti-epileptics	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	03	60.00	21.08 ±18.49	63.23	54.00	0.90
	40 ≥ 60	02	40.00	26.93 ±16.33	53.87	46.00	1.15
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**05**	**100.00**		**117.10**	**100.00**	
Anti allergic (for anaphylaxis)	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Psychotic disorders	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 5	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Anti-helmenthics	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	01	100.00	1.35	1.35	100.00	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**			**1.35**	**100.00**	
Antacids / antiulcer	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	04	40.00	2.46 ±1.56	9.83	27.72	0.69
	40 ≥ 60	02	20.00	4.79	9.58	27.02	1.36
	>60	04	40.00	4.01 ±1.56	16.05	45.26	1.13
	Total	**10**	**100.00**		**35.46**	**100.00**	
Anti emetics	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Anti haemmorrhoidal	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	01	100.00	9.92	9.92	100.00	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**9.92**	**100.00**	
Cathartic drugs / laxatives	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	01	100.00	2.96	2.96	100.00	1.00
	Total	**01**	**100.00**		**2.96**	**100.00**	
Constipation drugs and digestants	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 5	Age Group (years)	Frequency parameters		Cost related parameters			
		Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Oral Electrolytes and anti acid base disturbance agents	0 ≥ 6	01	50.00	4.95	4.95	41.67	0.83
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	50.00	6.93	6.93	58.33	1.17
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**11.88**	**100.00**	
Mouth wash and throat preparations	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Parenteral electrolytes and anti acid base disturbance agent	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Vitamins and minerals	0 ≥ 6	06	26.09	0.92	5.52	5.49	0.21
	6 ≥ 12	01	4.35	0.92	0.92	0.92	0.21
	12 ≥ 19	01	4.35	0.66	0.66	0.66	0.15
	19 ≥ 40	03	13.04	0.98 ±0.33	2.95	2.94	0.23
	40 ≥ 60	04	17.39	0.74 ±0.17	2.97	2.96	0.17
	>60	08	34.78	10.93 ±6.35	87.46	87.04	2.50*
	Total	**23**	**100.00**		**100.48**	**100.01**	
Feeding and nutritional supplements	0 ≥ 6	01	9.09	12.45	12.45	9.09	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	9.09	12.45	12.45	9.09	1.00
	19 ≥ 40	09	81.81	12.45	112.05	81.82	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**11**	**99.99**		**136.95**	**100.00**	
Analgesics (non opoids) and NSAIDS	0 ≥ 6	12	22.64	082 ±0.08	9.79	28.60	1.26
	6 ≥ 12	04	7.55	0.75 ±0.18	3.00	8.76	1.16
	12 ≥ 19	01	1.89	0.84	0.84	2.45	1.29
	19 ≥ 40	09	16.98	0.52 ±0.03	4.65	13.58	0.79
	40 ≥ 60	12	22.64	0.56 ±0.14	6.70	19.57	0.86
	>60	15	28.30	0.62 ±0.19	9.25	27.02	1.05
	Total	**53**	**100.00**		**34.23**	**99.98**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 5	Age group (years)	Frequency parameters		Cost related parameters			
		Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Vaccines	0 ≥ 6	16	94.12	7.19 ±11.17	115.04	99.63	1.06
	6 ≥ 12	01	5.88	0.43	0.43	0.37	0.06
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**17**	**100.00**		**115.47**	**100.00**	
Diagnostic agents	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	25.00	1.86	1.86	25.00	1.00
	19 ≥ 40	03	75.00	1.86	5.58	75.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**04**	**100.00**		**7.44**	**100.00**	
Anti-asthmatic and mucolytics	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	03	75.00	29.39 ±5.17	88.19	48.00	0.64
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	01	25.00	95.55	95.55	52.00	2.08*
	Total	**04**	**100.00**		**183.74**	**100.00**	
Cough mixtures	0 ≥ 6	03	12.50	0.86	2.58	8.84	0.71
	6 ≥ 12	06	25.00	0.99 ±0.34	5.99	20.51	0.82
	12 ≥ 19	01	4.17	0.86	0.86	2.95	0.71
	19 ≥ 40	07	29.17	1.36 ±0.34	9.54	32.67	1.12
	40 ≥ 60	03	12.50	1.56	4.68	16.03	1.28
	>60	04	16.67	1.39±0.35	5.55	19.01	1.14
	Total	**24**	**100.01**		**29.20**	**100.01**	
Antimycobacterials	0 ≥ 6	02	1.18	11.40 ±3.22	22.80	5.01	4.25*
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	23	13.61	2.12	48.76	10.73	0.79
	19 ≥ 40	144	85.21	2.66 ±1.02	382.80	84.25	0.99
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**169**	**100.00**		**454.36**	**99.99**	
Anti-fungals	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

Appendix 1.64 : Parameters of pharmacological group for all consultations according to age group in clinic 6

PHARMACOLOGICAL GROUP IN CLINIC 6	Age Group (years)	Frequency parameters		Cost related parameters			
		Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Antibacterial (Penicillin's)	0 ≥ 6	04	21.05	3.07 ±0.43	12.27	20.33	0.97
	6 ≥ 12	01	5.26	3.28	3.28	5.43	1.04
	12 ≥ 19	03	15.79	3.32 ±1.44	9.96	16.50	1.04
	19 ≥ 40	09	47.37	3.32 ±2.29	29.91	49.55	1.05
	40 ≥ 60	01	5.26	2.47	2.47	4.09	0.78
	>60	01	5.26	2.47	2.47	4.09	0.78
	Total	**19**	**99.99**		**60.36**	**99.99**	
Anti-effectives (amino glycosides)	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Antibacterials (Chloramphenicol, erythromicns)	0 ≥ 6	12	66.67	2.57±1.93	30.83	62.25	0.93
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	06	33.33	3.12 ±2.61	18.70	37.75	1.13
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**18**	**100.00**		**49.53**	**100.00**	
Anti-fungal oral / injections	0 ≥ 6	01	20.00	6.25	6.25	17.54	0.88
	6 ≥ 12	01	20.00	5.46	5.46	15.32	0.77
	12 ≥ 19	01	20.00	2.51	2.51	7.04	0.35
	19 ≥ 40	01	20.00	5.46	5.46	15.32	0.77
	40 ≥ 60	01	20.00	15.96	15.96	44.78	2.24*
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**05**	**100.00**		**35.64**	**100.00**	
Anti-anginal	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Antihypertensives	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	09	21.95	11.55 ±6.95	103.94	18.58	0.85
	40 ≥ 60	18	43.90	14.60 ±9.31	262.86	46.98	1.07
	>60	14	34.15	13.76 ±8.28	192.67	34.44	1.01
	Total	**41**	**100.00**		**559.47**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 6	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Congestive heart failure drugs	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	10.00	2.36	2.36	6.99	0.70
	40 ≥ 60	04	40.00	3.47 ±2.23	13.89	41.12	1.03
	>60	05	50.00	3.51 ±1.93	17.53	51.89	1.04
	Total	**10**	**100.00**		**33.78**	**100.00**	
Drugs affecting blood	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	02	15.38	1.09	2.18	11.70	0.76
	19 ≥ 40	11	84.62	1.49 ±0.90	16.45	88.30	1.04
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**13**	**100.00**		**18.63**		
Anti-fungal (topical)	0 ≥ 6	01	20.00	0.55	0.55	8.50	0.43
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	20.00	1.79	1.79	27.67	1.38
	19 ≥ 40	01	20.00	0.55	0.55	8.50	0.43
	40 ≥ 60	02	40.00	1.79	3.58	55.33	1.38
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**05**	**100.00**		**6.47**	**100.00**	
Antiseptics / dermatological disinfectants	0 ≥ 6	01	33.33	2.39	2.39	33.33	1.00
	6 ≥ 12	01	33.33	2.39	2.39	33.33	1.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	01	33.33	2.39	2.39	33.33	1.00
	Total	**03**	**99.99**		**7.17**	**99.99**	
Anti-pruritics	0 ≥ 6	03	27.27	1.85 ±0.66	5.55	29.23	1.07
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	02	18.19	1.09	2.18	11.48	0.63
	19 ≥ 40	03	27.27	1.85 ±0.66	5.55	29.23	1.07
	40 ≥ 60	03	27.27	1.90 ±0.71	5.71	30.07	1.10
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**11**	**100.00**		**18.99**	**100.01**	
Scabicides and Pedicullocides	0 ≥ 6	03	75.00	3.20	9.60	75.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	25.00	3.20	3.20	25.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**04**	**100.00**		**12.80**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 6	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Other ointments, creams and emollients	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	01	14.29	0.98	0.98	14.22	0.99
	12 ≥ 19	01	14.29	0.98	0.98	14.22	0.99
	19 ≥ 40	01	14.29	0.98	0.98	14.22	0.99
	40 ≥ 60	01	14.29	0.52	0.52	7.55	0.53
	>60	03	42.86	1.14 ±1.08	3.43	49.78	1.16
	Total	**07**	**100.02**		**6.89**	**99.99**	
Anti-effective eye preparations	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	100.00	2.91	2.91	100.00	1.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**2.91**	**100.00**	
Anti allergic eye preparations	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Other ear and nose preparations	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	100.00	0.63	0.63	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**0.63**	**100.00**	
Contraceptives (injectables)	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	09	20.00	4.94 ±0.36	44.44	20.69	1.03
	19 ≥ 40	36	80.00	4.73 ±0.49	170.31	79.31	0.99
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**45**	**100.00**		**214.75**	**100.00**	
Oral contraceptives	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	04	100.00	2.55	10.20	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**04**	**100.00**		**10.20**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 6	Age Group (years)	Frequency parameters		Cost related parameters			
		Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Oral Electrolytes and anti acid base disturbance agents	0 ≥ 6	03	75.00	0.33	0.99	75.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	25.00	0.33	0.33	25.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**04**	**100.00**		**1.32**	**100.00**	
Mouth wash and throat preparations	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Parenteral electrolytes and anti acid base disturbance agent	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Vitamins and minerals	0 ≥ 6	17	56.67	0.92	15.64	29.62	0.52
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	3.33	0.65	0.65	1.23	1.89*
	19 ≥ 40	06	10.00	3.04 ±5.86	18.26	34.58	3.46*
	40 ≥ 60	05	16.67	3.52 ±6.07	17.61	33.35	2.00
	>60	01	3.33	0.65	0.65	1.23	0.37
	Total	**30**	**100.00**		**52.81**	**100.01**	
Feeding and nutritional supplements	0 ≥ 6	78	82.10	12.32 ±1.69	961.04	81.95	0.99
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	02	2.11	12.45	24.90	2.12	1.00
	40 ≥ 60	15	15.79	12.45	186.75	15.92	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**95**	**100.00**		**1172.69**	**99.99**	
Analgesics (non opoids) and NSAIDS	0 ≥ 6	23	25.27	0.81 ±0.08	18.74	34.09	1.35
	6 ≥ 12	01	1.09	0.55	0.55	1.00	0.92
	12 ≥ 19	08	8.79	0.53 ±0.02	4.25	7.73	0.88
	19 ≥ 40	25	27.47	0.55 ±0.11	13.79	25.09	0.91
	40 ≥ 60	25	27.47	0.53 ±0.02	13.13	23.89	0.87
	>60	09	9.89	0.50 ±0.02	4.51	8.20	0.83
	Total	**91**	**99.98**		**54.97**	**100.00**	

APPENDIX 1: RESULTS OF PHARMACOLOGICAL GROUP ANALYSIS

PHARMACOLOGICAL GROUP IN CLINIC 6	Age group (years)	Frequency parameters		Cost related parameters			
		Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Vaccines	0 ≥ 6	28	100.00	12.46 ±12.38	348.85	100.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**28**	**100.00**		**348.85**	**100.00**	
Diagnostic agents	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	100.00	1.86	1.86	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**1.86**	**100.00**	
Anti-asthmatic and mucolytics	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	01	50.00	9.13	9.13	52.02	1.04
	>60	01	50.00	8.42	8.42	47.98	0.96
	Total	**02**	**100.00**		**17.55**	**100.00**	
Cough mixtures	0 ≥ 6	33	61.11	1.14 ±0.69	37.66	57.89	0.95
	6 ≥ 12	02	3.70	0.87 ±0.01	1.73	2.66	0.72
	12 ≥ 19	04	7.40	1.04 ±0.35	4.17	6.41	0.87
	19 ≥ 40	10	18.52	1.37 ±0.51	13.70	21.06	1.14
	40 ≥ 60	02	3.70	1.56	3.12	4.80	1.30
	>60	03	5.56	1.56	4.68	7.19	1.29
	Total	**54**	**99.99**		**65.06**	**100.01**	
Antimycobacterials	0 ≥ 6	62	16.76	1.85 ±0.66	114.60	10.03	0.60
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	169	45.68	3.32 ±1.69	560.60	49.07	1.07
	40 ≥ 60	139	37.57	3.36 ±0.74	467.29	40.90	1.09
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**370**	**100.01**		**1142.49**	**100.00**	
Anti-fungals	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

Appendix 1.65: Parameters of individual medicine item description in all clinics for all consultations

INDIVIDUAL ITEM DESCRIPTION IN ALL CLINICS FOR ALL CONSULTATIONS	Frequency parameters		Cost related parameters			
	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Amoxycillin 250mg capsules 15's	37	0.90	2.94 ±0.99	108.76	0.62	0.69
Amoxycillin Suspension 125mg / 5ml	13	0.32	3.22 ±0.22	41.83	0.24	0.75
Penicillin VK Suspension 125mg / 5ml	2	0.05	2.43	4.86	0.03	0.60
Penicillin VK Suspension 250mg / 5ml	4	0.09	3.42 ±0.61	13.67	0.08	0.89
Penicillin VK Tablets 250mg 20's	11	0.27	6.85 ±6.93	75.30	0.43	1.59*
Benzathine Penicillin 2.4 MU injection	14	0.34	2.70	37.80	0.22	0.65
Flucloxacillin suspension 125mg / 5ml	2	0.04	10.55	21.10	0.12	3.00*
Flucloxacillin 250mg capsules 20's	8	0.19	11.78 ±6.66	94.20	0.54	2.84*
Ciprofloxacin 500mg tablets 10's	29	0.70	5.42 ±1.02	157.173	0.90	1.29
Cotrimoxazole 400 / 80mg tablets 20's	11	0.27	1.69	18.59	0.11	0.41
Cotrimoxazole 200/40mg / 5ml suspension	14	0.34	1.53	21.42	0.12	0.35
Doxycycline 100mg capsules 14's	21	0.51	1.70	35.70	0.20	0.39
Doxycycline 100mg capsules 20's	6	0.15	2.23	13.38	0.08	0.53
Doxycycline 100mg capsules 30's	1	0.02	3.42	3.42	0.02	1.00
Erythromycin 250mg capsules 20's	4	0.09	6.61	26.44	0.15	1.67*
Erythromycin 250 mg capsules 56's	4	0.09	50.90 ±27.77	203.61	1.16	12.89*
Erythromycin suspension 125mg / 5ml	4	0.09	6.30	25.20	0.14	1.56*
Perindropril 4mg tablets 28's	60	1.45	18.85 ±2.40	1133.69	6.47	4.46*
Reserpine 0.25mg tablets 14's	35	0.85	6.70	234.50	1.34	1.58*
Digoxin 0.25mg tablets 28's	8	0.19	3.17	25.36	0.14	0.74
Furosemide 40mg tablets 28'	11	0.27	1.28	14.08	0.08	0.30

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION IN ALL CLINICS FOR ALL CONSULTATIONS	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Potassium chloride 600mg tablets 84's	1	0.02	7.09	7.09	0.04	2.00*
Ferrous sulphate tablets 28's	42	1.02	2.07 ±0.40	86.82	0.49	0.48
Ferrous gluconate syrup 100ml	2	0.05	8.66	17.32	0.09	1.80*
Folic acid 5mg tablets 28's	40	0.97	1.09	43.60	0.25	0.26
Metronidazole 200mg tablets 28's	25	0.61	2.09 ±1.16	52.48	0.30	0.49
Metronidazole 200mg / 5ml suspension	2	0.05	4.46	8.92	0.05	1.00
Nystatin ointment 15g	5	0.12	6.25	31.25	0.18	1.50*
Nystatin suspension 20ml	4	0.09	5.26	21.84	0.12	1.33
Griseofulvin 500mg tablets 28's	1	0.02	15.96	15.96	0.09	4.50*
Glyceryltrinaitrate 0.5mg sublingual tablets, 50's	1	0.02	17.24	17.24	0.09	4.50*
Atenelol 50mg tablets 28's	28	0.68	2.82 ±0.51	78.88	0.45	0.66
Enalapril 5mg tablets 28's	21	0.51	5.49	115.29	0.66	1.18
Enalapril 10mg tablets 28's	34	0.82	14.21 ±8.01	483.16	2.76	3.37*
Hydrochlorthiazide 25mg tablets 14's	7	0.17	2.03 ±0.69	14.23	0.08	0.47
Hydrochlorthiazide 25mg tablets 28's	177	4.29	2.72 ±1.61	481.05	2.75	0.64
Methyldopa 250mg tablets 28's	60	1.45	5.09 ±3.92	305.16	1.74	1.20
Methyldopa 250mg tablets 56's	18	0.44	12.99 ±6.81	233.82	0.14	0.32
Methyldopa 250mg tablets 84's	16	0.39	25.80 ±19.88	412.82	2.36	6.05*
Nifedipine 5mg tablets 100's	4	0.09	8.24 ±8.14	32.97	0.19	2.11*
Nifedipine 30mg XL capsule 30's	6	0.15	26.60 ±9.30	159.60	0.91	6.07*
Indapamide tablets 28's	2	0.05	2.62	5.24	0.02	0.40
Benzoic acid ointment 25g	10	0.24	0.64	6.40	0.03	1.25
Clotrimazole 1% cream 20g	5	0.12	1.79 ±0.00	8.95	0.05	0.42

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION IN ALL CLINICS FOR ALL CONSULTATIONS	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Micanazole oral gel 30g	6	0.15	17.45 ±18.06	104.68	0.60	4.00*
Nystatin ointment 15g	2	0.05	6.25	12.50	0.07	1.40
Povidone iodine ointment 25g	14	0.34	2.39	33.46	0.19	0.56
Calamine lotion 100ml	13	0.32	1.09	14.17	0.08	0.25
Hydrocortisone 1% cream 25g	8	0.19	2.23	17.84	0.10	0.53
Monosulfiram soap 5% , 75g	12	0.29	3.20	38.40	0.22	0.76
Methylsalicylate ointment 25g	41	0.99	0.57 ±0.29	23.19	0.13	0.13
Aqueous cream	10	0.24	0.98	9.80	0.05	0.21
Zinc & castor oil ointment 25g	4	0.09	0.88	3.52	0.02	0.22
Chloramphenicol ophthalmic ointment	5	0.12	2.91	14.55	0.08	0.67
Norethisterone enath 200mg injection	99	2.40	5.23 ±0.07	517.98	2.96	1.23
Medroxyprogesterone 150mg injection	145	3.51	4.57 ±0.08	662.56	3.78	1.08
Microval tablets 28's	1	0.02	7.56	7.56	0.04	2.00*
Triphasil tablets 28's	33	0.80	6.77 ±2.08	223.25	1.27	1.59*
Ovral tablets 28's	15	0.36	7.49 ±1.93	112.35	0.64	1.78*
Prednisone 5mg tablets 28's	1	0.02	1.69	1.69	0.01	0.50
Carbamazepine 200mg tablets 56's	8	0.19	17.31 ±5.44	138.51	0.79	4.16*
Carbamazepine 200mg tablets 84's	5	0.12	29.25 ±8.43	146.23	0.84	7.00*
Carbamazepine 200mg tablets 28's	5	0.12	7.70	38.50	0.22	1.83*
Phenobarbitone 30mg tablets 84's	1	0.02	1.66	1.66	0.01	0.50
Phenytoin 100mg tablets 28's	2	0.05	4.47	8.94	0.05	1.00
Sodium valporate 200mg tablets 28's	1	0.02	31.35	31.35	0.18	9.00*
Sodium valporate 500mg tablets 28's	2	0.05	62.70 ±44.36	125.40	0.72	14.40*

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION IN ALL CLINICS FOR ALL CONSULTATIONS	Frequency (F)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Promethazine25mg / 2ml injection	2	0.05	1.07	2.14	0.01	0.20
Bismuth subgallate ointment	4	0.09	9.92	39.68	0.23	2.56*
Sennoside 7.5mg A& B tablets, 28's	3	0.07	2.96	8.88	0.05	0.71
Multivitamin syrup 100ml	45	1.09	0.92	41.40	0.24	0.22
Multivitamin tablets 28's	3	0.07	0.66	1.98	0.01	0.14
Pyridoxine 25mg tablets 28's	209	5.07	0.46 ±0.59	96.66	0.55	0.12
Thiamine HCL 100mg tablets 28's	6	0.15	0.65	3.90	0.02	0.13
Vitamin B complex tablets 28's	186	4.51	0.44 ±0.29	82.53	0.47	0.10
Vitamin C 100mg tablets 28's	7	0.17	1.00	7.00	0.04	0.24
Feeding milk 500g	55	1.33	10.98 ±0.29	604.19	3.45	2.59*
PVM maize meal mix 1kg	152	3.68	13.89 ±4.05	2111.94	12.06	3.28*
Asprin Soluble tablets 300mg	26	0.63	0.48	12.46	0.07	0.11
Ibuprofen 200mg tablets	89	2.16	0.51 ±0.01	45.55	0.26	0.12
Paracetamol 500mg tablets	162	3.92	0.55 ±0.03	89.60	0.51	0.13
Paracetamol 120mg / 5ml syrup 50ml	78	1.89	0.82 ±0.07	64.22	0.37	0.20
BCG vaccine injection 20 dose	1	0.02	0.48	0.48	0.002	0.10
DPT vaccine injection 20dose	9	0.22	0.43	3.87	0.02	0.09
DT vaccine injection 20 dose	23	0.56	0.51	11.73	0.07	0.13
Hepatitis B vaccine injection 10 dose	43	1.04	3.23 ±0.43	139.09	0.79	0.76
Measles vaccine 10 dose	41	0.99	0.62 ±0.02	25.29	0.14	0.14
Poliomyelitis vaccine oral solution 10 dose	70	1.70	0.49 ±0.02	34.43	0.20	0.12
Tetanus vaccine injection 20 dose	13	0.32	0.36 ±0.04	4.69	0.03	0.09
Heamophillius influeanzae conjunct vaccine 10 dose	47	1.14	22.12	1039.64	5.94	5.21

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION IN ALL CLINICS FOR ALL CONSULTATIONS	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Pregnancy test kit	12	0.29	1.86	22.32	0.13	0.45
Beclamethasone inhaler 100ug 300 dose	4	0.97	22.5 ±9.00	90.00	0.51	0.53
Aminophylline 250mg / 10ml injection	1	0.02	1.69	1.69	0.01	0.50
Salbutamol sulphate inhaler 100ug / dose 300dose	8	0.19	9.47 ±2.98	75.78	0.43	2.26*
Salbutamol nebule 5mg / 2.5ml	1	0.02	1.20	1.20	0.01	0.50
Theophylline sustained release tablet 200mg 28's	4	0.97	5.11	20.44	0.12	0.12
Theophylline sustained release tablet 200mg 56's	2	0.05	10.15	20.30	0.12	2.40*
Theophylline sustained release tablet 300mg 28's	2	0.05	9.13	18.26	0.10	2.00*
Mist tussi infant 100ml	76	1.84	0.86	65.36	0.37	0.20
Mist expectorant stim 200ml	68	1.65	1.59 ±0.40	108.61	0.62	0.38
Ethambutol HCL 400mg tablets, 100's	109	2.64	0.88 ±1.41	95.80	0.55	0.21
Rifampicin300 / 150INH tablets 20's	535	12.97	4.03 ±4.51	2157.23	14.32	1.10
Rifampicin 60mg INH 30 mg tablets 4's	26	0.63	2.98 ±2.56	77.52	0.44	0.70
HRZ-E-200 tablets 100,s	282	6.83	3.60 ±4.54	1016.44	5.80	0.85
HREZ-Myrin plus tablets, 100's	250	6.06	4.48 ±6.12	1119.83	6.40	1.06
Rifampicin 60mg / INH 30mg PZA150mg tablets 80's	25	0.61	4.93 ±4.44	123.34	0.70	1.15
Streptomycin1g / 3ml injection	198	4.80	3.26	645.48	3.69	0.77
Cotrimazole vaginal tablets 500mg 1's	3	0.07	17.45	52.35	0.30	4.29*
Micanazole vaginal cream 40g	3	0.07	29.13	87.39	0.50	7.14*
Total	**4691**	**100.05**		**19669.50**	**100.03**	

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

Appendix 1.66: Parameters of individual medicine item description according to gender for all consultations in all clinics

INDIVIDUAL ITEM DESCRIPTION IN ALL CLINICS FOR ALL CONSULTATIONS	Gender	Frequency parameters		Cost related parameters			
		Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Amoxycillin 250mg capsules 15's	Male	08	21.62	3.09 ±1.15	24.74	22.75	1.05
	Female	29	78.38	2.89 ±0.95	84.02	77.25	0.99
	Total	**37**	**100.00**		**108.76**	**100.00**	
Amoxycillin Suspension 125mg / 5ml	Male	09	69.23	3.19 ±0.27	28.71	68.67	0.99
	Female	04	30.77	3.28	13.1	31.33	1.02
	Total	**13**	**100.00**		**41.81**	**100.00**	
Penicillin VK Suspension 125mg / 5ml	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	02	100.00	2.43	4.86	100.00	1.00
	Total	**02**	**100.00**		**4.86**	**100.00**	
Penicillin VK Suspension 250mg / 5ml	Male	02	50.00	3.72	7.44	54.43	1.09
	Female	02	50.00	3.12 ±0.86	6.23	45.57	0.91
	Total	**04**	**100.00**		**13.67**	**100.00**	
Penicillin VK Tablets 250mg 20's	Male	05	45.45	10.04 ±9.22	50.20	66.67	1.47
	Female	06	54.55	4.18 ±3.04	25.10	33.33	0.61
	Total	**11**	**100.00**		**75.30**	**100.00**	
Benzathine Penicillin 2.4 MU injection	Male	08	57.14	2.70	21.60	57.14	1.00
	Female	06	42.86	2.70	16.20	42.86	1.00
	Total	**14**	**100.00**		**37.80**	**100.00**	
Flucloxacillin suspension 125mg/5ml	Male	02	100.0	10.55	21.10	100.00	1.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**21.1**	**100.00**	
Flucloxacillin 250mg capsules 20's	Male	03	37.50	9.42	28.26	30.00	0.80
	Female	05	62.50	13.19	65.94	70.00	1.12
	Total	**08**	**100.00**		**94.20**	**100.00**	
Ciprofloxacin 500mg tablets 10's	Male	06	20.69	5.21 ±1.34	31.27	54.70	2.64*
	Female	23	79.31	5.47 ±0.95	25.90	45.30	0.57
	Total	**29**	**100.00**		**57.17**	**100.00**	
Cotrimoxazole 400 / 80mg tablets 20's	Male	05	45.45	1.69	8.45	45.45	1.00
	Female	06	54.55	1.69	10.14	54.55	1.00
	Total	**11**	**100.00**		**18.59**	**100.00**	
Cotrimoxazole 200 / 40mg / 5ml suspension	Male	09	64.29	1.53	13.77	64.29	1.00
	Female	05	35.71	1.53	7.65	35.71	1.00
	Total	**14**	**100.00**		**21.42**	**100.00**	
Doxycycline 100mg capsules 14's	Male	04	19.05	1.70	6.80	19.04	0.99
	Female	17	80.95	1.70	28.90	80.96	1.00
	Total	**21**	**100.00**		**35.7**	**100.00**	
Doxycycline 100mg capsules 20's	Male	01	16.67	2.23	2.23	16.67	1.00
	Female	05	83.33	2.23	11.15	83.33	1.00
	Total	**06**	**100.00**		**13.38**	**100.00**	

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION IN ALL CLINICS FOR ALL CONSULTATIONS	Gender	Frequency n	FP %	(AC) (Rands)	(TC) (Rands)	(PC) %	(CPI)
Doxycycline 100mg capsules 30's	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	3.42	3.42	100.00	1.00
	Total	**01**	**100.00**		**3.42**	**100.00**	
Erythromycin 250mg capsules 20's	Male	03	75.00	6.61	19.83	75.00	1.00
	Female	01	25.00	6.61	6.61	25.00	1.00
	Total	**04**	**100.00**		**26.44**	**100.00**	
Erythromycin 250 mg capsules 56's	Male	02	50.00	55.53	111.06	54.55	1.09
	Female	02	50.00	46.28	92.55	45.45	0.09
	Total	**04**	**100.00**		**203.61**	**100.00**	
Erythromycin suspension 125mg / 5ml	Male	03	75.00	6.30	18.90	75.00	1.00
	Female	01	25.00	6.30	6.30	25.00	1.00
	Total	**04**	**100.00**		**25.2**	**100.00**	
Perindropril 4mg tablets 28's	Male	17	28.33	18.59	316.03	27.88	0.98
	Female	43	71.67	19.02 ±2.84	817.66	72.12	1.01
	Total	**60**	**100.00**		**1133.69**	**100.00**	
Reserpine 0.25mg tablets 14's	Male	04	11.43	6.70	26.80	11.43	1.00
	Female	31	88.57	6.70	207.70	88.57	1.00
	Total	**35**	**100.00**		**234.5**	**100.00**	
Digoxin 0.25mg tablets 28's	Male	06	75.00	3.17	19.02	75.00	1.00
	Female	02	25.00	3.17	6.34	25.00	1.00
	Total	**08**	**100.00**		**25.36**	**100.00**	
Furosemide 40mg tablets 28's	Male	05	45.45	1.28	6.40	45.45	1.00
	Female	06	54.55	1.28	7.68	54.55	1.00
	Total	**11**	**100.00**		**14.08**	**100.00**	
Potassium chloride 600mg tablets 84's	Male	01	100.00	7.09	7.09	100.00	1.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**7.09**	**100.00**	
Ferrous sulphate tablets 28's	Male	04	9.52	2.23	8.92	10.27	1.08
	Female	38	90.48	2.05 ±0.42	77.90	89.73	0.99
	Total	**42**	**100.00**		**86.82**	**100.00**	
Ferrous gluconate syrup 100ml	Male	02	100.00	8.66	17.32	100.00	1.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**17.32**	**100.00**	
Folic acid 5mg tablets 28's	Male	02	5.00	1.09	2.18	5.00	1.00
	Female	38	95.00	1.09	41.42	95.00	1.00
	Total	**40**	**100.00**		**43.60**	**100.00**	
Metronidazole 200mg tablets 28's	Male	01	4.00	1.28	1.28	2.44	0.61
	Female	24	96.00	2.13 ±1.17	51.20	97.56	1.02
	Total	**25**	**100.00**		**52.48**	**100.00**	
Metronidazole 200mg / 5ml suspension	Male	01	50.00	4.46	4.46	50.00	1.00
	Female	01	50.00	4.46	4.46	50.00	1.00
	Total	**02**	**100.00**		**8.92**	**100.00**	
Nystatin ointment 15g	Male	01	20.00	6.25	6.25	20.00	1.00
	Female	04	80.00	6.25	25.00	80.00	1.00
	Total	**05**	**100.00**		**31.25**	**100.00**	

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION IN ALL CLINICS FOR ALL CONSULTATIONS	Gender	Frequency n	FP %	(AC) (Rands)	(TC) (Rands)	(PC) %	(CPI)
Nystatin suspension 20ml	Male	04	100.00	5.46	21.84	100.00	1.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**04**	**100.00**		**21.84**	**100.00**	
Griseofulvin 500mg tablets 28's	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	15.96	15.96	100.00	1.00
	Total	**01**	**100.00**		**15.96**	**100.00**	
Glycery ltrinitrate 0.5mg sublingual tablets, 50's	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	17.24	17.24	100.00	1.00
	Total	**01**	**100.00**		**17.24**	**100.00**	
Atenelol 50mg tablets 28's	Male	03	10.71	2.72	8.16	10.34	0.97
	Female	25	89.29	2.83 ±0.54	70.72	89.66	1.00
	Total	**28**	**100.00**		**78.88**	**100.00**	
Enalapril 5mg tablets 28's	Male	03	14.29	5.49	16.47	14.29	1.00
	Female	18	85.71	5.49	98.82	85.71	1.00
	Total	**21**	**100.00**		**115.29**	**100.00**	
Enalapril 10mg tablets 28's	Male	08	23.53	15.42 ±5.49	123.36	25.53	1.08
	Female	26	76.47	13.84 ±8.69	359.80	74.47	0.97
	Total	**34**	**100.00**		**483.16**	**100.00**	
Hydrochlorthiazide 25mg tablets 14's	Male	03	42.86	2.59	7.77	54.60	1.27
	Female	04	57.14	1.62 ±0.65	6.46	45.40	0.79
	Total	**07**	**100.00**		**14.23**	**100.00**	
Hydrochlorthiazide 25mg tablets 28's	Male	28	15.82	2.59	72.52	15.08	0.95
	Female	149	84.18	2.74 ±1.75	408.53	84.92	1.01
	Total	**177**	**100.00**		**481.05**	**100.00**	
Methyldopa 250mg tablets 28's	Male	10	16.67	5.26 ±2.49	52.60	17.24	1.03
	Female	50	83.33	5.05 ±4.16	252.56	82.76	0.99
	Total	**60**	**100.00**		**305.16**	**100.00**	
Methyldopa 250mg tablets 56's	Male	02	11.11	8.66	17.32	7.41	0.67
	Female	16	88.89	13.53 ±7.05	216.50	92.59	1.04
	Total	**18**	**100.00**		**233.82**	**100.00**	
Methyldopa 250mg tablets 84's	Male	04	25.00	44.45±34.78	177.79	43.07	1.72*
	Female	12	75.00	19.59±6.37	235.03	56.93	0.76
	Total	**16**	**100.00**		**412.82**	**100.00**	
Nifedipine 5mg tablets 100's	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	04	100.00	8.24±8.14	32.97	100.00	1.00
	Total	**04**	**100.00**		**32.97**	**100.00**	
Nifedipine 30mg XL capsule 30's	Male	02	33.33	34.20±16.12	68.40	42.85	1.29
	Female	04	66.67	22.80	91.20	57.15	0.86
	Total	**06**	**100.00**		**159.61**	**100.00**	
Indapamide tablets 28's	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	02	100.00	2.62	5.24	100.00	1.00
	Total	**02**	**100.00**		**5.24**	**100.00**	
Benzoic acid ointment 25g	Male	06	60.00	0.64	3.84	60.00	1.00
	Female	04	40.00	0.64	2.56	40.00	1.00
	Total	**10**	**100.00**		**6.40**	**100.00**	

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION IN ALL CLINICS FOR ALL CONSULTATIONS	Gender	Frequency n	FP %	(AC) (Rands)	(TC) (Rands)	(PC) %	(CPI)
Clotrimazole 1% cream 20g	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	05	100.00	1.79	8.95	100.00	1.00
	Total	**05**	**100.00**		**8.95**	**100.00**	
Micanazole oral gel 30g	Male	03	50.00	12.09 ±18.92	36.27	34.65	0.69
	Female	03	50.00	22.80 ±19.27	68.41	65.35	1.31
	Total	**06**	**100.00**		**104.68**	**100.00**	
Nystatin ointment 15g	Male	01	50.00	6.25	6.25	50.00	1.00
	Female	01	50.00	6.25	6.25	50.00	1.00
	Total	**02**	**100.00**		**12.50**	**100.00**	
Povidone iodine ointment 25g	Male	07	50.00	2.39	16.73	50.00	1.00
	Female	07	50.00	2.39	16.73	50.00	1.00
	Total	**14**	**100.00**		**33.46**	**100.00**	
Calamine lotion 100ml	Male	02	15.38	1.09	2.18	15.38	1.00
	Female	11	84.62	1.09	11.99	84.62	1.00
	Total	**13**	**100.00**		**14.17**	**100.00**	
Hydrocortisone 1% cream 25g	Male	01	12.50	2.23	2.23	12.50	1.00
	Female	07	87.50	2.23	15.61	87.50	1.00
	Total	**08**	**100.00**		**17.84**	**100.00**	
Monosulfiram soap 5%, 75g	Male	06	50.00	3.20	19.20	50.00	1.00
	Female	06	50.00	3.20	19.20	50.00	1.00
	Total	**12**	**100.00**		**38.4**	**100.00**	
Methylsalicylate ointment 25g	Male	14	34.15	0.65 ±0.49	9.15	39.46	1.16
	Female	27	65.85	0.52	14.04	60.54	0.92
	Total	**41**	**100.00**		**23.19**	**100.00**	
Aqueous cream	Male	02	20.00	0.98	1.96	20.00	1.00
	Female	08	80.00	0.98	7.84	80.00	1.00
	Total	**10**	**100.00**		**9.80**	**100.00**	
Zinc & castor oil ointment 25g	Male	02	50.00	0.88	1.76	50.00	1.00
	Female	02	50.00	0.88	1.76	50.00	1.00
	Total	**04**	**100.00**		**3.52**	**100.00**	
Chloramphenicol ophthalmic ointment	Male	03	60.00	2.91	8.73	60.00	1.00
	Female	02	40.00	2.91	5.82	40.00	1.00
	Total	**05**	**100.00**		**14.55**	**100.00**	
Norethisterone enath 200mg injection	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	99	100.00	5.23 ±0.07	517.98	100.00	1.00
	Total	**99**	**100.00**		**517.98**	**100.00**	
Medroxyprogesterone 150mg injection	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	145	100.00	4.57 ±0.08	662.56	100.00	1.00
	Total	**145**	**100.00**		**662.56**	**100.00**	
Microval tablets 28's	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	7.56	7.56	100.00	1.00
	Total	**01**	**100.00**		**7.56**	**100.00**	
Triphasil tablets 28's	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	33	100.00	6.77 ±2.08	223.25	100.00	1.00
	Total	**33**	**100.00**		**223.25**	**100.00**	

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION IN ALL CLINICS FOR ALL CONSULTATIONS	Gender	Frequency n	FP %	(AC) (Rands)	(TC) (Rands)	(PC) %	(CPI)
Ovral tablets 28's	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	15	100.00	7.49 ±1.93	112.35	100.00	1.00
	Total	**15**	**100.00**		**112.35**	**100.00**	
Prednisone 5mg tablets 28's	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	1.69	1.69	100.00	1.00
	Total	**01**	**100.00**		**1.69**	**100.00**	
Carbamazepine 200mg tablets 56's	Male	05	62.50	15.39	76.95	55.56	0.89
	Female	03	37.50	20.52 ±8.89	61.56	44.44	1.19
	Total	**08**	**100.00**		**138.51**	**100.00**	
Carbamazepine 200mg tablets 84's	Male	05	100.00	29.25 ±8.43	146.23	100.00	1.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**05**	**100.00**		**146.23**	**100.00**	
Carbamazepine 200mg tablets 28's	Male	01	20.00	7.70	7.70	20.00	1.00
	Female	04	80.00	7.70	30.80	80.00	1.00
	Total	**05**	**100.00**		**38.50**	**100.00**	
Phenobarbitone 30mg tablets 84's	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	1.66	1.66	100.00	1.00
	Total	**01**	**100.00**		**1.66**	**100.00**	
Phenytoin 100mg tablets 28's	Male	02	100.00	4.47	8.94	100.00	1.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**8.94**	**100.00**	
Sodium valporate 200mg tablets 28's	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	31.35	31.35	100.00	1.00
	Total	**01**	**100.00**		**31.35**	**100.00**	
Sodium valporate 500mg tablets 28's	Male	02	100.00	62.70 ±44.34	125.40	100.00	1.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**125.4**	**100.00**	
Promethazine25mg / 2ml injection	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	02	100.00	1.07	2.14	100.00	1.00
	Total	**02**	**100.00**		**2.14**	**100.00**	
Bismuth subgallate ointment	Male	01	25.00	9.92	9.92	25.00	1.00
	Female	03	75.00	9.92	29.76	75.00	1.00
	Total	**04**	**100.00**		**39.68**	**100.00**	
Sennoside 7.5mg A& B tablets, 28's	Male	01	33.33	2.96	2.96	33.33	1.00
	Female	02	66.67	2.96	5.92	66.67	1.00
	Total	**03**	**100.00**		**8.88**	**100.00**	
Multivitamin syrup 100ml	Male	22	48.89	0.92	20.24	48.89	1.00
	Female	23	51.11	0.92	21.16	51.11	1.00
	Total	**45**	**100.00**		**41.40**	**100.00**	
Multivitamin tablets 28's	Male	01	33.33	0.66	0.66	33.33	1.00
	Female	02	66.67	0.66	1.32	66.67	1.00
	Total	**03**	**100.00**		**1.98**	**100.00**	
Pyridoxine 25mg tablets 28's	Male	137	65.55	0.40 ±0.57	55.36	57.27	0.87
	Female	72	34.45	0.57 ±0.64	41.30	42.73	1.24
	Total	**209**	**100.00**		**96.66**	**100.00**	

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION IN ALL CLINICS FOR ALL CONSULTATIONS	Gender	Frequency n	FP %	(AC) (Rands)	(TC) (Rands)	(PC) %	(CPI)
Thiamine HCL 100mg tablets 28's	Male	04	66.67	0.65	2.60	66.67	1.00
	Female	02	33.33	0.65	1.30	33.33	1.00
	Total	**06**	**100.00**		**3.90**	**100.00**	
Vitamin B complex tablets 28's	Male	87	46.77	0.49 ±0.27	42.75	51.80	1.11
	Female	99	53.23	0.40 ±0.31	39.78	48.20	0.91
	Total	**186**	**100.00**		**82.53**	**100.00**	
Vitamin C 100mg tablets 28's	Male	04	57.14	1.00	4.00	57.14	1.00
	Female	03	42.86	1.00	3.00	42.86	1.00
	Total	**07**	**100.00**		**7.00**	**100.00**	
Feeding milk 500g	Male	24	43.64	10.93	262.32	45.45	1.04
	Female	31	56.36	11.03 ±0.38	314.87	54.55	0.97
	Total	**55**	**100.00**		**577.19**	**100.00**	
PVM maize meal mix 1kg	Male	67	44.08	13.49 ±3.62	904.29	42.82	0.97
	Female	85	55.92	14.21 ±4.36	1207.65	57.18	1.02
	Total	**152**	**100.00**		**2111.94**	**100.00**	
Asprin Souluble tablets 300mg	Male	09	34.62	0.48	4.32	34.67	1.00
	Female	17	65.38	0.48	8.14	65.33	0.99
	Total	**26**	**100.00**		**12.46**	**100.00**	
Ibuprofen 200mg tablets	Male	33	37.08	051	16.91	37.12	1.00
	Female	56	62.92	0.51	28.64	62.88	0.99
	Total	**89**	**100.00**		**45.55**	**100.00**	
Paracetamol 500mg tablets	Male	47	29.01	0.55 ±0.01	25.81	28.81	0.99
	Female	115	70.99	0.55 ±0.04	63.79	71.19	1.00
	Total	**162**	**100.00**		**89.60**	**100.00**	
Paracetamol 120mg / 5ml syrup 50ml	Male	34	43.59	0.84	28.56	44.47	1.02
	Female	44	56.41	0.81 ±0.09	35.66	55.53	0.98
	Total	**78**	**100.00**		**64.22**	**100.00**	
BCG vaccine injection 20 dose	Male	01	100.00	0.48	0.48	100.00	1.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**0.48**	**100.00**	
DPT vaccine injection 20dose	Male	05	55.56	0.43	2.15	55.56	1.00
	Female	04	44.44	0.43	1.72	44.44	1.00
	Total	**09**	**100.00**		**3.87**	**100.00**	
DT vaccine injection 20 dose	Male	11	47.83	0.51	5.61	47.83	1.00
	Female	12	52.17	0.51	6.12	52.17	1.00
	Total	**23**	**100.00**		**11.73**	**100.00**	
Hepatitis B vaccine injection 10 dose	Male	18	41.86	3.30	56.40	41.44	0.99
	Female	25	58.14	3.19 ±0.56	79.69	58.56	1.01
	Total	**43**	**100.00**		**136.09**	**100.00**	
Measles vaccine 10 dose	Male	20	48.78	0.62	12.40	49.03	1.01
	Female	21	51.22	0.61 ±0.03	12.89	50.97	0.99
	Total	**41**	**100.00**		**25.29**	**100.00**	
Poliomyelitis vaccine oral solution 10 dose	Male	31	44.29	0.49	15.19	44.12	0.99
	Female	39	55.71	0.49 ±0.02	19.24	55.88	1.00
	Total	**70**	**100.00**		**34.43**	**100.00**	

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION IN ALL CLINICS FOR ALL CONSULTATIONS	Gender	Frequency n	FP %	(AC) (Rands)	(TC) (Rands)	(PC) %	(CPI)
Tetanus vaccine injection 20 dose	Male	03	23.08	0.39 ±0.08	1.19	25.37	1.09
	Female	10	76.92	0.35	3.50	74.63	0.97
	Total	**13**	**100.00**		**4.69**	**100.00**	
Heamophillius influeanzae conjunct vaccine 10 dose	Male	18	38.30	22.12	398.16	38.30	1.00
	Female	29	61.70	22.12	641.48	61.70	1.00
	Total	**47**	**100.00**		**1039.64**	**100.00**	
Pregnancy test kit	Male	01	8.33	1.86	1.86	8.33	1.00
	Female	11	91.67	1.86	20.46	91.67	1.00
	Total	**12**	**100.00**		**22.32**	**100.00**	
Beclamethasone inhaler 100ug 300 dose	Male	03	75.00	24.00 ±10.39	72.00	80.00	1.07
	Female	01	25.00	18.00	18.00	20.00	0.80
	Total	**04**	**100.00**		**90.00**	**100.00**	
Aminophylline 250mg / 10ml injection	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	01	100.00	1.69	1.69	100.00	1.00
	Total	**01**	**100.00**		**1.69**	**100.00**	
Salbutamol sulphate inhaler 100ug / dose 300dose	Male	06	75.00	9.82 ±3.44	58.94	77.78	1.04
	Female	02	25.00	8.42	16.84	22.22	0.89
	Total	**08**	**100.0**		**75.78**	**100.00**	
Salbutamol nebule 5mg/2.5ml	Male	01	100.00	1.20	1.20	100.00	1.00
	Female	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**1.2**	**100.00**	
Theophylline sustained release tablet 200mg 28's	Male	03	75.00	5.11	15.33	75.00	1.00
	Female	01	25.00	5.11	5.11	25.00	1.00
	Total	**04**	**100.00**		**20.44**	**100.00**	
Theophylline sustained release tablet 200mg 56's	Male	01	50.00	10.15	10.15	50.00	1.00
	Female	01	50.00	10.15	10.15	50.00	1.00
	Total	**02**	**100.00**		**20.3**	**100.0**	
Theophylline sustained release tablet 300mg 28's	Male	01	50.00	9.13	9.13	50.00	1.00
	Female	01	50.00	9.13	9.13	50.00	1.00
	Total	**02**	**100.00**		**18.26**	**100.00**	
Mist tussi infant 100ml	Male	29	38.16	0.86	24.94	38.16	1.00
	Female	47	61.84	0.86	40.42	61.84	1.00
	Total	**76**	**100.00**		**65.36**	**100.00**	
Mist expectorant stim 200ml	Male	21	30.88	1.68 ±0.73	35.29	32.49	1.05
	Female	47	69.12	1.56	73.32	67.51	0.98
	Total	**68**	**100.00**		**108.61**	**100.00**	
Ethambutol HCL 400mg tablets, 100's	Male	103	94.50	0.75 ±0.77	76.93	80.30	0.85
	Female	06	5.50	3.15 ±4.96	18.87	19.70	3.58*
	Total	**109**	**100.00**		**95.80**	**100.00**	
Rifampicin300 / 150INH tablets 20's	Male	354	66.17	3.63 ±3.51	1283.90	59.52	0.89
	Female	181	33.83	4.83 ±5.92	873.33	40.48	1.20
	Total	**535**	**100.00**		**2157.23**	**100.00**	
Rifampicin 60mg INH 30 mg tablets 4's	Male	25	96.15	2.74 ±2.28	68.40	88.24	0.92
	Female	01	3.85	9.12	9.12	11.76	3.05*
	Total	**26**	**100.00**		**77.52**	**100.00**	

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION IN ALL CLINICS FOR ALL CONSULTATIONS	Gender	Frequency n	FP %	(AC) (Rands)	(TC) (Rands)	(PC) %	(CPI)
HRZ-E-200 tablets 100,s	Male	118	41.84	3.12 ±1.93	367.99	36.20	0.87
	Female	164	58.16	3.95 ±5.71	648.44	63.80	1.10
	Total	**282**	**100.00**		**1016.43**	**100.00**	
HREZ-Myrin plus tablets, 100's	Male	168	67.20	4.79 ±7.45	805.66	71.94	1.07
	Female	82	32.80	3.83 ±0.26	314.17	28.06	0.86
	Total	**250**	**100.00**		**1119.83**	**100.00**	
Rifampicin 60mg / INH 30mg PZA 150mg tablets 80's	Male	19	76.00	4.56	86.64	70.24	0.92
	Female	06	24.00	6.12 ±9.62	36.70	29.76	1.24
	Total	**25**	**100.00**		**123.34**	**100.00**	
Streptomycin 1g / 3ml injection	Male	109	55.05	3.26	355.34	55.05	1.00
	Female	89	44.95	3.26	290.14	45.95	1.00
	Total	**198**	**100.00**		**645.48**	**100.00**	
Cotrimazole vaginal tablets 500mg 1's	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	03	100.00	17.45	52.35	100.00	1.00
	Total	**03**	**100.00**		**52.35**	**100.00**	
Micanazole vaginal cream 40g	Male	00	0.00	0.00	0.00	0.00	0.00
	Female	03	100.00	29.13	87.39	100.00	1.00
	Total	**03**	**100.00**		**87.39**	**100.00**	

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

Appendix 1.67: Parameters for Individual medicine item descirption according to age group in all consultations in all clinics

INDIVIDUAL ITEM DESCRIPTION IN ALL CLINICS FOR ALL CONSULTATIONS	Age Group (years)	Frequency (n)	Frequency Percentage (FP) %	Cost related parameters			
				Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Amoxycillin 250mg capsules 15's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	04	10.81	3.09 ±1.26	12.39	11.39	1.05
	19 ≥ 40	21	56.76	3.06 ±1.08	64.22	59.05	1.04
	40 ≥ 60	11	29.73	2.69 ±0.76	29.68	27.29	0.92
	>60	01	2.70	2.47	2.47	2.27	0.84
	Total	**37**	**100.00**		**108.76**	**100.00**	
Amoxycillin Suspension 125mg/5ml	0 ≥ 6	10	76.92	3.28	32.8	78.41	1.02
	6 ≥ 12	02	15.38	3.28	6.56	15.68	1.02
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	01	7.69	2.47	2.47	5.90	0.77
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**13**	**99.99**		**41.83**	**99.99**	
Penicillin VK Suspension 125mg/5ml	0 ≥ 6	02	100.00	2.43	4.86	100.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**4.86**	**100.00**	
Penicillin VK Suspension 250mg/5ml	0 ≥ 6	01	25.00	3.72	3.72	27.21	1.09
	6 ≥ 12	02	50.00	3.72	7.44	54.42	1.09
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	01	25.00	2.51	2.51	18.36	0.73
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**04**	**100.00**		**13.67**	**100.00**	
Penicillin VK Tablets 250mg 20's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	03	27.27	2.51	7.53	10.00	0.37
	19 ≥ 40	04	36.36	5.02 ± 3.55	20.08	26.67	0.73
	40 ≥ 60	03	27.27	9.20 ± 9.50	27.61	36.67	1.34
	>60	01	9.10	20.08	20.08	26.67	2.93*
	Total	**11**	**100.00**		**75.3**	**100.01**	
Benzathine Penicillin 2.4 MU injection	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	14	100.00	2.7	37.80	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**14**	**100.00**		**37.8**	**100.00**	

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Flucloxacillin suspension 125mg/5ml	0 ≥ 6	01	50.00	10.55	10.55	50.00	1.00
	6 ≥ 12	01	50.00	10.55	10.55	50.00	1.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**21.1**	**100.00**	
Flucloxacillin 250mg capsules 20's	0 ≥ 6	01	12.50	9.42	9.42	10.00	0.80
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	05	62.50	13.19 ±8.43	65.94	70.00	1.12
	40 ≥ 60	02	25.00	9.42	18.84	20.00	0.80
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**08**	**100.00**		**94.20**	**100.00**	
Ciprofloxacin 500mg tablets 10's	0 ≥ 6	01	3.45	2.47	2.47	4.32	1.25
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	3.45	5.76	5.76	10.07	2.92*
	19 ≥ 40	23	79.31	5.62 ±0.69	29.19	51.06	0.64
	40 ≥ 60	04	13.79	4.94 ±1.65	19.75	34.55	2.51*
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**29**	**100.00**		**57.17**	**100.00**	
Cotrimoxazole 400/80mg tablets 20's	0 ≥ 6	01	9.10	1.69	1.69	9.10	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	10	90.90	1.69	16.90	90.90	1.00
	40 ≥ 60	00	0.00		0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**11**	**100.00**		**18.59**	**100.00**	
Cotrimoxazole 200/40mg/5ml suspension	0 ≥ 6	14	100.00	1.53	21.42	100.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**14**	**100.00**		**21.42**	**100.00**	
Doxycycline 100mg capsules 14's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	4.76	1.70	1.70	4.76	1.00
	19 ≥ 40	18	85.71	1.70	30.60	85.71	1.00
	40 ≥ 60	02	9.52	1.70	3.40	9.52	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**21**	**100.00**		**35.70**	**100.00**	

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Doxycycline 100mg capsules 20's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	04	66.67	'2.23	8.92	66.67	1.00
	40 ≥ 60	01	16.67	2.23	2.23	16.67	1.00
	>60	01	16.67	2.23	2.23	16.67	1.00
	Total	**06**	**100.01**		**13.38**	**100.00**	
Doxycycline 100mg capsules 30's	0 ≥ 6	01	100.00	3.42	3.42	100.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**3.42**	**100.00**	
Erythromycin 250mg capsules 20's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	01	25.00	6.61	6.61	25.00	1.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	03	75.00	6.61	19.83	75.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**04**	**100.00**		**26.44**	**100.00**	
Erythromycin 250 mg capsules 56's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	04	100.00	50.90 ±27.77	203.61	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**04**	**100.00**		**203.61**	**100.00**	
Erythromycin suspension 125mg/5ml	0 ≥ 6	03	75.00	6.30	18.90	75.00	1.00
	6 ≥ 12	01	25.00	6.30	6.30	25.00	1.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**04**	**100.00**		**25.20**	**100.00**	
Perindropril 4mg tablets 28's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	04	6.67	18.59	74.36	6.56	0.98
	40 ≥ 60	25	41.67	18.59	464.75	40.99	0.98
	>60	31	51.67	19.18 ±3.34	594.58	52.45	1.02
	Total	**60**	**100.00**		**1133.69**	**100.00**	

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Reserpine 0.25mg tablets 14's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	04	11.43	6.70	26.80	11.43	1.00
	40 ≥ 60	16	45.71	6.70	107.20	45.71	1.00
	>60	15	42.86	6.70	100.50	42.86	1.00
	Total	**35**	**100.00**		**234.50**	**100.00**	
Digoxin 0.25mg tablets 28's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	03	37.50	3.17	9.51	37.50	1.00
	>60	05	62.50	3.17	15.85	62.50	1.00
	Total	**08**	**100.00**		**25.36**	**100.00**	
Furosemide 40mg tablets 28's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	06	54.55	1.28	7.68	54.55	1.00
	>60	05	45.45	1.28	6.40	45.45	1.00
	Total	**11**	**100.00**		**14.08**	**100.00**	
Potassium chloride 600mg tablets 84's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	01	100.00	7.09	7.09	100.00	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**7.09**	**100.00**	
Ferrous sulphate tablets 28's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	03	7.14	1.85 ±0.66	5.55	6.39	0.89
	19 ≥ 40	35	83.33	2.07 ±0.40	72.35	83.33	1.00
	40 ≥ 60	03	7.14	2.23	6.69	7.71	1.08
	>60	01	2.39	2.23	2.23	2.57	1.08
	Total	**42**	**100.00**		**86.82**	**100.00**	
Ferrous gluconate syrup 100ml	0 ≥ 6	02	100.00	8.66	17.32	100.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**17.32**	**100.00**	

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Folic acid 5mg tablets 28's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	04	10.26	1.09	4.36	10.26	1.00
	19 ≥ 40	35	89.74	1.09	38.15	89.74	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**39**	**100.00**		**42.51**	**100.00**	
Metrinidazole 200mg tablets 28's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	4.00	1.28	1.28	2.44	0.61
	19 ≥ 40	19	76.00	2.22 ±1.19	42.24	80.49	1.06
	40 ≥ 60	05	20.00	1.79 ±1.14	8.96	17.07	0.85
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**25**	**100.00**		**52.48**	**100.00**	
Metrinidazole 200mg/5ml suspension	0 ≥ 6	01	50.00	4.46	4.46	50.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	50.00	4.46	4.46	50.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**8.92**	**100.00**	
Nystatin ointment 15g	0 ≥ 6	01	20.00	6.25	6.25	20.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	20.00	6.25	6.25	20.00	1.00
	19 ≥ 40	03	60.00	6.25	18.75	60.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**05**			**31.25**	**100.00**	
Nystatin suspension 20ml	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	03	75.00	5.46	16.38	75.00	1.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	25.00	5.46	5.46	25.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**04**	**100.00**		**21.84**	**100.00**	
Griseofulvin 500mg tablets 28's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	01	100.00	15.96	15.96	100.00	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**15.96**	**100.00**	

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Glyceryl trinitrate 0.5mg sublingual tablets, 50's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	01	100.00	17.24	17.24	100.00	1.00
	Total	**01**	**100.00**		**17.24**	**100.00**	
Atenelol 50mg tablets 28's	0 ≥ 6	01	3.57	2.72	2.72	3.45	0.97
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	04	14.29	2.72	10.88	13.79	0.97
	40 ≥ 60	18	64.29	2.87 ±0.64	51.68	65.52	1.02
	>60	05	17.86	2.72	13.60	17.24	0.96
	Total	**28**	**100.01**		**78.88**	**100.00**	
Enalapril 5mg tablets 28's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	02	9.52	5.49	10.98	9.52	1.00
	40 ≥ 60	15	71.43	5.49	82.35	71.43	1.00
	>60	04	19.05	5.49	21.96	19.05	1.00
	Total	**21**	**100.00**		**115.29**	**100.00**	
Enalapril 10mg tablets 28's	0 ≥ 6	01	3.03	10.28	10.28	2.17	0.72
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	06	18.18	11.99 ±4.19	71.96	15.22	0.84
	40 ≥ 60	13	39.39	12.65 ±8.55	164.48	34.78	0.88
	>60	13	39.39	17.39 ±8.79	226.16	47.83	1.21
	Total	**33**	**99.99**		**472.88**	**100.00**	
Hydrochlorthiazide 25mg tablets 14's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	05	71.43	1.81 ±0.71	9.05	63.60	0.89
	>60	02	28.57	2.59	5.18	36.40	1.27
	Total	**07**	**100.00**		**14.23**	**100.00**	
Hydrochlorthiazide 25mg tablets 28's	0 ≥ 6	01	0.57	2.59	2.59	0.54	0.95
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	34	19.83	2.48 ±0.37	84.16	17.69	0.89
	40 ≥ 60	85	48.57	2.61 ±0.20	221.91	46.63	0.96
	>60	55	31.43	3.04 ±2.84	167.21	35.14	1.12
	Total	**175**	**100.40**		**475.87**	**100.00**	

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Methyldopa 250mg tablets 28's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	15	25.00	3.70 ±1.58	55.57	18.21	0.73
	40 ≥ 60	26	43.33	6.33 ±5.64	164.66	53.96	1.25
	>60	19	31.67	4.47	84.93	27.83	0.89
	Total	**60**	**100.00**		**305.16**	**100.00**	
Methyldopa 250mg tablets 56's	0 ≥ 6	01	5.88	17.32	17.32	8.00	1.36
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	5.88	34.64	34.64	16.00	2.72*
	40 ≥ 60	11	64.71	11.81 ±4.37	129.90	60.00	0.93
	>60	04	23.53	8.66	34.64	16.00	0.68
	Total	**17**	**100.00**		**216.50**	**100.00**	
Methyldopa 250mg tablets 84's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	03	18.75	32.99 ±14.28	98.96	23.97	1.28
	40 ≥ 60	12	75.00	24.09 ±22.01	289.12	70.04	0.93
	>60	01	6.25	24.74	24.74	5.99	0.96
	Total	**16**	**100.00**		**412.82**	**100.00**	
Nifedipine 5mg tablets 100's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	02	50.00	1.23 ±1.29	2.45	7.43	0.15
	40 ≥ 60	01	25.00	15.26	15.26	46.28	1.85*
	>60	01	25.00	15.26	15.26	46.28	1.85*
	Total	**04**	**100.00**		**32.97**	**99.99**	
Nifedipine 30mg XL capsule 30's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	16.67	22.80	22.80	14.29	0.86
	40 ≥ 60	04	66.67	28.50 ±11.40	114.00	71.43	1.07
	>60	01	16.67	22.80	22.80	14.29	0.86
	Total	**06**	**100.01**		**159.60**	**100.00**	
Indapamide tablets 28's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	02	100.00	2.62	5.24	100.00	1.00
	Total	**02**	**100.00**		**5.24**	**100.00**	

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Benzoic acid ointment 25g	0 ≥ 6	02	20.00	0.64	1.28	20.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	10.00	0.64	0.64	10.00	1.00
	19 ≥ 40	04	40.00	0.64	2.56	40.00	1.00
	40 ≥ 60	03	30.00	0.64	1.92	30.00	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**10**	**100.00**		**6.40**	**100.00**	
Clotrimazole 1% cream 20g	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	20.00	1.79	1.79	20.00	1.00
	40 ≥ 60	04	80.00	1.79	7.16	80.00	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**05**	**100.00**		**8.95**	**100.00**	
Micanazole oral gel 30g	0 ≥ 6	03	50.00	22.80 ±19.27	68.41	65.35	1.31
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	16.67	1.79	1.79	1.71	0.10
	19 ≥ 40	01	16.67	0.55	0.55	0.53	0.03
	40 ≥ 60	01	16.67	33.93	33.93	32.41	1.94*
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**06**	**100.00**		**104.68**	**100.00**	
Nystatin ointment 15g	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	50.00	6.25	6.25	50.00	1.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	01	50.00	6.25	6.25	50.00	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**12.5**	**100.00**	
Povidone iodine ointment 25g	0 ≥ 6	03	21.43	2.39	7.17	21.43	1.00
	6 ≥ 12	05	35.71	2.39	11.95	35.71	1.00
	12 ≥ 19	01	7.14	2.39	2.39	7.14	1.00
	19 ≥ 40	03	21.43	2.39	7.17	21.43	1.00
	40 ≥ 60	01	7.14	2.39	2.39	7.14	1.00
	>60	01	7.14	2.39	2.39	7.14	1.00
	Total	**14**	**100.00**		**33.46**	**100.00**	
Calamine lotion 100ml	0 ≥ 6	03	23.08	1.09	3.27	23.08	1.00
	6 ≥ 12	01	7.69	1.09	1.09	7.69	1.00
	12 ≥ 19	02	15.38	1.09	2.18	15.38	1.00
	19 ≥ 40	04	30.77	1.09	4.36	30.91	1.00
	40 ≥ 60	03	23.08	1.09	3.27	23.08	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**13**	**100.00**		**14.17**	**100.14**	

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Hydrocortisone 1% cream 25g	0 ≥ 6	02	25.00	2.23	4.46	25.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	04	50.00	2.23	8.92	50.00	1.00
	40 ≥ 60	02	25.00	2.23	4.46	25.00	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**08**	**100.00**		**17.84**	**100.00**	
Monosulfiram soap 5% 75g	0 ≥ 6	05	41.67	3.20	16.00	41.67	1.00
	6 ≥ 12	01	8.33	3.20	3.20	8.33	1.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	03	25.00	3.20	9.60	25.00	1.00
	40 ≥ 60	03	25.00	3.20	9.60	25.00	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**12**	**100.00**		**38.4**	**100.00**	
Methylsalicylate ointment 25g	0 ≥ 6	01	2.44	0.52	0.52	2.24	0.92
	6 ≥ 12	01	2.44	0.52	0.52	2.24	0.92
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	07	17.07	0.52	3.64	15.70	0.92
	40 ≥ 60	13	31.71	0.52	6.76	29.15	0.92
	>60	19	46.34	0.62 ±0.43	11.75	50.67	1.09
	Total	**41**	**100.00**		**23.19**	**100.00**	
Aqueous cream	0 ≥ 6	03	30.00	0.98	2.94	30.00	1.00
	6 ≥ 12	01	10.00	0.98	0.98	10.00	1.00
	12 ≥ 19	01	10.00	0.98	0.98	10.00	1.00
	19 ≥ 40	05	50.00	0.98	4.90	50.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**10**	**100.00**		**9.80**	**100.00**	
Zinc & castor oil ointment 25g	0 ≥ 6	02	50.00	0.88	1.76	50.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	25.00	0.88	0.88	25.00	1.00
	40 ≥ 60	01	25.00	0.88	0.88	25.00	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**04**	**100.00**		**3.52**	**100.00**	
Chloramphenicol ophthalmic ointment	0 ≥ 6	02	40.00	2.91	5.82	40.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	20.00	2.91	2.91	20.00	1.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	02	40.00	2.91	5.82	40.00	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**05**	**100.00**		**14.55**	**100.00**	

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Norethisterone enath 200mg injection	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	16	29.09	5.24	83.84	29.14	1.00
	19 ≥ 40	36	65.45	5.22±0.11	187.96	65.37	0.99
	40 ≥ 60	03	5.45	5.24	15.72	5.47	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**55**	**99.99**		**287.52**	**99.98**	
Medroxyprogesterone 150mg injection	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	04	4.17	4.56	18.24	4.17	1.00
	19 ≥ 40	82	85.42	4.56	373.92	85.42	1.00
	40 ≥ 60	10	10.42	4.56	45.60	10.42	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**96**	**100.01**		**437.76**	**100.01**	
Microval tablets 28's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
Triphasil tablets 28's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	3.57	7.65	7.65	4.00	1.12
	19 ≥ 40	27	96.43	6.80 ±2.12	183.60	96.00	0.99
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**28**	**100.00**		**191.25**	**100.00**	
Ovral tablets 28's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	05	71.43	7.21 ±2.48	36.05	68.42	0.96
	40 ≥ 60	02	28.57	8.32	16.64	31.58	1.11
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**07**	**100.00**		**52.69**	**100.00**	
Prednisone 5mg tablets 28's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	01	100.00	1.69	1.69	100.00	1.00
	Total	**01**	**100.00**		**1.69**	**100.00**	

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Carbamazepine 200mg tablets 56's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	04	50.00	19.24 ±7.69	76.95	55.56	1.11
	40 ≥ 60	02	25.00	15.39	30.78	22.22	0.89
	>60	02	25.00	15.39	30.78	22.22	0.89
	Total	**08**	**100.00**		**138.51**	**100.00**	
Carbamazepine 200mg tablets 84's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	02	40.00	30.79 ±10.88	61.57	42.10	1.05
	40 ≥ 60	03	60.00	28.22 ±8.89	84.66	57.90	0.97
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**05**	**100.00**		**146.23**	**100.00**	
Carbamazepine 200mg tablets 28's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	02	40.00	7.70	15.40	40.00	1.00
	19 ≥ 40	02	40.00	7.70	15.40	40.00	1.00
	40 ≥ 60	01	20.00	7.70	7.70	20.00	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**05**	**100.00**		**38.5**	**100.00**	
Phenobarbitone 30mg tablets 84's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	100.00	1.66	1.66	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**1.66**	**100.00**	
Phenytoin 100mg tablets 28's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	02	100.00	4.47	8.94	100.00	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**8.94**	**100.00**	
Sodium valporate 200mg tablets 28's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	100.00	31.35	31.35	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**31.35**	**100.00**	

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Sodium valporate 500mg tablets 28's	0 ≥ 6	01	50.00	31.35	31.35	25.00	0.50
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	01	50.00	94.05	94.05	75.00	1.50*
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**125.4**	**100.00**	
Promethazine25mg/2ml injection	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	02	100.00	1.07	2.14	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**02**	**100.00**		**2.14**	**100.00**	
Bismuth subgallate ointment	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	03	75.00	9.92	29.76	75.00	1.00
	40 ≥ 60	01	25.00	9.92	9.92	25.00	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**04**	**100.00**		**39.68**	**100.00**	
Sennoside 7.5mg A& B tablets, 28's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	02	66.67	2.96	5.92	66.67	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	01	33.33	2.96	2.96	33.33	1.00
	Total	**03**	**100.00**		**8.88**	**100.00**	
Multivitamin syrup 100ml	0≤ 6	42	95.45	0.92	38.64	95.45	1.00
	6≤12	02	4.55	0.92	1.84	4.55	1.00
	12≤19	00	0.00	0.00	0.00	0.00	0.00
	19≤40	00	0.00	0.00	0.00	0.00	0.00
	40≤60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**44**	**100.00**		**40.48**	**100.00**	
Multivitamin tablets 28's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	33.33	0.66	0.66	33.33	1.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	02	66.67	0.66	1.32	66.67	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**03**	**100.00**		**1.98**	**100.00**	

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Pyridoxine 25mg tablets 28's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	02	0.96	1.35	2.70	2.83	2.95*
	19 ≥ 40	147	70.67	0.47 ±0.59	68.86	72.25	1.02
	40 ≥ 60	57	27.40	0.37 ±0.56	21.05	22.09	0.81
	>60	02	0.96	1.35	2.70	2.83	2.95*
	Total	**208**	**100.00**		**95.31**	**100.00**	
Thiamine HCL 100mg tablets 28's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	02	33.33	0.65	1.30	33.33	1.00
	40 ≥ 60	04	66.67	0.65	2.60	66.67	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**06**	**100.00**		**3.90**	**100.00**	
Vitamin B complex tablets 28's	0 ≥ 6	01	0.54	0.65	0.65	0.79	1.46
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	07	3.76	0.65	4.55	5.51	1.47
	19 ≥ 40	111	59.68	0.43±0.29	48.27	58.49	0.98
	40 ≥ 60	57	30.65	0.39 ±0.31	22.56	27.34	0.89
	>60	10	5.38	0.65	6.50	7.88	1.46
	Total	**186**	**100.01**		**82.53**	**100.01**	
Vitamin C 100mg tablets 28's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	01	14.29	1.00	1.00	14.29	1.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	04	57.14	1.00	4.00	57.14	1.00
	40 ≥ 60	02	28.57	1.00	2.00	28.57	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**07**	**100.00**			**100.00**	
Feeding milk 500g	0 ≥ 6	53	96.36	10.99 ±0.29	582.33	96.38	1.00
	6 ≥ 12	01	1.82	10.93	10.93	1.81	0.99
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	01	1.82	10.93	10.93	1.81	0.99
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**55**	**100.00**		**604.19**	**100.00**	
PVM maize meal mix 1kg	0 ≥ 6	82	53.95	13.06±2.69	1070.70	50.69	0.94
	6 ≥ 12	02	1.32	12.45	24.90	1.18	0.89
	12 ≥ 19	01	0.66	12.45	12.45	0.59	0.89
	19 ≥ 40	43	28.29	16.39 ±5.99	705.09	33.39	1.18
	40 ≥ 60	24	15.78	12.45	298.80	14.15	0.89
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**152**	**100.00**		**2111.94**	**100.00**	

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Asprin Soluble tablets 300mg	0 ≥ 6	01	3.85	0.48	0.48	3.85	1.00
	6 ≥ 12	01	3.85	0.48	0.48	3.85	1.00
	12 ≥ 19	01	3.85	0.48	0.48	3.85	1.00
	19 ≥ 40	06	23.08	0.48	2.88	23.11	1.00
	40 ≥ 60	08	30.75	0.48	3.84	30.82	1.00
	>60	09	34.62	0.48	4.30	34.52	0.99
	Total	**26**	**100.00**		**12.46**	**100.00**	
Ibuprofen 200mg tablets	0 ≥ 6	02	2.27	0.53±0.03	1.06	2.35	1.04
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	04	4.55	0.51	2.04	4.53	0.99
	19 ≥ 40	30	34.09	0.51 ±0.01	15.38	34.15	1.00
	40 ≥ 60	31	35.23	0.51	15.85	35.19	0.99
	>60	21	23.86	0.51	10.71	23.78	0.99
	Total	**88**	**100.00**		**45.04**	**100.00**	
Paracetamol 500mg tablets	0 ≥ 6	08	4.97	0.62±0.13	4.98	5.59	1.12
	6 ≥ 12	07	4.35	0.55	3.85	4.32	0.99
	12 ≥ 19	09	5.59	0.55	4.95	5.56	0.99
	19 ≥ 40	66	40.99	0.55	36.26	40.72	0.99
	40 ≥ 60	53	32.92	0.55 ±0.01	29.11	32.69	0.99
	>60	18	11.18	0.55	9.90	11.12	0.99
	Total	**161**	**100.00**		**89.05**	**100.00**	
Paracetamol 120mg/5ml syrup 50ml	0 ≥ 6	64	84.20	0.84	53.76	85.99	1.02
	6 ≥ 12	07	9.21	0.84	5.88	9.40	1.02
	12 ≥ 19	01	1.32	0.84	0.84	1.34	1.12
	19 ≥ 40	01	1.32	0.51	0.51	0.82	0.62
	40 ≥ 60	02	2.63	0.51	1.02	1.63	0.62
	>60	01	1.32	0.51	0.51	0.82	0.62
	Total	**76**	**100.00**		**62.52**	**100.00**	
BCG vaccine injection 20 dose	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**00**	**0.00**		**0.00**	**0.00**	
DPT vaccine injection 20dose	0 ≥ 6	07	77.78	0.43	3.01	77.78	1.00
	6 ≥ 12	02	22.22	0.43	0.86	22.22	1.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**09**	**100.00**		**3.87**	**100.00**	

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
DT vaccine injection 20dose	0 ≥ 6	22	95.65	0.51	11.22	95.65	1.00
	6 ≥ 12	01	4.35	0.51	0.51	4.35	1.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**23**	**100.00**		**11.73**	**100.00**	
Hepatitis B vaccine injection 10 dose	0 ≥ 6	42	100.00	3.23 ±0.43	135.79	100.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**42**	**100.00**		**135.79**	**100.00**	
Measles vaccine 10 dose	0 ≥ 6	40	97.56	0.62 ±0.02	24.67	97.55	1.00
	6 ≥ 12	01	2.44	0.62	0.62	2.45	1.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**41**	**100.00**		**25.29**	**100.00**	
Poliomyelitis vaccine oral solution 10 dose	0 ≥ 6	66	97.06	0.49 ±0.02	32.47	97.07	1.00
	6 ≥ 12	02	2.94	0.49	0.98	2.93	0.99
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**68**	**100.00**		**33.45**	**100.00**	
Tetanus vaccine injection 20 dose	0 ≥ 6	04	30.77	0.39 ±0.07	1.54	32.84	1.07
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	01	07.69	0.35	0.35	7.46	0.97
	19 ≥ 40	08	61.54	0.35	2.80	60.87	0.99
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**13**	**100.00**		**4.69**	**100.00**	
Heamophillius influeanzae conjunct vaccine 10 dose	0 ≥ 6	45	100.00	22.12	995.40	100.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**45**	**100.00**		**995.4**	**100.00**	

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Pregnancy test kit	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	02	16.67	1.86	3.72	16.67	1.00
	19 ≥ 40	10	83.33	1.86	18.60	83.33	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**12**	**100.00**		**22.32**	**100.00**	
Beclamethasone inhaler 100ug 300 dose	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	25.00	18.00	18.00	20.00	0.80
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	03	75.00	24.00 ±10.39	72.00	80.00	1.07
	Total	**04**	**100.00**		**90.00**	**100.00**	
Aminophylline 250mg/10ml injection	0 ≥ 6	01	100.00	1.69	1.69	100.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**1.69**	**100.00**	
Salbutamol sulphate inhaler 100ug/dose 300dose	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	03	37.50	8.42	25.26	33.33	0.89
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	05	62.50	10.10 ±3.77	50.52	66.67	1.07
	Total	**08**	**100.00**		**75.78**	**100.00**	
Salbutamol nebule 5mg / 2.5ml	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	01	100.00	1.20	1.20	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**01**	**100.00**		**1.2**	**100.00**	
Theophylline sustained release tablet 200mg 28's	0 ≥ 6	01	25.00	5.11	5.11	25.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	01	25.00	5.11	5.11	25.00	1.00
	>60	02	50.00	5.11	10.22	50.00	1.00
	Total	**04**	**100.00**		**20.44**	**100.00**	

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Theophylline sustained release tablet 200mg 56's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0:00
	19 ≥ 40	01	50.00	10.15	10.15	50.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	01	50.00	10.15	10.15	50.00	1.00
	Total	**02**	**100.00**		**20.30**	**100.00**	
Theophylline sustained release tablet 300mg 28's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	01	50.00	9.13	9.13	50.00	1.00
	>60	01	50.00	9.13	9.13	50.00	1.00
	Total	**02**	**100.00**		**18.26**	**100.00**	
Mist tussi infant 100ml	0 ≥ 6	62	84.93	0.86	53.32	84.93	1.00
	6 ≥ 12	08	10.96	0.86	6.88	10.96	1.00
	12 ≥ 19	01	1.37	0.86	0.86	1.37	1.00
	19 ≥ 40	02	2.74	0.86	1.72	2.74	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**73**	**100.00**		**62.78**		
Mist expectorant stim 200ml	0 ≥ 6	05	7.35	1.42 ±0.31	7.10	6.54	0.89
	6 ≥ 12	01	1.47	1.56	1.56	1.44	0.98
	12 ≥ 19	02	2.94	1.56	3.12	2.87	0.98
	19 ≥ 40	29	42.65	1.67 ±0.59	48.47	44.63	1.05
	40 ≥ 60	24	35.29	1.56	37.44	34.47	0.98
	>60	07	10.29	1.56	10.92	10.05	0.98
	Total	**68**	**100.00**		**108.61**	**100.00**	
Ethambutol HCL 400mg tablets, 100's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	26	24.07	0.91 ±0.89	23.59	24.68	1.03
	40 ≥ 60	77	71.30	0.72 ±1.46	55.39	57.95	0.81
	>60	05	4.63	3.32	16.60	17.37	3.75*
	Total	**108**	**100.00**		**95.58**	**100.00**	
Rifampicin300 / 150INH tablets 20's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	25	4.67	3.64 ±5.27	91.06	4.22	0.90
	19 ≥ 40	337	62.99	4.08 ±4.87	1375.70	63.77	1.01
	40 ≥ 60	168	31.40	3.79 ±3.44	637.57	29.56	0.94
	>60	05	0.94	10.58	52.90	2.45	2.61*
	Total	**535**	**100.00**		**2157.23**	**100.00**	

APPENDIX 1: RESULTS OF INDIVIDUAL MEDICINE ITEM ANALYSIS

INDIVIDUAL ITEM DESCRIPTION	Age Group (Years)	Frequency (n)	Frequency Percentage (FP) %	Average Cost (AC) (Rands)	Total Cost (TC) (Rands)	Percentage Cost (PC) %	Cost Prevalence Index (CPI)
Rifampicin 60mg INH 30 mg tablets 4's	0 ≥ 6	26	100.00	2.98 ±2.56	77.52	100.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**26**	**100.00**		**77.52**	**100.00**	
HRZ-E-200 tablets 100,s	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	164	58.16	3.62 ±3.54	593.52	58.39	1.00
	40 ≥ 60	118	41.84	3.58 ±5.67	422.92	41.61	0.99
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**282**	**100.00**		**1016.44**	**100.00**	
HREZ-Myrin plus tablets, 100's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	139	55.60	4.48 ±4.48	623.07	55.64	1.00
	40 ≥ 60	111	44.40	4.48 ±7.73	496.76	44.36	0.99
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**250**	**100.00**		**1119.83**	**100.00**	
Rifampicin 60mg / INH 30mg PZA150mg tablets 80's	0 ≥ 6	25	100.00	4.93 ±4.44	123.34	100.00	1.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	00	0.00	0.00	0.00	0.00	0.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**25**	**100.00**		**123.34**	**100.00**	
Streptomycin1g / 3ml injection	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	125	63.13	3.26	407.50	63.13	1.00
	40 ≥ 60	73	36.87	3.26	237.98	36.87	1.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**198**	**100.00**		**645.48**	**100.00**	
Cotrimazole vaginal tablets 500mg 1's	0 ≥ 6	00	0.00	0.00	0.00	0.00	0.00
	6 ≥ 12	00	0.00	0.00	0.00	0.00	0.00
	12 ≥ 19	00	0.00	0.00	0.00	0.00	0.00
	19 ≥ 40	03	100.00	17.45	52.35	100.00	1.00
	40 ≥ 60	00	0.00	0.00	0.00	0.00	0.00
	>60	00	0.00	0.00	0.00	0.00	0.00
	Total	**03**	**100.00**		**52.35**	**100.00**	